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A mis padres

LAS RANITAS EN LA NATA
Había una vez dos ranas que cayeron en un recipiente de nata. Inmediatamente 
se dieron cuenta de que se hundían: era imposible nadar o flotar demasiado tiempo en 
esa masa espesa como arenas movedizas. Al principio, las dos ranas patalearon en la 
nata para llegar al borde del recipiente. Pero era inútil; sólo conseguían chapotear en el 
mismo lugar y hundirse. Sentían que cada vez era más difícil salir a la superficie y 
respirar.
Una de ellas dijo en voz alta: “No puedo más. Es imposible salir de aquí. En esta 
materia no se puede nadar. Ya que voy a morir, no veo por qué prolongar este
sufrimiento. No entiendo qué sentido tiene morir agotada por un esfuerzo estéril”.
Dicho esto, dejó de patalear y se hundió con rapidez, siendo literalmente tragada 
por el espeso líquido blanco.
La otra rana, más persistente o quizá más tozuda se dijo: “¡No hay manera! Nada 
se puede hacer para avanzar en esta cosa. Sin embargo, aunque se acerque la muerte, 
prefiero luchar hasta mi último aliento. No quiero morir ni un segundo antes de que 
llegue mi hora”.
Siguió pataleando y chapoteando siempre en el mismo lugar, sin avanzar ni un 
centímetro, durante horas y horas.
Y de pronto, de tanto patalear y batir las ancas, agitar y patalear, la nata se 
convirtió en mantequilla.
Sorprendida, la rana dio un salto y, patinando, llegó hasta el borde del recipiente. 
Desde allí, pudo regresar a casa croando alegremente.
JORGE BUCAY
Déjame que te cuente…
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INTRODUCTION
1. DIABETES
Diabetes mellitus is a disease characterized by uncontrolled hyperglycemia, the 
result of either the failure of insulin production, or a combined defect in insulin
production and action. This leads to the dysregulation of glucose metabolism. 
Concurrent with the spread of the western lifestyle, which is linked with an 
increasingly overweight and sedentary population, the prevalence of diabetes is rising
dramatically. It is estimated to affect 4% of the world’s population, with the number of 
diabetics increasing by 4-5% per year1. The statistics are alarming: the global figure of 
people with diabetes is set to rise from about 118 million in 1995 to 220 million in 2010 
and 300 million in 20252.
Diabetes is characterized by fasting hyperglycemia as a consequence of the lack 
of insulin or of its correct action in the liver and in peripheral tissues, accompanied by 
increased levels of glucagon. In addition, free fatty acids (FFA) from the adipose tissue 
are abnormally mobilized, promoting the stimulation of hepatic ketogenesis. These 
metabolic disorders lead to the typical symptoms of diabetes: polyuria, polyphagia,
polydipsia and loss of weight. Diabetes is associated with neuropathy, nephropathy, 
retinopathy, coronary heart disease and early death. The result is disability, impact on 
the quality of life of the patients and shortened life expectancy; which have a serious
impact on both the social and economic costs of diabetes to the health care system in the 
developed and developing world.
Clinical diabetes is considered to be attained when fasting plasma glucose levels 
exceed 126 mg/dl. Maintaining a healthy diet and an active exercise program are 
important components in the prevention and treatment of diabetes. Even while
maintaining a healthy lifestyle, most patients need pharmacological intervention which 
might consist of one or a combination of the following oral medications: sulfonylureas, 
1 Wagman A, Nuss JM. Current therapies and emerging targets for the treatment of Diabetes. Curr. Pharm. Des.
7:417-450, 2001
2 King H, Aubert RE, Herman WH. Global burden of Diabetes, 1995-2025. Prevalence, numerical estimates and 
projections. Diabetes Care. 21:1414-1431, 1998
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metformin or thiazolidinediones. However 30-40% of patients are not adequately
controlled by these therapies and require subcutaneous insulin injections intended to 
restore normoglycemia, but they can inadvertently lead to hypoglycemia, a potentially 
fatal consequence. Thus, new drugs and novel methods of treatment such as gene 
therapy are needed.
Diabetes mellitus has been known since the time of Aristotle. In 1889 Oskar 
Minkowski observed that the urine from pancreatectomized dogs attracted an unusual 
number of flies. Intrigued, he tasted the urine and was struck by its sweetness. From this
simple but astute observation, he established for the first time that the pancreas
produced some entity essential for control of the blood sugar concentration, which, 
when absent, resulted in diabetes mellitus. Several decades later, in 1921 Frederick 
Banting identified the active pancreatic principle as insulin. Thus, the concept of an 
insulin-glucose axis as a central component of fuel homeostasis came into being. In 
keeping with its etymological derivation, diabetes mellitus has been viewed ever since 
as a disorder primarily associated with abnormal glucose metabolism. However, it is 
now clear that glucose metabolism and lipid metabolism are intimately interrelated. 
McGarry3 postulated that if Minkowski had focused on the smell of acetone in the 
diabetic urine, generated from fatty acid metabolism, instead of the taste of the sugar, 
perhaps we would have advanced our understanding of the disease more rapidly.
1.1 TYPE 1 DIABETES
Among diabetic patients, 10-25% fall into the category of insulin-dependent
diabetes mellitus (IDDM) or Type 1 diabetes, which generally appears before age 40, 
frequently in adolescence, and results from autoimmune destruction of insulin-
producing pancreatic β-cells. Type 1 diabetic patients dramatically depend on insulin
administration for their survival. 
1.1 TYPE 2 DIABETES
Non-insulin-dependent diabetes mellitus (NIDDM) or Type 2 diabetes is far 
more common than IDDM, affecting 75-90% of diabetic patients. It is characterized by 
a combination of genetic and environmental factors that affect the organism’s ability to 
respond to insulin. The condition has two hallmark features: 1) insulin resistance, 
3 McGarry  JD. What if Minkowski had been ageusic? An alternative angle of Diabetes. Science. 258:766-770, 1992
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defined as an impaired ability of the hormone to suppress hepatic glucose output and to 
promote peripheral glucose disposal and 2) compromised function of the pancreatic β-
cell such that insulin secretion is insufficient to match the degree of insulin resistance.
The early stages of Type 2 diabetes are characterized by a conjunction of 
metabolic and hormonal abnormalities including insulin resistance, hyperinsulinemia, 
hyperlipidemia, glucose intolerance and, in some instances, hypertension. These
symptoms are often collectively referred to as syndrome X4. The temporal sequence in 
which these component derangements appear and how they relate to one another has 
been extensively debated5.
Despite the gaps in our knowledge, there is general agreement that Type 2 
diabetes, unlike IDDM, is tightly associated with obesity6. Over 80% of individuals 
with Type 2 diabetes are obese. However, only 10% of obese individuals are diabetic. In 
the prediabetic phase, when insulin resistance has already begun, the β-cell actually 
hypersecretes insulin despite normal blood glucose levels. What has defied explanation 
is precisely what causes this insulin resistance in the first place and how it relates in a 
temporal sense to the accompanying hyperinsulinemia. Type 2 diabetes is related almost 
invariably to a serious breakdown in lipid dynamics, often reflected by elevated levels 
of circulating FFA and triglycerides, together with excessive deposition of fat in various 
tissues including the muscle bed7. Less clear has been whether this breakdown in lipid 
homeostasis is a result of the diabetic state or is in fact instrumental in its development. 
1.2.1 Monogenic forms of Type 2 diabetes
A minority of Type 2 diabetic patients (2-5%) have a form of diabetes that 
results from mutations in a single gene, which might result in either β-cell dysfunction 
or, less frequently, insulin resistance. The most common genetic subtypes are the 
dominantly inherited maturity-onset diabetes of the young (MODY) and maternally 
inherited diabetes and deafness (MIDD). MODY is a genetically heterogeneous
monogenic form of Type 2 diabetes mellitus, characterized by early onset, usually 
4 Reaven GM. The role of insulin resistance and hyperinsulinemia in coronary heart disease. Metabolism. 41:16-19,
1992
5 McGarry JD. Glucose-fatty acid interactions in health and disease. Am. J. Clin. Nutr . 67:500S-504S, 1998
6 Nadler ST, Stoehr JP, Schueler KL, Tanimoto G, Yandell BS, Attie AD. The expression of adipogenic genes is 
decreased in obesity and Diabetes mellitus. Proc. Natl. Acad. Sci. USA. 97:11371-11376, 2000
7 Reaven GM. The fourth musketeer-from Alexadre Dumas to Claude Bernard. Diabetologia. 38:3-13, 1995
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before 25 years of age and often in adolescence or childhood and by autosomal
dominant inheritance8. Mutations in five different genes allow the classification of the 
different types of MODY: hepatocyte nuclear factor (HNF)-4α (MODY 1), glucokinase 
(MODY 2), HNF-1α in chromosomal 12q (MODY 3), insulin promoter factor-1α
(MODY 4) and HNF-1α in chromosomal 17q (MODY 5). MIDD is characterized by 
maternally inherited mitochondrial gene mutations. This causes a reduced oxidative 
phosphorylation capacity, resulting in a lower ATP/ADP ratio and therefore, a reduced 
capacity to secrete insulin (see Section 4.1). Patients with MIDD have early onset Type
2 diabetes that frequently progresses to insulin requirement owing to progressive β-cell
loss9.
2. STRUCTURE AND FUNCTION OF THE PANCREAS
The pancreas consists of acinar (exocrine) cells and islets of endocrine cells 
embedded within the much larger mass of the exocrine pancreas. These hormone-
secreting islets are called islets of Langerhans in honor of the scientist who first 
described them in 1869. Each islet of Langerhans is composed of about 2,000 cells, they
are ductless, have a rich blood supply, and are innervated in many species. An adult 
human has roughly 1 g of islet tissue constituted by approximately 1 to 2 million islets, 
but they represent only about 1 to 2% of pancreatic tissue. Each islet is composed of 
distinct α, β , δ and PP cells (Fig. 1), which constitute 25%, 60%, 10% and 5% of the 
total islet cells, respectively. The α, β , δ and PP cells secrete glucagon, insulin,
somatostatin and pancreatic polypeptide, respectively. Glucagon and insulin are
inhibited reciprocally while somatostatin inhibits both glucagon and insulin.
8 Frayling T. Maturity-onset Diabetes of the young: a monogenic model of Diabetes. In Type 2 Diabetes: Prediction 
and Prevention. Hitman G. ed. John Wiley & Sons. 107-126, 1999
9 Permutt MA, Hattersley AT. Searching for Type 2 Diabetes Genes in the post-genome Era. Trends in endocrinology 
and metabolism. 11: 383-393, 2000
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Fig. 1. Islet of Langerhans. (A) Photomicrograph of a human pancreatic islet. (B) Diagrammatic representation of 
the endocrine cell distribution in a typical mammalian islet of Langerhans. 
In addition to the pancreatic enzyme secretion by the exocrine cells, the pancreas 
has an important endocrine role: to maintain a constant blood glucose level, to facilitate 
cellular storage of nutrients following a meal, and to provide for the mobilization of 
these depot metabolic substrates during periods of fasting. The underproduction or 
overproduction of insulin or glucagon therefore can profoundly affect the storage and 
use of carbohydrates, fats and proteins within the different tissues and thus severely 
affect cellular metabolic processes. 
Glucose homeostasis involves a push-pull system that controls glucose flux into 
and out of the extracellular space. By their actions on the liver, adipose tissue, and 
muscle, glucagon and insulin maintain a balance of glucose production and utilization, 
respectively, that requires a coordinated action of both hormones under the guidance of 
a perceptive glucose sensor. 
2.1 INSULIN
Insulin is one of a number of hormones that is required for normal growth and 
development. In addition, it is the only hormone that directly lowers blood glucose 
levels, therefore it is a dominant metabolic regulatory factor. Absolute insulin
deficiency results in unrestrained glucose production, lipolysis, ketogenesis, proteolysis 
and, ultimately, death. Insulin excess results in hypoglycemia with consequent brain 
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failure and again, ultimately, death. Clearly, insulin is a potent and critically important 
hormone 10.
Insulin is a member of a gene family which includes insulin- like growth factor 
(IGF)-I, IGF-II and relaxin.  However, unlike the other members of this gene family, 
expression of insulin is restricted exclusively to the β-cells of the pancreas. The insulin 
gene is transcribed and translated as preproinsulin. This contains a 24-amino acid signal 
sequence which is cleaved during transit through the rough endoplasmic reticulum to 
yield the 81-amino acid proinsulin molecule (Fig. 2). This is a single polypeptide chain
with three internal disulphide bonds. From the trans-Golgi network proinsulin is sorted 
into vesicles destined for secretion. These vesicles undergo a process of maturation,
during which a series of specific endopeptidases sequentially cleave the proinsulin. The 
processing of proinsulin to insulin is thought to be largely effected by Ca2+ dependent 
soluble proteases that specifically cleave proinsulin in the low pH environment of the 
maturing insulin storage granule. The insulin granules are 300 nm in diameter.
Fig. 2. Insulin maturation. Proinsulin is cleaved specifically by β-cell peptidases producing the mature insulin and 
the C-peptide.
Fully processed insulin consists of two chains, the 30-amino acid chain and the 
21-amino acid chain, which are linked by two disulphide bonds. The central portion of 
the proinsulin molecule which is released is known as the C-peptide and is largely 
10 Hadley Mac E. Endocrinology. Prentice Hall Ed. 2000
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retained in the mature storage granule and secreted along with insulin. There is some 
evidence that this C-peptide may serve some function(s), along with insulin, in glucose 
homeostasis10.
3. GLUCOSE-SENSING IN THE β-CELL
Insulin secretion is accurately linked to blood glucose levels in the physiological 
range, and the mechanism by which the pancreatic β-cells sense changes in glucose 
concentrations has been a major focus of research efforts. Therefore, the rate- limiting
steps regulating glucose influx and metabolism in the β-cell are likely to function as 
glucose sensors.
The role of the β-cell is to sense an increase in the concentration of nutrients in 
the blood and to synthesize, package and release insulin to control blood glucose 
homeostasis. The metabolism of glucose is an absolute requirement for the stimulation 
of insulin release. This conclusion is based on the evidence that the insulinotropic effect 
of glucose is inhibited by agents that interfere with its cellular metabolism and is 
mimicked only by metabolized sugars. Various agents such as amino acids (particularly
arginine and leucine) and  fatty acids can increase the secretion of insulin but only in the 
presence of facilitating concentrations of glucose (above 3 mM), whilst non-
metabolizable analogues of glucose such as galactose or fructose are largely inactive as 
secretagogues11. This effect, mediated by the metabolism of the sugar, was dubbed the 
“fuel hypothesis”12.
The above fuel secretagogues are true “initiators” of secretion, but there are also 
other agents including neurotransmitters (such acetylcholine), and enteric factors (e.g. 
glucagon-like peptide, GLP-1, gastric inhibitory peptide, GIP, and pituitary adenylate 
cyclase-activating polypeptide, PACAP) that act as “potentiators”, enhancing secretion 
only at permissive concentrations of fuel secretagogues. These molecules usually act via
G-protein coupled receptors and the generation of classical second messengers such as 
cAMP and Ca2+ 13.
11 Hedeskov CJ. Mechanisms of glucose-induced insulin secretion. Physiol. Rev. 60:442-509, 1980
12 Coore HG, Randle PJ. Inhibition of glucose phosphorylation by mannoheptulose. Biochem. J. 91:56-59, 1964
13 Rutter GA. Nutrient-secretion coupling in the pancreatic islet β-cell: recent advances. Molecular Aspects of 
Medicine. 22:247-284, 2001
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3.1 GLUCOSE TRANSPORT IN THE β -CELL
Islet β-cells are equipped with high-capacity glucose transporters located at the 
plasma membrane that are known as GLUT-2 in rodents. Whether this or another 
GLUT isoform (GLUT-1 or GLUT-3) is present in human β-cells is unclear14. GLUT-2
has a relatively high Vmax. The Km for glucose is also high, and so the rate of glucose 
transport into the cell will vary as the concentration of glucose fluctuates over the 
physiological range. GLUT-2 is required for efficient glucose-stimulated insulin
secretion (GSIS), as demonstrated by studies in transgenic mice in which antisense 
RNA reduced GLUT-2 levels in β-cells by 80%15. These mice develop impaired insulin 
secretion and elevated blood glucose levels. Studies performed in knockout mice of 
GLUT-216 showed that homozygous (-/-), but not heterozygous (-/+), mice deficient in 
GLUT-2 are hyperglycemic and relatively hypoinsulinemic and have elevated plasma 
levels of glucagon, free fatty acids and beta-hydroxybutyrate. In vivo, their glucose 
tolerance is abnormal while in vitro, β-cells display loss of control of insulin gene 
expression by glucose and impaired GSIS. This is accompanied by alterations in the 
postnatal development of pancreatic islets, evidenced by an inversion of the alpha- to 
beta-cell ratio. As its absence leads to symptoms characteristic of NIDDM, it was
suggested that GLUT-2 is thus required to maintain normal glucose homeostasis and 
normal function and development of the endocrine pancreas. However, as glucose
transport across the β-cell membrane is rapid, it is thus unlikely that GLUT-2 is a strong 
controller of glucose metabolism.
3.2 GLUCOSE PHOSPHORYLATION IN THE β -CELL
The glucose-phosphorylating hexokinase enzyme called glucokinase (GK) has 
also been considered to be a crucial step in the control of glucose metabolism in
pancreatic β-cells. β-cells contain a high Km glucokinase, which displays strongly
14 Schuit FC. Is GLUT2 required for glucose sensing? Diabetologia. 40:104-111, 1997
15 Valera A, Solanes G, Fernández-Alvarez J, Pujol A, Ferrer J, Asins G, Gomis R, Bosch F. Expression of GLUT-2
antisense RNA in β cells of transgenic mice leads to Diabetes. J. Biol. Chem. 269:28543-28546, 1994
16 Guillam MT, Hummler E, Schaerer E, Yeh JI, Birnbaum MJ, Beermann F, Schmidt A, Deriaz N, Thorens B, Wu 
JY. Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2. Nat. Genet. 17:327-
330, 1997
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cooperative kinetics and has thus been termed the β-cell “glucose sensor”17. This high 
Km (approximately 10 mM for glucose) explains the concentration dependence of the β-
cell response to glucose in the physiological range, which stimulates insulin release. 
The importance of GK in this regulation is highlighted by transgenic approaches using 
β-cell-specific antisense RNA18 and homologous recombination to knockout the GK
gene19, where the reduction in β-cell GK levels was associated with reduced capacity to 
secrete insulin in response to glucose. However, the most convincing evidence for the 
role of GK comes from the finding that mutations which reduce GK function in humans 
are associated with impaired GSIS20 and the development of a subclass of NIDDM, 
MODY 221. Overall, GK has been proposed as the rate- limiting enzyme in glycolysis 
that acts as a glucose-sensor. Nevertheless, it is now evident that subsequent metabolic 
steps, in the lower glycolytic pathway, may also play an important role in determining 
the fate of glucose carbon atoms22, and that β-cells display a highly unusual range of 
glucose-sensing enzymes.
4. SIGNAL TRANSDUCTION IN INSULIN SECRETION
The study of stimulus-secretion coupling in β-cells began in the 1960s and 
rapidly led to three key discoveries: glucose must be metabolized by β-cells to induce 
insulin secretion; Ca2+ has an essential role in insulin secretion; and pancreatic β-cells
are electrically excitable. 
17 Meglasson MD, Matschinsky FM. Pancreatic islet glucose metabolism and regulation of insulin secretion. 
Diabetes/Metab. Rev . 2:163-214, 1986
18 Efrat S, Leiser M, Wu Y-J, FuscoDeMane D, Emran OA, Surana M, Jetton TL, Magnuson MA, Weir G, Fleischer 
N. Ribozyme-mediated attenuation of pancreatic beta-cell glucokinase expression in transgenic mice results in 
impaired glucose-induced insulin secretion. Proc. Natl. Acad. Sci. USA. 91:2051-2055, 1994
19 Grupe A, Hultgren B, Ryan A, Ma YH, Bauer M, Stewart TA. Transgenic mice knockouts reveal a critical 
requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis. Cell. 83:69-78, 1995
20 Byrne MM, Sturis J, Clement K, Vionnet N, Pueyo ME, Stoffel M, Takeda J, Passa P, Cohen D, Bell GI, et al. 
Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J. Clin. Invest. 93:1120-
1130, 1994 
21 Frogel P, Vaxillaire M, Sun F, Vehlo G, Zouali H, Butel MO, Lesage S, Vionnet N, Clement K, Fougerousse F. 
Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. 
Nature. 356:162-164, 1992.
22 Berman HK, Newgard CB. Fundamental metabolic differences between hepatocytes and islet beta-cells revealed 
by glucokinase overexpression. Biochemistry. 37:4543-4552, 1998
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Glucose stimulation of insulin secretion involves two pathways: the triggering or 
KATP channel-dependent pathway, and the amplifying or KATP channel- independent
pathway.
4.1 KATP CHANNEL-DEPENDENT PATHWAY
The demonstration in isolated β-cells of ATP-inhibitable K+ currents23 and their 
closure in intact cells by glucose24 provided the first evidence that changes in
intracellular ATP concentrations, [ATP], may be critical for the response to glucose. An 
ATP-sensitive K+ channel was later cloned25 and shown to be made of four Kir 6.2
subunits (forming the ionic pore) and four regulatory SUR1 subunits (containing the site 
to which antidiabetic sulfonylureas bind). The KATP channel is closed by the oral
hypoglycemic sulfonylureas such as tolbutamide and glibenclamide while it is opened 
by diazoxide26. SUR1 also mediates the opening action of Mg2+-ADP, whereas the
closing action of ATP is on Kir 6.2 itself. Kir 6.2 also possesses a near-consensus
phosphorylation site for AMP-activated protein kinase (AMPK)27.
Glucose enters the β-cell through the high-capacity GLUT-2, which allows for 
rapid equilibration of glucose across the β-cell plasma membrane (Fig. 3). Glucose is 
then phosphorylated by GK, the first enzyme in the glycolytic pathway in the β-cell,
which acts as a glucose sensor. The production of ATP from glycolysis and the Krebs 
cycle results in oscillations in the ATP/ADP ratio. These oscillations are thought to lead 
to oscillations in membrane potential through modulation of the KATP channel. Thus, 
elevated extracellular glucose concentrations increase the ATP/ADP ratio and therefore 
close KATP channels. This, in turn, suppresses efflux of K+ ions, leading to progressive 
23 Cook DL, Hales CN. Intracellular ATP directly blocks K+ channels in pancreatic β-cells. Nature. 311:271-273,
1984
24 Ashcroft FM, Harrison DE, Ashcroft SJH. Glucose induces closure of single potassium channels in isolated rat 
pancreatic β-cells. Nature. 312:446-448, 1984
25 Inagaki N, Gonoi T, Clement IV, Namba N, Inazawa J, Gonzalez G, AguilarBryan L, Seino S, Bryan J.
Reconstitution of I(KATP): an inward rectifier subunit plus the sulfonylurea receptor. Science. 270:1166-1170, 1995
26 Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes . 49:1751-
1760, 2000
27 Woods A, Salt I, Scott J, Hardie DG, Carling D. The alpha 1 and alpha 2 isoforms of the AMP-activated protein 
kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro. FEBS Lett. 397:347-
351, 1996
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depolarization of the plasma membrane (resting potential of about -70mV)28. The drop 
in voltage leads to the opening of voltage-sensitive L-type Ca2+ channels and the influx 
of Ca2+ ions. The resulting increase in intracellular free Ca2+ concentration [Ca2+]i
modulates kinases or other effector systems involved in secretion, triggering the 
movement of dense-core secretory vesicles to the cell surface, prompting their fusion 
with the plasma membrane and finally releasing stored insulin. However, the precise 
connection between elevated intracellular [Ca2+]i and triggering of the insulin exocytotic 
mechanism remains unknown.
Fig. 3. KATP channel-dependent pathway of glucose sensing in the β -cell. Glucose enters the β-cell through the 
glucose transporter GLUT-2 and is phosphorylated by glucokinase (GK), the first enzyme in the glycolytic pathway 
in the β-cell, which acts as a glucose sensor. Mitochondrial metabolism increases the cytosolic ATP/ADP ratio. This 
leads to closure of KATP channels and depolarization of the plasma membrane. As a consequence, the cytosolic Ca
2+
concentration is raised by the opening of voltage-sensitive Ca2+ channels. This increase in the cytosolic Ca2+
concentration is the main trigger for exocytosis, fusion of the insulin-containing secretory granules with the plasma 
membrane and insulin secretion. 
28 Henquin JC, Meissner HP. Significance of ionic fluxes and changes in membrane potent ial for stimulus-secretion
coupling in pancreatic β-cells. Experientia. 40:1043-1052, 1984
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4.2 KATP CHANNEL-INDEPENDENT PATHWAY
During the past decade, a substantial amount of new evidence has emerged 
which indicates that other mechanisms, apart from the closure of KATP channels, are 
involved in the stimulation of insulin release at high glucose concentrations. This was
first demonstrated by the finding that glucose can stimulate insulin release under
conditions of fixed, high [Ca2+]c29. Under maximal activation of the KATP channel-
dependent pathway, glucose still increases insulin secretion in a concentration-
dependent manner. This increase in secretion is highly sensitive to glucose (produced by 
as little as 1-6 mM glucose) and requires glucose metabolism. More recently, knockout 
mouse models lacking either of the two functional subunits of the KATP channel showed
marked reductions, albeit not eliminations, of GSIS30. These β-cells show a partial
secretory response to glucose without changes in [Ca2+]c, which is already elevated at 
low glucose concentration. Taken together, all these studies suggest the existence of 
metabolic coupling factors generated by glucose. Thus, the Ca2+ signal in the cytosol is 
necessary, but not sufficient, for the full development of insulin secretion. This second 
mechanism was called the amplifying pathway or KATP channel- independent pathway
(Fig. 4).
29 Gembal M, Gilon P, Henquin JC. Evidence that glucose can control insulin release independently from its action 
on ATP-sensitive K+ channels in mouse β-cells. J. Clin. Invest. 89:1288-1295, 1992
30 Seghers V, Nakazaki M, DeMayo F, Aguilar-Bryan L, Bryan J. SUR1 knockout mice: a model for K(ATP) 
channel-independent regulation of insulin secretion. J. Biol. Chem. 275:9270-9277, 2000
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Fig. 4. Schematic representation of the KATP channel-dependent and -independent pathways of glucose sensing
in the β -cell. Glucose metabolism produces an increase in the ATP/ADP ratio. Subsequently, closure of the KATP
channels depolarizes the cytosolic membrane, which opens voltage-sensitive Ca2+-channels, raising [Ca2+]i and
triggering insulin exocytosis (KATP channel-dependent pathway, yellow arrows). Under high [Ca
2+]c, glucose 
metabolism produces other factors that still increase insulin secretion. These other metabolic coupling factors such as
protein kinase A (PKA), PKC, glutamate and/or malonyl-CoA are believed to stimulate insulin secretion via a KATP
channel-independent pathway (green arrows).
The molecular mechanisms involved in the KATP channel- independent pathway 
are still under discussion. The aim of this thesis is to gain more insight into the 
metabolic coupling factors implicated in the KATP channel- independent pathway of 
glucose sensing. 
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4.3 HIERARCHY BETWEEN THE KATP CHANNEL-DEPENDENT AND -
INDEPENDENT PATHWAYS
Glucose-stimulated insulin release from human and rat islets is markedly
biphasic in vitro31, with an initial peak after approximately 5 min followed by a trough, 
and a second, more sustained phase. It now seems likely that the fast increase in [Ca2+]i
induced by the KATP channel-dependent pathway is responsible for the first phase and 
that the second phase involves the activation by glucose of mechanisms which are at 
least in part KATP channel- independent 32. The first phase is thought to be due to a small 
pool of readily releasable granules and the second phase to granules that have
translocated from reserve pools to a releasable pool at the membrane. Therefore, in the 
presence of elevated [Ca2+]i, the KATP channel- independent pathway is responsible for 
the selection and translocation of insulin-containing granules from the reserve pools to 
the cell membrane, their assembly at the plasma membrane, priming to achieve fusion 
competence, and finally exocytosis.
Low concentrations of glucose (1-6 mM) can influence insulin secretion, but
only when a triggering signal has been produced26. This establishes a clear hierarchy 
between the two pathways: the KATP channel- independent pathway remains functionally 
silent as long as the KATP channel-dependent pathway has not depolarized the
membrane and raised [Ca2+]i; i.e., as long as glucose has not reached its threshold 
concentration. The KATP channel- independent pathway serves to optimize the secretory 
response induced by the KATP channel-dependent signal. This hierarchy between the two 
pathways ensures that no insulin is inappropriately secreted in the presence of low 
glucose concentrations. 
4.4 USE OF K+ AND DIAZOXIDE TO DISCERN BETWEEN THE TWO
PATHWAYS
Elevated K+ and diazoxide can be used to discern between the KATP channel-
dependent and - independent pathways of glucose sensing. When KATP channels are 
opened by diazoxide, the stimulation of insulin secretion by glucose is abrogated
31 Curry DL, Bennett LL, Grodsky GM. Dynamics of insulin secretion by the perfused rat pancreas. Endocrinology.
83:572-584, 1968
32 Komatsu M, Schermerhorn T, Noda M, Straub SG, Aizawa T, Sharp GW. Augmentation of insulin release by 
glucose in the absence of extracellular Ca2+: new insights into stimulus-secretion coupling. Diabetes. 46:1928-1938,
1997
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because the β-cell membrane does not depolarize and [Ca2+]i does not increase. But β-
cells could be depolarized by increasing the concentration of extracellular K+, a 
manoeuvre that simply shifts the equilibrium potential for K+ to more positive values. 
Under these conditions, elevated K+ plus diazoxide, Ca2+ influx and insulin secretion are 
stimulated, and ne ither of these effects is inhibited by diazoxide33. Moreover, glucose 
still increases insulin secretion from islets depolarized with high K+, although it does
not close KATP channels in the presence of diazoxide. This effect of glucose is
concentration-dependent, requires glucose metabolism, and does not involve any change 
in membrane potential or [Ca2+]i29.
Using the same paradigm of K+-induced depolarization in the presence of
diazoxide, many laboratories have confirmed that glucose can increase insulin secretion
independently of its action on KATP channels in rodent islets34, human islets35, perfused 
rat pancreas36 and insulin-secreting cell lines37.
5. MITOCHONDRIAL ANAPLEROSIS
Signals generated from glucose metabolism in the β-cell modulate the relative 
rates of glucose and FFA oxidation. At low glucose levels the mitochondria fill the 
energy needs of the β-cell by FFA oxidation. When the glucose level rises, FFA
oxidation is decreased and glucose oxidation fulfils a larger part of the cellular energy 
needs. The first step in glucose- induced inhibition of FFA oxidation is an increase in 
mitochondrial Krebs cycle intermediates known as anaplerosis, resulting in citrate
formation. The citrate content of insulin-secreting cells increases rapidly and precedes 
the increase in insulin release, consistent with a role for elevated citrate levels in
33 Henquin JC, Charles S, Nenquin M, Mathot F, Tamagawa TD. Diazoxide and D600 inhibition of insulin release:
distinct mechanisms explain the specificity for different stimuli. Diabetes. 31:776-783, 1982
34 Fujimoto S, Ishida H, Kato S, Okamoto Y, Tsuji K, Mizuno N, Ueda S, Mukai E, Seino Y. The novel 
insulinotropic mechanism of pimobendan: direct enhancement of the exocytotic process of insulin secretory granules 
by increased Ca2+ sensitivity in β-cells. Endocrinology. 139:1133-1140, 1998
35 Straub SG, James RFL, Dunne MJ, Sharp GWG. Glucose activates both KATP channel-dependent and KATP
channel-independent signaling pathways in human islets. Diabetes. 47:758-763, 1998
36 Abdel-Halim SM, Guenifi A, Khan A, Larsson O, Berggren PO, Östenson CG, Efendic S. Impaired coupling of 
glucose signal to the exocytotic machinery in diabetic GK rats: a defect ameliorated by cAMP. Diabetes. 45:934-940,
1996
37 Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB. Isolation of INS-1-derived cell lines 
with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes.
49(3):424-430, 2000
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nutrient- induced insulin secretion38. Mitochondrial citrate production leads to increased 
cytosolic citrate that is converted to malonyl-CoA by the combined enzymatic actions 
of citrate lyase (CL) and acetyl-CoA carboxylase (ACC) (Fig. 5). Malonyl-CoA is a 
potent inhibitor of carnitine palmitoyltransferase I (CPTI), which controls the transport 
of long-chain fatty acyl-coenzyme A (LC-CoA) into the mitochondria to be oxidized. 
Thus, malonyl-CoA switches β-cell metabolism from fatty acid oxidation to glucose 
oxidation. An important consequence of this switch is an increase in cytosolic LC-CoA,
which is believed to act as an effector molecule in the β-cell39 (Section 7).
Fig. 5. Mitochondrial anaplerosis in the β -cell. PC: pyruvate carboxylase, PDH: pyruvate dehydrogenase, GDH: 
glutamate dehydrogenase, CL: citrate lyase, ACC: acetyl-CoA carboxy lase, MCD: malonyl-CoA decarboxylase.
38 Brun T, Roche E, Assimacopoulos-Jeannet F, Corkey BE, Kim KH, Prentki M. Evidence for anaplerotic/malonyl-
CoA pathway in pancreatic β-cell nutrient signalling. Diabetes . 45:190-198, 1996
39 Prentki M, Corkey BE. Are the β-cell signaling molecules malonyl-CoA and cytosolic long-chain acyl-CoA
implicated in multiple tissue defects of obesity and NIDDM? Diabetes. 45: 273-283, 1996
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Anaplerosis is likely to be important in β-cell activation for several reasons. 
Firstly, it is required for the efficient operation of either a pyruvate/malate or
pyruvate/citrate shuttle allowing the production of cytosolic malonyl-CoA and NADPH. 
Secondly, the dose dependence of anaplerosis, citrate, malate and malonyl-CoA
accumulation in response to glucose correlate well with secretion in β-cells40,41. Thirdly,
methylsuccinate is a potent secretagogue in intact β-cells42 and succinate directly
promotes exocytosis of insulin in permeabilized pancreatic β-cells43. Fourthly,
phenylacetic acid reduces anaplerosis and insulin secretion in clonal INS β-cells and rat 
islets40 by inhibition of pyruvate carboxylase.
An interesting feature of the β-cell is not only the tight link between glycolysis 
and mitochondrial oxidative metabolism, but also the extremely high proportion of
glucose-derived carbons oxidized in the mitochondria. β-cell glucose metabolism is 
remarkably aerobic: more than 80% of the glucose carbons are converted to CO2 and 
H2O41. As a result, pyruvate produced from glucose by glycolysis enters mitochondria, 
rather than exiting the cell across the plasma membrane, whilst NADH generated at the 
glyceraldehyde phosphate dehydrogenase step of glycolysis is oxidised by the
mitochondrial respiratory chain. In the mitochondria, pyruvate is a substrate for both 
pyruvate dehydrogenase (PDH) and pyruvate carboxylase (PC). The latter forms
oxaloacetate, providing anaplerotic input to the tricarboxylic acid (TCA) cycle.
Reducing equivalents generated by the TCA cycle activate the electron transport chain,
resulting in hyperpolarization of the mitochondrial membrane and formation of ATP.
Mitochondrial metabolism plays a pivotal role in the pancreatic β-cell by
generating signals that couple glucose sensing to insulin secretion. As explained above, 
the Ca2+ signal alone is not sufficient to reproduce the complete and sustained secretion 
elicited by glucose. Therefore, glucose metabolism must generate other factors to
40 Farfari S, Schulz V, Corkey B, Prentki M. Glucose-regulated anaplerosis and cataplerosis in pancreatic β-cells:
possible implication of a pyruvate/citrate shuttle in insulin secretion. Diabetes . 49:718-726, 2000
41 Schuit F, De Bos A, Farfai S, Moens K, Pipeleers D, Brun T, Prentki M. Metabolic fate of glucose in purified islet 
cells: glucose-regulated anaplerosis in beta cells. J. Biol. Chem. 272:18572-18579, 1997
42 MacDonald MJ, Fahien LA. Insulin release in pancreatic islets by a glycolytic and a Krebs cycle intermediate: 
contrasting patterns of glyceraldehyde phosphate and succinate. Arch. Biochem. Biophys . 279:104-108, 1990
43 Maechler P, Kennedy ED, Pozzan T, Wollheim CB. Mitochondrial activation directly triggers the exocytosis of 
insulin in permeabilized pancreatic β-cells. EMBO J. 16:3833-3841, 1997
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stimulate insulin secretion. Such metabolites may be generated in different
compartments, the mitochondrion being the most likely source. 
Ultrastructural examination of the β-cell has shown that mitochondria are often 
in close proximity to the secretory insulin granules (Fig. 6), suggesting that this may 
facilitate metabolism-secretion coupling.
Fig. 6. β -cell cytoplasm. Electron micrograph of the rat 
β-cell cytoplasm showing mitochondria (m) and insulin-
containing secretory granules (sg). The mitochondrial 
outer and inner membranes are visible. The scale bar 
represents 0.5 µm. Picture obtained from44.
In permeabilized INS-1 cells, mitochondrial activation is associa ted with a 
marked stimulation of insulin release, which depends both on activation of the
mitochondrial respiratory chain and on provision of carbons for the TCA cycle44.
Glucose, glyceraldehyde and dihydroxyacetone, which feed directly into glycolysis, are
all secretagogues11. However, glucose, which provides anaplerosis, is required for fatty 
acid- and ketone body-induced insulin release45. Leucine (acetyl-CoA production) and 
glutamine (anaplerosis) synergize to promote secretion45.
In conclusion, all these features of β-cell fuel stimuli favour the concept that 
acetyl-CoA production and anaplerosis are the earliest mitochondrial events synergizing 
to promote the production of coupling factors activating the β-cell secretory process.
This secretory response requires a factor(s) generated by mitochondrial metabolism
44 Maechler P, Wollheim CB. Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis. 
Nature. 402:685-689, 1999
45 Malaisse WJ, Malaisse-Lagae F, Rasschaert J, Zahner D, Sener A, Davies DR, Van Schaftingen E. The fuel 
concept for insulin release: regulation of glucose phosphorylation in pancreatic islets. Biochem. Soc. Trans. 18:107-
108, 1990
Introduction
19
distinct from ATP. There have been proposed several candidates for the metabolic 
coupling factors generated by glucose, such as citrate40, glutamate44, AMPK46, protein
kinases A and C47, and malonyl-CoA/LC-CoA48. The present thesis will focus on
malonyl-CoA/LC-CoA as a metabolic coupling factor in insulin secretion.
6. METABOLIC COUPLING FACTORS IN INSULIN SECRETION
6.1 GLUTAMATE
In 1999 Maechler and Wollheim demonstrated that glutamate could trigger
insulin secretion in permeabilized clonal β-cells, and that the concentration of this 
molecule increases in INS-1 cells in response to elevated glucose concentration44. Thus,
glutamate, which can be produced from the TCA cycle intermediate α-ketoglutarate or 
by transamination reactions, would seem to satisfy the criteria for an important
signalling molecule in the β-cell. Glutamate is believed to act on the secretory vesicle, 
by undefined mechanisms which may involve uptake of the molecule, and which
enhance the competence of the vesicle for fusion with the plasma membrane. It is most 
likely to affect the second phase of insulin secretion.
This hypothesis has met with some resistance, since it has been pointed out that 
increases in the islet content of glutamate do not always occur in response to glucose, 
under conditions in which insulin secretion is robustly stimulated49. However,
transgenic over-expression of glutamate decarboxylase (GAD65) in mouse β-cells leads 
to an inhibition of insulin release, and glucose intolerance, in vivo50. Further studies in 
INS-1E cells and rat islets overexpressing GAD65 using an adenoviral vector showed 
46 daSilvaXavier G, Leclerc I, Salt IP, Doiron B, Hardie DG, Kahn A, Rutter GA. Role of AMP-activated protein 
kinase in the regulation by glucose of islet beta-cell gene expression. Proc. Natl. Acad. Sci. USA. 97:4023-4028, 2000
47 Aizawa T, Komatsu M, Asanuma N, Sato Y, Sharp GG. Glucose action ‘beyond ionic events’ in the pancreatic 
beta cell. Trends Pharmacol. Sci. 19:496-499, 1998
48 Prentki M, Vischer S, Glennon MC, Regazzi R, Deeney JT, Corkey BE. Malonyl-CoA and long chain acyl-CoA
esters as metabolic coupling factors in nutrient-induced insulin secretion. J. Biol. Chem . 267:5802-5810, 1992
49 MacDonald MJ, Fahien LA. Glutamate is not a Messenger in insulin secretion. J. Biol. Chem . 275:34025-34027,
2000
50 Shi Y, Kanaani J, Menard-Rose V, Ma YH, Chang PY, Hanahan D, Tobin A, Grodsky G, Baekkeskov S. Increased 
expression of GAD65 and GABA in pancreatic beta-cells impairs first-phase insulin secretion. Am. J. Physiol. 
Endocrinol. Metab. 279:E684-E694, 2000
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reduced glutamate levels and impaired GSIS, demonstrating a positive correlation
between cellular glutamate concentrations and the secretory response to glucose51.
Overall, data both for and against the “glutamate hypothesis” have emerged, 
although the precise mechanism of glutamate action on exocytosis is unknown. Further
investigation is needed to clarify the role of glutamate as an intracellular messenger or 
cofactor in insulin secretion.
6.2 AMPK
AMP-activated protein kinase (AMPK) is a heterotrimer containing α-, β- and γ-
subunits. The α-subunit contains the catalytic site; the β-subunit, a glycogen-binding
domain; and the γ-subunit the AMP-binding site. Increases in the ratio of AMP/ATP 
activate AMPK by AMPK kinase phosphorylation. AMPK acts as a “fuel gauge”, such 
that when it detects a “low fuel” situation it protects the cell by regulating processes that 
generate and utilize ATP. Therefore, activation of AMPK leads to the phosphorylation 
of a number of target molecules that result in increases in fatty acid oxidation (to 
generate more ATP) and in the decrease of their esterification and use in other non-β-
oxidative pathways 52. AMPK phosphorylates and activates malonyl-CoA decarboxylase 
(MCD) and suppresses the synthesis of ACC, fatty acid synthetase (FAS), glycerol-3-
phosphate acyltransferase (GPAT) and other enzymes of lipid biogenesis by inhibiting 
the generation of the transcription factor sterol regulatory element binding protein-1c
(SREBP-1c)53.
AMPK is expressed in β-cells and it is acutely inhibited by elevated glucose 
concentrations46. AMPK has been suggested to be a key regulator of both insulin 
secretion and insulin gene expression46. The effects of AMPK may result, at least in 
part, from changes in the rate of insulin release. Thus, increases in AMPK activity can 
block GSIS in rat islets and clonal MIN6 β-cells without affecting the basal secretory
51 Rubi B, Ishihara H, Hegardt FG, Wollheim CB, Maechler P. GAD65-mediated glutamate decarboxylation reduces 
glucosa-stimulated insulin secretion in pancreatic beta cells. J. Biol. Chem. 276:36391-36396, 2001
52 Ruderman N, Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nature.
3:340-351, 2004
53 Ferre P, Azzout -Marniche D, Foufelle F. AMP-activated protein kinase and hepatic genes involved in glucose 
metabolism. Biochem. Soc. Trans. 31:220-223, 2003
Introduction
21
machinery54. Therefore, AMPK could be involved as a metabolic coupling factor in
insulin secretion. AMPK has also been proposed as a target, along with malonyl-CoA,
for therapy of the metabolic syndrome52, a state of metabolic dysregulation
characterized by insulin resistance, hyperinsulinemia, central obesity and a
predisposition to Type 2 diabetes, dyslipidemia, hypertension, premature atherosclerosis 
and other diseases.
6.3 PKC 
Protein kinase C (PKC) isoforms are reasonable candidates to either initiate
secretion or augment GSIS, as they respond to both energy excess (lipid signals) and 
Ca2+.
PKC is a family of different isozymes which are divided into three classes, based 
on structure and co-factor requirements. The conventional class (cPKC: α, β and  γ)
requires phosphatidylserine (PS), diacylglycerol (DAG) and Ca2+, while the novel class 
(nPKC: ε, η, θ and δ) does not require Ca2+. The atypical class (aPKC: ζ, λ, τ) requires
only an acidic phospholipid like PS. PKCµ can be considered a separate class of kinase 
or an nPKC isoform with a modified phorbol ester binding site (C1 domain) and a 
putative transmembrane leader sequence. The β-cell expresses seven isoforms of PKC: 
α, β, δ, ε, τ, ζ and µ55. Unlike many enzymes, cPKC and nPKC isozymes require
intracellular translocation and targeting to membrane surfaces for their activation. The 
mechanism of this targeting involves both lipid (C1) and Ca2+ binding domains (C2) as 
well as protein-protein interactions with adaptor molecules contained in the cytosol.
The stimulus-secretion coupling of some non-nutrient secretagogues occurs via
PKC in receptor-mediated events linked to phospholipase C. Phospholipase C activation 
generates DAG, which translocates and activates PKC isoforms to phosphorylate
endogenous substrates. In pancreatic β-cells PKC is activated by glucose56 and by lipids 
(DAG and LC-CoA)55. A follow-up study showed that palmitate translocated PKC 
54 daSilvaXavier G, Leclerc I, Varadi A, Tsuboi T, Moule SK, Rutter GA. Role for AMP-activated protein kinase in 
glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem. J. 371:761-774, 2003
55 Yaney GC, Korchak HM, Corkey BE. Long-chain acyl-CoA regulation of protein kinase C and fatty acid 
potentiation of glucose-stimulated insulin secretion. Endocrinology. 141:1989-1998, 2000
56 Ganesan S, Calle R, Zawalich K, Smallwood JI, Zawalich WS, Rasmussen H. Glucose-induced translocation of 
protein kinase C in rat pancreatic islets. Proc Natl Acad Sci U S A. 87:9893–9897, 1990
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activity to a membrane fraction only in the presence of stimulating glucose57.
Significantly, blocking the metabolism of the se non-esterified fatty acids (NEFA), i.e.,
activation to LC-CoA, also blocked their ability to translocate PKC activity and
stimulate insulin secretion. This suggests that either the LC-CoA or its esterification 
into a complex lipid such as DAG or phosphatidate was required for this effect. In 
addition, the activity of cPKC has been enhanced by palmitoylation through increased 
targeting to cell membranes58.
However, the role of PKC in glucose- induced insulin secretion is unresolved,
with several arguments for and against its involvement. Glucose causes a rise in DAG 
and promotes the translocation of PKCα in the β-cell. This is consistent with the 
observation that the mass of PKCα correlates with the ability of phorbol myristate 
acetate (PMA), a high affinity surrogate for DAG, to stimulate secretion59. Therefore, 
the short-term activation of PKC is thought to be a positive signal for insulin secretion. 
However, down-regulation of PKC activity by chronic phorbol ester stimulation led to
the differential loss of PKC isoforms in HIT cells, and after down-regulation GSIS was 
not only preserved but enhanced, while the absolute potentiation due to exogenous 
NEFA did not change55. Overall, PKC seems most likely to stimulate insulin secretion
through a KATP channel- independent mechanism.
7. THE MALONYL-CoA/LC-CoA MODEL OF GSIS
Malonyl-CoA is both an intermediate in the de novo synthesis of fatty acids and 
an allosteric inhibitor of CPTI, the enzyme that controls the transfer of LC-CoA
molecules from the cytosol to the mitochondria, where they are oxidized. However, in
pancreatic β-cells the level of FAS is very low38, therefore the physiological role of 
malonyl-CoA in the endocrine pancreas, unlike many other tissues, is not de novo
synthesis of fatty acids but rather the regulation of CPTI activity. By virtue of this, 
malonyl-CoA is a key physiological regulator of cellular fatty acid oxidation and lipid 
partitioning.
57 Alcázar O, Qiu-yue Z, Giné E, Tamarit-Rodriguez J. Stimulation of islet protein kinase C translocation by 
palmitate requires metabolism of the fatty acid. Diabetes. 46:1153-1158, 1997
58 Ford DA, Horner CC, Gross RW. Protein kinase C acylation by palmitoyl coenzyme A facilitates its translocation 
to membranes. Biochemistry. 37:11953-11961, 1998
59 Yaney GC, Fairbanks JM, Deeney JT, Korchak HM, Tornheim K, Corkey BE. Potentiation of insulin secretion by 
phorbol esters is mediated by PKCα and nPKC isoforms. Am. J. Physiol. 283:E880-E888, 2002
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Prentki and Corkey48 were the first to propose that malonyl-CoA, besides its 
metabolic actions, acts as a coupling factor and signal of plenty that controls insulin
secretion. They proposed a model that links β-cell nutrient sensing to insulin secretion 
in which, in addition to the KATP channel-dependent pathway, a parallel
anaplerotic/lipid signalling pathway exists wherein malonyl-CoA acts as a coupling 
factor. The malonyl-CoA/LC-CoA model of GSIS holds that during glucose
stimulation, anaplerosis increases citrate41, which is exported to the cytosol
(cataplerosis) and finally converted to malonyl-CoA, resulting in inhibition of CPTI and 
fatty acid oxidation. Therefore, the increase in malonyl-CoA may be responsible for the 
accumulation of LC-CoAs in the cytosol60, which signal directly or indirectly via fatty 
acid esterification and/or protein acylation processes to augment insulin release48 (Fig.
7). This model does not oppose, but rather complements, other candidate mechanisms of 
metabolic signal transduction, such as the cataplerotic output of glutamate, etc.
60 Liang Y, Matschinsky FM. Content of CoA-esters in perifused rat islets stimulated by glucose and other fuels. 
Diabetes. 40:327-333, 1991
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Fig. 7. The malonyl -CoA/LC-CoA model of GSIS in the β-cell. The malonyl-CoA/LC-CoA model acts as a KATP
channel-independent pathway (blue arrows) in parallel to the KATP channel-dependent pathway (green arrows). At 
elevated glucose, anaplerosis-derived malonyl-CoA inhibits CPTI which modulates the partitioning of exogenous 
fatty acids via LC-CoA from fatty acid oxidation to lipid signaling involved in insulin vesicle exocytosis. CK: Krebs 
cycle, CPTI: carnitine palmitoyltransferase I, ACC: acetyl-CoA carboxylase, MCD: malonyl-CoA decarboxylase.
Many lines of evidences61 supporting the malonyl-CoA/LC-CoA model of an 
anaplerotic/lipid signalling pathway of insulin secretion have been verified by different 
groups:
1- Pyruvate carboxylase is abundant in the islet, yet it is neither a gluconeogenic nor a 
lipogenic tissue; anaplerosis is very active in islet tissue because 50% of β-cell pyruvate 
is carboxylated to oxaloacetate62.
61 Prentki M. New insights into pancreatic β-cell metabolic signaling in insulin secretion. European J.
Endocrinology. 134:272-286, 1996
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2- Citrate rises markedly in response to glucose before secretion occurs38.
3- Glucose activates ACC, which is abundant in the β-cell, and basal insulin secretion 
correlates with the content of the ACC protein63.
4- Malonyl-CoA rises rapidly and markedly in response to glucose before secretion 
occurs64.
5- Fatty acids potentiate glucose- induced insulin secretion. There is a correlation
between the level of fatty acyl-CoA (FA-CoA) in response to different nutrients, and 
insulin secretion48.
6- Elevated glucose inhibits fatty acid oxidation in β-cells65 and increases esterified 
lipids such as DAG48.
7- Inhibition of the pathway with hydroxy-citrate, an inhibitor of citrate lyase, curtails 
glucose- induced insulin secretion66.
8- Inhibition of CPTI by pharmacological agents promotes the release of insulin48,66.
10- Diacylglycerol64 and phosphatidic acid 67, which can be formed de novo via
esterification of FA-CoA to α-glycerophosphate, rise upon glucose stimulation of β-
cells.
11- 2-Bromopalmitate, an inhibitor of CPTI, restores glucose sensitivity to islets from 
fasted animals68, and allows foetal pancreas and islets from very young rats to become 
much more responsive to glucose69.
62 MacDonald MJ. Glucose enters mitochondrial metabolism via both carboxylation and decarboxylation of pyruvate 
in pancreatic islets. Metabolism. 42:1229-1231, 1993
63 Brun T, Roche E, Kim KH, Prentki M. Glucose regulates acetyl-CoA carboxylase gene expression in a pancreatic 
beta-cell line (INS-1). J Biol Chem. 268:18905-18911, 1993
64 Corkey BE, Glennon MC, Chen KS, Deeney JT, Matschinsky FM, Prentki M. A role for malonyl-CoA in glucose-
stimulated insulin secretion from clonal pancreatic beta-cells. J. Biol. Chem. 264:21608-21612, 1989
65 Segall L, Lameloise N, Assimacopoulos-Jeannet F, Roche E, Corkey P, Thumelin S, Corkey BE, Prentki M. Lipid 
rather than glucose metabolism is implicated in altered insulin secretion caused by oleate in INS-1 cells. Am. J. 
Physiol. 277:E521-528, 1999
66 Chen S, Ogawa A, Ohneda M, Unger RH, Foster DW, McGarry JD. More direct evidence for a malonyl-CoA-
carnitine palmitoyltransferase I interaction as a key event in pancreatic beta-cell signaling. Diabetes. 43:878-883,
1994
67 Farese RV, DiMarco PE, Barnes DE, Sabir MA, Larson RE, Davis JS, Morrison AD. Rapid glucose-dependent
increases in phosphatidic acid and phosphoinositides in rat pancreatic islets. Endocrinology. 118:1498-1503, 1986
68 Vara E, Fernandez-Martin O, Garcia C, Tamarit-Rodriguez J. Palmitate dependence of insulin secretion, "de novo" 
phospholipid synthesis and 45Ca2+-turnover in glucose stimulated rat islets. Diabetologia. 31:687-693, 1988 
69 Bliss CR, Sharp GW. Glucose-induced insulin release in islets of young rats: time-dependent potentiation and 
effects of 2-bromostearate. Am. J. Physiol. 263:E890-E896, 1992
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12- Islets incubated in the absence of bicarbonate, a substrate for pyruvate carboxylase 
and ACC, show a marked decrease in glucose- induced secretion70.
13- Sulfonylureas, which inhibit CPTI and curtail fatty acid oxidation71, have been
proposed to promote insulin release both via KATP channel closure and by CPTI 
inhibition61.
14- Islets from hormone sensitive lipase-deficient mice do not release insulin in
response to glucose either in vivo or in vitro72, and pharmacological inhibition of islet 
lipase with 3,5-dimethylpyrazole curtails GSIS73.
15- A patient with a mutation in the fat oxidation gene L-3-hydroxyacyl-CoA
dehydrogenase showed hyperinsulinism74.
16- Stable expression of an ACC-antisense construct in INS-1 cells decreased malonyl-
CoA levels, increased LC-CoA oxidation and decreased insulin secretion75.
17- The overexpression of native LCPTI in clonal INS-1E β-cells increased beta
oxidation of fatty acids and decreased insulin secretion (40%) at high glucose76. The 
effect of LCPTI was reverted by etomoxir, an irreversible inhibitor of CPTI, and by the 
exogenous addition of fatty acids.
18- MCD overexpression in rat islets and β-cell stable clones curtailed GSIS (50%),
only in the presence of fatty acids77.
70 Henquin JC, Lambert AE. Extracellular bicarbonate ions and insulin secretion. Biochim Biophys Acta. 381:437-
442, 1975
71 Cook GA. The hypoglycemic sulfonylureas glyburide and tolbutamide inhibit fatty acid oxidation by inhibiting 
carnitine palmitoyltransferase. J. Biol. Chem. 262:4968-4972, 1987
72 Roduit R, Masiello P, Wang SP, Li H, Mitchell GA, Prentki M. A role for hormone-sensitive lipase in glucose-
stimulated insulin secretion: a study in hormone-sensitive lipase-deficient mice. Diabetes . 50:1970-1975, 2001
73 Masiello P, Novelli M, Bombara M, Fierabracci V, Vittorini S, Prentki M, Bergamini E. The antilipolytic agent 
3,5-dimethylpyrazole inhibits insulin release in response to both nutrient secretagogues and cyclic adenosine 
monophosphate agonists in isolated rat islets. Metabolism. 51:110-114, 2002
74 Clayton PT, Eaton S, Aynsley-Green A, Edginton M, Hussain K, Krywawych S, Datta V, Malingre HE, Berger R, 
van den Berg IE. Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the 
importance of beta-oxidation in insulin secretion. J. Clin. Invest. 108:457-465, 2001
75 Zhang S, Kim K H. Essential role of acetyl-CoA carboxylase in the glucose-induced insulin secretion in a β-cell
line. Cell Signal. 10:35-42, 1998
76 Rubi B, Antinozzi PA, Herrero L, Ishihara H, Asins G, Serra D, Wollheim CB, Maechler P, Hegardt FG. 
Adenovirus-mediated overexpression of liver carnitine palmitoyltransferase I in INS1E cells: effects on cell 
metabolism and insulin secretion. Biochem. J. 364:219-226, 2002
77 Roduit R, Nolan C, Alarcon C, Moore P, Barbeau A, Delghingaro-Augusto V, Przybykowski E, Morin J, Masse F, 
Massie B, Ruderman N, Rhodes C, Poitout V, Prentki M. A Role for the Malonyl-CoA/Long-Chain Acyl-CoA
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On the other hand, the malonyl-CoA/LC-CoA hypothesis has been challenged 
by other authors. In a recent study78 where pancreatic β-cells were chronically exposed
to high FFA concentrations, the overexpression of MCD did not improve the lipid-
induce impairment in GSIS. Instead, GSIS was partially restored with the addition of a 
pyruvate cycling intermediate. The authors propose that impaired GSIS is not a simple 
result of saturation of lipid storage pathways and that chronic exposure of islet β-cells to 
fatty acids grossly alters a mitochondrial pathway of pyruvate metabolism that is
important for GSIS. The same authors had previously reported unimpaired secretion of 
insulin in β-cells overexpressing MCD in the cytoplasm79. However, this apparent
discrepancy with the malonyl-CoA/LC-CoA hypothesis has been reconciled by a recent 
study demonstrating the importance of the availability of fatty acids for lipid signalling 
in the β-cell77. In this study, MCD overexpression in rat islets and β-cell stable clones 
curtailed GSIS, but only in the presence of exogenous fatty acids.
Overall, both malonyl-CoA and LC-CoA are thought to participate in the signal 
transduction for insulin secretion: the former as a regulator and the latter as an
effector80. Systems that regulate both malonyl-CoA and LC-CoA appear to be involved 
in insulin secretion. Accordingly, ACC, which controls the synthesis of malonyl-CoA,
MCD, which catalyzes malonyl-CoA degradation, and CPTI, which is regulated by 
malonyl-CoA, are components of a metabolic signalling network that senses the level of 
fuel stimuli. The metabolism of several nutrients that converge to form malonyl-CoA
and increase LC-CoA esters (carbohydrate, amino acids and ketoacids) might play a key 
role in fuel regulated- insulin secretion in the β-cell81. To further investigate the
implication of LC-CoA in insulin release, the present thesis will examine the hypothesis 
Pathway of Lipid Signaling in the Regulation of Insulin Secretion in Response to Both Fuel and Nonfuel Stimuli. 
Diabetes. 53:1007-1019, 2004
78 Boucher A, Lu D, Burgess SC, Telemaque-Potts S, Jensen MV, Mulder H, Wang MY, Unger RH, Sherry AD, 
Newgard CB. Biochemical mechanism of lipid-induced impairment of glucose-stimulated insulin secretion and 
reversal with a malate analogue. J. Biol. Chem. 279:27263-27271, 2004
79 Mulder H, Lu D, Finley IV J, An J, Cohen J, Antinozzi PA, McGarry JD, Newgard CB. Overexpression of a 
modified human malonyl-CoA decarboxylase blocks the glucose-induced increase in malonyl-CoA level but has no 
impact on insulin secretion in INS-1-derived (832/13) β-cells. J. Biol. Chem. 276: 6479-6484, 2001
80 Corkey BE, Deeney JT, Yaney GC, Torheim, Prentki M. The role of long-chain fatty acyl-CoA esters in β-cell
signal transduction. J. Nutr. 130:299S-304S, 2000
81 Yaney GC, Corkey BE. Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia.
46:1297-1312, 2003
Introduction
28
that the CPTI/malonyl-CoA interaction is involved in GSIS, supporting the malonyl-
CoA/LC-CoA model.
7.1 EFFECTOR MOLECULES IN INSULIN SECRETION
It is generally accepted that exogenous NEFA increases LC-CoA and potentiates 
GSIS and that this action is phys iologically relevant. What is missing is a signalling 
cascade linking changes in LC-CoA to changes in insulin release. Malonyl-CoA, as a 
nutrient-derived coupling factor, regulates the partitioning of fatty acid into effector 
molecules of the insulin secretory pathway important for all classes of secretagogues. 
The precise nature of these effector molecules and their mechanisms of action on insulin 
secretion are poorly understood. Possible candidates for these effector molecules are 
non-esterified palmitate, LC-CoA, phospholipids and/or DAG. PKC isoforms are also 
reasonable candidates to either initiate secretion or augment GSIS as they respond to 
both lipid signals and Ca2+.
Insulin exocytosis is a complex sequential process involving many steps,
including vesicle movement, docking, priming, fusion with the plasma membrane and 
ultimately dissociation and recycling of exocytotic components. This is a likely site for 
regulation by fatty acid moieties, acting directly on signal transducing effectors of
secretion or indirectly via activation of some kinases, in particular the PKC enzymes by 
DAG and LC-CoA. Possibilities of more direct distal effects include LC-CoA acylation 
of proteins. Protein acylation is a post-translational event, which usually links palmitate 
in the form of a fatty acyl-CoA, as the preferred substrate, to a cysteine residue through 
a thioester linkage in a variety of proteins. Because it is a reversible modification with 
dynamic cycles of acylation and deacylation, it may have a role in signal transduction. 
This was supported by a study with rat islets in which the protein acylation inhibitor 
cerulenin inhibited GSIS82. Moreover, in the presence of KCl and diazoxide (conditions
which allow us to differentiate the KATP channel-dependent from KATP channel-
independent pathways of glucose sensing), cerulenin powerfully inhibited the
augmentation of insulin release by glucose and palmitate, thus implicating protein
acylation in the KATP channel- independent pathway. PKC has been suggested as one
possible target for acylation, because its translocation to membrane bilayers was
82 Yajima H, Komatsu M, Yamada S, Straub SG, Kaneko T, Sato Y, Yamauchi K, Hashizume K, Sharp GWG, 
Aizawa T. Cerulenin, an inhibitor of protein acylation, selectively attenuates nutrient stimulation of insulin release. 
Diabetes. 49:712-717, 2000
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facilitated upon palmitoylation58. Moreover, acylation also occurs on proteins directly 
linked to exocytosis such as the synaptosomal-associated protein-25 (SNAP-25)83 and 
synaptogamin84, which can enhance their association with target membranes. Another
possibility of a distal effect in secretion is DAG modulation of exocytotic machinery 
proteins such as the synaptic vesicle priming protein Munc-1385. Of potential
importance, Munc-13 has a C1 domain binding site for DAG, and it is direct binding to 
this site, rather than PKC activation, by which β-phorbol esters and DAG mediate
augmentation of neurotransmitter release from neurons. Munc-13 is present in β-cells86
and therefore could be an important site for fatty acid induction/augmentation of insulin 
secretion.
In addition, three recent reports suggested that exogenous FFAs could also act 
directly on β-cells as a ligand for the orphan G-protein receptor GPR4087,88,89. These 
reports are preliminary, and, in particular, the secretory action of the FFA was tested in 
the absence of BSA. Thus, the real importance of this pathway of FFA-signalling in 
physiological insulin secretion is uncertain. It remains an attractive possibility that both 
FFA metabolism and direct effects via GPR40 are involved in the regulation of insulin 
secretion.
83 Gonzalo S, Linder ME. SNAP-25 palmitoylation and plasma membrane targeting require a functional secretory 
pathway. Mol. Biol. Cell. 9:585-597, 1998
84 Chapman ER, Blasi J, An S, Brose N, Johnston PA, Sudhof TC, Jahn R. Fatty acylation of synaptotagmin in PC12 
cells and synaptosomes. Biochem. Biophys. Res. Commun. 225:326-332, 1996
85 Rhee JS, Betz A, Pyott S, Reim K, Varoqueaux F, Augustin I, Hesse D, Sudhof TC, Takahashi M, Rosenmund C, 
Brose N. Beta phorbol ester- and diacylglycerol-induced augmentation of transmitter release is mediated by Munc13s 
and not by PKCs. Cell. 108:121-133, 2002
86 Sheu L, Pasyk EA, Ji J, Huang X, Gao X, Varoqueaux F, Brose N, Gaisano HY. Regulation of insulin exocytosis 
by Munc13-1. J. Biol. Chem. 278:27556-27563, 2003
87 Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, Uejima H, 
Tanaka H, Maruyama M, Satoh R, Okubo S, Kizawa H, Komatsu H, Matsumura F, Noguchi Y, Shinohara T, Hinuma 
S, Fujisawa Y, Fujino M. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. 
Nature. 422:173-176, 2003
88 Kotarsky K, Nilsson NE, Flodgren E, Owman C, Olde B. A human cell surface receptor activated by free fatty 
acids and thiazolidinedione drugs. Biochem Biophys Res Commun. 301:406-410, 2003
89 Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, Ellis C, Elshourbagy NA, Goetz 
AS, Minnick DT, Murdock PR, Sauls HR Jr, Shabon U, Spinage LD, Strum JC, Szekeres PG, Tan KB, Way JM, 
Ignar DM, Wilson S, Muir AI. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain 
fatty acids. J. Biol. Chem. 278:11303-11311, 2003
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Further investigation on these novel lipid-signalling processes will have many
implications for the understanding of the link between fat and β-cell adaptation and 
failure in the cause of diabetes.
8. GLUCOLIPOTOXICITY
The roles of glucose and FFA as “toxic” factors of the (pre)diabetic milieu
influencing β-cell function and the etiology of diabetes are controversial. It was first 
proposed that chronic hyperglycemia is progressively deleterious to the islet, which led 
to the concept of “glucotoxicity”90. However, more recent evidence suggests that
elevated circulating and intracellular lipids, in addition to glucose, play an important 
role in the etiology of adipogenic diabetes39. Diabetes may therefore be considered as 
much a lipid disorder as a disease of glucose tolerance.
Lipid metabolism in the β-cell is critical for the regulation of insulin secretion81.
Interestingly, glucose- induced insulin secretion by the perfused pancreas isolated from 
starved rats is absolutely dependent on the prior provision of exogenous fatty acid, 
whereas that by the pancreas isolated from fed animals is not91, 92. Similarly, inhibition 
of adipose tissue lipolysis in starved rats prevents the insulin secretory response that 
normally accompanies re- feeding, and this is restored by simultaneous infusion of
triglyceride and heparin93. Long-term exposure of β-cells to NEFAs in vitro has several 
effects: 1) it increases basal insulin release and decreases secretion in response to 
glucose94; 2) it alters the coupling of glucose metabolism to insulin secretion by acting 
on the expression of specific genes, such as uncoupling protein-2 (UCP-2)95,96; 3) it 
90 Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and 
insulin resistance: implications for the management of diabetes. Diabetologia. 28:119-121, 1985
91 Stein DT, Stevenson BE, Chester MW, Basit M, Daniels MB, Turley SD, McGarry JD. The insulinotropic potency 
of fatty acids is influenced profoundly by their chain length and degree of saturation. J. Clin. Invest. 100:398-403,
1997
92 Dobbins RL, Chester MW, Daniels MB, McGarry JD, Stein DT. Circulating fatty acids are essential for efficient 
glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes . 47:1613-1618, 1998
93 Stein DT, Esser V, Stevenson BE, Lane KE, Whiteside JH, Daniels MB, Chen S, McGarry JD. Essentiality of 
circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J. Clin. Invest. 97:2728-2735, 1996
94 Zhou YP, Grill V. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin 
secretion and biosynthesis through a glucose fatty acid cycle. J. Clin. Invest. 93:870-876, 1994
95 Lameloise N, Muzzin P, Prentki M, Assimacopoulos-Jeannet F. Uncoupling protein 2: a possible link between 
fatty acid excess and impaired glucose-induced insulin secretion? Diabetes . 50:803-809, 2001
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increases the expression of CPTI97. CPTI upregulation following chronic NEFA
exposure of the β-cell may contribute to reduced GSIS.
In addition, the effects of nutrients on the β-cell can be quite different depending
on whether the exposure is acute or chronic. Elevated levels of glucose and FFA
stimulate insulin release acutely while chronic exposure, as is the case in NIDDM, can 
lead to deleterious effects described as “glucotoxicity” and “lipotoxicity”. Chronic 
increases in the concentration of glucose and saturated FFA cause dysfunction and 
damage to the β-cell, and ultimately result in apoptosis98,99. This β-cell apoptosis
resulting from the increased circulating free fatty acids and cellular lipid accumulation 
has been called lipotoxicity100. But, this is a confusing concept, since other authors have
suggested that glucotoxicity is the prerequisite for lipotoxicity101,102.
Nevertheless, recent studies demonstrate that even moderately elevated
concentrations of glucose synergize with saturated FFAs to cause β-cell apopotosis, a 
phenomenon named “glucolipotoxicity”98. The authors propose103 that when both
glucose and FFA levels are high, cytosolic FA-CoA increases because the ability of 
fatty acids to increase their oxidation is diminished due to decreased PPARα activation, 
enhanced SREBP-1c expression, reduced AMPK activity and increased malonyl-CoA
levels caused by the rise in glucose. This, in turn, increases FA-CoA partitioning toward 
potentially toxic cellular products, including possibly DAG, ceramide and lipid
96 Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, Hagen T, Vidal-Puig AJ, Boss O, Kim YB, Zheng 
XX, Wheeler MB, Shulman GI, Chan CB, Lowell BB. Uncoupling protein-2 negatively regulates insulin secretion 
and is a major link between obesity, beta cell dysfunction and type 2 diabetes. Cell. 105:745-755, 2001
97 Assimacopoulos-Jeannet F, Thumelin S, Roche E, Esser V, McGarry JD, Prentki M. Fatty acids rapidly induce the 
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Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology. 144:4154-
4163, 2003 
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100 Unger RH. Lipotoxic diseases. Annu. Rev. Med. 53:319-336, 2002
101 Poitout V, Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetes-a convergence of
glucotoxicity and lipotoxicity. Endocrinology. 143:339-342, 2002
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peroxides. The nature of the downstream events tha t lead to β-cell death is not entirely 
clear; however, increases in oxidant stress and the production of nitric oxide could be 
involved100.
Emerging evidence suggests that changes in malonyl-CoA-AMPK signalling are
important in the pathogenesis of both β-cell glucolipotoxicity and Type 2 diabetes52.
Metformin and 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), agents that 
activate AMPK and thereby favour fatty acid β-oxidation, prevent glucolipotoxicity-
induced apoptosis in INS(832/13) cells98; overexpression of SREBP-1c in β-cells leads 
to activation of FAS gene expression, an accumulation of triglycerides (TG) and a 
profound inhibition of GSIS104; and finally, in the Zucker diabetic fatty (ZDF) rat, a 
rodent with a mutated, non-functioning leptin receptor (Ob-Rb), overexpression of the 
Ob-Rb gene in islet tissue in vitro allowed leptin, which activates AMPK105, to reverse 
the diabetogenic phenotype, reduce TG stores and inhibit FFA-induced apoptosis100.
In conclusion, when both glucose and FFA levels are high, then the problems 
arises, and together they may progressively alter the function of various cell types and 
cause insulin resistance in muscle tissue, impair glucose induced secretion, or promote 
β-cell apoptosis and the progressive neural diabetes complications. Thus, as Aristotle
said: “Everything in moderation”.
9. PPAR
Tight regulation of metabolic pathways involves the rapid modulation of the 
activity of specific proteins (enzymes, transporters) but also, on a longer-term basis, 
changes in their quantity. This can be achieved by modulating their transcription rate 
through the action of specific transcription factors. The discovery of the peroxisome 
proliferator-activated receptor (PPAR) family of transcription factors has revealed the 
mechanism of the strong link between lipid/glucose availability and long-term
metabolic adaptation. PPARs play a critical physiological role as lipid sensors and 
regulators of lipid metabolism. 
104 Wang H, Maechler P, Antinozzi PA, Herrero L, Hagenfeldt-Johansson KA, Björklund A, Wollheim CB. The
Transcription factor SREBP-1c is instrumental in the development of β-cell dysfunction. J. Biol. Chem. 278:16622-
16629, 2003
105 Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB. Leptin stimulates fatty-acid
oxidation by activating AMP-activated protein kinase. Nature. 415:339-343, 2002
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PPARs form a subfamily of the nuclear receptor superfamily. Three isoforms, 
encoded by separate genes, have been identified thus far: PPARα, PPARδ, and PPARγ.
The PPARs are ligand-dependent transcription factors that regulate target gene
expression by binding to specific peroxisome proliferator response elements (PPREs) in 
enhancer sites of regulated genes. Each receptor binds to its PPRE as a heterodimer with 
the 9-cis-retinoic acid receptor or retinoid X receptor (RXR)106. Upon binding an
agonist, the conformation of a PPAR is altered and stabilized such that a binding cleft is 
created and transcriptional coactivators are recruited. The result is an increase in gene 
transcription (Fig. 8).
Fig. 8. Mechanism of action of PPARs. Upon ligand binding, PPAR changes its structural conformation, which 
stimulates its heterodimerization with the 9-cis-retinoic acid receptor (RXR), and facilitates the recruitment of 
cofactors required for the activation of transcription. This heterodimer-cofactor complex controls the expression of 
genes that contain the peroxisome proliferator response element (PPRE).
PPARδ
PPARδ is expressed in a wide range of tissues and cells, with relatively higher 
levels of expression in brain, adipose tissue and skin. No PPARδ-specific gene targets 
have been identified and as PPARα and PPARγ are the most strongly implicated in lipid
metabolism and insulin sensitivity they will be further discussed.
106 Berger J, Moller DE. The mechanisms of action of PPARs. Annu. Rev. Med. 53:409-435, 2002
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PPARα
PPARα is highly expressed in numerous metabolically active tissues including 
liver, heart, kidney, skeletal muscle and brown fat. It is also present in monocytic, 
vascular endothe lial, and vascular smooth muscle cells. Its natural ligands are
unsaturated fatty acids such as palmitic, oleic, linoleic and arachidonic, and among the 
synthetic ligands, compounds of the fibrate family (clofibrate, fenofibrate, and
bezafibrate) and their derivatives have been widely used to characterize PPARα
functions.
In addition to the effects of PPARα on circulating lipoproteins and cholesterol 
metabolism, it is involved in the regulation of cellular uptake, activation and β-
oxidation of fatty acids.  PPARα induces expression of fatty acid transport proteins,
acetyl-CoA synthetase, pyruvate dehydrogenase kinase 4 (PDK4) and enzymes
involved in ketone body synthesis, peroxisomal β-oxidation and mitochondrial β-
oxidation such as CPTI, although the latter remains a disputed issue 107.
It has been reported that in PPARα-null mice there is no gross alteration of 
insulin sensitivity108 whereas they are protected from high-fat diet- induced insulin
resistance109. In addition, activation of PPARα in nutritional (high-fat diet), genetic
(Zucker obese fa/fa rat), or lipoatrophic (A-ZIP/F-1) models of insulin resistance
markedly improves insulin sensitivity108,110,111 and reduces visceral fat in the two former 
models. So far, no clear explanation has been offered for this discrepancy. In pancreatic 
β-cells, adenovirus-mediated overexpression of PPARα in INS-1 cells increases fatty 
107 Louet J, Chatelain F, Decaux J, Park E, Kohl C, Pineau T, Girard J, Pegorier J. Long-chain fatty acids regulate 
liver carnitine palmitoyltransferase I gene (L-CPTI) expression through a peroxisome-proliferator-activated receptor 
alpha (PPARalpha)-independent pathway. Biochem. J. 354:189-197, 2001
108 Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herber JM, Winegar DA, Willson TM, 
Fruchart JC, Berge RK, Staels B. Peroxisome proliferator-activated receptor alpha activators improve insulin
sensitivity and reduce adiposity. J. Biol. Chem. 275:16638-16642, 2000
109 Guerre-Millo M, Rouault C, Poulain P, Andre J, Poitout V, Peters JM, Gonzalez FJ, Fruchart JC, Reach G, Staels 
B. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes. 50:2809-2814, 2001
110 Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor 
(PPAR) alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with 
PPAR gamma activation. Diabetes . 50:411-417, 2001
111 Chou CJ, Haluzik M, Gergory C, Dietz KR, Vinson C, Gavrilova O, Reitman ML. WY14,643, a peroxisome
proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin 
resitance in lipoatrophic A-ZIP/F-1 mice. J. Biol. Chem. 277:24484-24489, 2002
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acid oxidation and UCP-2 expression, and decreases GSIS suggesting that PPARα-
stimulated fatty acid oxidation can impair β-cell function112.
In summary, PPARα is an important lipid sensor and regulator of cellular 
energy-harvesting metabolism. PPARα activation favours fatty acid oxidation, mainly 
in the liver and heart and to a lesser extent in muscles, and induces glucose sparing, 
either directly by inducing the expression of PDK4 or indirectly through the synthesis of 
ketone bodies and the increased fatty acid oxidation capacity. This increased fatty acid 
oxidation is one of the reasons why fibrates have lipid- lowering effects and why 
PPARα ligands could in some situations improve insulin sensitivity by reducing lipid 
accumulation in tissues.
PPARγ
PPARγ is expressed mainly in white and brown adipose tissue, and to a lesser 
extent in heart, skeletal muscle, colon, small and large intestines, kidney, pancreas, and 
spleen. PPARγ exists in two protein isoforms (γ1 and γ2) because of the use of
alternative promoter and alternative splicing. γ2 has 28 additional amino acids on the N-
terminal side in humans. In rodents, the γ2 isoform is the dominant form in adipose 
tissue, whereas the converse is true in humans. Its natural ligands are polyunsaturated 
fatty acids such as oleate, linoleate, eicosapentaenoic, and arachidonic acids. It is now 
clear that members of the thiazolidinedione (TZD) family of antidiabetic compounds are 
specific PPARγ ligands. 
PPARγ is a potent stimulator of fatty acid storage in adipose tissue because it 
increases both the storage capacity and the fatty acid flux into adipocytes, thus
decreasing the circulating free fatty acids. PPARγ is necessary and sufficient to
differentiate adipocytes. In adipocytes, PPARγ regulates the expression of numerous 
genes involved in lipid metabolism by, on one hand, activating those genes involved in 
fatty acid trapping and storage in adipocytes, such as the genes coding for fatty acid 
binding proteins, lipoprotein lipase, acyl-CoA synthetase and phosphoenol pyruvate 
carboxykinase, and, on the other hand, by repressing those genes that induce lipolysis 
and release of fatty acids, such as the cytokines leptin and the tumor-necrosis factorα
112 Tordjman K, Standley KN, Bernal-Mizrachi CB, Leone TC, Coleman T, Kelly DP, Semenkovich CF. PPARα
suppresses insulin secretion and induces UCP-2 in insulinoma cells. J. Lipid Research. 43:936-943, 2002
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(TNFα). In addition, PPARγ regulates genes that control cellular energy homeostasis 
such as the uncoupling proteins (UCPs).  PPARγ has also been involved in insulin 
sensitivity by decreasing the expression of the adipocyte-derived hormones TNFα,
leptin and resistin and by increasing the expression of adiponectin and the insulin 
receptor substrate-2 (IRS-2) 113.
In the pancreatic β-cell evidence is accumulating that PPARγ activation can 
restore or protect β-cell function from failure and apoptosis during the development of
Type 2 diabetes. When circulating glucose and free fatty acids are elevated, energy 
homeostasis in β-cells is altered, resulting in intracellular accumulation of triglycerides. 
Treatment with TZD inhibits intracellular triglyceride accumulation in pancreatic β-
cells through increases in fatty acid oxidation, thereby delaying β-cell failure114.
Improvement of cell viability after treatment with troglitazone, a TZD, has also been 
found in a rodent model of Type 2 diabetes115, which further suggests that activation of 
PPARγ prevents β-cell death. In addition, a functional PPRE has been found in the 
promoter region of GLUT-2116, the protein responsible for glucose transport in β-cells.
PPARγ-mediated stimulation of GLUT-2 expression would increase glucose uptake and
trigger the initial steps leading to insulin release. All these observations hence support 
the hypothesis that PPARγ-mediated restoration or protection of β-cell function is likely 
to contribute, at least in part, to the mechanisms by which TZD improves and controls 
glucose homeostasis in diabetic patients. 
Some discrepancies have been found concerning with the involvement of PPARγ
in insulin sensitivity. When PPARγ (+/-) mice are fed a high-fat diet, they are less 
insulin resistant 117, but TZD treatment paradoxically decreases their insulin sensitivity. 
113 Picard F, Auwerx J. PPARγ and glucose homeostasis. Annu. Rev. Nutr. 22:167-197, 2002
114 Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH. Troglitazone prevents mitochondrial alterations, 
beta cell destruction, and diabetes in obese prediabetic rats. Proc. Natl. Acad. Sci. USA. 96:11513-11518, 1999
115 Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, Buckingham RE. β-cell mass 
dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes. 50:1021-1029, 2001
116 Kim HI, Kim JW, Kim SH, Cha JY, Kim Ks, Ahn YH. Identification and functional characterization of the 
peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes. 49:1517-1524, 2000
117 Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, 
Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara Ha, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota 
K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Nagai R, Tobe K, Kimura S, Kadowaki T. PPAR gamma mediates high-
fat diet-induced adipocytes hypertrophy and insulin resistance. Mol. Cell. 4:597-609, 1999
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These and other studies involving PPARγ mutations113 with counterintuitive results 
remain to be explained.
In conclusion, PPARα, by increasing fatty acid oxidation and ketone body
production, is a “fasting- lipid oxidation-glucose sparing” regulator, while PPARγ, by 
increasing triglyceride storage and improving insulin sensitivity, is rather a “well- fed-
lipid storing-glucose utilizing” regulator118. Clearly, their activation is a means of
improving syndromes such as Type 2 diabetes, but their activation in physiological and 
pathophysiological situations must be further investigated to explain the discrepancies 
seen in insulin sensitivity. 
10. SREBP
The lipogenic transcription factors, sterol regulatory element binding proteins 
(SREBPs) are transmembrane proteins of the endoplasmic reticulum (ER). In response 
to low sterol and other unidentified factors, SREBP cleavage-activating protein (SCAP)
escorts SREBPs from the ER to the Golgi, where SREBPs are sequent ially cleaved by 
Site-1 protease and Site-2 protease. The processed mature SREBPs enter the nucleus and
bind to sterol regulatory elements (SREs) on the promoter regions of target genes 
involved in the lipid biosynthesis pathway, and activate their transcription119.
Three SREBP isoforms have been identified: SREBP-1a and -1c (alternatively 
known as adipocyte determination and differentiation factor-1 (ADD1)), which are
derived from the same gene through alternative splicing, and SREBP-2, which is
encoded by a distinct gene. 
SREBPs play an essential role in the regulation of lipid homeostasis and have 
been shown to directly activate the expression of more than 30 genes involved in the 
biosynthesis of cholesterol, fattyacids, triglycerides and phospholipids120. SREBP-1a is 
a potent activator of both the cholesterol and fatty acid biosynthetic pathways. SREBP-
1c is relatively specific for fatty acid biosynthesis in the liver and adipocytes, and
SREBP-2 preferentially activates genes involved in cholesterol synthesis119. In
118 Ferré P. The biology of peroxisome proliferator-activated receptors. Relationship with lipid metabolism and 
insulin sensitivity. Diabetes. 53:S43-S50, 2004
119 Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a 
membrane-bound transcription factor. Cell. 89:331-340, 1997
120 Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid 
synthesis in the liver. J. Clin. Invest. 109:1125-1131, 2002
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particular, SREBP-1c mediates insulin effects on lipogenic gene expression in both
adipocytes and liver121,122.
The activities of the SREBPs in liver are controlled at two levels: transcriptional 
and posttranscriptional. Transcription of the SREBP-1c gene is markedly enhanced by 
insulin and suppressed by glucagon123. The insulin-mediated enhancement of SREBP-
1c gene transcription provides a mechanism by which insulin increases the synthesis of 
fatty acids in the liver. SREBP-1c transcription is also activated by liver X receptors 
(LXRs), whose endogenous ligands include sterol intermediates in the cholesterol
biosynthetic pathway124. Inhibition of LXR by polyunsaturated fatty acids down-
regulates SREBP-1c mRNA levels125. Posttranscriptionally, SREBP activity is regulated 
primarily by sterols, which inhibit the proteolytic processing of the membrane-bound
SREBP precursors. This control is mediated by two proteins: SCAP and Insig126, an
intrinsic membrane protein of the ER. Under conditions of sterol excess, the
SCAP/SREBP complex binds to Insig which traps it in the ER and prevents the
proteolytic process and therefore the maturation of SREBP. As a result, the synthesis of 
cholesterol and fatty acids declines. Recently it has been reported that the Insig gene is 
down-regulated by insulin127 in the liver, thus in conditions of energy excess Insig
allows the synthesis of cholesterol and fatty acids by SREBP. 
121 Kim JB, Sarraf P, Wright M, Yao KM, Mueller E, Solanes G, Lowell BB, Spiegelman BM. Nutritional and 
insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J. Clin. Invest. 101:1-
9, 1998
122 Foretz M, Guichard C, Ferre P, Foufelle F. Sterol regulatory element binding protein-1c is a major mediator of 
insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc. Natl. Acad. Sci. U. S. A.
96:12737-12742, 1999
123 Zhang J, Ou J, Bashmakov Y, Horton JD, Brown MS, Goldstein JL. Insulin inhibits transcription of IRS-2 gene in 
rat liver through an insulin response element (IRE) that resembles IREs of other insulin-repressed genes. Proc. Natl. 
Acad. Sci. USA. 98:3756-3761, 2001
124 DeBose-Boyd RA, Ou J, Goldstein Jl, Brown MS. Expression of sterol regulatory element-binding protein 1c 
(SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands. Proc. Natl. Sci. USA. 98:1477-1482,
2001
125 Ou J, Tu H, Shan B, Luk A, DeBose-Boyd RA, Bashmakov Y, Goldstein JL, Brown MS. Unsaturated fatty acids 
inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-
dependent activation of the LXR. Proc. Natl. Sci. USA. 98:6027-6032, 2001
126 Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R, Goldstein JL, Brown MS. Crucial step in 
cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention 
of SREBPs in ER. Cell. 110:489-500, 2002
127 Yabe D, Komuro R, Liang G, Goldstein JL, Brown MS. Liver-specific mRNA for Insig-2 down-regulated by 
insulin: implications for fatty acid synthesis. Proc. Natl. Sci. USA. 100:3155-3160, 2003
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Many studies have implicated the up-regulation of SREBP in β-cell dysfunction 
and Type 2 diabetes. Elevated expression of SREBP-1c has been demonstrated in islets 
or liver of diabetic animals, such as ZDF rats (fa/fa)128, ob/ob mice129, IRS-2 deficient 
mice130, and a transgenic mouse model of lipodystrophy131. On the other hand,
preventing SREBP-1c overexpression is a common function of leptin, metformin, and 
PPARγ agonists, which is well correlated with their antidiabetic effects128-131. An
important function of leptin in the regulation of fatty acid homeostasis is to restrict the 
lipid storage in adipocytes and to limit lipid accumulation in non-adipocytes, thereby 
protecting them from lipotoxicity100.
Related to insulin secretion, it has been reported that overexpression of SREBP-
1c in MIN-6 cells132, INS-1 cells104,133 and rat islets134 results in massive accumulation 
of cellular TG and impaired GSIS. SREBP-1c induces β-cell dysfunction by targeting 
multiple genes involved in lipid biosynthesis, carbohydrate metabolism, cell growth, 
and apoptosis.  In INS-1 cells104 induction of SREBP-1c significantly increased the 
expression of genes involved in biosynthesis of fatty acids and cholesterol (fatty acid 
synthase, acetyl-CoA carboxylase, glycerol-phosphate acyltransferase, and 3-hydroxy-
3-methyl-glutaryl-CoA), but did not alter the expression of genes involved in β-
128 Katuma T, Lee Y, Higa M, Wang ZW, Pan W, Shimomura I, Unger RH. Leptin, troglitazone, and the expression
of sterol regulatory element binding proteins in liver and pancreatic islets. Proc. Natl. Sci. USA. 97:8536-8541, 2000
129 Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Lin, H. Z., Yang, S. Q., Chuckaree, C., 
Kuhajda, F., Ronnet, G., and Diehl, A. M. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat.
Med. 6:998-1003, 2000
130 Tobe K, Suzuki R, Aoyama M, Yamauchi T, Kamon J, Kubota N, Terauchi Y, Matsui J, Akanuma Y, Kimura S, 
Tanaka J, Abe M, Ohsumi J, Nagai R, Kadowaki T. Increased Expression of the Sterol Regulatory Element-binding
Protein-1 Gene in Insulin Receptor Substrate-2-/- Mouse Liver. J. Biol. Chem. 276:38337-38340, 2001
131 Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes 
mellitus in mice with congenital lipodystrophy. Nature. 401:73-76, 1999
132 Andreolas C, da Silva Xavier G, Diraison F, Zhao C, Varadi A, Lopez-Casillas F, Ferre P, Foufelle F, Rutter GA. 
Stimulation of acetyl-CoA carboxylase gene expression by glucose requires insulin release and sterol regulatory 
element binding protein 1c in pancreatic MIN6 β-cells. Diabetes. 51:2536-2545, 2002
133 Yamashita T, Eto K, Okazaki Y, Yamashita S, Yamauchi T, Sekine N, Nagai R, Noda M, Kadowaki T. Role of
UCP-2 up-regulation and TG accumulation in impaired glucose-stimulated insulin secretion in a β-cell lipotoxicity 
model overexpressing SREBP-1c. Endocrinology. 145:3566-3577, 2004
134 Diraison F, Parton L, Ferré P, Foufelle F, Briscoe CP, Leclerc I, Rutter GA. Over-expression of sterol-regulatory-
element-binding protein-1c (SREBP1c) in rat pancreatic islets induces lipogenesis and decreases glucose-stimulated
insulin release: modulation by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR). Biochem. J. 378:769-778,
2004
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oxidation of fatty acids (CPTI and acyl-CoA oxidase) which would explain the
increased TG accumulation. SREBP-1c induction also caused marked down-regulation
of GK and GLUT-2 but up-regulation of UCP-2. GK is the rate- limiting enzyme for 
glycolysis and thereby determines β-cell glucose sensing (see section 3.2) and UCP-2
may act as a protonophore and dissipate the mitochondrial membrane potential, thereby 
uncoupling respiration from ATP synthesis. This would explain the impairment of
GSIS. Induction of SREBP-1c also leads to INS-1 cell growth arrest and apoptosis 
likely due because, as SREBP-1c is a known substrate for caspase 3, it may function as 
a proapoptotic gene in β-cells. The AMPK agonist AICAR increased fatty acid
oxidation and restored TG levels and the impaired GSIS in SREBP-1c-overexpressing
β-cells133, although the effects of AICAR on insulin secretion seem easily influenced by 
experimental conditions, giving opposite results in other studies135.
Taken together, these results provide strong evidence that SREBP-1c mediates 
β-cell dysfunction and may be implicated in the pathogenesis of β-cell glucolipotoxicity 
and Type 2 diabetes. It is hypothesized that as a result of the persistent hyperglycemia 
and hyperinsulinemia present in diabetes, SREBP-1c protein is processed and modified 
to an active form. Activated SREBP-1c alters the expression of various target genes that 
contribute to β-cell dysfunction and therefore exacerbates the progression of Type 
2 diabetes. Development of chemical compounds acting like leptin, PPARγ agonists, 
and metformin through suppression of SREBP-1c function should have therapeutic 
potential in the treatment ofType 2 diabetes and its complications.
11. FATTY ACID IMPORT INTO MITOCHONDRIA
11.1 CELL UPTAKE AND ACTIVATION OF LONG-CHAIN FATTY ACIDS
Long-chain fatty acids are the main energy source for many organs, especially 
muscle and liver. In the liver, oxidation of fatty acids also serves an additional role. It 
produces ketone bodies which are important fuels for extrahepatic organs. Since most 
tissues contain only small amounts of storage lipids, energy production depends on a 
continuous supply of fatty acids, mostly from adipose tissue. Fatty acids are produced 
by lipolysis, transported bound to albumin in blood and taken up by tissues in a process 
135 da Silva Xavier G, Leclerc I, Varadi A, Tsuboi T, Moule SK, Rutter GA. Role for AMP-activated protein kinase 
in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem. J. 371:761-774, 2003
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mediated by transport proteins present in the plasma membrane 136. Once within the cell, 
free fatty acids are bound to fatty acid binding proteins which are present in the cytosol 
in high amounts137. Depending on the tissue and its metabolic demand, fatty acids are 
either converted to triglycerides or membrane phospholipids or oxidized in the
mitochondria for energy production. The β-oxidation of activated fatty acids occurs 
within the mitochondrial matrix and is catalyzed by the sequential action of four 
enzyme families (acyl-CoA dehydrogenase, enoyl-CoA hydratase, 3-hydroxyacyl-CoA
dehydrogenase and 3-ketoacyl-CoA thiolase), each with different substrate specificity 
for short-, medium- and long chain-CoAs138.
Before being directed into storage, membranes or oxidation, fatty acids are first 
activated to acyl-CoAs. This reaction is catalyzed by long-chain acyl-CoA synthetase 
(LCAS), which is abundant in microsomes and mitochondria139. LCAS is associated 
with the mitochondrial outer membrane (MOM) and appears to be a transmembrane 
protein with the active site exposed to the cytosol140.
This orientation of LCAS gives rise to cytosolic production of LC-CoA, which must 
cross both mitochondrial boundary membranes for β-oxidation.
Esterification of carboxylic acids to coenzyme A (CoA) through a thioester bond 
is a common strategy used in metabolic processes to ‘activate’ the relevant metabolite.
This activation has two universal consequences: 1) it renders the acyl-CoA ester 
impermeant through cellular membranes, and 2) it sequesters CoA from the limited 
pools that exist in individual subcellular compartments. As a result, the pools of acyl-
CoA esters are maintained separate in the different cellular compartments, which is 
imperative due to the high biological activity displayed by some of them.
Consequently, the cell has two requirements: 1) a mechanism for the control of CoA 
ester concentrations that is rapid and does not involve the energetically expensive 
hydrolysis and resynthesis of the esters from the free acid, and 2) a system that, after the 
136 Van Nieuwenhoven FA, Van der Vusse GJ, Glatz JFC. Membrane-associated and cytoplasmic fatty acid-binding
proteins. Lipids. 31:S223-S227, 1996
137 Bernlohr DA, Simpson MA, Vogel-Hertzel AV, Banaszak LJ. Intracellular lipid-binding proteins and their genes. 
Annu. Rev. Nutr. 17:277-303, 1997
138 Eaton S, Barlett K, Pourfarzam M . Mammalian mitochondrial β-oxidation. Biochem. J. 320:345-357, 1996
139 Watkins PA. Fatty acid activation. Prog. Lipid Res . 36:55-83, 1997
140 Hesler CB, Olymbios C, Haldar D. Transverse-plane topography of long-chain acyl-CoA synthetase in the 
mitochondrial outer membrane. J. Biol. Chem. 265: 6600-6605, 1990
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initial synthesis of the CoA ester, enables the acyl moiety to permeate membranes 
without the need to re-expend energy.
The cell achieves all these requirements through a single mechanism, the
transesterification between acyl-CoA esters and L-carnitine to form the corresponding 
carnitine ester and regenerate unesterified CoA:
RCO-S-CoA + carnitine-OH RCO-O-carnitine + CoA-SH
These reactions are catalysed by a family of carnitine acyltransferases141. They 
enable the cell to move the required moieties between intracellular compartments while 
keeping its pools of CoA esters distinct in their respective compartments. The enzyme 
involved depends on the length of the fatty acyl moiety to be transported. Carnitine 
acetyltransferase142 (CAT) acts with acetyl-CoA as substrate, while carnitine
octanoyltransferase (COT) facilitates the transport of medium-chain fatty acids (C8-
C10) from peroxisomes to mitochondria through the conversion of shortened fatty acyl-
CoA from peroxisomal β-oxidation into fatty acylcarnitine 143. Peroxisomal β-oxidation
does not directly provide energy but is able to shorten very long-chain fatty acids, thus 
allowing their subsequent mitochondrial β-oxidation. It also has a detoxifying action by 
oxidizing molecules such as eicosanoids and xenobiotics. Finally, carnitine
palmitoyltransferases144 (CPTs) I and II facilitate the transport of long-chain acyl groups
(C16) into the mitochondrial matrix, where they undergo β-oxidation.
One characteristic that differentiates the various carnitine acyltransferases
activities is their sensitivity to inhibition by malonyl-CoA. CPTI and COT are sensitive
to malonyl-CoA, while CAT and CPTII are not144.
141 Zammit VA. Carnitine acyltransferases: functional significance of subcellular distribution and membrane
topology. Progress in lipid research. 38:199-224, 1999
142 Bieber LL. Carnitine. Annu.Rev. Biochem . 57:261-283, 1988
143 Ferdinandusse S, Mulders J, Ijlst L, Denis S, Dacremont G, Waterham HR, Wanders RJ. Molecular cloning and 
expression of human carnitine octanoyltransferase: evidence for its role in the peroxisomal β-oxidation of branched-
chain fatty acids. Biochem. Biophys. Res. Commun. 263:213-218, 1999
144 McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular 
analysis. Eur. J. Biochem. 244:1-14, 1997
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11.2 CARNITINE PALMITOYLTRANSFERASE SYSTEM
The carnitine-dependent transport of activated fatty acids precedes their β-
oxidative chain shortening. This transport system consists of three proteins145, CPTI,
carnitine:acylcarnitine translocase (CACT) and CPTII, each with a different
submitochondrial localization. As a first step, LC-CoAs formed by the catalytic action 
of LCAS in the MOM are converted to acylcarnitines. This transesterification is
catalyzed by transmembrane CPTI protein, also localized in the MOM. The reaction 
products, LC-acylcarnitines, are then translocated into the mitochondrial matrix in an 
exchange reaction catalyzed by CACT, an integral inner membrane protein. Within the 
matrix the acylcarnitines are then reconverted to the respective acyl-CoAs by CPTII, an 
enzyme associated with the inner leaflet of the mitochondrial inner membrane (MIM) 
(Fig. 9).
Fig. 9. LC-CoA translocation into the mitochondria by the carnitine palmitoyltransferase system. Long-chain
fatty acids (LCFA) are activated to LC-CoA by the action of the acyl-CoA synthetase (ACS). Transport of LC-CoA
from the cytosol to the mitochondrial matrix involves the conversion of LC-CoA to acylcarnitines by CPTI, 
translocation across the mitochondrial inner membrane by the carnitine:acylcarnitine translocase (CACT) and
reconversion to LC-CoA by CPTII. MOM: mitochondrial outer membrane; MIM: mitochondrial inner membrane.
145 Kerner J, Hoppel C. Fatty acid import into mitochondria. Review. Biochimica et Biophysica Acta. 1486:1-17,
2000
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CPTI is tightly regulated by its physiological inhibitor malonyl-CoA, and thus 
CPTI is the most physiologically important regulatory step in mitochondrial fatty acid
oxidation146. This process allows the cell to signal the relative availability of lipid and 
carbohydrate fuels in liver, heart, skeletal muscle, and pancreatic β-cells147 and converts 
CPTI into a potential pharmacological target for the treatment of metabolic disorders 
such as coronary diseases and diabetes148.
11.2.1 CPTI isoforms and distribution
Mammals express two isoforms of CPTI, a liver isoform (LCPTI) 149,150 and a
heart/skeletal muscle isoform (MCPTI)151,152, which are the products of two different 
genes. The human codifying genes are localized at the 11q13 (LCPTI) and 22q13.3 
(MCPTI) chromosomes153. LCPTI protein contains 773 amino acids (88 kDa) and
MCPTI is a protein of 772 amino acids (88 kDa). The identity in amino acids residues is 
high (62%) but they are differentially regulated by malonyl-CoA. The LCPTI isoform is 
inhibited by malonyl-CoA to a much lesser extent than the MCPTI isoform (the IC50
value for MCPTI is about 2 orders of magnitude lower than for LCPTI)154. This
146 McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Annu. Rev. 
Biochem. 49:395-420, 1980
147 Zammit VA. The malonyl-CoA-long-chain acyl-CoA axis in the maintenance of mammalian cell function.
Biochem. J. 343:505-515, 1999
148 Ruderman NB, Saha AK, Vavvas D, Witters LA. Malonyl-CoA, fuel sensing, and insulin resistance. Am. J. 
Physiol. 276:E1-E18, 1999
149 Esser V, Britton CH, Weis BC, Foster DW, McGarry JD. Cloning and sequencing and expression of a cDNA 
encoding rat liver carnitine palmitoyltransferase I. J. Biol. Chem. 268:5817-5822, 1993
150 Britton CH., Schultz RA., Zhang B. Esser V. Foster DW. and McGarry JD. Human liver mitochondrial carnitine 
palmitoyltransferase I: characterization of its cDNA and chromosomal localization and partial analysis of the gene. 
Proc. Natl. Acad. Sci. USA. 92:1984-1988, 1995
151 Yamazaki N, Shinohara Y, Shima A, Terada H. High expression of a novel carnitine palmitoyltransferase I like 
protein in rat brown adipose tissue and heart: isolation and characterization of its cDNA clone. FEBBS Lett. 363:41-
45, 1995
152 Yamazaki N, Shinohara Y, Shima A, Yamanaka Y, Terada H. Isolation and characterization of cDNA and 
genomic clones encoding human muscle type carnitine palmitoyltransferase I. Biochim. Biophys. Acta. 1307:157-161,
1996
153 Britton CH, Mackey DW, Esser V, Foster DW, Burns DK, Yarnall DP, Froguel P, McGarry JD. Fine
chromosome mapping of the genes for human liver and muscle carnitine palmitoyltransferase I (CPT1A and CPT1B). 
Genomics. 40:209-211, 1997
154 Esser V, Brown NF, Cowan AT, Foster DW, McGarry JD. Expression of a cDNA isolated from rat brown adipose 
tissue and heart identifies the product as muscle isoform of carnitine palmitoyltransferase I (M-CPTI). M -CPTI is the 
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property is probably involved in the finer regulation of fatty acid oxidation in heart and 
skeletal muscle in comparison to liver. 
Recently a novel CPTI family member (CPTIc) has been described which is 
mainly expressed in brain and testis 155. The protein sequence contains all the residues 
known to be important for both carnitine acyltransferase activity and malonyl-CoA
binding in other family members. However, yeast-expressed protein had no detectable 
catalytic activity with several different acyl-CoA esters that are good substrates for 
other carnitine acyltransferases, while displaying high-affinity malonyl-CoA binding. It 
is hypothesized that this novel CPTI related protein may be specialized for the
metabolism of a distinct class of fatty acids involved in brain function and/or appetite 
control.
The distribution and kinetic characteristics of the mitochondrial CPTI enzymes 
are summarized in the next table:
predominant CPTI isoform expressed in both white (epididymal) and brown adipocytes. J. Biol. Chem. 271:6972-
6977, 1996
155 Price NT, van der Leij FR, Jackson VN, Corstorphine CG, Thomson R, Sorensen A, Zammit V. A novel brain-
expressed protein related to carnitine palmitoyltransferase I. Genomics. 80:433-442, 2002
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LCPTI MCPTI CPTII CPTIc
Mass 88 kDa 88 kDa 70 kDa 88 kDa
Malonyl-CoA IC50 2.5 µM 0.03 µM −
Carnitine Km 30 µM 500 µM 120 µM
Human chromosome locus 11q13 22q13.3 1p32 19q13.33
Tissue expression
Liver ++++  −  +
Skeletal muscle (+)  ++++  + 
Heart +  +++  + 
Kidney ++++  (+)  + 
Lung ++++  (+)  + 
Spleen ++++  −  + 
Intestine ++++  −  +  (+) 
Pancreas (islets and acinar) ++++  −  + 
Brown adipose tissue (+)  ++++  + 
White adipocytes +  +++  + 
Ovary ++++  (+)  +  (+) 
Testis (+)  ++++  +  (+) 
Human fibroblasts ++++  −  + 
Brain: +
Cerebellum −  ++++  +  − 
 
Human deficiency described:yes no yes no
Table 1. Overview of mitochondrial CPTI enzymes. Relative levels of CPTI isoform expression for each organ are 
based on northern blot analysis (and in some cases [3H]etomoxir-CoA labelling), but do not indicate precise ratios. 
(+), trace expression compared with the alternative isoform; −, undetected. Tissue expression data refer to the rat, 
except in the case of fibroblasts and brain. The Km for carnitine of CPTII was measured after solubilization of 
mitochondria in 1% octyl glucoside and therefore should not be compared directly with the values for CPTI. Table
obtained from144 with some modifications.
11.3 CPTI REGULATION
11.3.1 Regulation at transcriptional level
Changes in CPTI mRNA levels are related with changes in the glucagon/insulin
ratios and are associated with elevated levels of NEFA and decreased glucose
availability156. Physiological concentrations of fatty acids induced rapid CPTI gene
156 Park EA, Mynatt RL, Cook GD, Kashfi K. Insulin regulates enzyme activity, malonyl-CoA sensitivity and mRNA 
abundance of hepatic carnitine palmitoyltransferase-I. Biochem. J. 310:853-858, 1995
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expression in pancreatic β-cells. However, fatty acid metabolism beyond LC-CoA
formation was not required for the induction97, 157.
The transcriptional effects of fatty acids may be mediated through PPARα158
although this is controversial107. Functional peroxisome proliferator response elements 
(PPRE) have been identified in the regulatory region of numerous genes encoding
enzymes involved in lipid metabolism159 including CPTI160,161.
11.3.2 Malonyl-CoA dependent regulation
CPTI exerts is believed to exert its control as the rate limiting step in fatty acid 
oxidation via changes in concentration of malonyl-CoA (acute or short-term control) 
and/or through changes in the sensitivity of CPTI to inhibition by malonyl-CoA (long-
term control).
If tissue malonyl-CoA concentrations play a key role in the rapid adjustment in 
fatty acid oxidation rates, then the reactions producing and/or disposing of malonyl-
CoA also must be subject to acute regulation. The formation of malonyl-CoA is
catalyzed by ACC, which is expressed in two isoforms (ACCα and ACCβ). ACCα
predominates in lipogenic tissues while ACCβ  is the predominant form in heart and 
skeletal muscle 162. There is an interesting correlation between the tissue distribution of 
the L and M CPTI isoforms and the α and β  ACC isoforms163. ACCα predominates in 
those tissues where LCPTI also predominates, while ACCβ  is present where MCPTI is 
mainly expressed. Isoform expression appears to depend on the particular metabolite 
157 Chatelain F, Kohl C, Esser V, McGarry JD, Girard J, Pegorier JP. Cyclic AMP and fatty acids increase carnitine 
palmitoyltransferase I gene transcription in cultured fetal rat hepatocytes. Eur. J. Biochem. 235:789-798, 1996
158 Gulick T, Cresci S, Caira T, Moore DD, Nelly DP. The peroxisome proliferator-activated receptor regulates 
mitochondrial fatty acid oxidative enzyme gene expression. Proc. Natl. Acad. Sci. USA. 91:11012-11016, 1994
159 Latruffe N, Vamecq J. Peroxisome proliferators and peroxisome proliferator activated (PPARs) as regulators of 
lipid metabolism. Biochemie. 79:81-84, 1997
160 Brady PS, Marine KA, Brady LJ, Ramsay RR. Co-ordinate induction of hepatic mitochondrial and peroxisomal 
carnitine acyltransferase synthesis by diet and drugs. Biochem. J. 260:93-100, 1989
161 Marcaro C, Acosta E, Ortiz JA, Marrero PF, Hegardt FG, Haro D. Control of human muscle-type carnitine 
palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J. Biol. Chem. 273:8560-
8563, 1998
162 Brownsey RW, Zhande R, Boone AN. Isoforms of acetyl-CoA carboxylase: structures, regulatory properties and 
metabolic functions. Biochem. Soc. Trans. 25:1232-1238, 1997
163 Zammit V. The malonyl-CoA-long-chain acyl-CoA axis in the maintenance of mammalian cell function.
Biochem. J. 343:505-515, 1999
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requirement of the different tissues. The activity of ACC isoforms is subject to acute 
control by rapid covalent modification of the enzyme (inactivation and activation by 
phosphorylation and dephosphorylation, respectively) and by feed-forward activation by 
citrate and feed-back inhibition by LC-CoA164. When energy supply is scarce, the
enzymes responsible for producing malonyl-CoA and synthesizing fatty acids are 
inhibited while MCD is activated. This enzyme catalyzes the conversion of malonyl-
CoA to acetyl-CoA and has a critical role in the regulation of intracellular malonyl-CoA
concentration165.
11.3.2.1 Abolition of malonyl-CoA sensitivity: mutation of methionine 593
Various groups have attempted to establish the basis of the LCPTI/malonyl-CoA
interactions. From studies on the pH dependence of the affinity of CPTI for its substrate
and from the ability of palmitoyl-CoA to displace [14C]malonyl-CoA bound to skeletal 
muscle mitochondria, it was hypothesized166 that the palmitoyl-CoA and malonyl-CoA
bind at different sites. A number of studies have shown that in rat liver CPTI there are
two malonyl-CoA binding sites: one with greater capacity for binding and regulation of 
the inhibitor and not susceptible to competition from acyl-CoA, which behaves as an 
allosteric component 167; and a second acyl-CoA binding site, which is located near the
catalytic site168.
Either the C-terminus or the N-terminus of LCPTI have been shown to influence
the enzyme/inhibitor interaction169,170. On the basis of these studies, it was proposed that 
164 Allred JB, Reilly KE. Short-term regulation of acetyl-CoA carboxylase in tissues of higher animals. Prog. Lipid 
Res. 35:371-385, 1997
165 Dyck JRB, Berthiaume LG, Thomas PD, Kantor PF, Barr AJ, Barr R, Singh D, Hopkins TA, Voilley N, Prentki 
M, Lopaschuk GD. Characterization of rat liver malonyl-CoA decarboxylase and the study of its role in regulating 
fatty acid metabolism. Biochem. J. 350:599-608, 2000
166 Mills SE, Foster DW, McGarry JD. Effects of pH on the interaction of substrates and malonyl-CoA with 
mitochondrial carnitine palmitoyltransferase I. Biochem. J. 219:601-608, 1984
167 Cook GA, Mynatt RL, Kashfi K. Yonetani-Theorell analysis of hepatic carnitine palmitoyltransferase-I inhibition 
indicates two distinct inhibitory binding sites. J. Biol. Chem. 269:8803-8807, 1994
168 Grantham BD, Zammit VA. Binding of [14C]malonyl-CoA to rat liver mitochondria after blocking of the active 
site of carnitine palmitoyltransferase I. Displacement of low-affinity binding by palmitoyl-CoA. Biochem. J. 233:589-
593, 1986
169 Jackson VN, Zammit VA, Price NT. Identification of positive and negative determinants of malonyl-CoA
sensitivity and carnitine affinity within the amino termini of rat liver- and muscle-type carnitine palmitoyltransferase 
I. J. Biol. Chem. 275:38410-38416, 2000
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the two malonyl-CoA inhibitable domains might be located at the C-terminus as 
suggested by several kinetic studies. The development of a CPTI catalytic core model171
allowed our group to assign the low-affinity binding site to a domain near the catalytic
channel in which palmitoyl-CoA is bound, containing the catalytic acyl-CoA binding 
domain172.
A recent study by our group 173 used the SequenceSpace algorithm program to 
identify the amino acid residue methionine  593 (Met593), which contributed to the 
sensitivity of CPTI to malonyl-CoA. The site-directed mutagenesis study used to
identify amino acids responsible for malonyl-CoA inhibition is based on the comparison
of the sequences in a range of carnitine and choline acyltransferases, taking the positive 
or negative sensitivity to malonyl-CoA as a discriminatory criterion (Fig. 10). The
proposal was based on the finding that the amino acid Met593 is present in malonyl-CoA-
inhibitable carnitine acyltransferases (CPTI, isoforms L and M, and COT) from various
organisms and absent in non-inhibitable acyltransferases (CPTII, CAT, and choline
acetyltransferase (ChAT)).
Mutation of the amino acid Met593 to its counterpart in CPTII, serine (Ser)
showed that the mutation by itself, M593S, practically abolished malonyl-CoA
sensitivity of LCPTI when this mutated LCPTI was expressed in yeast (80% activity at 
100 µM malonyl-CoA). It is interesting that this mutant showed higher catalytic
efficiency for palmitoyl-CoA as substrate than the wild type. It is proposed that the 
occurrence of Ser in this position has probably been evolutionary conserved in non-
malonyl-CoA-sensitive carnitine acyltransferases because it prevents sensitivity to
malonyl-CoA.
170 Shi J, Zhu H, Arvidson DN, Woldegiorgis G. The first 28 N-terminal amino acid residues of human heart muscle 
carnitine palmitoyltransferase I are essential for malonyl CoA sensitivity and high-affinity binding. Biochemistry.
39:712-717, 2000
171 Morillas M, Gómez-Puertas P, Roca R, Serra D, Asins G, Valencia A, Hegardt FG. Structural model of the 
catalytic core of carnitine palmitoyltransferase I and carnitine octanoyltransferase (COT): mutation of CPTI histidine 
473 and alanine 381 and COT alanine 238 impairs the catalytic activity. J. Biol. Chem. 276:45001-45008, 2001
172 Morillas M, Gómez-Puertas P, Rubí B, Clotet J, Ariño J, Valencia A, Hegardt FG, Serra D, Asins G. Structural 
model of a malonyl-CoA-binding site of carnitine octanoyltransferase and carnitine palmitoyltransferase I: mutational 
analysis of a malonyl-CoA affinity domain. J. Biol. Chem. 277:11473-11480, 2002
173 Morillas M, Gomez-Puertas P, Bentebibel A, Selles E, Casals N, Valencia A, Hegardt FG, Asins G, Serra D. 
Identification of conserved amino acid residues in rat liver carnitine palmitoyltransferase I critical for malonyl-CoA
inhibition. Mutation of methionine 593 abolishes malonyl-CoA inhibition. J. Biol. Chem. 278:9058-9063, 2003
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Fig. 10. Alignment of representative sequences of mammalian carnitine-choline acyltransferases. Amino acid 
sequence of 18 representative members of the malonyl-CoA inhibitable enzymes: LCPTI (CPT1) from rat, mouse, 
and human; MCPTI (CPTM) from human, rat, and mouse; and COT (OCTC) from human, bovine and rat; and the 
malonyl-CoA-insensitive enzymes: CPTII (CPT2) from rat, mouse, and human; CAT (CACP) from human and 
mouse and ChAT (CLAT) from human, pig, rat, and mouse are aligned. The subfamily conserved residue (methionine
or serine) according to malonyl-CoA regulation are shaded. Table obtained from173 with some modifications.
In the present study the malonyl-CoA insensitive form of LCPTI (LCPTI
M593S) was overexpressed in pancreatic β-cells to test the hypothesis that the
CPTI/malonyl-CoA interaction is involved in GSIS.
11.3.3 Malonyl-CoA independent regulation
In addition to the malonyl-CoA dependent control of mitochondrial fatty acid 
oxidation, other malonyl-CoA independent mechanisms of CPTI activity regulation
have been described.
It has been suggested that CPTI is regulated by direct phosporylation174,175.
Another mechanism proposed involves direct interaction of cytoskeletal proteins with 
174 Guzman M, Geelen MJH. Activity of carnitine palmitoyltransferase in mitochondrial outer membranes and 
peroxisomes in digitonin-permeabilized hepatocytes. Biochem. J. 287:487-492, 1992
175 Kerner J, Distler AM, Minkler PE, Parland W, Peterman SM, Hoppel CL. Phosphorylation of rat liver
mitochondrial carnitine palmitoyltransferase-I (CPT-I): Effect on the kinetic properties of the enzyme.
J. Biol.Chem. 279:41104-41113, 2004
CPT1_RAT    460 VVFKNSKIGINAEHSWADAPIVGHLWEYV 488  584 KFCLTYEASMTRLFREGRTETVRSCTME 611
CPT1_MOUSE  451 VVFKNSKIGINAEHSWADAPIVGHLWEYV 479  575 KFCLTYEASMTRLFREGRTETVRSCTTE 602
CPT1_HUMAN  460 VVFKNGKMGLNAEHSWADAQIVAHLWEYV 488  584 KFCLTYEASMTRLFREGRTETVRSCTTE 611
CPTM_HUMAN  460 ISFKNGQLGLNAEHAWADAPIIGHLWEFV 488  584 KFCLTYEASMTRMFREGRTETVRSCTSE 611
CPTM_RAT    460 ISCKNGQLGLNTEHSWADAPIIGHLWEFV 488  584 KFCLTYEASMTRMFREGRTETVRSCTSE 611
CPTM_MOUSE  460 ISCKNGLLGLNTEHSWADAPIIGHLWEFV 488  584 KFCLTYEASMTRMFREGRTETVRSCTNE 611
OCTC_HUMAN  314 ISFSNGVFGCNCDHAPFDAMIMVNISYYV 342  434 HPGCCYETAMTRHFYHGRTETMRSCTVE 461
OCTC_BOVIN  314 IAFSNGVFGSNCDHAPFDAMVLVKVCYYV 342  434 RPGCCYETAMTRLFYHGRTETVRPCTVE 461
OCTC_RAT    314 ISFANGIFGCSCDHAPYDAMLMVNIAHYV 342  434 RPGCCYETAMTRYFYHGRTETVRSCTVE 461
CPT2_RAT    359 IVAEDGTAAVHFEHSWGDGVAVLRFFNEV 387  481 QTVATYESCSTAAFKHGRTETIRPASIF 508
CPT2_MOUSE  359 IVAKDGTAAVHFEHAWGDGVAVLRFFNEV 387  481 QTVATYESCSTAAFKHGRTETICPASIF 508
CPT2_HUMAN  359 IIAKDGSTAVHFEHSWGDGVAVLRFFNEV 387  481 QTVATYESCSTAAFKHGRTETIRPASVY 508
CACP_HUMAN  328 IVAEDGSCGLVYEHAAAEGFPIVTLLDYV 356  445 QACATYESASLRMFHLGRTDTIRSASMD 472
CACP_MOUSE  331 IVAEDGSCGMVYEHAAAEGPPIVALVDHV 359  448 QACATYESASLRMFHLGRTDTIRSASID 475
CLAT_MOUSE  321 VVGRDGTCGVVCEHSPFDGIVLVQCTEHL 349  441 RLVPTYESASIRRFQEGRVDNIRSATPE 468
CLAT_RAT    320 VVGRDGTCGVVCEHSPFDGIVLVQCTEHL 348  440 RLVPTYESASIRRFQEGRVDNIRSATPE 467
CLAT_PIG    321 VVGRDGTCGVVCEHSPFDGIVLVQCTEHL 349  441 RLVPTYESASIRRFHEGRVDNIRSATPE 468
CLAT_HUMAN  429 VVGRDATCGVVCEHSPFDGIVLVQCTEHL 457  549 RLVPTYESASIRRFQEGRVDNIRSATPE 576
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CPTI in the mitochondrial outer membrane176,177. Other studies provide supportive
evidence for stimulation of CPTI by AMPK via phosporylation of cytoskeletal
components178,179. They propose that Ca2+/calmodulin-dependent protein kinase II and 
possibly AMPK play a central role, not only by activating CPTI but also by
phosphorylating (inactivating) ACC, and therefore reinforcing CPTI activation by
decreasing tissue malonyl-CoA concentrations. Finally, malonyl-CoA independent
regulation of CPTI has been observed, which involves extramitochondrial factors180, but 
the mechanism has not been established. 
11.3.4 Pharmacological regulation
Inhibition of fatty acid oxidation is clearly an effective strategy for lowering 
blood glucose levels in diabetic animal models and in NIDDM itself. However,
approaches to the direct inhibition of fatty acid oxidation at the level of β-oxidation
have so far been unsuccessful due to toxicities and uncontrolled hypoglycemia.
Attention has therefore been directed towards an intermediate step, the CPT system. The
inhibition of CPTI seems to be a viable target181 for the treatment of Type 2 diabetes.
Etomoxir is one of the most extensively studied CPTI inhibitors. It acts as an
irreversible, active site-directed inhibitor of liver, heart and skeletal muscle CPTI and is 
functionally active only after metabolic conversion to its CoA-ester, etomoxiryl-CoA182.
176 Guzmán M, Velasco G, Geelen MJH. Do cytoskeletal components control fatty acid translocation into liver 
mitochondria? Trends Endocrinol. Metab. 11:49-53, 2000
177 Velasco G, Geelen MJH, Gomez del Pulgar T, Guzman M. Malonyl-CoA-independent acute control of hepatic 
carnitine palmitoyltransferase I activity. J. Biol. Chem. 273:21497-21504, 1998
178 Velasco G, Geelen MJH, Guzman M. Control of hepatic fatty acid oxidation by 5’-AMP-activated protein kinase 
involves a malonyl-CoA-dependent and a malonyl-CoA-independent mechanism. Arch. Biochem. Biophys . 337:169-
175, 1997
179 Velasco G, Gomez del Pulgar T, Carling M, Guzman M. Evidence that the AMP-activated protein kinase 
stimulates rat liver carnitine palmitoyltransferase I by phosphorylating cytoskeletal components. FEBS Lett. 439:317-
320, 1998
180 Sleboda J, Risan KA, Spydevold O, Bremen J. Short-term regulation of carnitine palmitoyltransferase I in 
cultured rat hepatocytes: spontaneous inactivation and reactivation by fatty acids. Biochim. Biophys. Acta. 1436:541-
594, 1999
181 Anderson RC. Carnitine palmitoyltransferase: A viable target for the treatment of NIDDM? Curr. Pharmacut. 
Design 4:1-15, 1998
182 Weis BC, Cowan AT, Brown N, Foster DW, McGarry JD. Use of a selective inhibitor of liver carnitine 
palmitoyltransferase I (CPT I) allows quantification of its contribution to total CPT I activity in rat heart. Evidence 
Introduction
52
Etomoxir is an orally effective inhibitor of fatty acid oxidation in liver and muscle 
tissues, thereby giving rise to antiketogenic and hypoglycemic activity in animal models 
of NIDDM. It has been shown to improve insulin sensitivity in NIDDM patients183.
However, the drug has not been developed as an antidiabetic agent, probably because 
mechanism-based myocardial hypertrophy was associated with its use. Therefore, major 
efforts are required to develop alternative agents targeted at this site. 
Finally, a novel compound, the FAS inhibitor C75, has been proposed to
pharmacologically regulate CPTI activity (see Section 13.3).
12. TETRACYCLINE-REGULATED INDUCIBLE GENE
EXPRESSION SYSTEM
The ability to express gene products in a temporally restricted manner has been 
an essential experimental strategy in determining gene function in tissue culture and in
vivo. The best-characterized and most versatile inducible approaches use the
tetracycline (tet)-mediated expression systems. The first tet-regulated gene expression 
system for use in mammalian cells was developed by Gossen and Bujard184 and it has 
been widely applied in cultured cells from mammals, plants, amphibians and insects as 
well as in whole organisms including yeast, Drosophila, plants, mice and rats, or 
implemented in viral vectors. Nowadays these Tet systems are commercially
available185.
The Tet system has two central components: transcriptional transactivators that 
interact specifically with bacterial cis regulatory elements, and antibiotics that modulate 
the binding of the transactivators at low, non-toxic doses. These rely on the specific, 
high-affinity binding of the Escherichia Coli Tet repressor protein (TetR), or its
derivatives, to the tet resistance operator of Tn10 (TetO). When TetR is fused to the 
herpes simplex virus VP16 activation domain, the hybrid TetR/VP16 protein becomes a 
powerful tet-responsive transactivator (tTA). In the absence of tet or its analogs as 
that the dominant cardiac CPT I isoform is identical to the skeletal muscle enzyme. J. Biol. Chem. 269:26443-26448,
1994
183 Hubinger A, Weikert G, Wolf HP, Gries FA. The effect of etomoxir on insulin sensitivity in type 2 diabetic 
patients. Horm. Metab. Res. 24:115-118, 1992
184 Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. 
Proc. Natl. Acad. Sci. USA. 89:5547-5551, 1992
185 Clontech Laboratories, Inc., Palo Alto, California 94303
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doxycycline (dox), the tTA protein binds TetO and initiates transcription from artificial 
promoters containing these sequences as the PhCMV*-1 promoter. The PhCMV*-1 contains
the tet responsive element (TRE), which consists of seven copies of the 42-bp TetO, and 
the minimal cytomegalovirus promoter (PminCMV), which lacks the enhancer that is part 
of the complete CMV promoter. In the presence of the antibiotic, the tTA binds the 
drug, resulting in a conformational change that disrupts DNA binding and inactivates 
transcription. This is called the Tet-off system. 
A second tet-regulated system was developed to address biological problems 
where prolonged exposure to antibiotics is undesirable (such as during development, in
gene therapy or in transgenic animals) or to express potentially toxic target genes during 
very discrete periods of time. Random mutagenesis of the TetR gene produced a protein 
that bound to TetO sequences only in the presence of the tet analog doxycycline186.
Fusion of this mutant to VP16 produced a reverse tTA (rtTA), a protein that required 
drug interaction to bind TetO sequences and activate transcription. This is called the 
Tet-on system (Fig. 11).
Fig. 11. Schematic representation of the Tet-on system. The reverse tetracycline-controlled transactivator (rtTA) is 
composed of the reverse tetracycline repressor (rTetR) and the VP16 moiety, driven by an appropriate promoter. In 
the absence of the effector doxycycline (dox), the transactivator does not recognize its specific DNA target sequence,
tetracycline operator (TetO); therefore, transcriptional activation of the target gene will not occur (right). Addition of 
the effector dox results in binding of rtTA to TetO, which allows the activation of the reporter unit (left). The 
promoter PhCMV*-1 consits of seven copies of TetO located upstream of a minimal sequence of the CMV promoter
(PminCMV).
186 Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in 
mammalian cells. Science. 268:1766-1769, 1995
TetO PminCMV Target gene
Promoter rTetR VP16
rtTA
+dox
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When considering properties of the Tet system, such as degree (tightness) of 
control, expression levels and regulation factors, it is crucial to distinguish between 
experimental situations in which the systems are stably inserted in the genome of cells 
in culture or of transgenic organisms, and situations in which the respective regulatory 
elements are in a nonintegrated state, as in transient expression experiments or when 
contained in episomes187. Therefore, the control of gene activity can be achieved with 
the Tet systems whenever the experimental strategy permits screening or selection for 
events in which the expression unit carrying the target gene is  integrated into a proper 
chromosomal site. In transient expression, i.e., when the target gene controlled by the
PhCMV*-1 is not integrated in the chromosome, an intrinsic basal activity is observed that 
can reach considerable levels depending on the cell type and experimental conditions 188.
Further analysis of rtTA has revealed that this transactivator has indeed a low 
residual affinity for TetO in the absence of dox, and that this affinity can cause an 
elevated basal activity of the PhCMV*-1 depending on the intracellular concentration of 
rtTA187. These findings have sparked a reinvestigation of the sequence space of TetR, 
which yielded a second generation of rtTAs189,190.
The Tet system has been applied to produce transgenic mice by improving the 
Cre/lox recombination system in which the genetic changes are irreversible and follow a 
program that cannot be influenced after its onset191. For instance, pancreatic studies
show the effectiveness and utility of the Tet-on system in β-cell transplantation192 and in 
187 Baron U, Bujard H. Tet Repressor-based system for regulated gene expression in eukaryotic cells: principles and 
advances. Methods in enzymology, 327:401-421, 2000
188 Freundlieb S, Schirra-Müller C, Bujard H. A tetracycline controlled activation/repression system with increased 
potential for gene transfer into mammalian cells. J. Gene Med. 1:4-12, 1999
189 Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W. Exploring the sequence space for 
tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc. Natl. 
Acad. Sci. USA. 97:7963-7968, 2000
190 Stebbins MJ, Urlinger S, Byrne G, Bello B, Hillen W, Yin JCP. Tetracycline-inducible systems for Drosophila. 
Proc. Natl. Sci. USA. 98:10775-10780, 2001
191 Kistner A, Gossen M, Zimmermann F, Ferecic J, Ullmer C, Lübbert H, Bujard H. Doxycycline-mediated
quantitative and tissue-specific control of gene expression in transgenic mice. Proc. Natl. Sci. USA. 93:10933-10938,
1996
192 Milo-Landesman D, Surana M, Berkovich I, Compagni A, Christofori G, Fleischer N, Efrat S. Correction of 
hyperglycemia in diabetic mice transplanted with reversibly immortalized pancreatic beta cells controlled by the tet -
on regulatory system. Cell Transplant. 10:645-650, 2001
Introduction
55
transgenic mice where the target gene was expressed under the rat or mouse insulin 
promoter193,194.
In the present study we decided to utilize the Tet-on system to generate an
LCPTI β-cell stable cell line because of the simplicity of the system and the non-toxic
effect of doxycycline at the effective concentrations used. The  induction of the system 
in cultured cells is fast as it depends largely on the diffusion constant of the antibiotic.
13. C75, THE FATTY ACID SYNTHASE INHIBITOR
C75 is a chemically stable synthetic inhibitor of fatty acid synthase (FAS) 
derived from cerulenin, a natural FAS inhibitor obtained from the fungus
Cephalosporium caerulens. It binds irreversibly to the catalytic site of both type I 
(mammalian and yeast) and type II (bacterial) FAS, by covalent modification of the β-
ketoacyl-acyl carrier protein synthase domain195,196. Structurally, C75 is a cell-
permeable α-methylene-γ-butyrolactone, designed to be less reactive and potentially 
safer than cerulenin. It lacks the reactive epoxide present on cerulenin, which enhances 
chemical stability and specificity allowing its use as a drug (See Fig. 14). Cerulenin,
(2R, 3S)-2,3-epoxy-4-oxo-7,10-transdodecadienamide, irreversibly inhibits FAS by
forming a covalent adduct with FAS, whereas C75 is probably a slow-binding
inhibitor197.
13.1 C75 AS AN ANTITUMOR DRUG
FAS (EC. 2.3.1.85) is the sole enzyme responsible for the de novo synthesis of 
fatty acids from carbohydrates. It catalyzes the reductive synthesis of long-chain fatty 
acids from acetyl-CoA and malonyl-CoA. The mechanism by which two carbon units 
from malonyl-CoA are sequentially added to the growing fatty acid chain is unique 
193 Berkovich I, Efrat S. Inducible and reversible beta-cell autoimmunity and hyperplasia in transgenic mice 
expressing a conditional oncogene. Diabetes . 50:2260-2267, 2001
194 Lottmann H, Vanselow J, Hessabi B, Walther R. The Tet-On system in transgenic mice: inhibition of the mouse 
pdx-1 gene activity by antisense RNA expression in pancreatic beta-cells. J Mol Med. 79:321-328, 2001
195 Moche M, Schneider G, Edwards P, Dehesh K, Lindqvist Y. Structure of the Complex between the Antibiotic 
Cerulenin and Its Target, -Ketoacyl-Acyl Carrier Protein Synthase. J Biol Chem., 274:6031-6034, 1999
196 Price AC, Choi KH, Heath RJ, Li Z, White SW, Rock CO. Inhibition of β-ketoacyl-acyl carrier protein synthases 
by thiolactomycin and cerulein. J. Biol. Chem., 276:6551-6559, 2001
197 Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an 
inhibitor of fatty acid synthase. Proc. Natl. Acad. Sci. USA. 97:3450-3454, 2000
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among vertebrates, making FAS an attractive target for the design of therapeutic agents. 
In fact, elevated expression of FAS and abnormally active endogenous fatty acid
synthetic metabolism are frequent phenotypic alterations in many human cancers,
including carcinomas of breast, prostate, ovary, colon, lung, stomach, skin, and
endometrium198. This differential expression of FAS between normal tissues and cancer 
has led to the notion that FAS is a target for anticancer drug development. 
Therefore, C75 was first developed as an antitumor drug to enable FAS
inhibition and to be tested for in vivo treatment of human cancer xenografts. C75
produced rapid and potent inhibition of DNA replication and S-phase progression in 
human cancer cells leading to apoptosis199. TOFA, 5-(tetradecyloxy)-2-furoic acid, a 
competitive inhibitor of ACC, the rate- limiting enzyme of fatty acid synthesis,
profoundly inhibits fatty acid synthesis, but is essentially non-toxic to cultured human 
cancer cells200.  Moreover, treatment of human cancer cells with TOFA before C75
administration reproducibly rescued them from C75 cytotoxicity, and prevented the C75
induced increase in malonyl-CoA200. Thus, because C75 blocked FAS, increased
malonyl-CoA levels and triggered apoptosis, whereas TOFA blocked the C75 increase 
in malonyl-CoA, protecting the cells from apoptosis, the authors point to high levels of 
malonyl-CoA as proapoptotic. Therefore, C75 acts as an antitumor drug and whereas 
induction of apoptosis in cancer cells appeared related to accumulation of the substrate, 
malonyl-CoA, after FAS inhibition, the cytostatic effects were independent of malonyl-
CoA accumulation and may have resulted from product depletion201.
198 Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition.
16:202-208, 2000
199 Pizer ES, Chrest FJ, DiGiuseppe JA, HanWF. Pharmacological inhibitors of mammalian fatty acid syntase 
suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res. 58:4611-4615, 1998
200 Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, Townsend CA, Kuhajda FP. Malonyl-
coenzyme-A is a potential mediator of cytotoxicity induced by fatty acid synthase inhibition in human breast cancer 
cells and xenografts. Cancer Res. 60:213-218, 2000
201 Li JN,  Gorospe M, Chrest FJ, Kumaravel TS, Evans MK, Han WF, Pizer ES. Pharmacological inhibition of fatty 
acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Research. 61:1493-
1499, 2001
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13.2 CENTRAL EFFECT OF C75
However, a source of great interest in C75, related with obesity and the
mechanism that control appetite and body weight, was the study by Kuhajda’s team202.
Both systemic and intracerebroventricular (ICV) treatment with C75 led to inhibition of 
feeding and dramatic weight loss in lean, diet- induced obese (DIO) and genetically 
obese leptin-deficient (ob/ob) mice. This action was independent of leptin, since C75 
caused profound weight loss in leptin-deficient mice. Lean mice, however, become 
resistant to C75 over the next few days of treatment and exhibit rebound hyperphagia 
upon cessation of treatment. In contrast, obese mice showed incipient tolerance to C75,
which became evident only after substantial weight loss had occurred.
Recent evidence203,204 has implicated malonyl-CoA as a possible mediator in the 
hypothalamic pathway that indicates energy status and mediates the feeding behaviour 
of mice. Thus C75, by increasing malonyl-CoA levels, was found to alter the
metabolism of neurons in the hypothalamus that regulate feeding behaviour. In addition, 
TOFA largely restored food intake in C75-treated mice, supporting the hypothesis that 
malonyl-CoA mediates feeding inhibition.
Energy balance is monitored by the hypothalamus, which responds to peripheral 
status signals by releasing neuropeptides that regulate energy intake and expenditure. 
Restriction of food intake leads to increased expression of the hypothalamic orexigenic 
neuropeptides, neuropeptide Y (NPY), and agouti-related protein (AgRP) mRNAs, and 
decreased expression of the hypothalamic anorexigenic neuropeptides, pro-
opiomelanocortin (POMC), and cocaine-amphetamine-regulated transcript (CART). In 
combination, these changes provoke increased food intake and reduced energy
expenditure. When fasted animals are re-fed, the inverse response occurs (Fig. 12).
202 Loftus TM, Jaworsky DE, Freywot GL, Townsend CA, Ronet GV, Lane MD, Kuhajda FP. Reduced food intake 
and body weight in mice treated with fatty acid synthase inhibitors. Science 288:2379-2381, 2000
203 Gao S, Lane D. Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus 
and brainstem. Proc. Natl. Acad. Sci. USA. 100:5628-5633, 2003
204 Hu Z, Cha SH, Chohnan S, Lane MD. Hypothalamic malonyl-CoA as a mediator of feeding behavior, Proc. Natl. 
Acad. Sci. USA. 100:12624-12629, 2003
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Fig. 12. Model of hypothalamic malonyl -CoA as mediator of expression of orexigenic and anorexigenic 
neuropeptides and food intake.Figure taken from204.
ICV administration of C75 increases cellular malonyl-CoA in the hypothalamus, 
caused by inhibition of FAS, and blocks fasting- induced up-regulation of hypothalamic 
neuropeptide Y, thus reducing food intake202. Furthermore, it appears that C75 exerts its 
short and long-term effects on food intake by preventing the up-regulation of the 
orexigenic neuropeptides and down-regulation of the anorexigenic neuropeptides205,206.
In addition, recent data suggest that modulation of FAS activity by C75 in the
hypothalamus can alter energy perception by reducing AMPK, which functions as a 
physiological energy sensor in the hypothalamus207.
13.3 PERIPHERAL EFFECT OF C75
In addition to its hypothalamic action, it has been reported that C75 reduces in 
fatty liver and adipose tissue mass202. The question was then, how could there be a 
selective reduction in the fat mass of peripheral tissues in the setting of elevated levels 
of malonyl-CoA as a result of FAS inhibition? This paradox was investigated under the 
205 Shimokawa T, Kumar MV, Lane MD. Effect of fatty acid synthase inhibitor on food intake and expression of 
hypothalamic neuropeptides. Proc. Natl. Acad. Sci. USA. 99:66-71, 2002
206 Cha SH, Hu Z, Lane MD. Long-term effects of a fatty acid synthase inhibitor on obese mice: food intake, 
hypothalamic neuropeptides, and UCP3. BBRC. 317:301-308, 2004
207 Kim EK, Miller I, Aja S, Landree LE, Pinn M, McFadden J, Kuhajda FP, Moran TH, Ronnett GV. C75, a fatty 
acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase. J. Biol. Chem.
279:19970-19976, 2004
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hypothesis that C75 might have additional effects on fatty acid oxidation and CPTI 
activity.
C75 was found to increase energy expenditure in DIO mice through an increase 
in fatty acid oxidation, because the use of etomoxir, the irreversible inhibitor of CPTI, 
restored this increase in energy production208. In addition, C75 treatment of rodent
adipocytes and hepatocytes and human breast cancer cells increased fatty acid oxidation 
and ATP levels by increasing CPTI activity, even in the presence of elevated
concentrations of malonyl-CoA. Thus, the authors proposed a second mechanism of 
action for C75 that is outlined in Fig. 13. In the central nervous system, C75 inhibits 
FAS, leading to changes in neuropeptide expression that result in a reduced food intake. 
In peripheral tissues, C75 stimulates CPTI activity, increasing fatty acid oxidation and 
energy production, thus leading to selective reduction of adipose tissue, liver fat and 
weight loss. These data describe, for the first time, a pharmacological agonist of CPTI 
and identify CPTI as a therapeutic target for obesity and Type II diabetes. In addition, it 
has recently been described that long-term treatment with C75 results in increased 
expression of UCP-3 mRNA in skeletal muscle of obese mice, suggesting that this up-
regulation of UCP-3 may increase thermogenesis and thereby, explain the increase in 
energy expenditure206.
Fig. 13. Model proposed by Thupari et al.208 for central and peripheral C75 mechanisms of action. Centrally, 
C75 inhibits FAS, leading to changes in neuropeptide expression that result in a net reduction in food consumption. 
In the peripheral tissues such as liver and adipose tissue, C75 increases CPTI activity, leading to increased fatty acid 
oxidation and energy production. Both mechanisms contribute to weight loss, but the peripheral mechanism is 
responsible for the selective reduction in adipose tissue mass and resolution of fatty liver.
208 Thupari JN, Landree LE, Ronnett GV, Kuhajda FP. C75 increases peripheral energy utilization and fatty acid 
oxidation in diet-induced obesity. Proc. Natl. Acad. Sci. USA. 99:9498-9502, 2002
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The amphipathic nature of C75 may account for the stimulation of CPTI activity
because palmitoyl-CoA, a CPTI substrate that is similarly amphipathic, also activates 
the enzyme, and in excess can reverse malonyl-CoA inhibition209 (Fig. 14).
Interestingly, cerulenin, the natural FAS inhibitor, has only a single dicarbonyl group in 
its cyclized form, it is not amphipathic, and in contrast to C75, it has been described to 
decrease CPTI activity210,211. In the former210, the decrease in CPTI activity was
correlated with a reduction in fatty acid oxidation and an increase in cytotoxicity in 
human breast cancer cells cultured with cerulenin. In the latter211, the authors showed 
that the effect of cerulenin on CPTI activity in mice was biphasic in liver and muscle, 
with an early suppression followed by a late stimulation after intraperitoneal treatment. 
They concluded that cerulenin- induced late-phase stimulating effects on CPTI activity 
were mediated by the activation of the sympathetic nervous system.
Fig. 14. Structures of C75, cerulenin, etomoxir and malonyl -CoA.
209 Bremen J, Woldegiorgis G, Schalinske K, Shrago E. Carnitine palmitoyltransferase. Activation by palmitoyl-CoA
and inactivation by malonyl-CoA. Biochim. Biophys. Acta. 833:9-16, 1985
210 Thupari JN, Pinn ML, Kuhajda FP. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-
CoA-induced inhibition of fatty acid oxidation and cytotoxicity. BBRC. 285:217-223, 2001
211 Jin YJ, Li SZ, Zhao ZS, An JJ, Kim RY, Kim YM, Baik JH, Lim SK. Carnitine palmitoyltransferase-1 (CPT-1)
activity stimulation by cerulenin via sympathetic nervous system activation overrides cerulenin’s peripheral effect. 
Endocrinology. 145:3197-3204, 2004
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In summary, C75 acts both centrally to reduce food intake and peripherally to 
stimulate CPTI activity208,212 and increase fatty acid oxidation, leading to rapid and
profound weight loss, loss of adipose mass and resolution of fatty liver. Thus, in
peripheral tissues in vivo, the inhibitory effect of the high content of malonyl-CoA, due 
to FAS inhibition, on CPTI seems to be overcome by C75-stimulated CPTI activity. 
The present study further examines the C75/CPTI interaction in vitro and in vivo
in the pancreatic β-cell.
212 Yang N, Kays JS, Skillman TR, Burris L, Seng TW, Hammond C. C75 activates carnitine palmitoyltransferase-1
in isolated mitochondria and intact cells without displacement of bound malonyl-CoA. J. Pharmacol. Exp. Ther .
PMID: 15356215, 2004
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OBJECTIVES
The objectives of the present thesis are:
1. Study of the malonyl-CoA/carnitine palmitoyltransferase I interaction in the
pancreatic β  cell and its involvement in glucose- induced insulin secretion.
2. Construction of an INS-1 stable cell line overexpressing LCPTI wt and LCPTI 
M593S.
3. Determine the effect of C75 on the carnitine palmitoyltransferase I activity and 
palmitate oxidation in pancreatic β-cells.

MATERIALS AND METHODS
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MATERIALS AND METHODS
1. DNA AND RNA BASIC TECHNIQUES
1.1 BACTERIAL STRAINS
Three bacterial strains of Escherichia coli were used in this study: DH5α, XL1-
Blue and DM1.
Strain    Genotype Resistant to
DH5α  sup E44, ∆lacU169 (φ80 lac Z∆M15), hsd R17, rec A1, Ampicillin
gyr A96, thi-1, rel A1
XL1-Blue end A1, hsd  R17 (rk-, mk+), sup E44, thi-1, ?-, rec  A1, Tetracycline
gyr A96, rel A1, lac-[F’, pro  AB, lac/q Z∆M15, Tn10(tetr)]
DM1 F- dam-13: dcm mcrB hsd R-M+ gal1 gal2 ara lac thr leu Ampicillin
 tonr tsxr Su0 λ-
The DM1 strain lacks the dam and dcm methylases which methylate the adenine 
residues in the sequence GATC and the internal cytosine residues in the sequence 
CCAGG and CCTGG. This lack of dam and dcm methylation allows DNA propagating
in DM1 to be cleaved by a variety of restriction endonucleases that are sensitive to 
methylated recognition sequences such as BclI, MboI, NdeII and EcoRI.
1.2 PLASMID AND COSMID VECTORS
The following plasmid and cosmid vectors were used for cloning strategies:
A) pTRE2 plasmid vector
pTRE2 plasmid vector (Clontech, ref. 6241-1) is a response plasmid of 3.8 kbp 
encoding the tetracycline-response element (TRE) that can be used to express a gene of 
interest upon activation by either the tTA (tetracycline transactivator) or the rtTA
Materials and methods
70
(reverse tTA) regulatory protein in a tetracycline-regulated expression system1, Tet-off
or Tet-on, respectively.
pTRE2 (Fig. 1) contains the ampicillin- resistance gene and a multiple cloning 
site (MCS) immediately downstream of the Tet-responsive PhCMV*-1 (human
cytomegalovirus) promoter. cDNAs or genes inserted into the MCS will be responsive 
to the tTA and rtTA regulatory proteins in the Tet-off and Tet-on systems, respectively. 
PhCMV*-1 contains the TRE, which consists of seven copies of the 42-bp tet operator 
sequence (tetO). The TRE is just upstream of the minimal CMV promoter (Pmin CMV),
which lacks the enhancer that is part of the complete CMV promoter. Consequently, 
PhCMV*-1 is silent in the absence of binding of tTA or rtTA to the tetO sequences. The 
cloned insert must have an initiating ATG codon. 
Fig. 1. pTRE2 vector.  Response plasmid encoding the tetracycline response element (TRE) for use in the Tet-off or 
Tet-on systems.
B) pCMV4 plasmid vector
pCMV4 is a high-copy mammalian expression vector of 4.9 kbp. It contains a 
bacteriophage origin of replication for production of single-stranded DNA, an
ampicillin- resistance gene, a promoter-regulatory region of the hCMV and the human 
growth hormone fragment, which contains transcription termination and poly-
adenylation signals.
C) pYES 2.0 plasmid vector
The pYES 2.0 (Stratagene, ref. V825-20) is a high-copy episomal vector of 5.9
kbp which contains the ampicillin-resistance gene. It also contains  a yeast gene, URA3, 
for protein expression in yeast under the galactose promoter GAL1.
1 Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in 
mammalian cells. Science. 268(5218):1766-1769, 1995
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D) pAxCA wt cosmid vector
pAxCA wt is a cosmid vector (Takara Biomedicals, ref. 6170) of 44.7 kbp which
contains the ampicillin- resistance gene and highly efficient CAG promoters (CMV
enhancer, chicken β-actin promoter, rabbit β-globin poly A signal) that act in mammals. 
A foreign DNA of about 5 kbp can be inserted. High gene expression levels can be 
achieved by inserting the coding regions of the target gene into this cosmid vector. 
1.3 BACTERIAL CULTURE
Bacterial strains are cultured in LB medium (Luria-Bertrani Broth) in the
presence of the appropriate antibiotic. When cells are grown in a solid medium, 2% of 
agar is added to the LB medium. 
In the case of the bacterial strains and vectors used in this study, the antibiotics
ampicillin and tetracycline were used. Ampicillin binds to and inhibits a number of 
enzymes in the bacterial membrane that are involved in the synthesis of the cell wall. 
The ampicillin-resistance (ampr) gene carried on the plasmid or on the bacterial strain 
genome codes for an enzyme that is secreted into the periplasmic space of the
bacterium, where it catalyzes hydrolysis of the β-lactam ring, with concomitant
detoxification of the drug. Therefore, only the cells with the ampr gene present on their
genome or in the target plasmid will survive in a medium containing this antibiotic. On 
the other hand, tetracycline binds to a protein of the 30S subunit of the ribosome and 
inhibits ribosomal translocation. The constitutively expressed tetracycline-resistance
(tetr) gene carried on the plasmid or on the bacterial strain genome encodes a 399-
aminoacid, a membrane-associated protein that prevents the antibiotic from entering the 
cell.
LB medium: 10 g/L tryptone, 5 g/L yeast extract and 5 g/L NaCl dissolved in distilled 
water. It is autoclaved immediately and kept at room temperature (r.t.). 100 mg/L
ampicillin prepared in water and/or 12.5 mg/L tetracycline prepared in H2O:ethanol
(1:1) is added at the moment of use.
Solid LB medium: LB medium plus 2% (w/v) agar. It is autoclaved immediately. When
the temperature is about 50ºC, 100 mg/L ampicillin and/or 12.5 mg/L tetracycline is
added and the medium is distributed into 10-cm plates with 30 ml of medium each.
Plates are stored at 4ºC.
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1.4 PLASMID DNA PREPARATION
Plasmid DNA could be obtained from bacterial cultures that contain the plasmid 
of interest by growing them in LB medium with the appropriate antibiotic and the later 
purification of the plasmid DNA from the cell lysate. 
Minipreparations of plasmid DNA were obtained using the Minipreps DNA
Purification System (Promega, A1460) where the yield of high-copy-number plasmids 
obtained is about 3-5 µg DNA per millilitre of the original bacterial culture. When 
higher amounts of plasmid DNA were needed or for the obtaining of cosmid DNA, the 
QUIAGEN Plasmid Maxi kit (QUIAGEN, ref. 12163) was used. In this case up to 500 
µg DNA could be obtained.
Minipreparations are obtained from 2 ml LB medium with the appropriate 
antibiotic which has been inoculated with a single colony of E. coli cells and grown
overnight (o/n) at 37ºC with moderate shaking. For the maxipreparations, 500 ml of LB 
medium with the appropriate antibiotic is inoculated with the 2 ml preinocul and grown 
o/n at 37ºC with moderate shaking.  In both cases cells are harvested by centrifugation 
and lysed with NaOH and SDS. The precipitate formed contains the bacterial genomic 
DNA, proteins, cell debris and SDS. The bacterial RNA is degraded by the action of 
RNase. Then, the plasmid or cosmid DNA is purified from the supernatant using ion-
exchange resin columns. After that, the DNA is washed and eluted, and it is pure 
enough for enzymatic modifications, PCR, sequencing, etc.
For future preparation of plasmid or cosmid DNA, a stab of each construct is 
prepared as follows: 1 ml aliquot from the 500 ml maxipreparation inoculum is mixed
with 500 µl 50% sterile glycerol and stored at -80ºC.
1.5 DNA ENZYMATIC MODIFICATIONS
1.5.1 DNA digestion with restriction enzymes
Restriction endonucleases are enzymes isolated and purified from bacteria or 
fungi which bind specifically to and cleave double-stranded DNA (phosphodiester
bonds) at specific sites within or adjacent to a particular sequence known as the 
recognition sequence. The most used restriction enzymes recognize specific sequences 
that are four, five or six nucleotides in length and display twofold symmetry. The 
location of cleavage sites within the axis of dyad symmetry differs from enzyme to 
enzyme: some cleave both strands exactly at the axis of symmetry, generating fragments 
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of DNA that carry blunt ends; others cleave each strand at similar locations on opposite 
sides of the axis of symmetry, creating fragments of DNA that carry protruding single-
stranded termini (cohesive ends). 
Each restriction enzyme requires specific reaction conditions of pH, ionic
strength and temperature; therefore in each case the manufacturer’s instructions were 
followed. In general, DNA is digested at a concentration of 0.5 µg/µl using 1-4 units 
(U) of the enzyme per µg of DNA. Restriction enzymes are stably stored at -20ºC in a 
buffer containing 50% glycerol. Reaction volumes must be kept to a minimum by
reducing the amount of water in the reaction as much as possible. However, the 
restriction enzyme must contribute less than 0.1 volume of the final reaction mixture; 
otherwise, the enzyme activity may be inhibited by glycerol. Digestions are carried out 
for 2-3 h in the specific buffer and the digestion products are analyzed in agarose gels.
When DNA is to be cleaved with two or more restriction enzymes, the
digestions can be carried out simultaneously if both enzymes work well at the same 
temperature and in the same buffer. If the enzymes have different requirements, two 
alternatives are possible:
1) The DNA should be digested first with the enzyme that works best in the 
buffer of lower ionic strength. The appropriate amount of salts, BSA, etc. and the 
second enzyme can then be added and the incubation continued.
2) When the conditions are completely incompatible, after the first digestion the 
DNA could be recovered using the QIAquick PCR purification kit (QUIAGEN, ref. 
28106). Up to 10 µg of DNA is selectively adsorbed to a silica-gel membrane and 
separated from enzymes, salts, etc. Then, the DNA is eluted in the desired volume of 
water and the second digestion or the next enzymatic modification is performed.
Enzyme digestion
DNA 0.5 µg/µl
10X Buffer 1X
Enzyme 1-4 U/µg DNA
1.5.2 DNA dephosphorylation
DNAs can be rendered resistant to ligation by enzymatic removal of phosphate 
residues from their 5’ termini with phosphatases. This process is useful to avoid  the 
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ligation of a linearized vector with itself and thus, increase the ligation probability of the 
vector with the desired insert in the ligation mixture.
The CIP (Calf Intestinal alkaline Phosphatase) is the most widely used
phosphatase and catalyzes the hydrolysis of the 5’-phosphate residues from linear DNA,
RNA and the ribo or deoxyribonucleoside triphosphate. The reaction is performed for 1 
h at 37ºC with the manufacturer’s buffer. This enzyme requires Zn2+, presents a high 
specific activity and is easily inactivated by heating to 70ºC for 10 min.
1.5.3 Blunt ends
The filling of 5’-protruding ends or the shortening of 3’-protruding ends allows 
the cloning by blunt-end ligation of non compatible restriction sites.
The enzyme used for blunt end generation was the Pfu DNA polymerase as its 
has 5’ 3’ polymerase activity and 3’  5’ exonuclease activity and its efficiency is 
higher than that obtained with Klenow or T4 DNA polymerase. In the presence of 
double-stranded DNA and deoxynucleoside triphosphate (dNTPs) this enzyme fills the 
gaps left by restriction enzymes that produce 5’ protruding ends. In the absence of 
dNTPs the enzyme eliminates the 3’ protruding end nucleosides. The reaction was
done following the manufacturer’s instructions.
1.6 DNA RESOLUTION AND PURIFICATION 
1.6.1 DNA resolution in agarose gels
Electrophoresis through agarose gels is the standard method used to separate, 
identify and purify DNA fragments. The technique is simple, rapid to perform and 
capable of resolving fragments of DNA from 50 bp to approximately 25 kbp in length 
on agarose gels of various concentrations. Higher fragments of DNA will need a lower 
concentration of agarose gel to be separated. For instance, 1% agarose gels are used to 
resolve DNA fragments between 0.5-7 kbp.
The location of DNA within the gel can be determined directly by staining the
gel with low concentrations of the fluorescent dye ethidium bromide which intercalates 
between the two strands of the DNA. The presence of the DNA is visualized with low 
wavelength (310 nm) ultraviolet (UV) light where the DNA fragment appears as a 
fluorescent orange band. Extra precautions should be taken because ethidium bromide is 
a powerful mutagen and is moderately toxic and UV radiation is dangerous, particularly
to the eyes.
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DNA which is negatively charged migrates to the anode of the electrophoresis 
chamber. This migration of the DNA is inversely proportional to its molecular weight
logarithm and therefore, the molecular weight of a desired DNA fragment could be 
calculated by its interpolation on the regression curve of a molecular marker with
known molecular weight DNA fragments or by directly comparison with the molecular 
marker DNA fragments.
The agarose gel is prepared with low-melting- temperature agarose dissolved in 
1X TAE electrophoresis buffer containing 0.5 µg/ml ethidium bromide (AppliChem 
Biochemica, ref. A1151,0001). Samples are loaded in 1X loading buffer and
electrophoresis is run with 1X TAE electrophoresis buffer at 75 V. 
1X TAE electrophoresis buffer
Tris-acetate pH 8.3 40 mM
EDTA 1 mM
5X sample loading buffer
sucrose 7 g
0.5 M EDTA 1.2 ml
1 M Tris pH 8 300 µl
glycerol 10 ml
bromophenol blue 8 mg
bd. H2O up to 20 ml
1.6.2 DNA purification
If necessary a DNA fragment can be recovered from the gel to be used for a 
variety of cloning purposes. To extract and purify a DNA fragment from the agarose gel 
the QIAEX II Gel Extraction kit (QUIAGEN, ref. 20021) was used. Briefly, the agarose 
gel fragment containing the desired DNA is dissolved in a chaotropic agent and the 
DNA is selectively adsorbed into a silica resin which has been optimized to enhance 
recovery of 40 bp to 50 kbp DNA fragments. Impurities such as RNA, proteins, salts
and other components of the sample are removed during washing steps. The pure DNA 
is eluted in water and is suitable for other manipulations.
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1.7 DNA AND RNA QUANTIFICATION
1.7.1 DNA and RNA spectrophotometric quantification
RNA and DNA could be quantified in a spectrophotometer measuring the
absorbance at 260 and  280 nm in 1 ml quartz cuvettes. The reading at 260 nm allows 
calculation of the concentration of nucleic acid in the sample. An OD of 1 corresponds 
to approximately 40 µg/ml for single-stranded DNA and RNA, and 50 µg/ml for 
double-stranded DNA. The ratio between the readings at 260 and 280 nm
(OD260/OD280) provides an estimate of the purity of the nucleic acid. Pure preparations 
of RNA and DNA have OD260/OD280 values higher than 1.65 and 1.8, respectively. 
Therefore, the RNA or DNA concentrations in a sample could be given as:
RNA (µg/µl) = OD x 40/v
DNA (µg/µl) = OD x 50/v
Where OD is the absorbance at 260 nm and v is the µl of RNA or DNA diluted 
in 1 ml of water and quantified in the spectrophotometer. 
1.7.2 DNA fluorescence quantification
When there is not sufficient DNA (<250 ng/ml) to assay spectrophotometrically
(Section 1.7.1), or the DNA is heavily contaminated with other substances that absorb 
ultraviolet irradiation and therefore impede accurate analysis, DNA could be quantified
by fluorescence. The ultraviolet- induced fluorescence emitted by ethidium bromide 
molecules intercalated into the DNA is used. Because the amount of fluorescence is 
proportional to the total mass of DNA, the quantity of DNA in the sample can be
estimated by comparing the fluorescent yield of the sample with that of a series of 
standards. As little as 10 ng of DNA can be detected by this method.
1.8 DNA LIGATION
Ligation of a segment of foreign DNA to a linearized plasmid vector involves 
the formation of new bonds between phosphate residues located at the 5’ termini of 
double-stranded DNA and adjacent 3’ hydroxyl moieties. When both strands of the 
plasmid vector carry 5’-phosphate residues, four new phosphodiester bonds are
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generated. However, when the plasmid DNA has been dephosphorylated, only two new 
phosphodiester bonds can be formed. In this case, the resulting hybrid molecules carry 
two single-strand nicks that are repaired after the hybrids have been introduced into 
competent bacteria.
The bacteriophage T4 DNA ligase was used for the ligation reactions following 
the manufacturer’s instructions. The reaction is done in the presence of the ligation 
buffer and ATP for 2-3 h at 16ºC in case of cohesive ends fragments and at 18ºC o/n in 
case of blunt ends fragments. The ligation reaction should contain between 20-60 µg
approx. of vector DNA per ml and an equal or slightly greater concentration of foreign 
DNA (insert) than of vector DNA. At low concentrations of DNA, recircularization of 
the plasmid DNA will occur with high efficiency. On the other hand, at high DNA 
concentrations the initial products of ligation will be dimmers and larger oligomers of 
the plasmid. Because of this, an adequate plasmid- insert rate is important for the 
ligation reaction.
When the ligation is done with different protruding termini DNA, the foreign 
DNA is inserted in only one orientation within the recombinant plasmid and the 
background of nonrecombinant clones is low. Ligation reactions involving blunt-ended
molecules are much less efficient and require higher concentrations both of DNA ligase 
and plasmid and insert DNAs. Moreover, recombinant plasmids may carry tandem
copies of foreign DNA and the background of nonrecombinant clones can be high.
Ligation was checked by PCR or by electrophoresis in an agarose gel before its 
transformation in competent E. coli.
1.9 PREPARATION AND TRANSFORMATION OF COMPETENT E. coli
Plasmid DNA can be introduced into competent bacteria by the process of 
transformation.
1.9.1 Obtaining of competent E. coli
Competent cells are those cells which have been treated to increase their
capacity to introduce a circular exogenous DNA. They are obtained by concentration
through successive washes in water and 10% glycerol. 
Competent cells could be purchased from a commercial source or prepared in 
the laboratory. In both cases, a yield of approx. 108-1010 transformed colonies/µg of 
supercoiled plasmid DNA could be achieved.
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To obtain competent cells a single colony of E. coli cells is inoculated into 5 ml 
LB medium with the appropriate antibiotic and grown o/n at 37ºC with moderate 
shaking. The next day, 500 ml of LB plus antibiotic is inoculated with the 5 ml 
preinocul and grown for approx. 3 h in the shaker at 37ºC to an OD600 of 0.5-0.6. Cells 
are then chilled on ice for 10 min and centrifuged at 4,000 x g for 20 min at 2ºC. Cells 
should be kept at 2ºC for the subsequent steps. After that, the pellet is immediately
resuspended in 500 ml of sterile and ice-cold water and centrifuged again. This process 
is repeated and then the pellet is resuspended by swirling in remaining liquid. 40 ml of 
sterile, ice-cold 10% glycerol is added and the suspension is centrifuged at 4,000 x g for 
10 min. Cells are then resuspended in 500 µl of 10% glycerol and 42 µl aliquots are 
stored at -80ºC.
1.9.2 Transformation of competent E.coli
The transformation process consists of introducing the plasmid DNA into the 
bacterial cells for later amplification and obtaining. Moreover, only the circular DNA 
will enter the cells, therefore if the DNA which is to be introduced into the cells is the 
result of a ligation, only the ligated plasmid will be obtained after the transformation. In
this way, the non ligated molecules of the ligation reaction will be discarded.
Plasmid DNA could be introduced by heat-shock or by electroporation and 
cosmid DNA by packaging.
A) Heat-shock transformation
In this process the DNA is introduced into the bacterial cells by a heat-shock.
Briefly, competent cells are thawed on ice at the moment of use and 1-3 µl (1-10
ng) of the DNA ligation reaction or control DNA is added directly to the cells. Cells and 
DNA are mixed and incubated on ice for 30 min. After that, a heat-shock of 1 min in a 
42ºC water bath is applied. Cells are kept on ice for 2 min, 900 µl of LB is added and 
cells are incubated for 1 h at 37ºC with moderate shaking. 
After that, 100 µl of the suspension is plated in LB plates with the appropriate 
antibiotic near the flame. Plates are incubated at 37ºC o/n.
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B) Electrotransformation
In this technique, a high-voltage electric field is applied briefly to cells,
apparently producing transient holes in the cell membrane through which plasmid DNA 
enters. Successful electroporation of E. coli requires long, strong pulses. Under these 
conditions up to 109 transformants/µg plasmid DNA can be achieved. In case of large 
DNA constructs this technique is more effective than the heat-shock transformation. 
The procedure was applied following the manufacturer’s instructions (BTX Inc. 
Electro Cell ManipulatorR 600) for DH5α cells.
Electroporation settings: 2 mm gap cuvettes, 129 ohm resistance, 2.45 kV,
which gives a 12.25 kV/cm field strength for 5-6 mseconds. 
Electroporation procedure: 1 µl (1 ng) of the DNA ligation reaction or control 
DNA is added to 40 µl of recently thawed competent cells, mixed and kept for 1 min on 
ice. After that, the cell mixture is placed on a chilled cuvette. The suspension must 
touch both side walls of cuvette. Immediately after the electroporation, 1 ml of LB is 
added to the cuvette, mixed thoroughly and incubated at 37ºC for 1 h with moderate 
shaking. Cells are plated as described before for the heat-shock transformation.
C) Cosmid packaging
For cosmid packaging the GigapackR III XL Packaging Extract kit (Stratagene, 
ref. 200208) was used. Packaging extracts are used to package recombinant lambda 
phage with high efficiency. These extracts are designed for use in cosmid constructions 
and package large inserts (i.e., 47- to 51-kbp recombinants) with high efficiency. 
The cosmid vector was packaged following the manufacturer’s instructions. First 
the cosmid ligation is packaged along with the packaging extract and then this
packaging mixture is added to the bacterial cells. Phage adhere to the bacterial cells,
infecting them and allowing the cosmid to enter. 
The procedure is as follows:
Packaging step: The packaging extract is thawed and mixed by gently pipetting 
with 1-4 µl (0.1-1.0 µg) of the cosmid ligation reaction. After a 2 h incubation at r.t., 
500 µl of SM buffer and 20 µl of chloroform are added. Suspension is briefly
centrifuged and the supernatant, diluted to 1:10 and 1:50 in SM buffer, which contains 
the phage is ready to infect bacterial cells. 
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Phage infection: A single colony of XL1-Blue cells is inoculated into 2 ml LB 
medium containing 10 mM MgSO4 and 0.2% (w/v) maltose and grown o/n at 37ºC with 
moderate shaking. No antibiotic is added since antibiotic will bind to the bacterial cell 
wall and will inhibit the ability of the phage to infect the cell. The next day, 10 ml of the
same medium is inoculated with 1 ml of the preinocul and grown for approx. 2 h in the 
shaker at 30ºC to a maximal OD600 of 1.0. Then, bacteria are centrifuged at 500 x g for 
10 min, resuspended in half the original volume with sterile 10 mM MgSO4 and diluted
to an OD600 of 0.5 with 10 mM MgSO4. Immediately, 25 µl of the cosmid packaging 
extract is mixed with 25 µl of the bacterial cells and incubated at r.t. for 30 min. Then, 
200 µl of LB broth is added and the mixture is incubated for 1 h at 37ºC to allow the 
expression of the antibiotic resistance. After that, cells are plated in
ampicillin/tetracycline plates as described before. 
SM buffer: 5.8 g of NaCl, 2.0 g of MgSO4.7H2O, 50 ml of 1 M Tris-HCl pH 7.5 and 5 
ml of 2% (w/v) gelatine are dissolved in 1 L of water, autoclaved and kept at r.t.
LB broth: 10 g of NaCl, 10 g of tryptone and 5 g of yeast extract are dissolved in 1 L of 
water. pH is adjusted to 7.0 with NaOH and the solution is autoclaved and kept at r.t. 
1.9.3 Recombinant plasmid selection
The bacteria which have incorporated the desired DNA are selected by plating 
the cells in LB plates with the appropriate antibiotic. After o/n incubation bacterial 
colonies are analyzed by PCR (PCR-Preps, Section 1.11.3) or by enzymatic digestion or
sequencing after growing them as described before for the DNA minipreparations
(Section 1.4).
1.10 DNA SUBCLONING
Subcloning techniques are used for various purposes, such as the obtaining of 
protein expression constructs, isolation of mutated DNA fragments, adenovirus cosmid 
construction, etc. The protocol differs in each case although the basic DNA techniques 
described above were used. Original DNAs were modified enzymatically. The desired 
DNA fragments were purified and ligated and the resultant DNA construct was
transformed, amplified and checked by PCR, sequencing or enzymatic digestion. 
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1.11 PCR DNA AMPLIFICATION
1.11.1 PCR
The polymerase chain reaction (PCR) is used to amplify a segment of DNA that
lies between two regions of known sequence. Two oligonucleotides are used as primers 
for a series of synthetic reactions that are catalyzed by a DNA polymerase. These 
oligonucleotides typically have different sequences and are complementary to
sequences that (1) lie on opposite strands of the template DNA and (2) flank the 
segment of DNA that is to be amplified.
The template DNA is first denatured by heating in the presence of a large molar 
excess of the two oligonucleotides and the four dNTPs. The reaction mixture is then 
cooled to a temperature that allows the oligonucleotide primers to anneal to their target
sequences, after which the annealed primers are extended with DNA polymerase. The 
cycle of denaturation, annealing and DNA synthesis is then repeated many times. 
Because the products of one round of amplification serve as templates for the next, each 
successive cycle essentially doubles the amount of the desired DNA product. 
The major product of this exponential reaction is a segment of double-stranded
DNA whose termini are defined by the 5’ termini of the oligonucleotide primers and 
whose length is defined by the distance between the primers. 
In 1988 Saiki et al.2 introduced a thermostable DNA polymerase purified from 
the thermophilic bacterium Thermus aquaticus (Taq DNA polymerase). Its optimal 
temperature for synthesis is 72ºC. This enzyme, which can survive extended incubation 
at 95ºC, is not inactivated by the heat denaturation step and does not need to be replaced 
at every round of the amplification cycle. This results in substantial improvements in 
the specificity and yield of the amplification reaction and in the size of the amplified 
product. For example, between 0.5 µg and 1 µg of target DNAs up to 2 kb in length can 
be obtained from 30-35 cycles of amplification with only 10-6 µg of starting DNA. 
We used a thermal cycler, Minicycler PTC-100TM (M. J. Research), with Peltier 
refrigeration. The PCR reaction mix and the PCR conditions were the following:
2 Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erich HA. Primer-directed enzymatic 
amplification of DNA with a thermostable DNA polymerase. Science. 239: 487-491, 1988
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PCR reaction mix
10X PCR buffer 1X
MgCl2 1.5-2.5 mM
Mixture of four dNTPs 0.25 mM
Primer forward 50 pmol
Primer reverse 50 pmol
Template DNA 1 ng
Taq DNA polymerase 2.5 U
bd. sterile H2O up to 50 µl
PCR conditions
First step 94ºC 2-5 min
Denaturation 94ºC 1 min
Annealing 50-65ºC 1 min
Polymerization 72ºC 1 min/kb DNA
25-30 cycles from step 2
Final extension 72ºC 10 min
At lower annealing temperatures the amplification is more efficient, but the 
amount of mispriming is significantly increased. At higher temperatures (50-65ºC), the 
specificity of the amplification reaction is increased, but its overall efficiency is
reduced. Usually, the annealing temperature chosen is 2ºC less than the lower melting 
temperature (Tm) of the two primers used. The Tm of an oligonucleotide could be 
approximately calculated as [2 x (A + T) + 4 x (C + G) – 9], where A, T, C and G are 
the number of Adenosine,  Thymidine, Cytidine and Guanosine nucleotides present in
the primer sequence. 
The PCR products are analyzed by electrophoresis in agarose gels.
1.11.2 Primer design 
Some previous primer design considerations have to be borne in mind for PCR 
and sequencing experiments. 
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The length of the oligonucleotide will be 18 plus one extra base for each 2% 
decrease related to the 50% of G + C. High A + T percentages prevent the correct
annealing of the primer, while high G + C percentages could produce unspecific 
amplifications due to accidental homology with G +C regions of the template DNA.
40-60% is the ideal range of G + C.
It is recommended to compare the oligonucleotide sequence with the template 
DNA to detect possible internal or adjacent homologies to the DNA fragment which is 
to be amplified. 
Finally, a G + C equilibrated composition at the 3’ terminus of the primer is
recommended because this is where the amplification will start. 
1.11.3 PCR-Preps
To select the desired recombinant DNA among the bacterial colonies obtained 
after DNA transformation, a rapid analysis by PCR could be used.
A PCR reaction is performed for each isolated bacterial colony by touching one 
by one with a sterile tip first the colony, then a new LB plate (for the later identification
of the selected colony) and then the PCR mixture placed in a PCR tube. A few cells are 
enough for the PCR reaction to amplify the desired DNA. The first step of the PCR is 5 
min at 94ºC, to break the bacterial membrane by heating and release the internal DNA. 
1.12 DNA SEQUENCING
For DNA sequencing we used the ABI PRISM® BidDye Terminator-Cycle
Sequencing Ready reaction Kit with the AmpliTaq DNA polymerase (Applied
Biosystems) following the manufacturer’s instructions. This kit contains fluorescent 
nucleosides therefore sequencing products can be detected by fluorescence. The
sequence of a single or double-stranded DNA can easily be determined with this kit
using an oligonucleotide and performing a PCR reaction. The PCR sequencing mix and 
the PCR conditions are the following:
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PCR sequencing mix plasmid cosmid
Template single-stranded DNA 50-100 ng
double-stranded DNA 200-500 ng 800-1000 ng
PCR product DNA 1-100 ng
Primer 3.2 pmol 13 pmol
     Ready reaction mix 2 µl 16 µl
     bd. sterile H2O up to 10 µl 40 µl
PCR conditions plasmid cosmid
First step 96ºC 1 min 95ºC      5 min
Denaturation 96ºC 10 sec 95ºC      30 sec
Annealing 50ºC 5 sec 50-55ºC 10 sec
Polymerization 60ºC 4 min 60ºC      4 min
Cycles from step 2 24 50
The primer must anneal near the DNA fragment to be sequenced because the 
PCR reaction extendeds up to 600 bp away from the primer annealing site. After the 
PCR amplification, samples are precipitated with ethanol for 15 min at r.t., centrifuged 
at 14,000 rpm for 20 min in a microcentrifuge and washed 3 times in 70% ethanol. 
Once samples are air-dried (protected from the light) they can be stored at -20ºC.
The polyacrylamide-urea gel electrophoresis and the later analysis of the
samples in an ABI PRISM 3700 DNA Analyzer (Applied Biosystems) were performed at 
the Scientific-Technique Services of the University of Barcelona.
1.13 RNA AND DNA ISOLATION FROM CELLS
RNA and DNA were obtained from cells using the TRIzol Reagent (Gibco, ref. 
15596-018). This reagent is a mono-phasic solution of phenol and guanidine
isothiocyanates, which allows the isolation of total RNA, DNA and protein from cells 
and tissues. This technique performs well with small quantities of tissue (50-100 mg) 
and cells (5 x 104 cells), and also with large quantities of tissue (= 1 g) and cells (>107
cells).
RNA and DNA from cells were extracted according to the manufacturer’s
instructions. Briefly, cells are grown in 35-mm dishes until confluence and washed in
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PBS (see Section 3.3). Cells are lysed by adding 1 ml of TRIzol Reagent directly to the 
dish, and passing the cell lysate several times through a pipette. The amount of TRIzol 
Reagent added is based on the area of the culture dish (1 ml per 10 cm2). An insufficient 
amount of TRIzol Reagent may result in contamination of the isolated RNA with DNA. 
During sample homogenization or lysis, TRIzol Reagent maintains the integrity of the 
RNA, while disrupting cells and dissolving cell components. Addition of chloroform 
followed by centrifugation, separates the solution into an aqueous phase and an organic 
phase. RNA remains exclusively in the aqueous phase, DNA in the interphase and 
proteins in the organic phase. After transfer of the aqueous phase, the RNA is recovered 
by precipitation with isopropyl alcohol and dissolved in RNase-free water or 0.5% SDS 
solution. Total RNA isolated by TRIzol Reagent is free of protein and DNA
contamination. It can be used for Northern blot analysis or molecular cloning, etc.
DNA and proteins that remain in the organic phase can be recovered by
sequential precipitation. Precipitation with ethanol yields DNA from the interphase, and 
an additional precipitation with isopropyl alcohol yields proteins from the organic 
phase. Total DNA is dissolved in 8 mM NaOH and pH is adjusted to 8.4 with 0.1 M 
HEPES. For PCR reaction 0.1-1 mg of the DNA sample could be used. 
RNase-free water and 0.5% SDS solution for RNA:
RNase-free water is prepared in RNase-free glass bottles. Diethylpyrocarbonate 
(DEPC) 0.01% (v/v) is added to the water and solution is left to stand overnight and 
autoclaved. The 0.5% SDS solution must be prepared using DEPC-treated, autoclaved 
water.
1.14 NORTHERN BLOT
The Northern blot technique allows identification and comparison a desired 
RNA within a RNA sample from cells or tissues. RNA obtained from cells or tissues is 
separated by electrophoresis, transferred to a nylon membrane and hybridized with a 
radiolabelled cDNA probe which is specific for the desired RNA. 
The procedure is as follows:
A) RNA separation by electrophoresis
Electrophoresis is performed in agarose/formaldehyde denaturalizing gels. These 
gels are used to separate the RNA because they contain formaldehyde which denatures
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the possible RNA secondary structures. This fact permits the RNA migration to be 
inversely proportional to its molecular weight logarithm and therefore, the molecular 
weight of the RNA transcripts can be calculated. 20 µg of RNA diluted in RNA loading 
buffer and a RNA molecular marker are incubated at 65ºC for 10 min and loaded into 
denaturalizing gels. Electrophoresis is performed at 30 V for 5 h or at 10 V o/n. 
Denaturalizing gels, electrophoresis buffer and RNA loading buffer must be prepared in 
RNase-free conditions to avoid RNA degradation. 
Denaturalizing gels : 1% agarose, 40 mM MOPS/NaOH pH 7, 10 mM sodium acetate, 
2.2 M formaldehyde and 1 mM EDTA in DEPC-treated water.
Electrophoresis buffer: 40 mM MOPS/NaOH pH 7, 10 mM sodium acetate, 2.2 M 
formaldehyde and 1 mM EDTA in DEPC-treated water.
RNA loading buffer: 2.2 M formaldehyde, 50% deionized formamide, 5% glycerol, 
0.13 mg/ml ethidium bromide and 5% bromophenol blue in electrophoresis buffer. 
B) Transfer
The RNA is transferred from the denaturalizing gel to a nylon membrane
(Schleicher and Schuell) by the method of Sambroock3 with 10X SSC. Then, RNA is 
fixed to the membrane by UV crosslinking or by a 1 h incubation at 80ºC.
C) Hybridization 
The cDNA probe of the desired gene, a cDNA fragment excised from a plasmid, 
is 32P-labelled using the Random prime labelling system (RediprimeTMII, Amersham 
Pharmacia Biotech, ref. RPN 1633). The labelled probe is denatured at 100ºC for 5 min 
and then rapidly placed on ice. Pre-hybridation, hybridation and washing steps are done 
with the ExpressHyb Hybridization solution (Clontech, ref. 8015-2) following the
manufacturer’s instructions. Briefly, pre-hybridization is done in ExpressHyb solution 
at 68ºC for 30 min. Hybridization is performed with ExpressHyb solution plus the 
labelled cDNA probe at 68ºC for 1 h and washing steps are performed first with 2X 
SSC and 0.1% SDS and then with a more stringency solution composed of 0.2X SSC 
and 0.1% SDS. 
3 Sambroock J, Frisch EF, Maniatis T. Molecular cloning: A laboratory Manual, 2nd Edn. Cold Spring Harbour 
Laboratory, Cold Spring Harbor, N.Y. USA. 1989
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20X SSC: 3M NaCl and 0.3 M sodium citrate pH 7.
D) Detection
RNA bands are detected by exposure to X-ray film or by using a Storm 840 
Laser scanning system (Molecular dynamics, Amersham Pharmacia Biotech).
To ensure equal RNA loading and even transfer, membranes are stripped and re-
hybridized with a “housekeeping gene” probe cyclophilin.
2. ANIMALS
Six-week-old C57BL/6J male mice were purchased from Harlam Co. Wistar rats 
weighing 200–250 g were used for islet isolation. Animals were maintained under a 12-
h dark/light cycle at 23ºC with free access to food and water. After a 1-week
acclimatization, experiments with animals were performed. The experimental protocols 
were approved by the Animal Ethics Committee at the University of Barcelona.
2.1 C75 TREATMENT
For C75 experiments with mice, animals are administered a single
intraperitoneal (ip) injection of C75 dissolved in RPMI 1640 medium at 20 mg/kg body 
weight. Control animals are administered RPMI 1640 medium. Mice are sacrificed at 
different times post- injection and mitochondrion-enriched fractions from liver and
pancreas are obtained for CPTI activity assay. 
C75: For the animals 5 mg of C75 is dissolved in 1 ml of RPMI 1640 medium. It is 
prepared on the day of the experiment and kept at 4ºC.
3. CELL CULTURE
All solutions used for cell culture were sterilized by autoclaving at 121ºC for 30 
min (PBS, bd. water, etc.) or by filtering them through a 0.22 µm filter (Millipore) if 
necessary.
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3.1 BETA CELL LINES
Reliable β-cell models are very important for diabetes research. It is generally 
accepted that the use of primary cells is preferable. However, this requires large
amounts of isolated pancreatic islets of Langerhans, which is work- intensive and has the 
inherent inconvenience of representing a mixed population of β , α, δ and F cells. 
Because of this, rodent β-cell lines are a usefulness alternative until clonal human β-
cells become available. 
The main requirements for an insulinoma cell line to faithfully and stably mimic 
the performance of β-cells within the normal pancreatic islets are the maintenance of 
tissue-specific differentiation and appropriate proliferation. Numerous rodent β-cell
lines have been reported. Among the mouse derived β-cell lines, MIN-6, βTC6-F7 and 
βHC9 have an insulin content closer to that of normal islets and retain some glucose-
stimulated insulin secretion. However, MIN-6 cells exhibit secretory responses to
pyruvate, which is not a secretagogue for normal islets, βTC6-F7 cells lose their stable 
glucose responsiveness after prolonged tissue culture, and βHC9 cells grow very slowly 
and are thus difficult to study. The hamster-derived β-cell line HIT cells have a lower 
insulin content and weaker glucose response with increasing passage. Rat-derived β-cell
lines, such as RINm5F, BRIN-BD11 and INS-1, have also been studied. RINm5F cells
have low insulin content, do not respond to glucose in the physiological concentration
range and lose differentiated features after prolonged tissue culture. BRIN-BD11 cells
are poorly differentiated, exhibiting low insulin content and weak secretory responses to 
glucose. INS-1 cells were isolated from a radiation-induced rat insulinoma4, they are
sensitive to physiological glucose concentrations and unresponsive to neurotransmitters, 
but they exhibit only a 2-to 4-fold increase in insulin secretion in response to glucose, 
which is far less than the 15-fold responses achievable with freshly isolated primary 
islets. Moreover, due to their nonclonal nature, INS-1 cells are heterogeneous and are 
not stable over extended culture periods. Consequently, two clonal INS-1 derived cell 
lines have been generated: INS-1E and INS(832/13). Clonal INS-1E5 cells were isolated 
4 Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB. Establishment of 2-mercaptoethanol-dependent
differentiated insulin-secreting cell lines. Endocrinology. 130:167-178, 1992
5 Merglen A, Theander S, Rubi B, Chaffard G, Wollheim CB, Maechler P. Glucose sensitivity and metabolism-
secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology.
145(2):667-678, 2004
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from parental INS-1 based on both their insulin content and their secretory responses to 
glucose (6.2-fold). INS(832/13)6 cells were stably transfected with a plasmid containing 
the human proinsulin gene and have a potent response to glucose (average of 10-fold).
Therefore, we chose INS(832/13) cells for our studies due to their higher
secretory response to glucose, their KATP channel- independent pathway of glucose 
sensing and their adequate proliferation in culture.
3.1.1 INS(832/13) cells
The INS(832/13) clone was kindly given by Dr. M. Prentki (Montreal, Canada). 
INS(832/13) cells (passages 48-60) are cultured in a humidified atmosphere containing 
5% CO2 in complete medium composed of RPMI 1640 (Gibco, ref. 21875-034)
containing 11 mM glucose and supplemented with 10% (v/v) heat-inactivated fetal
bovine serum (FBS) (Wisent Inc, USA, ref. 80150, Lot. 102703), 10 mM HEPES (pH 
7.4), 2 mM glutamine, 1 mM sodium pyruvate, 50 µM 2-β-mercaptoethanol, 100 U/ml 
penicillin and 100 µg/ml streptomycin. 
500 ml of complete medium contains the following:
INS(832/13) medium
RPMI 1640 430 ml
FBS 50 ml
100X HEPES 5 ml
100X Glutamine 5 ml
100X Na Pyruvate-2-β-mercaptoethanol 5 ml
Penicillin-Streptomycin (104 U/ml-104 mg/ml) 5 ml
INS cells grow correctly in plastic culture from Falcon. Medium is changed 
every 2-3 days: cells are first washed in PBS preheated to 37ºC and medium (also at 
37ºC) is added as follows:4 ml for 25 cm2 flasks, 15 ml for 75 cm2 flasks, 10 ml for 10-
cm dishes, 15 ml for 15-cm dishes or 2 ml/well for 12-well plates. 
6 Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB. Isolation of INS-1-derived cell lines 
with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes.
49(3):424-430, 2000
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The maintenance culture is passaged once a week by gentle trypsinization. To 
trypsinise the cells they are first washed in PBS preheated to 37ºC and then 1.5 ml of 
the proteolytic enzyme and chela ting agent mix Trypsin-EDTA 1X (Gibco, ref. 25300-
062) is added. The trypsin solution has to be enough to cover the cells. After 2 min 
when the cells have come detached, the medium is added, and the cells are gently 
resuspended by pipetting to avoid the aggregates and they are spread as desired. 
3.1.2 INS-r9 cells
The rat insulinoma INS-1 cell-derived clone, which stably expresses the reverse 
tetracycline-dependent activator7, was kindly given by Dr. CB Wollheim (Geneva,
Switzerland). INS-r9 cells are cultured in a humidified atmosphere containing 5% CO2
in complete medium composed of RPMI 1640 containing 11 mM glucose and
supplemented with 10% (v/v) heat- inactivated tetracycline-free FBS (Clontech, ref.
8630-1), 10 mM HEPES (pH 7.4), 2 mM glutamine, 1 mM sodium pyruvate, 50 µM 2-
β-mercaptoethanol, 0.1 mg/ml G418 (Calbiochem, ref. 345812), 100 U/ml penicillin 
and 100 µg/ml streptomycin. 
500 ml of complete medium contains the following:
INS-r9 medium
RPMI 1640 429 ml
FBS 50 ml
100X HEPES 5 ml
100X Glutamine 5 ml
100X Na Pyruvate-2-β-mercaptoethanol 5 ml
G418 (50 mg/ml) 1 ml
Penicillin-Streptomycin (104 U/ml-104 mg/ml) 5 ml
Cells are cultured and trypsinised as described above for INS(832/13) cells. 
7 Wang H, Iynedjian PB. Modulation of glucose responsiveness of insulinoma β-cells by graded overexpression of 
glucokinase. Proc. Natl. Acad. Sci. USA. 94:4372-4377, 1997
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3.1.3 naSREBP-1c STABLE CELL LINE
The rat insulinoma INS-1 cell-derived clone which stably expresses naSREBP-
1c was obtained from INS-r9 cells stably transfected with the naSREBP-1c gene8, a 
nuclear localized N-terminal form of SREBP-1c with intact transcriptional activity. 
naSREBP-1c stable cells are cultured in a humidified atmosphere containing 5% CO2 in 
complete medium composed of RPMI 1640 containing 11 mM glucose and
supplemented with 10% (v/v) heat- inactivated tetracycline-free FBS (Chemie
Brunschwig AG, ref. BRA 15-043, Lot. A01122-007), 10 mM HEPES (pH 7.4), 2 mM 
glutamine, 1 mM sodium pyruvate, 50 µM 2-β-mercaptoethanol, 0.1 mg/ml G418 
(Calbiochem, ref. 345812), 0.1 mg/ml hygromycin (Calbiochem, ref. 400051), 100 
U/ml penicillin and 100 µg/ml streptomycin.
500 ml of complete medium contains the following:
naSREBP-1c medium
RPMI 1640 428 ml
FBS 50 ml
100X HEPES 5 ml
100X Glutamine 5 ml
100X Na Pyruvate-2-β-mercaptoethanol 5 ml
G418 (50 mg/ml) 1 ml
Hygromycin (50 mg/ml) 1 ml
Penicillin-Streptomycin (104 U/ml-104 mg/ml) 5 ml
Cells are cultured and trypsinised as described above for INS(832/13) cells. 
3.2 HEK 293 CELLS
Human embryo kidney (HEK) 293 cells obtained from ECACC (European
Collection of Cell Cultures) are cultured in a humidified atmosphere containing 5% CO2
in complete medium composed of Dulbecco’s Modified Eagle Medium (DMEM,
8
  Wang H, Maechler P, Antinozzi PA, Herrero L, Hagenfeldt-Johansson KA, Björklund A, Wollheim CB. The 
transcription factor SREBP-1c is instrumental in the development of β-cell dysfunction. J. Biol. Chem.
278(19):16622-16629, 2003
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Gibco, ref. 41965-039) containing 4,500 mg/L glucose and supplemented with 10% 
(v/v) heat- inactivated FCS (Biological Industries, ref. 04-001-1A, Lot. 816983), 100 
U/ml penicillin and 100 µg/ml streptomycin. 
500 ml of complete medium contains the following:
HEK 293 medium
DMEM 445 ml
FCS 50 ml
Penicillin-Streptomycin (104 U/ml-104 mg/ml) 5 ml
The maintenance culture is passaged twice a week and the medium is changed 
every 2-3 days. To passage HEK 293 cells it is not necessary to trypsinise them. Cells 
are first washed in PBS preheated to 37ºC and then detached by simply up and down 
pippetting with medium preheated to 37ºC and spread as desired. For experiments cells 
are grown until confluence.
3.3 SOLUTIONS AND BASIC PROCEDURES IN CELL CULTURE
FBS inactivation
The main role of serum in cell cultures is to provide complexes of hormones and 
growth factors. The serum complement system has to be inactivated before use in
culture. The complement is a heat- labile cascade system in the sera of all vertebrates 
and composed of at least 20 glycoproteins. Activated complement has high proteolytic 
activity, which may affect the function of membrane proteins of the cultured cells and 
thus cell viability. 
Serum bottles are stored at -20ºC. To inactivate the FBS, serum is thawed in a 
water bath at 37ºC and mixed well by inverting the bottle. FBS is inactivated by 30 min 
incubation at 56ºC. Then it is kept at 4ºC or stored at -20ºC.
100X HEPES (1 M) 
11.91 g of HEPES is dissolved in 50 ml of RPMI 1640, pH is adjusted to 7.3 
with NaOH and the solution is filtered through a 0.22 µm filter and stored at 4ºC for 
about 2 months. HEPES gives the pH range that supports optimal cellular growth in 
culture cells.
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100X Glutamine (205 mM) 
3 g of L-Glutamine is dissolved in 100 ml of RPMI 1640 preheated to 37ºC.
When glutamine is dissolved, it is filtered through a 0.22 µm filter and aliquots of 5 ml 
are stored at -20ºC. The half life of the glutamine in solution at 4ºC is 15 days.
100X Na pyruvate plus 2-β -mercaptoethanol (14.33 M)
1.1 g of Na pyruvate and 34.9 µl of 2-β-mercaptoethanol are dissolved in 100 ml 
of RPMI 1640 and filtered through a 0.22 µm filter. 5 ml aliquots are stored at -20ºC.
Many types of culture cells as INS require pyruvate or other small alpha-oxo-acids. The 
requirement is relatively non-specific and may reflect the need of a substrate that can be 
used to oxidize NADH, rather than the requirement for a specific metabolic
intermediate. The main proposed role of 2-β-mercaptoethanol in INS cells and other cell 
lines is the activation of cystine uptake and the increase of glutathione levels. It also 
promotes cell proliferation.
Hygromycin (50 mg/ml)
To prepare a 50 mg/ml hygromycin stock, 2 ml of hygromycin (Calbiochem, ref. 
400051) is diluted in 14 ml of PBS, filtered through a 0.22 µm filter and stored at 4ºC.
PBS
To obtain 1 L of Phosphate-Buffered Saline (PBS) 8 g of NaCl, 1.44 g of 
Na2HPO4.2H2O, 0.2 g of KCl and 0.2 g of KH2PO4 are dissolved in 1 L of bd. water. 
Then, pH is adjusted to 7.4 and solution is autoclaved and stored at 4ºC. PBS is useful 
to remove floating and dead cells and for washing because it provides the cells with 
water and inorganic ions, while maintaining physiological pH and osmotic pressure.
Counting the cells
Cells are counted in a Neubauer chamber. One drop of cells resuspended in 
medium is placed between the coverslip and the chamber. Cells from one large square 
(which contains 16 small squares) are counted and multiplied by 10,000 to calculate the 
number of cells per ml. 
Materials and methods
94
Freezing the cells
The number of cells recommended for freezing is approximately 20 million for 
INS and 10 million for HEK 293. First cells are detached with medium (HEK 293) or 
with Trypsin-EDTA (INS) as described above. Then, they are resuspended in 10 ml of 
medium, centrifuged at 1,200 rpm for 5 min and resuspended in 1.5 ml of medium plus 
150 µl of DMSO in a 1.5 ml cryogenic tube. DMSO is a cryoprotector agent that 
physically protects the cells from the forming ice crystals, changes in osmotic pressure 
or fast freezing. However the 10% DMSO used to freeze the cells is toxic at 37ºC, so 
cells must be frozen immediately at -80ºC in a recipient with isopropanol and stored in 
liquid N2 the following day.
Thawing the cells
Cells stored in the cryogenic tube are thawed in a 37ºC water bath. Then, they 
are diluted in 10 ml of medium and centrifuged at 1,200 rpm for 5 min to eliminate 
medium with DMSO. After that, cells are resuspended in the desired volume of medium 
and seeded. Medium is changed the next day.
3.4 MYCOPLASMA DETECTION AND TREATMENT
Mycoplasma species are the smallest known free- living organisms. They
constitute a common and pervasive tissue culture contaminant. The small size and the
lack of a cell wall make mycoplasmas extraordinarily difficult to detect by conventional 
methods. The effects of mycoplasma infection are significant, including changes in cell 
morphology, growth rates, viability and metabolic states9,10. These changes can
profoundly affect the results obtained in any cell culture-based bioassay system. 
The more frequent contaminants are the mycoplasma species M. orale and M.
hominis (human origin), M. arginini (bovine) and M. hyorhinis (porcine). Sources of 
mycoplasma contamination are water, medium, serum and the cells. Cell culture can be 
contaminated by breath from the pharynx (M. orale), by using contaminated serum or,
more frequently, by the parallel use of other contaminated cell cultures. Commercial 
serum and media are both tested for mycoplasma contaminations.
9 Barile MF, Razin S. The mycoplasmas, vol. I. Cell Biology. Academic Press, Inc., New York, 1979
10 Masover GK, Buck DW. Detecting mycoplasmas in cell cultures. Med. Device & Diagn. Ind. 5(11):43-48, 1983
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Mycoplasmas usually grow slowly in the cell culture without destroying the host
cells and without producing gross turbidity. They are resistant to many antibiotics, they 
pass easily through 0.22 µm filters and they are relatively difficult to detect by
microscopy, so the cells must be checked periodically. The most common methods for 
mycoplasma detection are based on fluorescence, PCR or immuno-detection. PCR
detection, which is rapid, simple and sensitive, was applied as follows.
Mycoplasma PCR detection in tissue culture
Mycoplasma PCR detection uses a pair of primers that detect all the most 
frequent Mycoplasma species without cross-reacting with other common tissue culture 
contaminants such as bacteria or yeasts. 
Cell culture must be kept for 3 days in the same medium without antibiotics to 
allow maximum mycoplasma expression. One dish containing medium alone must also 
be kept to check for medium contamination. After 3 days 1 ml of the supernatant of the 
culture dish and the dish with medium alone is taken and the PCR is done as follows:
Mycoplasma PCR mix
10X PCR buffer 5 µl
MgCl2 (50 mM) 1.5 µl
dNTPs (2 mM) 5 µl
primer Myc.for (50 µM) 1 µl
primer Myc.rev (50 µM) 1 µl
Taq polymerase (5U/µl) 0.25 µl
Sample 2 µl
bd. A.C. H2O 34.25 µl
(Total volume = 50 µl)
Samples consists of: 2 µl of the supernatant of the cell culture, 2 µl of only the 
medium, 2 µl of sterile water as a negative control, 2 µl of a positive control and 2 µl of
a 1/100 dilution in water of the supernatant cell culture sample, because the degree of 
infection is unknown for each sample and a high degree of infection will inhibit the 
PCR.
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The amplification product is a band of 500 bp and the PCR program is: 
Mycoplasma PCR
95ºC 5 min
94ºC 1 min
60ºC 1 min
72ºC 2 min
30 cycles from step 2
72ºC 10 min
4ºC 30 min
It is also possible to use a Mycoplasma PCR detection kit from Takara
Biomedicals (ref. 20-700-20).
Mycoplasma treatment
If the cell culture is contaminated it is advisable to start again with a non-
contaminated new stock of cells. Extra precautions should be taken to avoid
contamination, by cleaning incubators and hoods with an appropriate detergent for
mycoplasma (70% ethanol does not kill mycoplasma) or by autoclaving PBS, water, etc. 
(not media or trypsin...). 
When it is impossible to start again with a new stock treatment with BAYCIP 
(Bayer, ref. 982421) could be applied. For 3 weeks the cell culture must be grown and 
cultured normally in the medium plus 0.01 mg/ml of BAYCIP. The treatment must be 
repeated until mycoplasma PCR detection is negative.
3.5 CELL CULTURE TREATMENTS
3.5.1 Basal treatment
This basal treatment is applied before experiments such as CPTI activity assay, 
palmitate oxidation, insulin secretion or viability, where the presence of etomoxir is 
examined or when there is a need to complex free fatty acids to BSA.
Cells are washed in KRBH 0.1% (w/v) defatted BSA, preincubated at 37ºC for 
30 min in KRBH plus 1% BSA in the absence or the presence of 200 µM etomoxir and 
washed again with KRBH 0.1% BSA. After this, the desired experiment is performed.
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Since this treatment was done for insulin secretion experiments, it was chosen as 
the basal conditions for the rest of the experiments. Consequently, the cells started at the 
same point at the beginning of all experiments, and the results were therefore
comparable.
KRBH buffer: 135 mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.5 mM MgSO4, 1.5 
mM CaCl2, 2 mM NaHCO3 and 10 mM HEPES, pH 7.4. KRBH is prepared on the day
of the experiment as follows: 
KRBH buffer (100 ml)
5X KRB 20 ml
100 mM NaHCO3 2 ml
1M HEPES pH 7.4   1 ml
bd. H2O 77 ml
5X KRB: It contains CaCl2, which must be dissolved separately because it precipitates. 
5X KRB is stored at 4ºC.
5X KRB (500 ml)
NaCl 19.72 g
KCl 0.67 g
NaH2PO4 0.17 g
MgSO4 0.25 g
CaCl2 0.55 g
bd. H2O up to 500 ml
BSA: To prepare a 10% (w/v) stock of defatted BSA, 3 g of BSA (Sigma-Aldrich, ref.
A-6003) is dissolved in 30 ml of KRBH. Solution is divided into 1 ml aliquots and 
stored at -20ºC.
3.5.2 C75 treatment
For C75 experiments with culture cells, INS(832/13) and HEK 293 cells are
grown in 12-well plates or 15-cm dishes until confluence. Cells are incubated for 1 h at 
37ºC in complete culture medium with either C75 (Alexis Biochemicals, ref. 270-286-
Materials and methods
98
M005, 5 mg) at 10 or 30 µg/ml or etomoxir at 30 µg/ml. C75 and etomoxir are added 
from a 100 mM stock solution in DMSO. Control cells are incubated with the same 
volume of DMSO. After this time, cells are washed in PBS and the experiment is 
performed.
C75: The stock solution is prepared at 100 mM in DMSO and it is stored at -20ºC.
Etomoxir : The stock solution is prepared at 100 mM in DMSO. It is stored at -20ºC.
3.5.3 Doxycycline induction
For tet-on systems, doxycycline induction is performed by incubating the cells 
with complete medium containing 500 ng/ml of doxycycline (Sigma-Aldrich, ref. D-
9891, 25 g) for 24 h or with 75 ng/ml of doxycycline for 48 h. Doxycycline is 
distributed in 1.5 ml tubes, stored at 4ºC and used fresh by dissolving it in bd. A.C. 
water at the moment of utilization.
3.6 VIABILITY
The cytotoxic effect of C75 or naSREBP-1c expression on cell growth and 
viability was measured in culture cells. Quantification of cell proliferation or viability 
was performed with an assay based on the reduction of a tetrazolium salt to formazan by 
cellular mitochondrial dehydrogenases11. Expansion in the number of viable cells results 
in an increase in the overall activity of the mitochondrial dehydrogenases and
subsequently an augmentation in the amount of formazan dye formed. The formazan 
dye produced by viable cells is quantified with a spectrophotometer by measuring the 
absorbance at 570 nm. 
The procedure is as follows:
Cells grown in 12-well plates are treated with C75 or etomoxir in case of
INS(832/13) and HEK 293 or with doxycycline in case of naSREBP-1c stable cells, as 
described in CELL CULTURE TREATMENTS (Section 3.5). Cells are cultured for 2 h with 
1 ml of fresh medium plus 200 µl of MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-
11 Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity 
assays. J. Immunol. Methods. 65:55-63, 1983
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diphenyltetrazolium bromide solution). MTT is reduced by cellular mitochondrial
dehydrogenases giving blue crystals of formazan. After that, cells are gently collected in 
a 1.5 ml tube and washed twice in PBS. The pellet of cells is resuspended in 1 ml of 
MTT lysis solution and therefore, cells are lysated and the blue crystals are released and 
dissolved. The formazan dye produced is quantified with a spectrophotometer at 570 nm 
with the MTT lysis solution as the blank. Results are expressed as the percentage of 
absorbance related to control cells.
MTT solution (0.25%): 25 mg of MTT (Sigma-Aldrich, ref. M-2128, 1 g) is dissolved 
in 10 ml of PBS, filtered through a 0.22 µm filter and stored at 4ºC, light protected.
MTT lysis solution: 10% SDS and 1 mM acetic acid in DMSO. For 30 ml, 171.6 µl of 
acetic acid and 3 g of SDS are dissolved in 30 ml of DMSO. It is prepared on the day of 
the experiment.
It is also possible to use the Quick Cell Proliferation Assay Kit (LabForce, MBL, 
Nunningen, Switzerland) which is based on the same method described above.
3.7 APOPTOSIS
DNA fragmentation and mitochondrial cytochrome c release are characteristic 
hallmarks of cells undergoing apoptosis. Both experiments were done with naSREBP-
1c cells cultured with 500 ng/ml doxycycline for 4 days or with 75 ng/ml doxycycline 
for a week.
Experiments for DNA fragmentation were performed using a Quick Apoptosis 
DNA Ladder Detection Kit (LabForce, MBL) following the manufacturer’s protocol. 
To detect the mitochondrial cytochrome c release into cytosol, cells are grown in 
15-cm dishes, resuspended in buffer A and homogenized by a Dounce homogenizer. 
Cell debris and nuclei are removed by centrifugation at 1,000 x g for 10 min at 4ºC. The 
supernatant is further centrifuged at 10,000 x g for 20 min and the cytosolic proteins 
(supernatant fractions) are separated by 15% SDS-PAGE and analyzed by Western 
blotting with a specific antibody against cytochrome c (LabForce, MBL).
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Buffer A
HEPES-KOH, pH 7.5 20 mM
KCl 10 mM
MgCl2 1.5 mM
EDTA 1 mM
EGTA 1 mM
DTT 1 mM
Sucrose 250 mM
PMSF 1 mM
4. CELL TRANSFECTION BY CALCIUM PHOSPHATE
The calcium phosphate method was chosen for transient transfection, for
adenovirus production and also to generate stable clones because it is the best choice for 
stable transfection of INS-1 cells. 
In calcium phosphate mediated transfection, the calcium ions bind to the
negatively charged phosphate groups of DNA. When phosphate ions are added to the 
mixture, they bind ionically to the calcium ions resulting in the formation of a
crystalline complex which precipitates. Although the exact mechanism is not
understood, it is believed that the precipitate attaches to the cell surface and uptake into 
the cell occurs via endocytosis.
Calcium-phosphate-DNA coprecipitation
Five million of cells are seeded in 10-cm dishes. The next day, cells which are
approximately 50% confluent, are fed with 5 ml of fresh and complete medium 2 h 
before transfection. It is important to use cells in exponential growth because the 
efficiency of transfection is poor in slow-growing cells. Plasmid DNA is prepared, as 
clean as possible, at a concentration of 1-10 µg /µl in sterilized bd. water.
The solution A (DNA-Ca mix) is prepared under sterile conditions in a 1.5 ml 
tube as follows:
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DNA-Ca mix
DNA 30 µg
2 M CaCl2/Tris (pH 7.6) 62.5 µl
bd. H2O up to 500 µl
500 µl of 2X HEBS (pH 7.1), solution B, is placed in a 15 ml sterile tube. 
Solution A is added dropwise to solution B while gently vortexing. The precipitate is
incubated at r.t. for 40 min. It should be visible, i.e., the solution should appear opaque. 
The precipitate is mixed by vortexing and poured onto the cells that have 5 ml of 
medium.  Precipitates are left on cells for 24 h. By observing the culture under the 
microscope, a fine precipitate should appear and settle.
The day after it could be optionally done a glycerol shock. The transfection 
medium is aspirated, washed twice in medium and 3 ml of 15% glycerol (v/v in medium
and filtered through a 0.22 µm filter) is added for 4 min. Cells are rinsed twice with 
medium and cultured in complete medium for 24-48 h. 
After this, cells are either removed for transient transfection or split into two 10-
cm dishes for clones generation.
20X HEBS: 2.8 M NaCl, 15 mM Na2HPO4 and 0.5 M HEPES. For 50 ml: 
20X HEBS
NaCl 8.18 g
HEPES 5.95 g
Na2HPO4 0.1065 g
bd. H2O 40 ml to dissolve
pH 7.1
bd. H2O up to 50 ml
The solution is passed through a 0.22 µm filter and stored in a 5 ml sterile tube 
at -20ºC.
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2X HEBS: 280 mM NaCl, 1.5 mM Na2HPO4 and 50 mM HEPES. For 40 ml:
2X HEBS
20X HEBS 4 ml
bd. H2O 30 ml
pH to 7.1
bd. H2O up to 40 ml
The solution must be filtered through a 0.22 µm filter and used fresh or stored in 
5 ml sterile tube at -20ºC for less than 6 months. An exact pH is extremely important in 
order to get a fine precipitate. The pH must never be below 7.0 or above 7.1. 
2M CaCl2/Tris. For 30 ml:
2M CaCl2/Tris
CaCl2. 2H2O (Merck) 8.82 g
1 M Tris-HCl (pH 7.5) 3 ml
bd. H2O 20 ml to dissolve
1 M Tris-Base pH to 7.6
bd. H2O up to 30 ml
The solution must be filtered through a 0.22 µm filter and stored in 1.5 ml sterile 
tubes at -20ºC.
For adenovirus generation the cosmid was transfected onto HEK 293 cells by 
calcium phosphate using the CellPhect Transfection kit  from Amersham Pharmacia 
Biotech (ref. 27-9268-01).
5. STABLE CELLS CONSTRUCTION
Stable cells are constructed by integrating a gene of interest into a cell line. DNA 
is stably transfected by calcium-phosphate-DNA coprecipitation along with a selection
plasmid in much less amount than the target DNA. After 5 days, selection with the 
selection plasmid antibiotic is initiated, therefore cells which have not been transfected 
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with this selection plasmid die. Usually, a few clones appear 3 weeks later. As the DNA 
of interest was added in much larger amounts than the selection plasmid, these clones 
are also assumed to have integrated the target DNA. Its presence is checked by Western 
blot, enzyme activity, Northern blot, etc. The clone with the highest expression of the 
gene is chosen and it is continuously grown with the selection antibiotic in the medium. 
The procedure is as follows:
A) DNA transfection
Cells are grown in four 10-cm dishes until approx. 50% confluence (5 x 106
million of cells per 10-cm dish seeded the day before). Calcium phosphate transfection 
is done as described above with 25 µg of the DNA of interest and 5 µg of hygromycin
selection plasmid (pTK-Hyg). 48 h after the glycerol shock, cells are washed first with 
PBS and then with 5 ml of trypsin because cells are difficult to detach. Then, they are 
trypsinised in 3 ml of trypsin plus 7 ml of medium by up and down pipetting. One dish 
of 10-cm is split into 2 dishes of 10-cm with 5 ml of medium. 
B) Clones selection
Three days later, medium with 0.1 mg/ml hygromycin is added to the cells and 
thus clone selection is started. Medium is changed every 3-4 days and three weeks later 
clones are clearly visible by simply eye observation. Medium with hygromycin is used 
from this point on. The concentration 0.1 mg/ml of hygromycin in the medium is 
chosen because it is the enough amount of hygromycin to kill all normal cells after a 3-
day incubation.
C) Clones trypsinization
To trypsinise the clones it is used small glass cloning cylinders (Bellco Glass, 
Inc. Size: 6 x 8 mm, ref. 2090-00608), a glass petri dish and silicone grease (Bayer 
Baysilone, ref. 85402, 35 g). Cloning cylinders are kept in a bottle with detergent. The 
day before, cylinders are washed inside the bottle several times with water and then, 
they are sterilized in a beaker covered with aluminium foil at 180ºC o/n. Silicone grease 
is put onto the base of the glass petri dish and it is also sterilized at 180ºC o/n wrapped 
with aluminium foil.
Next, the process is done under the hood. Cells are first washed in PBS. Not all 
the PBS is aspirated to keep the cells moist. Some cloning cylinders are placed with one
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base in contact with the grease of the petri dish. With a forceps one cylinder is located 
onto one clone. The cylinder is adhered to the 10-cm dish with silicone and the clone is
thus in the middle of the cylinder and isolated from the rest of the dish. After that, 30 µl
of trypsine is added to each clone. Five min later, 50 µl of medium is added to each 
clone and by up and down pipetting clones are detached and placed into one well of a 
24-well plate. Clones are grown for 2 weeks and medium is changed every 3-4 days. 
D) Clones growth and analysis
When clones have grown until 80% confluence, each clone is detached and split 
into one well of two 12-well plates. Clones grown in one 12-well plate will be analyzed 
by Western blot and the other 12-well plate will be used to keep on growing the clones 
to do more experiments. The clone with a higher expression of the target gene is chosen.
6. ADENOVIRUS CONSTRUCTION AND UTILIZATION
The ability to transfer DNA rapidly and efficiently in mammalian cells has been
improved by the development of a number of gene transfer vectors and techniques 
based on the properties of DNA viruses such as adenovirus, retrovirus and adeno-
associated virus. Among them, we have used the adenoviruses for gene delivery because 
of their growth and infectivity characteristics. Adenovirus rapid and efficiently deliver 
DNA into a wide range of mammalian cell types, including primary cell types with low 
replicative activity such as cells of the islets of Langerhans with a transfer efficiency of 
70-80%, and to insulinoma cell line models with an efficiency approaching 100%.
Moreover, they express relatively large DNA inserts (up to 5-7 kbp) and propagate
stable high-titer viral stocks. Adenovirus integrates into genomic DNA with very low 
efficiency and exists predominantly in an episomal mode, therefore the expression of 
the transgene is transient12.
12 Becker TC, Noel RJ, Coats WS, Gómez-Foix AM, Alam T, Gerard RD, Newgard CB. Use of Recombinant 
adenovirus for metabolic engineering of mammalian cells. Methods in cell biology. 43:161-189, 1994
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6.1 ADENOVIRUS BIOLOGY
Adenoviruses (Ad) are a large family of nonenveloped, double-stranded DNA 
viruses. The virus was originally isolated from human adenoidal tissue in 195313.
Human adenovirus serotypes 2 (Ad2) and 5 (Ad5) are the most extensively studied. For 
our study we chose the Ad5.
The adenoviral particle consists of an icosahedral protein capsid approximately
75 nm in diameter encasing a double-stranded DNA molecule of approx. 36 kb (see fig. 
2). The most abundant viral protein is hexon, which makes up most of the outer shell of 
the virus. At each vertex there is a complex composed of the penton base and fiber 
proteins, both of which interact with cellular receptors during the process of virus 
infection. Ad DNA is packaged in a complex with several viral proteins and each end of 
the chromosome is covalently attached to a single molecule of terminal protein (TP). TP 
acts as a primer for DNA synthesis and also anchors the viral chromosome to the 
nuclear matrix. 
Fig. 2. Cross section of the adenovirus particle. Hexon protein makes up most of the capsid by mass. A complex of 
penton base and fiber proteins is located at each vertex. The 36-kb double-stranded DNA chromosome is packaged as 
a complex with protein VII, and one molecule of terminal protein is attached covalently at each end.
13 Rowe WP, Huebner RJ, Gilmore LK, Parrott RH, Ward TG. Isolation of a cytopathogenic agent from human 
adenoids undergoing spontaneous degeneration in tissue culture. Proc. Soc. Exp. Biol. Med. 84:570-573, 1953
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The lytic life cycle of the wild-type virions can be divided into early and late 
phases, which are defined as occurring before and after the onset of viral DNA
replication, respectively. Therefore the adenoviral genome could be classified into early 
(E1, E2, E3 and E4) genes and late genes. Strategies for adenovirus vector design are 
focused on deleting portions of the genome to allow packaging of relatively large DNA 
inserts. Wild-type adenovirus can only accommodate 2 kbp of foreign DNA, but
deletion of E1 and E3 genes can allow recombinants with inserts up to 7 kbp. Deletion
of the E1 gene blocks most viral gene expression as well as DNA synthesis and 
therefore renders Ad replication defective. E3 proteins are involved in evading the host 
antiviral immune response. By using a replication-defective Ad vector, cells can be 
infected without grossly perturbing normal functions, thus allowing analysis of the 
functional properties of the recombinant protein.
In the case of deletion of the essential E1 gene, viral propagation is conditional 
because the function of the E1 gene must be provided in trans. This is achieved by 
growing E1-deleted recombinant virus in the HEK 293 cell line, which was originally 
transformed with Ad5 and contains the left 14% of the adenovirus genome integrated 
into cellular DNA, including the E1 region14.
Although the recombinant virus cannot propagate in cells other than HEK 293 
cells, if it attaches to the skin or the airway, it efficiently enters cells and expresses the 
target gene. Therefore, the use of security measures such as a safety hood to prevent 
inhala tion or adhesion of the virus is strongly recommended. 
6.2 PRINCIPLES OF GENERATION OF RECOMBINANT ADENOVIRUSES
The recombinant adenovirus cosmid was obtained using the Adenovirus
Expression Vector kit (Takara, ref. 6170). It is based on the DNA-TPC (terminal protein
complex) method15. Cosmid DNA is transfected into HEK 293 cells along with an
adenovirus DNA-TPC complex that has been digested by a restriction enzyme that cuts 
the viral backbone many times. Fragmentation of the viral backbone reduces
background due to the carryover of donor virus or to religation of its fragments. 
14 Graham FL, Smiley J, Russeell WC, Nairn R. Characteristics of a human cell line transformed by DNA from 
human adenovirus type 5. J. Gen. Virol. 36:59-72, 1977
15 Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda D, Saito I. Efficient generation of 
recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length
virus genome. Proc. Natl. Acad. Sci. U.S.A. 93:1320-1324, 1996
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Homologous recombination between the cosmid and the terminal fragments of the 
donor viral DNA regenerates a full- length chromosome that has a molecule of TP 
covalently attached at each end. Therefore, the desired recombinant adenovirus can be 
obtained with high viral particles production efficiency.
To generate a recombinant adenovirus the subsequent steps are followed: cosmid 
construction, cotransfection in HEK 293 cells, recombinant viruses analysis,
purification and titration. See fig. 3.
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Fig. 3. Principles of generation and use of recombinant adenoviruses. In the first step the desired target DNA is 
inserted into the cosmid vector. Then, the recombinant cosmid and the DNA-TPC, which has been digested with a 
restriction endonuclease, are cotransfected into HEK 293 cells. Homologous recombination occurs in the cells, and 
recombinant adenoviruses are generated. Since HEK 293 cells express E1 gene, non-proliferative type recombinant 
adenoviruses can proliferate. Adenoviruses are used to infect target cells where the desired protein is expressed 
without adenovirus replication.
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6.3 COSMID CONSTRUCTION
A) Cosmid digestion
The cosmid pAxCA wt (1.5 µg) is digested with SwaI at 25ºC for 3 h. The 
digestion is checked by resolving 1 µl of the digestion mixture in a 0.4% agarose gel. 
Then, the cosmid is dephosphorylated with CIP for 1 h at 37ºC. After CIP inactivation 
the cosmid is purified by phenol/chloroform extraction and precipitated with ethanol. 
The cosmid concentration is quantified by fluorescence in an agarose gel.
B) Plasmid digestion
The insert DNA fragment is prepared by digesting 10−20 µg of plasmid with the 
appropriate enzymes. The DNA is resolved in an agarose gel and the desired DNA 
fragment is purified. If the terminals are not blunt, they are made blunt-end using the 
Pfu DNA polymerase and the DNA fragment is purified by phenol/chloroform
extraction and precipitated with ethanol. The concentration is quantified by fluorescence 
in an agarose gel.
C) Ligation
0.2 µg of insert DNA is added to the digested and dephosphorylated cosmid, 
they are co-precipitated with ethanol and ligated at 25ºC for 30 min. The ligation is 
checked by PCR.
D) Recombinant cosmid packaging and transformation
4 µl of the cosmid ligation mixture is packaged, transformed in XL1-Blue cells 
and plated in ampicillin/tetracycline plates as described in Section 1.9.2.
E) Recombinant cosmid analysis
The bacterial colonies obtained are analyzed by PCR-Preps and the positive 
colony containing the desired recombinant cosmid is amplified performing a
maxipreparation. The presence and right orientation of the insert are checked by
restriction enzyme digestions using ClaI and BglII and the presence of a mutation by 
sequencing.
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6.4 COTRANSFECTION IN HEK 293 CELLS
The recombinant cosmid (8 µg) is cotransfected along with 1 µg of DNA-TPC
by calcium phosphate (CellPhect, Amersham Pharmacia Biotech) in HEK 293 cells
grown in a 25-cm2 flask until 80% confluence. Cells are incubated o/n without
removing the precipitate and on the morning of the next day the medium is changed. In 
the afternoon, cells are resuspended in 10 ml of 5% FCS-medium and undiluted cells or
1/10 and 1/100 dilutions are distributed in three 96-well plates with 100 µl per well. The
desired recombinant adenovirus is generated by overlapping recombination. 
After 5-6 days, as cells continue growing 50 µl of 10% FCS-medium is added to 
each well to avoid cells dying of starvation. Approximately 8-15 days after transfection
it is possible to see that in some wells cells start to be more rounded, inflated and 
detached indicating that they contain the viruses. The content of these wells (viral
clones) is placed in 1.5 ml tubes and is frozen in liquid N2 and thawed in a water bath at
37ºC three times to liberate the adenoviruses which remain in the cells. Then, tubes are 
centrifuged at 5,000 rpm for 5 min and the supernatant is stored at -80ºC as the first 
seed.
6.5 RECOMBINANT ADENOVIRUS ANALYSIS
Co-transfection of the cosmid and the DNA-TPC could give recombinant
adenoviruses carrying or not the desired DNA. Clones obtained after HEK 293
transfection are analyzed by Western blot performed in the target cells, i.e. INS(832/13) 
cells.
INS(832/13) cells are grown in 24-well plates until 90% confluence. Cells of one 
well are infected with 1-10 µl of each viral clone suspension (first seed) in 0.1 ml of 
medium. After 1 h viral suspension is removed, fresh medium is added and cells are 
further cultured for approx. 48h. 
All the cells from one well are resuspended in 80 µl of 1X loading buffer and
directly analyzed by Western blot probed with LCPTI-specific antibody. The viral clone 
that gives the highest protein expression is selected.
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6.6 ADENOVIRUS PURIFICATION
Once the desired viral clone is selected it is amplified and purified. This purified
adenovirus does not contain proteins or cellular membranes that are present in the HEK 
293 cell- lysate and is therefore preferred for infection of INS(832/13) cells or rat islets.
A) Amplification
HEK 293 cells grown in a 24-well plate until 90% confluence are infected with 
10 µl of the viral suspension of the first seed in 0.1 ml of 5% FCS-medium per well.
After 1 h, 0.4 ml of 5% FCS-medium is added. When cells start to detach,
approximately 3 days after infection, the culture medium containing the  cells is
collected and is frozen/thawed 3 times in liquid N2 and a water bath at 37ºC. Cell debris 
are removed by centrifugation at 3,000 rpm for 10 min at 4ºC and the supernatant 
obtained will be the second seed.
To obtain the third seed, 15 µl of the second seed along with 0.5 ml of 5% FCS-
medium is used to infect HEK 293 cells grown in a 25-cm2 flask until 70% confluence. 
After 1 h, 4.5 ml of 5% FCS-medium are added and 3-4 days later, when cells have 
died, the medium containing the cells is collected. After 3 freeze-thaw cycles cell debris 
are removed as described above and the third seed obtained is stored at -80ºC in 1 ml 
aliquots.
To obtain the fourth seed, 50 µl of the third seed along with 2 ml of 5% FCS-
medium is used to infect HEK 293 cells grown in a 75-cm2 flask until 70% confluence. 
After 1 h, 13 ml of 5% FCS-medium are added and 3-4 days later, when cytopathic
effects are complete, the medium containing the cells is collected. After 3 freeze-thaw
cycles cell debris are removed and the fourth seed is stored at -80ºC in 1 ml aliquots. 
This suspension has a high titer of about 109 pfu/ml (plaque forming units of adenovirus 
per ml). 
To obtain the final amplification, 400 µl of the fourth seed along with 9 ml of 
5% FCS-medium per dish is used to infect HEK 293 cells grown in eight 150-cm dishes 
until 60% confluence. After 1 h, 6 ml of 5% FCS-medium is  added to each dish and 3-4
days later, when cells just start to detach but are not completely died, the medium 
containing the cells is collected in 50 ml tubes. Cells are pelleted by centrifugation at 
1,000 rpm for 10 min at r.t. After that, cells are resuspended in 6 ml of 10 mM Tris-HCl
pH 8. To liberate the adenoviruses which are inside the cells, the suspension is
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subjected to 3 freeze-thaw cycles and centrifuged at 3,000 rpm for 10 min at 4ºC. The 
supernatant containing the adenovirus is stored at -80ºC.
B) Purification
The adenovirus was purified by the CsCl method16 which is extremely effective
and gives a final adenovirus titer of about 109-1010 pfu/ml. Adenovirus can also be 
purified chromatographically with the Adeno-XTM Virus Purification Kit (Clontech, ref. 
K1654-1).
The CsCl purification is as follows:
The supernatant containing the adenovirus from the final amplification is poured
onto 5 ml of a CsCl (density 1.43) solution in an ultraclear tube (Beckman, ref. 344059). 
Without mixing, the solution is ultracentrifuged at 25,000 rpm for 1 h at 4ºC in a 
Sw41Ti rotor using the mode 7 for acceleration and brake. After centrifugation a white 
adenovirus ring appears approximately in the middle of the tube. The virus layer (about 
2.5 ml) is collected carefully using a syringe and mixed with 8 ml of CsCl (density 
1.34) solution. The counterweight is also prepared with CsCl (density 1.34) solution. 
Tubes are ultracentrifuged at 30,000 rpm for 19-21 h (o/n) at 4ºC in a Sw41Ti rotor 
using the mode 7 for acceleration and brake. The white adenovirus ring of about 1-2 ml 
is collected using a syringe. 
CsCl (density 1.43) solution: 8.3 g of CsCl powder (Applichem, ref. A1126) are
dissolved in 12 ml of bd. autoclaved water. The solution is sterilized by filtering.
CsCl (density 1.34) solution: 7.6 g of CsCl powder are dissolved in 14.5 ml of bd. 
autoclaved water. The solution is sterilized by filtering.
C) Adenovirus concentration
The virus solution is loaded onto a Sephadex column (Pharmacia PD-10, ref. 17-
0851-01) which has been previously equilibrated with 25 ml of adenovirus elution
buffer. When the virus solution has completely entered the column, 3.5 ml of the 
adenovirus elution buffer is added on top of the column and the eluted solution is
16 Graham FL, Prevec L. Manipulation of adenovirus vectors. In Methods in Molecular Biology, vol. 7: Gene transfer 
and expression protocols. Ed. Murray, EJ. (Human Press Inc., Clifton, NJ). 109-128, 1991
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collected in 1.5 ml tubes in 8 drops fractions. The adenovirus peak is determined by
measuring the absorbance at 260 nm using 1/50 dilutions of the fractions in water. 
During this time the adenovirus fractions are kept on ice. Those fractions in which 
absorbance at 260 nm is higher than 0.05-0.07 are combined. The adenovirus is stored 
in 0.1% BSA plus 10% glycerol at -80ºC in 10 µl one-use aliquots.
Adenovirus elution buffer: 137 mM NaCl, 5 mM KCl, 1 mM MgCl2 and 10 mM Tris-
HCl pH 7.4
6.7 ADENOVIRUS TITRATION
Quantification of adenoviral stocks, i.e. the determination of the viral plaque
forming units (pfu) per ml, is important to ensure consistency between samples and to 
achieve the right level of transient expression. Careful titration was done using the 
Adeno-XTM Rapid Titer kit (Clontech, ref. K1653-1). This method takes advantage of
production of viral hexon proteins for the quantification of viral stocks. Dilutions of the 
viral stock are used to infect HEK 293 cells. Just 48 h later, these cells are fixed and 
stained with the antibody specific to the adenovirus hexon protein. Signal is detected 
after a secondary antibody conjugated with horseradish peroxidase (HRP) amplifies the 
signal of the antihexon antibody. Subsequent exposure to metal-enhanced 3,3’-
diaminobenzidine (DAB) peroxidase substrate turns only the infected cells dark brown.
Then the titer of the stock can be determined by counting the number of brown cells in a 
given area. Each stained cell corresponds to a single infectious unit.
The titration procedure is as follows:
One milliliter of HEK 293 cells (5 x 105 cells/ml) is seeded in each well of a 12-
well plate. Using medium as diluent, 10-fold serial dilutions from 10-2 to 10-7 of the 
viral stock are prepared and 100 µl of each one is added to each well. After 48 h of 
incubation, medium is aspirated and cells are allowed to dry in the hood for 5 min. 
Then, cells are fixed by adding very gently without dislodging the cell monolayer, 1 ml 
of ice-cold 100% methanol to each well. After keeping them at -20ºC for 10 min they
are gently rinsed three times with 1 ml PBS + 1% BSA (Sigma, Fraction V, ref. A-
3803). Cells are then incubated for 1 h at 37ºC with 0.5 ml/well of Anti-Hexon
Antibody diluted 1/3,000 in PBS + 1% BSA. Next, cells are gently rinsed three times 
with 1 ml PBS + 1% BSA and incubated for 1 h at 37ºC with 0.5 ml/well of Rat Anti-
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Mouse Antibody (HRP conjugate) diluted 1/500 in PBS + 1% BSA. The rinsing steps 
are repeated as before and then cells are finally incubated at r.t. for 10 min with 500 
µl/well of the DAB substrate.
To calculate the titer of the viral stock the DAB substrate is aspirated, 1 ml PBS 
is added to each well and at least three fields of brown/black positive cells are counted 
on a microscope with a 20X objective. The pfu/ml is calculated from the resulting 
average number of positive cells/unit dilution as follows:
Adenovirus titer (pfu/ml) = [(infected cells/field) x 573] : [0.1 x dilution factor]
Where 573 is the number of fields/well in a 20X objective and 0.1 is the volume 
of viral dilution used in ml.
6.8 ADENOVIRUS INFECTION
70-80% confluent cells are infected with adenovirus over a 90 min incubation 
with medium plus adenovirus. Then, medium is aspirated and cells are cultured in fresh 
medium for 24 h to allow the transgenes to be expressed before initiating metabolic 
studies or measurements of insulin secretion. At these incubation times no toxicity
effect of the adenoviruses was seen.
For INS(832/13) cells the protocol of infection is as follows:
INS(832/13) cells are homogeneously seeded in 12-well plates (0.5 x 106
cells/well), 25-cm2 flasks (2 x 106 cells), 10-cm dishes (7 x 106 cells) or 15-cm dishes 
(10 x 106 cells) depending on the experiment and further cultured for 48 h before 
infection. On the day of the infection, cells of one well or one dish are detached and
counted to calculate the required amount of virus. Cells are infected with 4.1 pfu/cell of 
Ad-LacZ (which expresses bacterial β-galactosidase), 1.7 pfu/cell of Ad-LCPTI wt or 
4.1 pfu/cell of Ad-LCPTI M953S. The required amount of each adenovirus is mixed 
with complete medium in 15 ml tubes. Infection is done in approx. ¼ volume of the 
total volume of the well or dish,  i.e. in 500 µl of medium for 12-well plates or in 5 ml of 
medium for 15-cm dishes. Therefore, proximity of the virus to the cells is enhanced. 
Cells are incubated with the different adenoviruses at 37ºC for 90 min. After this time,
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medium is aspirated and cells are cultured in fresh medium for further 24 h before the
experiment.
7. PROTEIN ANALYSIS
7.1 BRADFORD PROTEIN QUANTIFICATION 
The protein determination method introduced by Bradford17 is based on the fact 
that some colorants, when adsorbing onto protein molecules, change their absorption 
spectrum. The Bradford reagent contains copper in an acid medium of orthophosphoric 
acid and methanol. When the protein binds to copper its absorption maximum shifts in 
an acidic solution from 465 to 595 nm. This method, which has little interference, has 
large sensitivity and linearity. 
Protein is measured according to the manufacturer’s instructions (BioRad
protein assay), using BSA as a protein standard in the range of 2-20 µg/ml. Bradford 
reagent is diluted 1/5 in water and stored at 4ºC for about 2 months. BSA standard stock 
is prepared in water at 1 µg/µl and the absorbance of the blank, standard curve or the 
samples is measured at 595 nm in a spectrophotometer with plastic cuvettes in a total 
volume of 1 ml.
Sample Volume Bradford reagent
blank - 1000 µl
BSA 2 µg 2 µl 998 µl
BSA 5 µg 5 µl 995 µl
BSA 10 µg 10 µl 990 µl
BSA 15 µg 15 µl 985 µl
BSA 20 µg 20 µl 980 µl
Problem 2-10 µl up to 1000 µl
7.2 WESTERN BLOT
The Western Blot technique detects, with a specific antibody, a protein between 
a sample of proteins that have been separated by electrophoresis and transferred to a 
17 Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the 
principle of protein-dye binding. Anal. Biochem. 72:248-254, 1976
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nitrocellulose membrane. Western blot was applied for the analys is of LCPTI, SREBP-1
and PKC proteins. The procedure has the following steps: electrophoresis, transference, 
antibody incubation (Western Blot) and detection.
A) Electrophoresis
Electrophoresis in polyacrylamide-SDS gels (SDS-PAGE) is the most widely 
used technique for resolving proteins denatured with SDS. Proteins and protein subunits 
are separated by its molecular weight when they are migrating through the gel towards 
the anode. 
Sample preparation: For LCPTI or naSREBP-1c proteins, cells are directly
detached from one well of a 12-well plate, which contains approx. 50 µg of protein, by
resuspending them in 80-100 µl of 1X loading buffer. This loading buffer contains the 
denaturalizing agent SDS and β-mercaptoethanol that reduces disulfide bonds. For PKC
protein, cytosol or membrane fractions were diluted in 4X loading buffer. Samples are 
sonicated and dissolved by heating to 95ºC for 5 min. Then, they are briefly centrifuged 
and placed on ice before loading on-to the gel. Samples could be stored in loading
buffer at -20ºC for 4-6 months. However, after 10 or more freeze-thaw cycles the 
proteins will begin to degrade and fail to give sharp bands.
Gel preparation: For LCPTI and PKC proteins, an 8% separating gel is prepared 
(9% for naSREBP-1c protein). Separating gel is prepared by adding the polymerizing 
agent TEMED at the end and it is immediately cast between the two ethanol cleaned 
glasses of the electrophoresis apparatus. Some drops of isopropanol are added on the 
top to achieve a straight edge of the gel. Once the gel is polymerized isopropanol is 
removed. Then, stacking gel is prepared and cast and a 1.5 mm comb is adjusted
between the two glasses. Both the separating and stacking gel take approximately 30 
min to polymerize. Bubbles must be avoided during all the process.
Electrophoresis performance: To run the electrophoresis, the 1.5 mm comb is 
removed and electrophoresis buffer is added on to the electrophoresis chamber and on 
to the sample loading wells. Samples and protein marker (Invitrogen, ref. LC5925) are 
loaded on to the gel and electrophoresis is performed at a constant current of 25 mA for 
1 h approximately. Electrophoresis is stopped when bromophenol blue is just off the 
bottom of the gel. 
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1X Loading Buffer: 62.5 mM Tris-HCl pH 6.8, 4% SDS, 5% β-mercaptoethanol, 10% 
glycerol and 10% bromophenol blue. It is stored at -20ºC in 1 ml aliquots for 4-6
months. For 25 ml:
1X Loading Buffer
1.25 M Tris-HCl pH 6.8 1.25 ml
SDS 0.5 g
β-mercaptoethanol 1.25 ml
glycerol (87%) 2.9 ml
bromophenol blue 2.5 mg
H2O up to 25 ml
SDS-PAGE recipes for one 1.5 mm gel:
Separating gel 8% 9%
bd.H2O 4.4 ml 4.2 ml
40% Acrylamide 1.5 ml 1.7 ml
1.875 M Tris-HCl pH 8.8 1.5 ml 1.5 ml
10% SDS 75 µl 75 µl
10% ammonium persulphate 25 µl 25 µl
TEMED 3.75 µl 3.75 µl
Total volume for one 1.5 mm gel = 7.5 ml 7.5 ml
Stacking gel
bd.H2O 1.8 ml
40% Acrylamide 0.4 ml
1.25 M Tris-HCl pH 6.8 250 µl
10% SDS 25 µl
10% ammonium persulphate 8.5 µl
TEMED 2.5 µl
Total volume for one 1.5 mm gel = 2.5 ml
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Acrylamide is a potent cumulative neurotoxin. Contact with the skin and
inhalation must be avoided. 10% Ammonium persulphate is prepared by dissolving 0.5 
g of ammonium persulfate in 5 ml of bd. H2O and it is stored at -20ºC.
Electrophoresis buffer: 25 mM Tris, 192 mM glycine and 0.1% SDS. It is stored at r.t. 
For 1 L:
Electrophoresis buffer
Tris 3.03 g
Glycine 14.42 g
SDS 1 g
H2O up to 1 L
B) Transference
Once electrophoresis is finished, stacking gel is removed and proteins in the 
separating gel are transferred to a nitrocellulose membrane for its later antibody
incubation. The transference sandwich contains, in the following order from the
negative to the positive pole: a sponge, 3 Whatman papers, the gel, the nitrocellulose 
membrane, 3 Whatman papers and another sponge. All must be submersed in transfer 
buffer avoiding bubbles. Whatman papers and the nitrocellulose membrane must have 
the same size as the gel. The side of the membrane in contact with the gel is marked to 
identify the side where proteins are, for later antibody incubation and detection. The 
transference is performed at 4ºC for 1 h at 250 mA or for 2 h at 125 mA. Once it is 
finished, membrane is washed in water and effectiveness of the transference is checked 
by Ponceau S solution (Sigma-Aldrich, ref. P-7170) staining of the protein bands. To 
remove the red staining, membrane is washed in PBS-Tween for a few minutes.
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Transfer buffer: 20 mM Tris, 20% methanol and 150 mM glycine. It is stored at 4ºC.
Transfer buffer
Tris 2.42 g
Glycine 12 g
Methanol 200 ml
H2O up to 1 L
PBS-Tween: Tween 0.1% in 1X PBS. 1 ml of Tween-20 is diluted in 1000 ml of PBS. It 
is stored at r.t.
C) Antibody incubation
For the immunoblotting, we used the Enhanced ChemiFluorescence (ECF)
Western Blotting kit (Amersham Biosciences, ref. RPN 5781-anti-mouse and RPN
5783-anti-rabbit), which allows the use of a Storm 840 Laser scanning system
(Molecular dynamics, Amersham Pharmacia Biotech) to quantify by fluorescence the 
intensity of the bands. This immunodetection permits the use of either anti-mouse (for 
PKC) or anti-rabbit (for LCPTI) alkaline phosphatase- linked immunoglobulin, followed 
by addition of ECF substrate. The alkaline phosphatase catalyses the conversion of ECF 
substrate to a highly fluorescent product which fluoresces strongly at 540-560 nm. 
According to the manufacturer’s instructions the protocol is as follows:
Blocking the membrane: Non-specific binding sites are blocked by immersing 
the membrane in blocking solution for 1 h on an orbital shaker at r.t. After this time, 
membrane is rinsed and washed once for 15 min and twice for 5 min in PBS-Tween on 
an orbital shaker. 
First antibody incubation: First antibodies used were the rabbit LCPTI-specific
polyclonal antibody against amino acids 317-430 of the rat liver CPTI18, the mouse anti-
PKC monoclonal antibody specific for the conventional PKC isoforms present in the 
pancreatic β-cell: α, β  and γ (MC5, Santa Cruz Biotechnology, Santa Cruz, CA) and the 
antibody against the N terminus of SREBP-1 (Santa Cruz Biotechnology). First
antibody is diluted (1/6,000 for LCPTI Ab., 1/100 for PKC Ab. or 1/1,000 for SREBP 
18 Prip-Buus C, Cohen I, Kohl C, Esser V, McGarry JD, Girard J. Topological and functional analysis of the rat liver 
carnitine palmitoyltransferase 1 expressed in Saccharomyces cerevisiae. FEBS Lett. 429(2):173-178, 1998
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Ab.) in blocking solution. Incubation is done over 1 h at r.t. or o/n at 4ºC on an orbital 
shaker. After this time, membrane is rinsed and washed once for 15 min and twice for 5 
min in PBS-Tween on an orbital shaker. The first antibody could be reused by storing it 
at -20ºC.
Second antibody incubation: The second antibody (anti- rabbit for LCPTI or anti-
mouse for PKC) is diluted 1/10,000 in PBS-Tween. Incubation is done over 1 h at r.t. on 
an orbital shaker. After this time, membrane is rinsed and washed once for 15 min and 
twice for 5 min in PBS-Tween on an orbital shaker. 
Blocking solution: 5% (w/v) skimmed milk in PBS-Tween.
Blocking solution
skimmed milk 2.5 g
PBS-Tween 50 ml
pH is adjusted to 7.4 with KOH
D) Detection
The membrane is incubated for 20 min with the ECF substrate. The volume of 
ECF should be enough to cover the membrane surface. After this time, the membrane is 
drained and placed directly on to the sample holder of the fluorescence scanning
instrument and intensity of the bands is quantified.
7.3. IMMUNOFLUORESCENCE
The immunofluorescence technique permits the localization of a protein inside 
the cell using a confocal fluorescent microscope. Cells have to be fixed, permeabilized 
and incubated with a specific antibody. Immunofluorescence staining was performed for 
the subcellular detection of naSREBP-1c protein in naSREBP-1c stable cells. 
The protocol for the immunofluorescence technique is as follows:
A) Preparing the cells
On the hood, one flamed glass coverslip is located in each well of a 6-well plate. 
1 ml of polyornithine solution is added to the wells to facilitate the later attachment of 
the cells onto the coverslip. After 30 min, polyornithine solution is removed and 
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coverslips are washed twice with PBS. 0.2 x 106 cells are seeded in each well and 
grown in 2 ml of medium for 48 h. If desired, cells are treated during this period. 
B) Fixing the cells
A piece of parafilm is placed onto the base of a 15-cm dish and the coverslips 
with the cells are located onto the parafilm. Cells must never become dry. Cells are 
washed in 500 µl of PBS and 100 µl of 4% (w/v) paraformaldehyde in PBS is added to 
each coverslip to fix the cells for 10 min at r.t. Then, cells are washed twice with PBS. 
C) Permeabilizing the cells 
Cells are permeabilized for 10 min with 100 µl of 0.1% (v/v) Triton X-100 in 
PBS containing 1% BSA. Then, cells are washed in PBS.
D) Blocking and first antibody incubation
Cells are blocked for 1 h with 100 µl of 1% BSA-PBS, washed in PBS and 
incubated o/n with 100 µl of the first antibody diluted in 1% BSA-PBS (1/100 dilution 
in the case of SREBP-1 antibody).
E) Second antibody incubation
Cells are washed five times with PBS, incubated for 1 h with 100 µl of the 
second fluorescent antibody diluted in 1% BSA-PBS and washed again 4 times with 
PBS. Coverslips are maintained isolated from the light to avoid loss of fluorescence.
F) Immunofluorescence detection
One drop of mounting medium for fluorescence (Vectashield, ref. H-100,
Vector) is placed onto a glass microscope slide. Coverslips are drained with a Whatman
paper, without touching the cells, and located onto the microscope slide with the cells 
facing the drop of mounting medium. Cells are dried at r.t. and stored at 4ºC until 
visualizing them on the confocal fluorescent microscope. 
Polyornithine solution: Polyornithine (Sigma-Aldrich, ref. P-3655) is used to increase 
the attachment of the cells to the surface. Polyornithine has positive charge, therefore 
cells that have negative charge attach to it. To prepare the polyornithine solution, 1 g of 
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polyornithine is dissolved in 100 ml of bd. A.C. water. Then it is filtered through a 0.22 
µm filter, aliquoted and stored at 4ºC. 
8. CPTI ACTIVITY ASSAY
CPTI activity assays were performed with mitochondrion-enriched fractions 
from cell culture or mitochondria extracted from mice tissues. Fresh mitochondria are 
used for the CPTI activity assay or stored at -80ºC.
8.1 ISOLATION OF MITOCHONDRIA
8.1.1 Mitochondria from cell culture
To obtain the mitochondrion-enriched fractions, cells are washed in PBS and 
resuspended in 2 ml of the same solution. All the process is performed at 4ºC. Cells are
centrifuged for 5 min at 1,200 x g and after resuspension in 1 ml of homogenization 
buffer A, they are broken with a glass homogenizer fitted with a loose and a tight pestle.
20 cycles are done with each one. Further centrifugation is performed for 3 min at 2,000
x g to remove cell nucleus and membranes. Supernatant is centrifuged at 16,000 x g for 
30 min and mitochondria are resuspended in 25 µl of homogenization buffer A. The
concentration of the mitochondria obtained, quantified by the Bradford assay, is approx. 
3-5 µg/µl and 8-10 µg is used for the CPTI activity assay.
8.1.2 Mitochondria from mouse liver and pancreas
The tissue of interest is homogenized in an isotonic cold sucrose solution and 
mitochondria are separated from the other cellular components by centrifugation.  All 
the process is performed at 4ºC.
To obtain mitochondrion-enriched fractions from liver19, mice liver weighing
approx. 1 g is mechanically homogenized in 1/10 (w/v) buffer B, using a Potter-
Elvehjem homogenizer (600 rpm; 6 strokes). Liver suspension is centrifuged for 15 min 
at 560 x g and the supernatant is centrifuged again for 20 min at 12,000 x g. Pellet is
resuspended in 2 ml of homogenization buffer B, centrifuged for 10 min at 7,000 x g,
washed and finally resuspended in 1 ml of homogenization buffer B. The concentration 
19 Saggerson ED, Carpenter CA. Carnitine palmitoyltransferase in liver and five extrahepatic tissues in the rat. 
Inhibition by DL-2-bromopalmitoyl-CoA and effect of hypothyroidism. Biochem. J. 236:137-141, 1986
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of the mitochondria obtained, quantified by the Bradford assay, is approx. 4-10 µg/µl
and 20 µg is used for the CPTI activity assay.
To obtain mitochondrion-enriched fractions from pancreas20, mice pancreas is
mechanically homogenized (1,000 rpm; 10 strokes) in 1 ml of homogenization buffer C. 
Solution is centrifuged at 900 x g for 10 min to remove cell nucleus, membranes and 
unbroken cells. Supernatant is centrifuged at 5,500 x g for 10 min and pellet is
resuspended with a Dounce homogenizer. The homogenate is centrifuged at 2,000 x g
for 2 min and the supernatant is further centrifuged at 4,000 x g for 8 min. Pellet is 
resuspended in 250 µl of homogenization buffer A and 20 µg of mitochondria is  used 
for the CPTI activity assay.
Homogenization buffer A: It is stored at r.t.
KCl 150 mM
Tris-HCl pH 7.2 5 mM
Homogenization buffer B: It is stored at 4ºC.
Sucrose 250 mM
EDTA 1 mM
Tris-HCl pH 7.4 10 mM
Homogenization buffer C: It is stored at 4ºC and proteases inhibitors are added on the
day of the experiment.
Tris-HCl pH 7.4 20 mM
EDTA 0.5 mM
EGTA 0.5 mM
Sucrose 250 mM
DTT 1 mM
Leupeptin 10 µg/ml
Aprotinin 4 µg/ml
Pepsatin 2 µg/ml
PMSF 100 µM
20 Li G, Kowluru A, Metz A. Characterization of phenylcysteine methyltransferase in insulin-secreting cells. 
Biochem. J. 316:345-351, 1996
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8.2 CPTI ACTIVITY ASSAY
CPTI activity is determined by the radiometric method as previously described21
with minor modifications. CPTI was assayed with the mitochondrion-enriched fractions 
obtained as described above where the mitochondria remain largely intact. When
mitochondria are frozen, membranes could be broken, allowing CPTII to contribute to 
the measured activity. To avoid CPTII interferences freshly obtained mitochondria were 
used for each experiment. 
The substrates for the CPTI activity assay are L-[methyl-3H]carnitine
hydrochloride (Amersham Biosciences, ref. TRK762) and palmitoyl-CoA and the 
reaction is done in the following direction:
3H-carnitine + palmitoyl-CoA                 palmitoyl-3H-carnitine + CoA-SH
The procedure takes advantage of the fact that the product of the reaction, 
palmitoyl-3H-carnitine, is soluble in an organic medium. Therefore, it could be
separated by extraction from the radioactive substrate, 3H-carnitine, that has not been 
reacted and which will remain in the aqueous phase. 
The final concentration of the components in the reaction are:
CPTI reaction mix
Tris-HCl pH 7.2 105 mM
KCN 2 mM
KCl 15 mM
MgCl2 4 mM
ATP 4 mM
GSH 250 µM
Palmitoyl-CoA 50 µM
L-[methyl-3H]carnitine (0.3 µCi) 400 µM
defatted BSA 0.1 %
21 Morillas M, Clotet J, Rubi B, Serra D, Asins G, Ariño J, Hegardt FG. Identification of the two histidine residues 
responsible for the inhibition by malonyl-CoA in peroxisomal carnitine octanoyltransferase from rat liver. FEBS Lett.
466(1):183-186, 2000
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Deacylases convert the substrate acyl-CoA in acyl plus CoA-SH, generating 
ATP. This process will reduce the availability of the substrate palmitoyl-CoA in the 
reaction. Therefore, ATP is added to the reaction mix to minimize this process, by 
inverting the equilibrium of the deacylase reaction and by stimulating the reaction of the 
acyl-CoA synthetases and thus regenerating the substrate palmitoyl-CoA. KCN is added 
to avoid mitochondrial oxidation. Glutathione (GSH, reduced form) is used as a
reduction agent instead of dithiothreitol (DTT) or dithioeritrol (DTE) because DTT and 
DTE have been shown to reduce malonyl-CoA sensitivity22. Defatted BSA is added to 
protect mitochondria from the detergent effect of fatty acids. However, BSA
concentration must not be higher than 0.1% because this could give a sigmoidal effect 
in the enzyme v.s. acyl-CoA kinetic18. Finally, KCl is added because it increases
enzyme activity23.
Since activity and sensitivity to malonyl-CoA depend on pH24,25, we chose pH 
7.2, the optimum for both conditions. The temperature for the assay is 30ºC to
compensate a good enzymatic activity, which increases with the temperature, with a 
convenient inhibition, which decreases with the temperature26.
The procedure for the CPTI activity assay is as follows:
The reaction mix is prepared in a 15 ml tube kept on ice. GSH is prepared by 
dissolving it in water on the day of the experiment. Samples are done in duplicate. The
following amounts are per point:
22 Saggerson ED, Carpenter CA. Malonyl-CoA inhibition of carnitine acyltransferase activities: effects of thiol-group
reagents. FEBS Lett. 137:124-128, 1982
23 Saggerson ED. Carnitine acyltransferase activities in rat liver and heart measured with palmitoyl-CoA and 
octanoyl-CoA. Latency, effects of K+, bivalent metal ions and malonyl-CoA. Biochem. J. 202:397-405, 1982
24 Mills SE, Foster DW, McGarry JD. Effects of pH on the interaction of substrates and malonyl-CoA with 
mitochondrial carnitine palmitoyltransferase I. Biochem. J. 219:601-608, 1984
25 Bieber LL, Wagner M. Effect of pH and acyl-CoA chain length on the conversion of heart mitochondrial 
CPTI/CPTIo to a high affinity, malonyl-CoA-inhibited state. Biochim. Biophys. Acta 1290:261-266, 1996
26 Kashfi K, Cook GA. Temperature effects on malonyl-CoA inhibition of carnitine palmitoyltransferase I. Biochim.
Biophys. Acta 1257:133-139, 1995
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CPTI reaction mix/point
bd. water 92.33 µl
4X CPTI buffer 40 µl
1 mM palmitoyl-CoA 10 µl
80 mM ATP 10 µl
30% BSA 0.67 µl
25 mM GSH 2 µl
16 mM 3H-carnitine 5 µl
Total volume 160 µl
Protein samples are prepared on ice in 1.5 ml tubes by diluting the protein in 4X 
CPTI buffer and by adjusting the volume with bd. water up to 40 µl. The blank will 
contain bd. water instead of protein.
Protein samples
Protein 8-20 µg
4X CPTI buffer 10 µl
bd. water up to 40 µl
One by one, 160 µl of the reaction mix is added to each protein sample. Samples
are vortex-mixed and placed on a water bath at 30ºC for exactly 5 min. Reaction is 
stopped with the addition of 200 µl of 1.2 M HCl. Samples are vortex-mixed and placed
on ice. Extractions of the product of the reaction, palmitoyl-3H-carnitine, are done by 
adding 600 µl of water-saturated butanol. Samples are vortex-mixed and centrifuged for 
2 min at 13,000 rpm in a microcentrifuge. 400 µl of the upper phase is added to another 
1.5 ml tube with 200 µl of bd. water. Samples are vortex-mixed and centrifuged for 2 
min at 13,000 rpm. 250 µl of the upper phase is counted in plastic scintillation vials 
with 5 ml of scintillation liquid (Ecolite, ICN). 3H radioactivity is counted in a
RackBeta apparatus. 
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Specific activity of the enzyme is calculated as follows:
S.A.(nmol.mg-1 prot.min-1)= (cpm x 600 µl) / (S.R. x mg prot. x min x 250 µl)
Where cpm are the counts per minute and S.R. is the 3H-carnitine specific 
radioactivity (approx. 3000 cpm/nmol).
4X CPTI buffer: Stored at 4ºC.
Tris-HCl pH 7.2 420 mM
KCN 8 mM
KCl 60 mM
MgCl 16 mM
16 mM 3H-carnitine: 6.6 mg of cold carnitine is dissolved in 982.3 µl of 95% ethanol 
plus 982.3 µl of bd. water and 125 µl of L-[methyl-3H]carnitine hydrochloride (80
Ci/mmol) is added. Aliquots of 125 µl are stored at -80ºC.
8.3 MALONYL-CoA INHIBITION ASSAY
For malonyl-CoA inhibition assays, the different amounts of malonyl-CoA are
added to the protein samples adjusting the final volume up to 40 µl. The stock of 2 mM 
malonyl-CoA used is prepared in 1 mM sodium acetate pH 5.9 and stored at -20ºC.
Samples are vortex-mixed and preincubated for 1 min at 30ºC prior to the addition of 
the reaction mix. It has been described27 that this preincubation increases the inhibition 
level. CPTI activity assay is performed as described above. 
8.4 ETOMOXIRYL-CoA INHIBITION ASSAY
Etomoxir (R-(+)-sodium 2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate) is 
an irreversible inhibitor of CPTI which is only active when it is activated to the 
etomoxiryl-CoA form. Etomoxir was kindly provided by Dr. H. P. O. Wolf
(Allensbach, Germany).
27 Zammit VA. Time-dependence of inhibition of carnitine palmitoyltransferase I by malonyl-CoA in mitochondria 
isolated from livers of fed or starved rats. Evidence for transition of the enzyme between states of low and high 
affinity for malonyl-CoA. Biochem. J. 218:379-386, 1984
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The effect of etomoxir on CPTI activity was seen in culture cells and in
mitochondrion-enriched cell fractions. For culture cells, etomoxir is directly added to 
the medium for a 30 min or a 1 h preincubation as described above. In this case the 
cellular machinery converts etomoxir in its CoA derivative. After this, mitochondrion-
enriched cell fractions are obtained and CPTI activity assay is performed as described 
above. For etomoxir in vitro assays, mitochondrion-enriched cell fractions are
preincubated for 1 min at 30ºC with etomoxiryl-CoA as described for malonyl-CoA
inhibition assay. In this case the inhibitor has to be added to the protein sample already 
activated to etomoxiryl-CoA. Then, protein samples are vortex-mixed and CPTI activity 
assay is performed as described above.
Activation of etomoxir to etomoxiryl-CoA by Pseudomonas sp. Acyl-CoA
synthetase.
The activation of etomoxir is done by a simple enzymatic method28 which uses 
the Pseudomonas sp. Acyl-CoA synthetase (EC 6.2.1.3).
The reaction is performed with 1 µmol of etomoxir in a total volume of 1 ml of 
an activation buffer containing:
Activation buffer
Triton X-100 0.1% (w/v)
CoA-SH 5 mM
ATP 10 mM
DTT 1 mM
MgCl2 10 mM
MOPS-NaOH pH 7.5 100 mM
The mix is sonicated for 5 min to permit etomoxir emulsion and 0.25 U of the 
acyl-CoA synthetase is added. The reaction is carried out at 35ºC for 2 h and stock
aliquots are stored at –80ºC. It is assumed that all the etomoxir has been converted to 
etomoxiryl-CoA and thus its final concentration in the solution is 1 mM.
28 Taylor DC, Weber N, Hogge LR, Underhill EW. A simple enzymatic method for the preparation of radiolabelled
erucoyl-CoA and other long-chain fatty acyl-CoAs and their characterization by mass spectrometry. Anal. Biochem.
184:311-316, 1990
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8.5 CPTI ACTIVITY ASSAY IN THE PRESENCE OF C75
The effect of C75 on CPTI activity was seen in mitochondrion-enriched
fractions from cells and mouse tissues.
It has been described29 that C75 has to be previously activated to C75-CoA to 
interact with CPTI activity. Thus, as in the case of etomoxir, when CPTI activity is 
studied with mitochondrion-enriched cell fractions, C75-CoA is added to the protein 
sample and preincubated for 1 min at 30ºC prior to CPTI activity assay. Activation to 
C75-CoA by the acyl-CoA synthetase is done as described above for etomoxiryl-CoA.
For cells in culture, which are previously incubated with C75, and mice, which
are previously ip injected with C75, mitochondrion-enriched fractions are obtained and 
CPTI activity assay is performed as described above.
9. PKC TRANSLOCATION ASSAY
Protein kinase C (PKC) is a family of enzymes, the conventional isoforms α, β
and γ of which are expressed in the pancreatic β-cell. These PKC isoforms require
phosphatidylserine (PS), diacylglycerol (DAG) and Ca2+ for optimal activity. When 
PKC is activated by glucose, DAG or fatty acids, the protein is translocated from the 
cytosol to the cell membrane. Thus, to measure PKC translocation, cytosol and
membrane fractions from INS(832/13) cells were obtained and analyzed by Western 
blot with a specific PKC antibody. 
To measure the PKC translocation we followed the protocol described by
Alcázar et al.30 with minor modifications. INS(832/13) cells are grown in 10-cm dishes 
and infected with the different adenoviruses as described above. After a basal
preincubation as described in BASAL TREATMENTS (Section 3.5.1), cells are incubated 
for 30 min at 37ºC with KRBH 0.1% BSA plus 2.5 or 15 mM glucose. After that, cells
are washed in cold PBS, scraped into 1 ml of PBS and centrifuged at 2,000 rpm for 5 
min at 4ºC in a microcentrifuge. Then, cells are sonicated in 100 µl of PKC buffer and 
the homogenate is centrifuged at 100,000 x g at 4ºC for 1 h. The supernatant (cytosolic 
29 Bentebibel A, Sebastián D, Herrero L, Serra D, Asins G, Hegardt FG. C75-CoA inhibits Carnitine
Palmitoyltransferase I activity thus decreasing palmitate oxidation. Submitted.
30 Alcázar O, Qiu-yue Z, Giné E, Tamarit-Rodriguez J. Stimulation of islet protein kinase C translocation by 
palmitate requires metabolism of the fatty acid. Diabetes 46(7):1153-1158, 1997
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fraction) is separated, and the precipitate (membrane fraction) is resuspended with mild 
sonication in 100 µl of the same PKC buffer but supplemented with 0.1% (v/v) Triton 
X-100. Both fractions are incubated on ice for 45 min and Western blot is performed 
using a specific antibody against the PKC isoforms expressed in pancreatic β-cells (α, β
and γ) as described in Section 7.2.
PKC buffer: 20 mM Tris-HCl pH 7.5, 250 mM sucrose, 2 mM EDTA, 5 mM EGTA, 10 
mM β-mercaptoethanol, 1 mM PMSF and 10 µg/ml leupeptin. β-mercaptoethanol,
PMSF and leupeptin are added on the day of the experiment. PKC buffer is stored at 
4ºC. For 50 ml of PKC buffer it is needed:
PKC buffer
1 M Tris-HCl pH 7.5 1 ml
1 M sucrose 12.5 ml
0.5 M EDTA 200 µl
EGTA 95.1 mg
   β-mercaptoethanol 35 µl
100 mM PMSF 500 µl
leupeptin 50 µl
bd. water up to 50 ml
10. CELLULAR METABOLISM DETERMINATION
10.1 PALMITATE OXIDATION
Palmitate oxidation assay is done with attached cells and allows studying the 
capacity of the cells to oxidize palmitate. Cells are incubated with [1-14C]palmitate and 
the 14CO2 released and the acid-soluble products (ASP; essentially ketone bodies31) are
measured. Total palmitate oxidation will be the sum of both. Palmitate oxidation has 
been done by two different methods: 12-well plates or 25 cm2 flasks. Both are explained
here.
31 Fulgencio JP, Kohl C, Girard J, Pegorier JP. Troglitazone inhibits fatty acid oxidation and esterification, and 
gluconeogenesis in isolated hepatocytes from starved rats. Diabetes. 45:1556-1562, 1996
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A) Palmitate oxidation assay in 12-well plates
This method was originally described by Collins et al.32 and enables the use of 
cells in adherent culture and easy analysis of multiple samples. It is an improvement 
over previous methods that used detached cells and where oxidation was found to be 
reduced by 30-82%.
The procedure is as follows:
Cells seeded in 12-well plates are infected with the different adenoviruses or 
treated with C75 or etomoxir as described above. The day of the palmitate oxidation 
assay cells must be approx. 90% confluents. Before starting the experiment, cells are 
washed in KRBH 0.1% (w/v) defatted BSA, preincubated at 37ºC for 30 min with 500 
µl of KRBH 1% BSA with or without 200 µM etomoxir and washed again with KRBH 
0.1% BSA as described in BASAL TREATMENTS (Section 3.5.1). Then, 500 µl of the 
palmitate oxidation mix, prepared on the day of the experiment, is added to each well. 
Palmitate oxidation mix contains fresh KRBH with 2.5, 7.5 or 15 mM glucose in the 
presence of 0.8 mM carnitine plus 0.25 mM palmitate and 1 µCi/ml [1-14C]palmitate
bound to 1% (w/v) BSA. Blanks are wells without cells.
Palmitate oxidation mix (500 µl)
KRBH 400 µl
2.5 mM [1-14C]palmitate 50 µl
25, 75 or 150 mM glucose + 8 mM carnitine 50 µl
The system is closed as described in fig. 4. One rubber sheet the size of the 12-
well plate, with a 6-mm hole centered over the site of each well, is placed over the 
culture plate. Then, a Whatman paper of the same size and soaked in 0.1 N KOH is 
placed over the rubber sheet. Finally, another rubber sheet without holes is placed on 
32 Collins CL, Bode BP, Souba WW, Abcouwer SF. Multiwell 14CO2-capture assay for evaluation of substrate 
oxidation rates of cells in culture. BioTechniques 24:803-808, 1998
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the top and the system is closed with the cover of the culture plate and wrapped in
parafilm.
Fig. 4. Palmitate oxidation system in 12-well plates. Palmitate oxidation mix is added to the wells that contain cells 
still attached. The system is closed by placing in this order: a rubber sheet with holes centered over each well, a 
Whatman paper soaked in 0.1 N KOH, another rubber sheet without holes and the cover of the plate, all wrapped in
parafilm. The assembly is incubated at 37ºC for 2 h with a weight on the top to ensure no 14CO2 is escaped. 
The assembly is incubated at 37ºC in a CO2-free incubator for 2 h with a weight
on the top to ensure that no 14CO2 escapes. During this time the acid gas 14CO2 will pass 
through the rubber sheet holes and react with the base KOH being therefore caught in 
the Whatman paper. 14CO2 contamination from adjacent wells has been found not to be
significant and the captured radioactivity has a linear rate of accumulation between 2-6
h after apparatus assembly. 
After the incubation time, the piece of Whatman paper corresponding to each 
well is cut and placed inside scintillation vials with 5 ml of scintillation fluid and 
counted. Radioactive medium is removed and cells are scrapped in 250 µl of KRBH for
the Bradford protein assay. 
Results are expressed as: 
nmol of palmitate.mg-1 prot.h-1 = (cpm-blank cpm) x 125 / (total cpm x mg prot x h)
weight
12-well plate
cover of the plate
rubber sheet
rubbersheet
with holes
Whatman paper
soaked in 0.1 N KOH
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Where 125 is the total nmol of palmitate per well, total cpm are the counts 
resulting from directly counting on the scintillation fluid 50 µl of the 2.5 mM [1-
14C]palmitate used per well and h is the time of incubation. 
B) Palmitate oxidation assay in 25-cm2 flasks
This method has been described by Roduit et al.33 and utilizes 25-cm2 flasks in
which the 14CO2 released is also trapped in a KOH soaked Whatman paper. The reaction 
is stopped by the addition to the cells of perchloric acid. The system, still closed, is left 
o/n and therefore all the 14CO2 in the atmosphere of the flask is captured by the 
Whatman paper. Palmitate oxidation in 12-well plates is faster and needs fewer cells,
virus, solutions and reagents. On the other hand, palmitate oxidation in 25-cm2 flasks 
allows time for the 14CO2 to be taken up into the Whatman paper in a closed system 
giving slightly higher oxidation rates. 
The procedure is as follows:
Cells are seeded in 25-cm2 flasks, infected, treated and preincubated as described
above for the palmitate oxidation assay in 12-well plates. Then, 2 ml of the palmitate
oxidation mix is added to each flask. Blanks are flasks without cells.
The 25-cm2 flasks are sealed at the beginning of the incubation with a rubber 
stopper (size 14.5, Fisher, ref. 14-126BB) supporting a 3 cm length of PVC tubing (I.D. 
4.7 mm, Fisher, ref. 14-169-7B) containing a piece of Whatman paper soaked in 0.1 N 
KOH (fig. 5). One end of the PVC tubing is wrapped in parafilm without covering the 
lumen, so that tubing will fit firmly into the under-side of the stopper. The Whatman
paper inside the tubing must be well clear to the opening. Flasks are then incubated at 
37ºC in a CO2-free incubator for 2 h.
33 Roduit R, Nolan C, Alarcon C, Moore P, Barbeau A, Delghingaro-Augusto V, Przybykowski E, Morin J, Masse F, 
Massie B, Ruderman N, Rhodes C, Poitout V, Prentki M. A Role for the Malonyl-CoA/Long-Chain Acyl-CoA
Pathway of Lipid Signaling in the Regulation of Insulin Secretion in Response to Both Fuel and Nonfuel Stimuli. 
Diabetes 53(4):1007-1019, 2004
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Fig. 5. Palmitate oxidation system in 25-cm2 flasks. Palmitate oxidation mix is added to the flask with cells still 
attached. Flasks are sealed with a rubber stopper supporting a 3 cm length of PVC tubing containing a piece of 
Whatman paper soaked in 0.1 N KOH. Flasks are incubated at 37ºC in a CO2-free incubator for 2 h.
At the end of the incubation period, 0.2 ml of 40% (v/v) perchloric acid is
injected into each flask via a needle through the rubber stopper to acidify the medium,
liberate 14CO2 and stop palmitate oxidation.  Perchloric acid must be well mixed. After 
o/n isotopic equilibration at r.t., Whatman papers are removed and the trapped 14CO2 is 
measured by liquid scintillation counting after o/n equilibration in 5 ml of the
scintillation fluid. It is left o/n because it takes more than 12 h to 14CO2 to leach out of 
Whatman paper into scintillation fluid. The addition of perchloric acid generates a
precipitate, therefore for the Bradford protein assay cells from parallel flasks, without 
perchloric acid, are removed with 1 ml of KRBH.
Results are expressed as: 
nmol of palmitate.mg-1 prot.h-1 = (cpm-blank cpm) x 500 / (total cpm x mg prot x h)
Where 500 is the total nmol of palmitate per flask, total cpm are the counts 
resulting from directly counting on the scintillation liquid the amount of 2.5 mM [1-
14C]palmitate used per flask and h is the time of incubation.
25-cm2 flask with cells
Syringe with perchloric acid
rubber stopper
PVC tubing
Whatman paper
soaked in 0.1 N KOH
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C) Palmitate oxidation to ASP
Fatty acid oxidation into acid-soluble products (ASP) is measured from the 
perchloric acid treated medium. The perchloric acid injected into the media precipitates 
the fatty acid tracer bound to proteins leaving the ASPs in solution. In case of the 
palmitate oxidation assay performed in 25-cm2 flasks, 1 ml of the incubation media 
already treated with perchloric acid is taken and centrifuged at 14,000 rpm for 10 min in 
a microcentrifuge. 800 µl of the supernatant is counted on a scintillation vial with 5 ml 
of scintillation fluid. 
Results are expressed as: 
nmol of palmitate.mg-1 prot.h-1 = (cpm-blank cpm) x 500 x (2,200/800) / (total cpm x 
mg prot x h)
Where 500 is the total nmol of palmitate per flask, total cpm are the counts
resulting from directly counting on the scintillation liquid the amount of 2.5 mM [1-
14C]palmitate used per flask, 2,000/800 is the dilution factor and h is the time of
incubation.
2.5 mM [1-14C]palmitate bound to BSA
To prepare the labelled palmitate bound to BSA, 500 µl of [1-14C]palmitic acid
(Amersham Pharmacia Biotech, ref. CFA23, 250 µCi) is placed on a glass vial under the 
hood to evaporate the toluene solution. It is stirred and heated if necessary. 6.97 mg of 
cold palmitate and 1 ml of 0.1 N NaOH is added to the vial and heated at 80-100ºC until 
the solution is clear. On a beaker, 1 g of defatted BSA (Sigma-Aldrich, ref. A-6003) is 
dissolved in 8 ml of 0.9% NaCl by stirring and heating it in a water bath to 50ºC
maximum. Heating to more than 55ºC will turn the BSA solution into a gel. Palmitate
solution is added rapidly drop by drop onto the BSA solution. The resulting solution is 
filtered through a 0.45 µm filter and 1 ml aliquots are stored at -20ºC.
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25, 75 or 150 mM glucose plus 8 mM carnitine
To prepare 25, 75 or 150 mM glucose plus 8 mM carnitine 250 µl, 750 µl or 1.5 
ml of 1 M glucose, respectively are mixed with 16 mg of carnitine and dissolved in
KRBH up to a total volume of 10 ml. 1 ml aliquots are stored at -20ºC.
10.2 GLUCOSE OXIDATION
Glucose oxidation assay is done with attached cells and examines the capacity of 
the cells to oxidize glucose. Cells are incubated with [U-14C]glucose and the 14CO2
released is measured. Experimental procedure is similar to the one explained before for
the palmitate oxidation assay, except that the incubation mix contains fresh KRBH 1% 
BSA plus 2.5 or 15 mM glucose in the presence of 0.5 µCi/ml [U-14C]glucose.
Glucose oxidation mix (500 µl)
KRBH 400 µl
25 or 150 mM [U-14C]glucose 50 µl
10% BSA 50 µl
Cells are incubated at 37ºC in a CO2-free incubator for 2 h. Then, Whatman
papers are removed and the trapped 14CO2 is measured by liquid scintillation counting.
In case of glucose oxidation in a 12-well plate system, results are expressed as: 
For 2.5 mM glucose:
nmol of glucose.mg-1 prot.h-1 = (cpm-blank cpm) x 1250 / (total cpm x mg prot x h)
For 15 mM glucose:
nmol of glucose.mg-1 prot.h-1 = (cpm-blank cpm) x 7500 / (total cpm x mg prot x h)
Where 1250 or 7500 is the total nmol of glucose in 50 µl of the 25 or 150 mM 
[U-14C]glucose respectively, used per well, total cpm are the counts resulting from
directly counting on the scintillation liquid 50 µl of 25 or 150 mM [U-14C]glucose
respectively, used per well and h is the time of incubation. 
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25 or 150 mM [U-14C]glucose
A 150 mM glucose solution in KRBH is passed through a 0.22 µm filter. 
Sufficient quantity of D-[U-14C]glucose (Amersham Pharmacia Biotech, CFB96, 250 
µCi) to have 500,000 cpm per point is added. Some of this solution is diluted in KRBH 
to obtain the 25 mM [U-14C]glucose. 1 ml aliquots are stored at -20ºC.
10.3 LIPID ESTERIFICATION PROCESSES
In esterification experiments cells are incubated with [1-14C]palmitate and we
measure the glucose-induced incorporation of this fatty acid into the different lipid 
complexes such as phospholipids (PL), diacylglycerols (DAG), triacylglycerols (TG), 
cholesterol esters (CE) as well as the non-esterified labelled palmitate (NE palm). The 
esterification products are separated by thin layer chromatography (TLC) and quantified 
with a Storm 840 Laser scanning system.
The procedure is as follows:
A) [1-14C]palmitate incubation
The [1-14C]palmitate incubation is the same as the one described above for the 
palmitate oxidation assay in 12-well plates. INS(832/13) cells are seeded in 12-well
plates, infected with the different adenoviruses, preincubated with KRBH 1% BSA and
incubated for 2 h at 37ºC with fresh KRBH containing 2.5 or 15 mM glucose in the 
presence of 0.8 mM carnitine plus 0.25 mM palmitate and 1 µCi/ml [1-14C]palmitate
bound to 1% (w/v) BSA.
B) Lipids extraction
After the incubation period cells are washed in cold PBS and 1 ml of
methanol:PBS (2:3, v/v) is added to each well. Cells are gently collected in a pipette, 
centrifuged at 700 x g for 5 min at 4ºC and washed in PBS; 20 µl of the samples is
taken at this point for the Bradford protein assay. After that, 200 µl of 0.2 M NaCl is
added to the pellet and the mixture is immediately frozen in liquid N2. To separate 
aqueous and lipid phases, 750 µl of Folch reagent 34 (chloroform:methanol, 2:1) and 50 
µl of 0.1 M KOH are added and, after vigorous vortex-mixing, the phases are separated 
34 Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal 
tissues. J. Biol. Chem. 226(1):497-509, 1957
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by a 15 min centrifugation at 2000 x g at 4ºC. The top aqueous phase is removed and 
the lipid phase is washed with 200 µl of methanol/water/chloroform (48:47:3). After 
vortex-mixing and centrifugation at 700 x g for 5 min at 4ºC the lower phase is taken 
and dried with a speed vac.
C) TLC separation
Total lipids are dissolved in 30 µl of chloroform and separated by thin layer 
chromatography in TLC plates (Merck). Plates are eluted with
hexane:diethylether:acetic acid (70:30:1, v/v/v) 35 and quantified with a Storm 840 Laser 
scanning system (Molecular dynamics, Amersham Pharmacia Biotech). A known
amount of labelled palmitate is eluted in the same plate. This allows us to quantify the 
nmols present in each dot. Intensities of the spots are expressed as nmol.mg-1 prot.h-1
and results are given as the differences (∆G) between high (15 mM) and low (2.5 mM) 
glucose.
The labelled control palmitate is also assessed following TLC separation as a 
migration reference for NE palm. Migration references from Sigma-Aldrich prepared at 
2 mg/ml in chloroform:ethanol (2:1): phosphatidyl-serine (ref. P-5660), dipalmitoyl-
glycerol (ref. D-9135), glyceryl tripalmitate (ref. T-5888) and cholesteryl palmitate (ref.
C-6072) are developed in TLC plates with iodine. Complex lipids are easily oxidized, 
therefore migration references must be recently prepared and stored at -20ºC under N2
atmosphere.
To elute the TLC plates it is used an apolar solvent (hexane:diethylether:acetic
acid, 70:30:1, v/v/v), therefore apolar lipids will migrate with the solvent while the 
more polar ones will stay near the application point in the polar silica gel. CE are the 
most apolar lipids, so they will migrate further than the others. TGs have a glycerol 
molecule, so they will migrate less than CE. Then, we will find NE palm and DAG 
because they have only one fatty acid moiety or one molecule of glycerol, respectively. 
PLs are the most polar complex lipids so they will remain near the base. For the
conditions used, the Rf (rate factors) of these complex lipids are: PL (0.09), DAG 
(0.12), NE palm (0.27), TG (0.66) and CE (0.92).
35 Montell E, Turini M, Marotta M, Roberts M, Noé V, Ciudad CJ, Macé K, Gómez-Foix AM. DAG accumulation 
from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells. Am. J. Physiol. 
Endocrinol. Metab. 280:E229-E237, 2001
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10.4 MITOCHONDRIAL MEMBRANE POTENTIAL ∆Ψm
Mitochondrial membrane potential ∆Ψm reflects the electron transport chain
activity in the cell. Glucose metabolism in the Krebs cycle gives a hyperpolarization of 
the mitochondrial membrane. This electron transport chain activity or the
hyperpolarization in the mitochondrial membrane could be measured in attached cells 
by monitoring rhodamine-12336, a fluorescent compound which dyes cells mitochondria 
in a mitochondrial potential-dependent manner37.
Rhodamine-123 is a cationic cyanide which is accumulated in negative
compartments as mitochondria. The large surface of the membrane in the mitochondrial 
matrix could contribute to the dyeing, accumulating large amounts of rhodamine. 
Rhodamine has a maximal absorption peak at approximately 485 nm (blue) and a 
maximal emission peak at 530 nm. Uncoupling agents or inhibitors decrease the
mitochondrial fluorescence.
To measure the mitochondrial membrane potential ∆Ψm, naSREBP-1c stable 
cells are seeded in 24-well plates and cultured with or without 500 ng/ml of doxycycline 
for 1, 2 or 4 days. Cells are maintained for 2 h in 2.5 mM glucose medium at 37ºC 
before loading with 10 µg/ml rhodamine-123 for 20 min at 37ºC in KRBH. The ∆Ψm is 
monitored in a plate-reader fluorimeter (Fluostar Optima, BMG Labtechnologies,
Offenburg, Germany) with excitation and emission filters set at 485 and 520 nm, 
respectively, at 37ºC with automated injectors for glucose (addition of 13 mM on top of 
basal 2.5 mM) and carbonyl cyanide 4-trifluoromethoxyphenyl-hydrazone (FCCP)
which is a protonophore that depolarizes the ∆Ψm.
Rhodamine: It is soluble in DMSO or DMF. It is stored at 4ºC protected against the 
light.
36 Maechler P, Kennedy E, Pozzan T, Wollheim CB. Mitochondrial activation directly triggers the exocytosis of 
insulin in permeabilized pancreatic β-cells. EMBO J 16:3833-3841, 1997
37 Johnson LV, Walsh ML, Chen LB. Localization of mitochondria in living cells with rhodamine 123. Proc. Natl. 
Acad. Sci. USA 77:990-994, 1980
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11. METABOLITES DETERMINATION
11.1 TRIGLYCERIDE CONTENT
Triglyceride content measurement in culture cells is based on the lipid extraction 
of the cells fo llowed by the hydrolysis of the triglycerides to glycerol and free fatty 
acids and the quantification of the glycerol released. The Triglyceride (GPO-Trinder) kit 
(Sigma-Aldrich, ref. A-337), which allows the quantitative enzymatic determination of 
triglycerides by measuring the absorbance at 540 nm, is used.
The procedure is as follows:
A) Lipid extraction
Cells are grown in 12-well plates until approx. 80% confluence. Then, they are 
treated or infected and preincubated with KRBH 1% BSA as described above. Cells are 
washed in cold PBS and 1 ml of methanol:PBS (2:3, v/v) is added to each well. Then, 
cells are gently collected in a pipette, centrifuged at 700 x g for 5 min at 4ºC and 
washed with 1ml of PBS. 20 µl of the samples is taken at this point for the Bradford
protein assay. After another centrifugation at 700 x g for 5 min at 4ºC, 200 µl of 0.2 M 
NaCl is added to the pellet and the mixture is immediately frozen in liquid N2. Lipids
are extracted with Folch reagent as described in LIPID ESTERIFICATION PROCESSES
(Section 10.3).
Total lipids obtained are dissolved in 50 µl of chloroform. 20 µl of the lipid
samples, 20 µl of chloroform (blank) or 20 µl of a triolein standard curve are placed on 
1.5 ml tubes and air dried. Then, 10 µl of Thesit (Fluka, ref.  17228) 20% (v/v) in 
chloroform is added, samples are vortex-mixed, air dried o/n and dissolved in 50 µl of 
water. Thesit allows lipids to dissolve in water for the following enzymatic assay.
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Triolein standard curve:
µg triolein µl stock solutions µl chloroform:methanol (2:1)
0 0 20
1 2 (0.5 mg/ml) 18
2.5 5 (0.5 mg/ml) 15
5 10 (0.5 mg/ml) 10
10 2 (5 mg/ml) 18
25 5 (5 mg/ml) 15
50 10 (5 mg/ml) 10
Total volume 20 µl
Triolein stock solutions (5 mg/ml and 0.5 mg/ml): To prepare the 5 mg/ml stock 
solution, 5.5 µl of triolein (Sigma-Aldrich, ref. T-7140) is diluted in 1 ml of
chloroform:methanol (2:1). To prepare the stock at 0.5 mg/ml a 1/10 dilution in
chloroform:methano l (2:1) is done. Triolein solutions are stored at -20ºC under N2
atmosphere.
B) Triglyceride quantification
Triglycerides are measured enzymatically with the Triglyceride (GPO-Trinder)
kit following the manufacturer’s instructions. Briefly, triglycerides are hydrolyzed by 
lipoprotein lipase to glycerol and free fatty acids. The glycerol produced is then
measured by coupled enzyme reactions catalyzed by glycerol kinase, glycerol phosphate 
oxidase and peroxidase. This kit differentiates between endogenous glycerol and
glycerol derived by hydrolytic action of lipase allowing measuring true triglycerides. 
The product of the last enzymatic reaction shows absorbance at 540 nm and the increase 
in absorbance is directly proportional to triglycerides concentration of the sample. 
Triglycerides could be qualitatively observed by Oil O Red (Sigma-Aldrich, ref. 
O-0625) cells staining and the lipid droplets formed visualized using phase-contrast
microscopy.
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11.2 MALONYL-CoA MEASUREMENT
To quantify the malonyl-CoA content in culture cells, malonyl-CoA is extracted 
from the cells and assayed with a radioenzymatic method using [1-14C]acetyl-CoA
(ICN, ref. 13070, 48 mCi/mmol). The assay requires the enzyme fatty acid synthase 
(FAS) which is isolated from rat liver.
A) FAS isolation
Fatty acid synthase (FAS) catalyses the de novo synthesis of long-chain fatty 
acids from acetyl-CoA and malonyl-CoA. FAS was purified from rat liver using
polyethylene glycol (PEG) as described by Linn38. This procedure results in high yields
of the enzyme which is essentially free of endogenous proteolytic nicking and from 
proteases contamination.
Buffers used:
Buffer 1 Buffer 2 Buffer 3
0.1 M KH2PO4 pH 7.5 0.1 M KH2PO4 pH 7.2 0.1 M KH2PO4 pH 7.5
1 mM MgCl2 1 mM MgCl2
0.1 mM EDTA 0.1 mM EDTA
10% glycerol 10% glycerol
1 mM DTT 1 mM DTT
2% rabbit serum 2% rabbit serum
2 mg/ml defatted BSA
Buffer 4 Buffer 5 Buffer 6
0.05 M KH2PO4 pH 7.2 0.05 M KH2PO4 pH 7.5 0.15 M KH2PO4 pH 7.5
1 mM MgCl2 1 mM MgCl2 1 mM MgCl2
0.1 mM EDTA 0.1 mM EDTA 0.1 mM EDTA
10% glycerol 10% glycerol 10% glycerol
1 mM DTT 2 mM DTT 5 mM DTT
2 mg/ml defatted BSA
38 Linn TC. Purification and crystallization of rat liver fatty acid synthetase. Arch. Biochem. Biophysics  209:613-619,
1981
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DTT is added immediately before use and it prevents the formation of protein 
disulfide bonds. In order to minimize the proteolysis of the enzyme during isolation, 
rabbit serum is added to the crude fractions and the pH of all fractions is maintained at 
7.0 or above. It is assumed that the active components in the rabbit serum are the α2-
macroglobulins which adsorb proteases. Glycerol is added to give the adequate density 
to the fractions. 
The enzyme is purified with PEG (Mr 6000, Merck, ref. 807491) and ammonium 
sulphate, which absorb the water molecules and thus precipitates the protein. PEG is a 
neutral polymer and therefore is adequate for the later use of a DEAE Sepharose 
column.
10 male, Sprague-Dawley rats weighing 200-250 g are fasted 2 days and then 
fed ad libitum, a fat-free high-carbohydrate diet for 3 days. With this treatment FAS 
expression is maximized. 
The procedure is as follows:
To isolate the protein all the steps are carried out at 4ºC (fig. 6). After successive 
precipitations with PEG and ammonium sulphate FAS is purified by loading the last 
fraction through a column of DEAE Sepharose Fast Flow (Amersham Pharmacia
Biotech, ref. 17-0709-01). The gradient is arranged with buffer 5 and 6 and the FAS
obtained this way has a specific activity approx. between 0.5-0.9 U/ml. It is split into 1 
ml aliquots and stored at -80ºC.
A sample of the pellet (ppt.) or the supernatant (sup.) is taken at each step to 
check FAS activity before discarding the fraction. The activity is measured by a
spectrophometric assay which is faster but not as sensitive as the radioenzymatic
method described below. Therefore, the efficiency of the purification could be followed.
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Fig. 6. Scheme for FAS purification. FAS is isolated from rat liver with successive precipitations with PEG and 
ammonium sulphate. Finally FAS is purified with a DEAE Sepharose column.
Rat liver homogenate (rinsed in buffer 1 and homogenized in buffer 2)
PEG addition until 5% final
sup. ppt. (discard)
PEG addition until 13% final
centrifugation (9,000 rpm/30min GSA rotor)
centrifugation (9,000 rpm/30 min GSA rotor)
sup. (discard) ppt. (dissolved in buffer 3)
Ammoniumsulphate addition until 25% final
centrifugation (10,500 rpm/30 min SS34 rotor)
sup. (discard) ppt. (dissolved in buffer 4)
PEG addition until 10% final
centrifugation (9,000 rpm/15 min GSA rotor)
sup. (save) ppt. (dissolved in buffer 4)
centrifugation (9,000 rpm/15 min GSA rotor)
ppt. (discard)sup. (save)
PEG addition until 21% final
ppt. dissolved in buffer 5 and loaded on DE52 column
centrifugation (9,000 rpm/15 min GSA rotor)
PEG addition until 10% final
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Measurements are carried out in 1 cm cuvettes using a recording
spectrophotometer at 25ºC. The reaction measures the disappearance of NADPH which 
has a maximal absorbance at 340 nm.
Acetyl-CoA + Malonyl-CoA + NADPH FAS  palmitic acid
The reaction is started by the addition of the sample to the following
components:
FAS assay/point
FAS buffer 0.9 ml
25 mM NADPH 10 µl
20 mM acetyl-CoA 10 µl
20 mM malonyl-CoA 10 µl
H2O 20 µl
Sample 50 µl
FAS buffer: 0.1 M KH2PO4 pH 7.2, 0.2 mM EDTA, 4 mM DTT and 0.2% defatted 
BSA.
The initial velocity (∆OD) at 340 nm is recorded for each sample prior and after 
malonyl-CoA addition. The rate of NADPH oxidation prior to malonyl-CoA addition 
serves as a blank value which is subtracted from the overall rate. 
One unit of FAS activity is defined as the amount of enzyme which catalyzes the 
oxidation of 1 µmol of NADPH in 1 min at 25ºC.
B) Malonyl-CoA extraction from cells
INS(832/13) cells are grown in 10-cm dishes until 80% confluence. 24 h after 
the infection with the different adenoviruses, cells are preincubated with KRBH 1% 
BSA as described in BASAL TREATMENTS (Section 3.5.1) and incubated for 30 min at 
37ºC with fresh KRBH 0.1% BSA containing 2.5 or 15 mM glucose. Cells are then
collected into 2 ml tubes by adding 1.5 ml of ice-cold 3.5% (v/v) perchloric acid to each 
dish and centrifugation of the collected extract at 12,000 rpm for 5 min at 4ºC in a 
Materials and methods
146
microcentrifuge. Pellets of cells from parallel dishes without perchloric acid are kept for 
Bradford protein assay. The supernatant containing acid-soluble metabolites is
neutralized to pH 2-3 with 5 N KOH and to pH 6 with 2.5 M KHCO3. After 
centrifugation at 2,000 rpm for 5 min, the supernatant volume is measured and kept for 
the malonyl-CoA assay.
C) Malonyl-CoA assay
Malonyl-CoA is quantified by a radioenzymatic method39 based on the malonyl-
CoA-dependent incorporation of labelled acetyl-CoA into palmitic acid catalyzed by 
FAS in the presence of NADPH.
Malonyl-CoA + [1-14C]acetyl-CoA + NADPH FAS [14C]palmitic acid
The [14C]palmitic acid formed could be separated by successive extractions in an 
organic solvent. The advantage of this radioenzymatic method over the
spectrophotometric method is that it is extremely sensitive and allows the determination 
of pmol quantities of malonyl-CoA.
For the assay, each sample is divided into two 200 µl aliquots and 100 pmol of 
malonyl-CoA is added to one of the two samples. The reaction mixture contains, in a 
total volume of 1.025 ml/point:
Malonyl-CoA reaction mix/point
KH2PO4 pH 7 0.2 M
DTT 2.5 mM
EDTA 2 mM
NADPH 0.2 mM
defatted BSA 1 mg
[1-14C]acetyl-CoA 2 nmol
Total volume 1.025 ml
39 McGarry JD, Stark MJ, Foster DW. Hepatic malonyl-CoA levels of fed, fasted and diabetic rats as measured using 
a simple radioisotopic assay. J. Biol. Chem. 253:8291-8293, 1978
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200 µl of the samples with or without 100 pmol of malonyl-CoA is added to the 
reaction mix. Then, the reaction is initiated by the addition of 25 mU FAS to each tube. 
After a 45 min incubation at 37ºC, the reaction is terminated by the addition of 25 µl of 
70% (v/v) perchloric acid. Then, 1 ml of ethanol and 5 ml of petroleum ether are added 
to each tube and they are vortex-mixed for 30 sec. After centrifugation, 4 ml of the 
petroleum ether phase (superior) is transferred to another tube containing 2 ml of water.
The tubes are then shaken and, after a brief centrifugation, 2 ml of the petroleum ether 
phase is counted in scintillation vials with 5 ml of scintillation fluid. 
Tissue and cell extracts also contain malonyl-CoA and probably variable
quantities of acetyl-CoA or other acyl-CoA species that might act as primers for
condensation with malonyl-CoA in the FAS reaction. The presence of such compounds 
would effectively reduce to an unknown degree the specific activity of the labelled 
acetyl-CoA present in the assay mixture and thereby result in low artifact values for the 
malonyl-CoA content. This problem is solved by running the assay for each sample 
extract in the absence and presence of a standard quantity of malonyl-CoA. Thus, the 
malonyl-CoA content of the sample can be calculated as follows:
pmol malonyl-CoA.mg prot-1 = (a x b) x (Vt/200)/(c-b)
Where: a is the pmol of malonyl-CoA added to one sample (100 pmol)
b are the cpm of the sample without malonyl-CoA
 Vt is the total µl of the neutralized extract collected in perchloric acid
c are the cpm of the sample plus malonyl-CoA
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12. INSULIN SECRETION
To measure insulin secretion, cells are incubated with different secretagogues 
and the secreted medium is analyzed by radioimmunoassay (RIA) using 125I-insulin40.
A) Insulin secretion
INS-1 cells are seeded in 12-well plates at 0.5 x 106 cells/well. After 48 h cells 
are treated or infected as described above and further cultured before starting insulin 
secretion experiments. 
The day of the experiment cells are first washed in fresh KRBH 0.1% (w/v) 
defatted BSA (RIA grade, Sigma-Aldrich, ref. A-7888), preincubated at 37ºC for 30 
min in 500 µl of KRBH plus 1% BSA in the absence or the presence of 200 µM
etomoxir and finally washed again with KRBH 0.1% BSA. 
Then, cells are incubated for 1 h at 37ºC with 1 ml of KRBH 0.1% BSA in the 
presence of either 2.5 mM glucose, 15 mM glucose, 15 mM glucose plus 0.25 mM 
palmitate bound to 1% (w/v) BSA or 2.5 mM glucose plus 30 mM KCl. For studies of 
KATP channel- independent insulin secretion, cells are incubated for 1 h at 37ºC with 1 
ml of KRBH 0.1% BSA plus 35 mM KCl and 250 µM diazoxide at 2.5 mM glucose or 
15 mM glucose. These assays are performed at 35 mM KCl (depolarizing K+);
consequently, the Na+ concentration in the KRBH was reduced from 135 to 89.9 mM to 
maintain osmolarity. 
After the incubation the solution is collected in 1.5 ml tubes and centrifuged at 
10,000 rpm for 1 min in a microcentrifuge to remove cell debris. To measure the total 
insulin content, the liquid remaining in the wells is completely aspirated and cells are
extracted with 1 ml of 75% ethanol/0.2 M HCl per well. Solutions for insulin secretion 
measurement or insulin content measurement can be stored at -20ºC for a few days.
250 mM diazoxide: To prepare a 250 mM stock of diazoxide, 57.7 mg of diazoxide is
dissolved in 1 ml of DMSO and aliquots are stored at -20ºC.
40 Rubi B, Ishihara H, Hegardt FG, Wollheim CB, Maechler P. GAD65-mediated glutamate decarboxylation reduces 
glucose-stimulated insulin secretion in pancreatic beta cells. J. Biol. Chem. 276: 36391-36396, 2001
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Glucose and KCl stock solutions are prepared in KRBH, filtered through a 0.22 
µm filter and stored at 4ºC. Palmitate bound to 1% (w/v) BSA is prepared as described
before for PALMITATE OXIDATION (Section 10.1).
B) Radioimmunoassay
The insulin content was determined by radioimmunoassay using the Coated 
Tube Insulin RIA kit (Insulin-CT, Schering, ref. INK-0206). The principle of the assay 
is based on the competition between the labelled insulin contained in standards or
samples for a fixed and limited number of antibody binding sites bound on the solid 
phase (coated tubes). After the incubation, the unbound tracer is removed by washing.
The amount of labelled insulin bound to the antibody is inversely proportional to the 
amount of unlabelled insulin in the sample. 
The coated tubes contain guinea pig anti-porcine insulin serum coated to the 
bottom of the tube. This antibody also binds to human and rat insulin that are present in 
INS(832/13) cells. The labelled insulin used is 125I-porcine insulin dissolved in
phosphate buffer in the presence of bovine albumin and sodium azide. 
For the RIA, samples are thawed and diluted 1/10 (insulin secretion samples) or
1/100 (insulin content samples) in KRBH. 100 µl of KRBH (blank), standards (5.5, 15, 
35, 70, 175 and 310 µIU/ml) or diluted samples is placed into the coated tubes plus 1 ml 
of 125I-insulin. After vortex-mixing, samples are incubated 18-20 h at r.t. and, washed in
water, and the remaining radioactivity bound to the tubes is measured with a gamma 
scintillation counter calibrated for 125 iodine. Results for insulin secretion are
represented as % of insulin content.
13. PANCREATIC RAT ISLETS
13.1 RAT ISLET ISOLATION
Rat islets were isolated for adenovirus infection and Western blot or insulin 
secretion measurements. Pancreatic rat islets were isolated with collagenase as
previously described41. The following protocol is described for islet isolation from one 
rat.
41 Gotoh M, Maki T, Satomi S, Porter J, Bonner-Weir S, O’Hara Cj, Monaco AP. Reproducible high yield of rat 
islets by stationary in vitro digestion following pancreatic ductal or portal venous collagenase injection.
Transplantation 43:725-730, 1987
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Material preparation
First 25% Ficoll solution is prepared by dissolving in a beaker 5 g of Ficoll DL-
400 (Sigma-Aldrich, ref. F-9378, 100 g) in 15 ml of HBSS/HEPES 20 mM (Hanks 
Balanced Salt Solution/HEPES buffer) and mixing it with a magnet. When it is
dissolved, total volume is adjusted up to 20 ml with HBSS/HEPES buffer and filtered 
through a 0.45 µm filter.
Collagenase is prepared by dissolving 20 mg of collagenase type 4 (Worthington 
biochemical corporation, ref. S9J3119, 5 mg, 180 U/mg) kept at 4ºC in 10 ml of
HBSS/HEPES buffer and filtering it through a 0.22 µm filter. DNase at 1/3000 is added
just at the moment of collagenase utilization. DNase stock is prepared at 10 mg /ml, so 
for 10 ml of collagenase 3.33 µl of DNase will be added. The collagenase and a flask or 
a 50 ml tube for the pancreas location are kept on ice.
Surgery
One Wistar rat weighing approx. 200 g is sacrificed by dislocation and dissected.
All the organs are placed on the left side when the head of the animal is at the bottom.
In this position the pancreatic canal is visible. The clamp has to be done at the point 
where the pancreatic canal joins the duodenum intestine. This point could be identified 
by a whiter area in the intestine with a red dot. The clamp must be placed at the left, in 
the same direction on the canal. The clamp prevents the collagenase from escaping from
the pancreas through the intestine. 
The pancreatic canal area where the collagenase is to be injected i.e., the bottom 
part of the canal, near the liver, is cleaned and cleared of fat with the help of a forceps 
and a needle.  10 ml of collagenase is injected slowly with a needle connected to a 
syringe through this point. The syringe must not contain bubbles. It is possible to see 
how the pancreas is being inflated during this process. See fig. 7.
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Fig. 7. Scheme of collagenase injection into the pancreas of the rat. The pancreatic canal is clamped at the point 
where it joins the duodenum intestine. Then, 10 ml of collagenase is injected through the pancreatic canal.
Once the clamp is released, all the organs are placed on the right side of the rat 
to see if the collagenase reached the spleen. The pancreas is separated carefully, without 
cutting it to prevent the collagenase from escaping. First the spleen is taken out, then the 
pancreas is separated from the large intestine and after that the mesentery and the small 
intestine are cut. The intestine must not be cut, to avoid contamination. Finally the 
pancreas is detached from the stomach and the liver. 
Collagenase digestion
The pancreas is placed inside the flask or the 50 ml tube maintained on ice. If 
more pancreas samples are needed they will be added to the same flask. Collagenase 
digestion is done for 25 min at 37ºC shaking the flask once or twice to homogenize the 
digestion.
Ficoll gradient
For one rat two gradient steps are necessary. Each gradient is performed with 23, 
20.5 and 11% of Ficoll. The 23% Ficoll is prepared in a 15 ml tube by mixing 4.6 ml of 
collagenase
pancreas
pancreatic canal
clamp
small intestine
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25% Ficoll plus 0.4 ml of HBSS/HEPES buffer, 20.5% Ficoll with 4.1 ml of 25% Ficoll 
plus 0.9 ml of HBSS/HEPES buffer and 11% Ficoll with 2.2 ml of 25% Ficoll plus 2.8 
ml of HBSS/HEPES buffer (see table below of Ficoll gradients).
Collagenase digestion is stopped by the addition of 50 ml of cold HBSS/HEPES 
buffer, with vigorous shaking. The pancreas solution is centrifuged at 1,400 rpm for 1 
min at r.t. Supernatant is removed and more HBSS/HEPES buffer is added and mixed
vigorously. This process is repeated until supernatant is almost transparent (not red). 
To eliminate the floating fat, the solution is filtered with a gauze and the original 
tube is washed twice with HBSS/HEPES buffer and also filtered through the gauze. The 
solution is centrifuged at 1,400 rpm for 1 min at r.t. 
Islets are then distributed into 15 ml tubes with 10 ml HBSS/HEPES
buffer/rat/tube. The solution is centrifuged at 1,400 rpm for 1 min at r.t. All the 
supernatant must be well aspirated because the remaining liquid will change the
gradient. 4 ml of 25% Ficoll is added to each 15 ml tube by vortexing to yield a good 
homogenate. 25% Ficoll is viscous and does not damage the cells. With a 5 ml pipette, 2 
ml of 23% Ficoll, then 2 ml of 20.5% Ficoll and finally 2 ml of 11% Ficoll are added to 
the tube very slowly, leaving the liquid to slide down the wall of the tube and turning it 
at the same time. Solut ion is centrifuged at 1,700 rpm for 7 min at 24ºC without brake. 
With this gradient, islets will be separated from the rest of the cells and will remain in a 
ring between 11-20.5% and 20.5-23% Ficoll.
Islets are removed with a Pasteur pipette and placed in a 15 ml tube with
HBSS/HEPES buffer. The Pasteur pipette must be prewashed in HBSS/HEPES buffer 
to avoid losing islets, which attach to glass. Islets are centrifuged at 1,400 rpm for 1 min 
at r.t. with brake. Some islets are still floating because the gradient is still high. Half of 
the supernatant is aspirated and more HBSS/HEPES buffer is added to reduce the 
gradient and wash the islets out. This process is repeated until hardly any islets are 
floating. If more than one rat has been used, islets are placed together in one 15 ml tube 
and pelleted.
Once the supernatant is completely aspirated the gradient is repeated as
described above. 4 ml of 25%, 2 ml of 23%, 2 ml of 20.5% and 2 ml of 11% Ficoll are 
added and the solution is centrifuged at 1,700 rpm fo r 7 min at 24ºC without brake. 
Islets are removed with a Pasteur pipette and washed as described above.
Materials and methods
153
Preparing islets for culture
Under the hood 10 ml of PBS is added to the pellet of islets to resuspend them.
Islets are centrifuged at 1,400 rpm for 1 min at r.t., washed twice with PBS and then 
twice with medium preheated at 37ºC.
Islets from one rat (approx. 400 islets) are resuspended in medium and seeded at 
200 islets/10-cm dish using a microscope to count them (20 islets/ml). Islets are
cultured o/n at 37ºC.
HBSS/HEPES 20 mM
HBSS/HEPES buffer is prepared by mixing 50 ml of HBSS 10X (Gibco, ref. 
14065-056) with 10 ml of 1 M HEPES and adjusting the volume with bd. A.C. H2O up
to 500 ml. The solution is filtered through a 0.22 µm filter and stored at 4ºC. HBSS 
contains basically water, salts, glucose, penicillin, streptomycin and BSA at pH 7.2.
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Ficoll gradients
The next table shows how to prepare the different Ficoll gradients according to 
the number of rats used. 
Num. Rats Num.
Gradients
25%
(g Ficoll/ml 
HBSS/HEPES
buffer)
23%
(ml 25% 
Ficoll/ml
HBSS/HEPES
buffer)
20.5%
(ml 25% 
Ficoll/ml
HBSS/HEPES
buffer)
11%
(ml 25% 
Ficoll/ml
HBSS/HEPES
buffer)
1 2  5 g/20 ml 4.6/0.4 ml 4.1/0.9 ml 2.2/2.8 ml
2 3 7.5 g/30 ml 6.9/0.6 ml 6.15/1.35 ml 3.3/4.2 ml
3 4 10 g/40 ml 9.2/0.8 ml 8.2/1.8 ml 4.4/5.6 ml
4 5 12.5 g/50 ml 11.5/1 ml 10.25/2.25
ml
5.5/7 ml
5 6 15 g/60 ml 13.8/1.2 ml 12.3/2.7 ml 6.6/8.4 ml
6 7 17.5 g/70 ml 16.1/1.4 ml 14.35/3.15
ml
7.7/9.8 ml
7 8 20 g/80 ml 18.4/1.6 ml 16.4/3.6 ml 8.8/11.2 ml
13.2 RAT ISLET CULTURE
After the isolation step islets are maintained in culture at 20 islets/ml in regular 
RPMI 1640 medium containing 11 mM glucose supplemented with 10% (v/v) FBS, 100 
U/ml penicillin and 100 µg/ml streptomycin at 37ºC in a humidified atmosphere
containing 5% CO2.
13.3 RAT ISLET INFECTION
One day after the isolation, 200 islets are taken, centrifuged at 1,400 rpm for 1 
min and resuspended in 1 ml of medium. Islets are transferred to one 35-mm dish 
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containing 1 ml of medium plus the different purified adenoviruses at 10-150 x 104
pfu/islet. Islets are incubated with the adenoviruses for 1 h at 37ºC. After that, as much 
medium as possible is removed. This is possible because islets are grouped together.
Then they are resuspended in 4 ml of medium and transferred to a 60-mm dish. Islets 
are cultured for 24 h before experiments are done.
13.4 INSULIN SECRETION 
Islets were infected with the different adenoviruses one day after isolation and 
further cultured for 24 h before the insulin secretion experiments were done.
For the insulin secretion measurements, islets are first preincubated for 30 min in 
KRBH plus 2.8 mM glucose. Then, 10 islets/tube are incubated with 1 ml of KRBH 
0.1% BSA plus 2.8 or 16.7 mM glucose for another 30 min. After this incubation time 
the supernatant is collected. To measure the total insulin content, islets are dissolved in 
1 ml of 75% ethanol/0.2 M HCl. Insulin is detected by RIA as described in Section 12.
14. MASS SPECTROSCOPY
The MALDI-TOF mass spectra of C75, C75-CoA, etomoxir and etomoxiryl-
CoA were obtained on a Voyager DE-RP (Applied Biosystems) mass spectrometer 
equipped with a nitrogen laser (337 nm, 3 ns pulse). The acceleration voltage is set to 
20 kV. Data are acquired in the reflector mode with delay times of 320 ns for both the 
positive and negative polarities. Spectra are calibrated externally using a calibration 
mixture (Calibration Mixture 1, Applied Biosystems): CHCA, des-Arg1-Bradykinin,
Angiotensin I, Glu1-Fibrinopeptide B, Neurotensin m/z 300-1700.
Samples are prepared by diluting 1 µl of the activation buffer of each drug to 
100 µl with H2O, and mixing 1 µl of this diluted solution with 1µl of matrix solution
(10 mg/ml of 2,5-dihydroxybenzoic acid (2,5-DHB, Aldrich) in methanol:water 1:1). 
One microliter of the sample:matrix mixture is spotted onto the stainless steel sample 
plate, allowed to evaporate to dryness in air and introduced into the mass spectrometer.
Spectra are acquired in the positive and negative ion mode. 
MALDI-TOF spectra were performed by the Mass Spectrometry Service (SCT, 
University of Barcelona).
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15. STATISTICAL ANALYSIS
Data are expressed as means ± SE for at least four independent experiments 
performed in triplicate. Different experimental groups were compared either with the 
Student’s t test or with the  one-way ANOVA followed by Bonferroni’s test for
comparisons post hoc. A probability level of p<0.05 was considered to be statistically 
significant.
RESULTS
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RESULTS
1. ALTERATION OF THE MALONYL-CoA/CPTI INTERACTION 
IN THE PANCREATIC β-CELL
To directly test the hypothesis that the CPTI/malonyl-CoA interaction is
involved in glucose-stimulated insulin secretion (GSIS) we overexpressed LCPTI
M593S, a mutant LCPTI enzyme that is insensitive to malonyl-CoA1, in pancreatic β-
cells. In this way we would establish whether the availability of long-chain fatty acyl-
CoA (LC-CoA) affects the regulation of insulin secretion and whether malonyl-CoA
may acts as a metabolic coupling factor in the β-cell.
1.1 CONSTRUCTION OF THE RECOMBINANT ADENOVIRUS Ad-LCPTI
M593S
A) Ad-LCPTI M593S
We used the following adenoviruses: Ad-LCPTI wt, Ad-LacZ and Ad-LCPTI
M593S. Ad-LCPTI wt encoding LCPTI wt was constructed as previously described2.
Ad-LacZ, which expresses bacterial β-galactosidase, was used as a control adenovirus. 
Ad-LCPTI M593S, encoding the malonyl-CoA-insensitive LCPTI M593S cDNA under 
the chicken β-actin (CA) promoter, was constructed as described in Fig. 1.
1 Morillas M, Gomez-Puertas P, Bentebibel A, Selles E, Casals N, Valencia A, Hegardt FG, Asins G, Serra D. 
Identification of conserved amino acid residues in rat liver carnitine palmitoyltransferase I critical for malonyl-CoA
inhibition. Mutation of methionine 593 abolishes malonyl-CoA inhibition. J. Biol. Chem. 278:9058-9063, 2003
2 Rubi B, Antinozzi PA, Herrero L, Ishihara H, Asins G, Serra D, Wollheim CB, Maechler P, Hegardt FG. 
Adenovirus-mediated overexpression of liver carnitine palmitoyltransferase I in INS1E cells: effects on cell 
metabolism and insulin secretion. Biochem. J. 364:219-226, 2002
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Fig. 1. Generation of the recombinant adenovirus Ad-LCPTI M593S. Blunt-ended LCPTI M593S cDNA was 
subcloned into the cosmid pAxCA wt previously cut with SwaI and dephosphorylated. This cosmid contains the 
CMV enhancer, the chicken β-actin promoter, the rabbit β-globin poly A signal and the adenovirus genome which 
lacks the E1 gene and thus renders adenovirus replication defective. The recombinant cosmid was cotransfected with 
DNA-TPC (adenovirus DNA of terminal protein complex) in HEK 293 cells. The recombinant adenovirus was 
generated by homologous recombination and propagated in HEK 293 cells, which express the adenoviral E1 gene. 
Recombinant cosmid
TP TP
RestrictionEnzyme
RestrictionEnzyme digestedDNA-TPC
Cotransfection HEK 293 cells
E1
Homologous
recombination
Propagation
Ad-LCPTI M593S
pTRE2-LCPTI M593SCosmid pAxCA wt
LCPTI M593S
ClaI XbaI
PhCMV*-1 B-globin poly A
+Swa I
Subcloning
LCPTI M593S
LCPTI M593S
LCPTI M593S
LCPTI M593S
E1 E3
E1 E3
E3
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Briefly, the LCPTI M593S cDNA was obtained from pTRE2-LCPTI M593S 
(Section 2.1) by digestion with ClaI and XbaI. The terminals were blunt-ended and the 
cDNA was subcloned into the cosmid pAxCA wt which had been previously digested 
with SwaI and dephosphorylated. This cosmid contains the adenovirus genome which 
lacks the E1 gene and thus renders adenovirus replication defective. It also contains the 
CMV enhancer, the chicken β-actin promoter and the rabbit β-globin poly A signal. The 
presence and right orientation of the insert were checked by restriction enzyme
digestions using ClaI and BglII and the presence of the mutation was confirmed by
sequencing. The resultant pAxCA-LCPTI M593S cosmid was cotransfected with DNA-
TPC (adenovirus DNA of terminal protein complex) in HEK 293 cells. The
recombinant adenovirus was generated by homologous recombination and was
propagated in HEK 293 cells, which express the adenoviral E1 gene. 
B) Recombinant adenovirus analysis
To select the viral clone with highest LCPTI expression, INS(832/13) cells 
infected with the different clones were analyzed by Western blot.
INS(832/13) cells were infected with 2, 5 or 10 µl of the viral suspension of 
three viral clones obtained or with Ad-LacZ as a control. Cell lysate was collected and 
analyzed by Western blot with an anti-LCPTI specific antibody (Fig. 2).
Fig. 2. Western blot analysis of three Ad-LCPTI M593S clones. INS(832/13) cells were infected with 2, 5 or 10 µl
of a suspension of three different viral clones or with Ad-LacZ as a control. Cell lysate was analyzed by Western blot 
with an anti-LCPTI specific antibody, giving a single band of 88 kDa. The protein marker is shown as (M). 
Ad-LCPTI M593S clone 2 was selected since it showed the highest LCPTI 
expression by Western blot and no toxicity in INS(832/13) cells. The adenovirus was 
amplified in HEK 293 cells, purified by CsCl and carefully titrated as detailed in
2 5 10
Ad-LacZ clone 1 clone 2 clone 3
88 kDa
2 5 10 2 5 102 5 10 (µl)M
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MATERIALS AND METHODS (Section 6.7). The titer obtained was 8.1 x 109 pfu/ml. The
titers of Ad-LacZ and Ad-LCPTI wt were 2.3 x 109 and 1.9 x 108 pfu/ml, respectively.
1.2 CPTI ACTIVITY IN INS(832/13) CELLS INFECTED WITH Ad-LCPTI wt 
AND Ad-LCPTI M593S
1.2.1 CPTI inhibition by malonyl-CoA
The capacity of the LCPTI mutant to show enzyme activity despite the presence 
of malonyl-CoA was evaluated in pancreatic β-cells.
INS(832/13) cells were infected with Ad-LCPTI wt and Ad-LCPTI M593S as 
described in MATERIALS AND METHODS (Section 6.8). Mitochondrion-enriched cell
fractions were incubated with different amounts of malonyl-CoA and CPTI activity 
assay was performed.
Fig. 3. Malonyl-CoA inhibition of CPTI in INS(832/13) cells infected with Ad-LCPTI wt and Ad-LCPTI
M593S. INS(832/13) cells were infected with Ad-LCPTI wt or Ad-LCPTI M593S and 24 h later CPTI activity assay 
was performed with 8 µg of mitochondrion-enriched cell fractions incubated with different amounts of malonyl-CoA.
Data are expressed relative to control values in the absence of malonyl-CoA (100%) as the mean ± SE of 6 
independent experiments performed in duplicate.
As shown in Fig. 3 in the presence of 100 µM malonyl-CoA mitochondrion-
enriched fractions of cells infected with Ad-LCPTI M593S retained 84% of their 
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activity while that of the LCPTI wt was almost completely inhibited. LCPTI M593S 
showed enzyme activity despite the presence of malonyl-CoA, therefore this LCPTI 
mutant is indeed insensitive to malonyl-CoA in pancreatic β-cells.
1.2.2 CPTI inhibition by etomoxiryl-CoA
We also stud ied the behaviour of LCPTI M593S with the irreversible CPTI
inhibitor etomoxir. The active inhibitory form of etomoxir is its CoA-derivative,
etomoxiryl-CoA3, therefore mitochondrion-enriched fractions of INS(832/13) cells
infected with Ad-LCPTI wt and Ad-LCPTI M593S were incubated with different
amounts of etomoxiryl-CoA and CPTI activity was assayed.
Fig. 4. Etomoxiryl-CoA inhibition of CPTI in INS(832/13) cells infected with Ad-LCPTI wt and Ad-LCPTI
M593S. INS(832/13) cells were infected with Ad-LCPTI wt or Ad-LCPTI M593S and 24 h later CPTI activity assay 
was performed with 8 µg of mitochondrion-enriched cell fractions incubated with different amounts of etomoxiryl-
CoA. Data are expressed relative to control values in the absence of etomoxiryl-CoA (100%) as the mean ± SE of 6 
independent experiments performed in duplicate.
3 Weis BC, Cowan AT, Brown N, Foster DW, McGarry JD. Use of a selective inhibitor of liver carnitine
palmitoyltransferase I (CPT I) allows quantification of its contribution to total CPT I activity in rat heart. Evidence 
that the dominant cardiac CPT I isoform is identical to the skeletal muscle enzyme. J. Biol. Chem. 269:26443-26448,
1994
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In the presence of 100 µM etomoxiryl-CoA mitochondrion-enriched fractions  of 
cells infected with Ad-LCPTI M593S retained 18% of their activity while that of the 
LCPTI wt was almost completely inhibited (Fig. 4). Therefore, in INS(832/13) cells 
LCPTI M593S was partially inhibited by etomoxiryl-CoA although this LCPTI mutant
form was still less sensitive to etomoxiryl-CoA than LCPTI wt. The differences 
between Fig. 3 and Fig. 4 could be explained because etomoxir binds covalently and 
irreversibly to the protein LCPTI.
1.2.3 CPTI activity in INS(832/13) cells infected with different amounts of Ad-
LCPTI wt and Ad-LCPTI M593S 
To study the variation of CPTI activity vs the amount of virus used and to find 
equal conditions of CPTI activity for both Ad-LCPTI wt and Ad-LCPTI M593S, CPTI
activity was analysed in detail.
INS(832/13) cells were infected with different amounts of Ad-LCPTI wt (Fig.
5A) and Ad-LCPTI M593S (Fig. 5B) and CPTI activity assay was performed with 8 µg
of mitochondrion-enriched cell fractions. In both cases CPTI activity increased to a 
plateau of 9-10 fold compared with the endogenous LCPTI, calculated from Ad-LacZ
infected cells (5.0 ± 1.8 nmol.mg-1 prot.min-1). For subsequent experiments we decided 
to use the amount of adenovirus LCPTI wt (1.7 pfu/cell) and LCPTI M593S (4.1 
pfu/cell) that increased CPTI activity 6-fold (30 nmol. mg-1prot. min-1) with respect to 
the control Ad-LacZ.
Results
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Fig. 5. CPTI activity of INS(832/13) cells infected with different amounts of Ad-LCPTI wt and Ad-LCPTI
M593S. INS(832/13) cells were infected with different pfu/cell of Ad-LCPTI wt (A) or Ad-LCPTI M593S (B). 24 h 
later mitochondrion-enriched cell fractions were obtained and 8 µg of protein were used for the CPTI activity assay.
The amount of both viruses that  increased CPTI activity 6-fold, compared with Ad-LacZ (0 pfu/cell), were chosen for 
further experiments (1.7 pfu/cell for Ad-LCPTI wt and 4.1 pfu/cell for Ad-LCPTI M593S). Insert: expanded dose-
response curve. Data are the mean ± SE of 4 independent experiments performed in duplicate.
In an additional experiment cells were also incubated for 30 min with or without 
200 µM of etomoxir and CPTI activity assay was performed with 8 µg of
mitochondrion-enriched cell fractions. The 200 µM concentration of etomoxir was
chosen as is the amount of etomoxir enough to completely inhibit LCPTI wt (Fig. 4). 
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This irreversible CPTI inhibitor blocked CPTI activity in Ad-LacZ- and Ad-LCPTI wt-
infected cells, leaving the malonyl-CoA/etomoxiryl-CoA insensitive CPTII activity, 
probably present due to some broken mitochondria. However, etomoxir left 65% CPTI 
activity in Ad-LCPTI M593S-infected cells (Fig. 6).
Fig. 6. CPTI activity in INS(832/13) cells infected with Ad-LCPTI wt and Ad-LCPTI M593S. INS(832/13) cells 
were infected with Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI M593S. CPTI activity assay  was performed with
mitochondrion-enriched fractions of cells incubated for 30 min in KRBH 1% BSA with or without etomoxir (200 
µM). Data are the mean ± SE of 4 independent experiments performed in duplicate. *P<0.05 vs Ad-LCPTI M593S 
without etomoxir; **P<0.001 vs Ad-LacZ.
Thus, expression of LCPTI wt and LCPTI M593S in the β-cell was successful in 
markedly increasing enzymatic activity of CPTI. Moreover, in pancreatic β-cells LCPTI 
M593S showed enzyme activity despite the presence of malonyl-CoA and was even less 
sensitive to etomoxiryl-CoA than LCPTI wt. 
1.3 CPTI PROTEIN IN INS(832/13) CELLS AND RAT ISLETS INFECTED
WITH Ad-LCPTI wt AND Ad-LCPTI M593S
To examine whether the increase in CPTI activity seen with Ad-LCPTI wt and 
Ad-LCPTI M593S-infected cells was correlated with an increase in LCPTI protein 
expression, Western blot analysis was performed. 
INS(832/13) cells were infected with different amounts of Ad-LCPTI wt and 
Ad-LCPTI M593S and 24 h after the infection, total protein analyzed by Western blot 
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with the anti-LCPTI specific antibody revealed the expected 88 kDa band
corresponding to LCPTI protein. As shown in Fig. 7, in both adenoviruses the signal 
increased consistent with the increased pfu/cell used. 
Fig. 7. Western blot of INS(832/13) cells infected with diffe rent amounts of Ad-LCPTI wt and Ad-LCPTI
M593S. INS(832/13) cells were infected with different amounts of Ad-LCPTI wt and Ad-LCPTI M593S and with 30 
pfu/cell of Ad-LacZ as a control. Cell lysate was analyzed by Western blot with the anti-LCPTI specific antibody
giving a unique band of 88 kDa. 
As explained above, we used the amount of adenovirus LCPTI wt and LCPTI
M593S that increased CPTI activity 6-fold respect to the control Ad-LacZ. Therefore, a 
Western blot analysis was performed with INS(832/13) cells infected with 1.7 pfu/cell 
of Ad-LCPTI wt and 4.1 pfu/cell of Ad-LCPTI M593S (Fig. 8A) and, consistent with 
the activity assays, it showed similar amounts of protein in Ad-LCPTI wt and Ad-
LCPTI M593S-infected cells.
88 kDa
Ad-LCPTI M593SAd-LacZ
30 505 10 100 200 300 (pfu/cell)400
88 kDa
Ad-LCPTI wtAd-LacZ
30 101 2 20 30 40 (pfu/cell)50
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Fig. 8. Immunoblot analysis of LCPTI expressed in infected INS(832/13) cells and rat islets. (A) INS(832/13) 
cells infected with Ad-LacZ (4.1 pfu/cell), Ad-LCPTI wt (1.7 pfu/cell) and Ad-LCPTI M593S (4.1 pfu/cell) were
collected and protein extracts were separated by SDS/PAGE (8% gels) and subjected to immunoblotting by using a
specific antibody for CPTI from liver. A unique band corresponding to a protein of approx. 88 kDa was seen in 
control, Ad-LCPTI wt and Ad-LCPTI M593S infected cells. (B) Rat islets (batches of 100-200) were infected with 
the different adenoviruses as described in MATERIALS AND METHODS (Section 13.3) and 24 h later LCPTI protein 
expression was determined by Western blot.
When rat islets were infected with Ad-LacZ, Ad-LCPTI wt and Ad-LCPTI
M593S as detailed in MATERIALS AND METHODS (Section 13.3), again as with
INS(832/13) cells, Western blot analysis showed similar LCPTI protein levels with both 
LCPTI wt and LCPTI M593S constructs (Fig. 8B). Thus, expression of LCPTI wt and 
LCPTI M593S in the β-cell was successful in markedly increasing LCPTI protein.
A
Ad-LacZ Ad-LCPTI wt Ad-LCPTI M593S
B
Ad-LacZ Ad-LCPTI wt Ad-LCPTI M593S
88 kDa
88 kDa
INS(832/13) cells
Rat islets
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1.4 EFFECT OF LCPTI M593S EXPRESSION ON PALMITATE OXIDATION 
To test the metabolic relevance of a malonyl-CoA-insensitive LCPTI, we
assessed fatty acid oxidation in pancreatic β-cells. [1-14C]palmitate oxidation to CO2
and to acid soluble products (ASP), which is an important component of total fatty acid 
oxidation in β-cells4 composed essentially by ketone bodies5, was measured in
adenovirus-treated INS(832/13) cells. These cells were infected with Ad-LacZ, Ad-
LCPTI wt or Ad-LCPTI M593S. 24 h after viral treatment cells were preincubated for 
30 min in KRBH medium containing 1% BSA and then incubated for 2 h at 2.5, 7.5 or 
15 mM glucose in the presence of [1-14C]palmitate. Fatty acid oxidation to CO2 and to 
ASP was measured as detailed in MATERIALS AND METHODS (Section 10.1).
Elevated glucose suppressed palmitate oxidation in both control and LCPTI-
overexpressing cells (LCPTI wt and LCPTI M593S) (Fig. 9). This finding indicates that 
the overexpressing cells respond normally to glucose with respect to palmitate
oxidation. However, the degree of suppression observed in response to elevated glucose 
in LCPTI wt and LCPTI M593S overexpressing cells was insufficient to normalize
palmitate oxidation to the levels obtained in control Ad-LacZ-infected cells.
Interestingly, fatty acid oxidation was highest in cells infected with Ad-LCPTI
M593S at all the glucose concentrations tested. At high glucose (15 mM) fatty acid 
oxidation to CO2, ASP, and their sum were increased by 8.3, 3.4 and 4.4 fold
respectively, compared with Ad-LacZ-infected cells. These oxidation rates were higher 
than those obtained when overexpression was performed with Ad-LCPTI wt (3.3, 1.5 
and 1.8 fold, respectively).
These findings confirm that even at high malonyl-CoA concentrations (high 
glucose), fatty acid oxidation in LCPTI M593S overexpressing cells is much higher
than in the control Ad-LacZ-infected cells and still higher than in cells infected with 
Ad-LCPTI wt. Since LCPTI M593 is resistant to malonyl-CoA, β-oxidation to CO2 and 
ketone bodies (acid soluble compounds) is accelerated in cells overexpressing the 
mutated enzyme. 
4 Roduit R, Nolan C, Alarcon C, Moore P, Barbeau A, Delghingaro-Augusto V, Przybykowski E, Morin J, Masse F, 
Massie B, Ruderman N, Rhodes C, Poitout V, Prentki M. A Role for the Malonyl-CoA/Long-Chain Acyl-CoA
Pathway of Lipid Signaling in the Regulation of Insulin Secretion in Response to Both Fuel and Nonfuel Stimuli. 
Diabetes 53:1007-1019, 2004
5 Fulgencio JP, Kohl C, Girard J, Pegorier JP. Troglitazone inhibits fatty acid oxidation and esterification, and 
gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 45:1556-1562, 1996
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Fig. 9. Fatty acid oxidation in INS(832/13) cells infected with Ad-LCPTI wt and Ad-LCPTI M593S. Cells were 
infected with Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI M593S. 24 h after viral treatment cells were preincubated for 30 
min at 37ºC in KRBH medium containing 1% BSA and then incubated for 2 h at 2.5, 7.5 or 15 mM glucose in the 
presence of 0.8 mM carnitine, 1 µCi/ml [1-14C]palmitate and 0.25 mM unlabeled palmitate bound to 1% (w/v) BSA. 
Palmitate oxidation to CO2 (A), ASP (B), and total palmitate oxidation (CO2 + ASP) (C), was measured as described 
in MATERIALS AND METHODS (Section 10.1). Data are the mean ± SE of 5 independent experiments performed in 
triplicate.*P<0.05 vs Ad-LacZ; #P<0.05 vs Ad-LCPTI wt.
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In an additional experiment cells were also incubated for 30 min with or without 
200 µM of etomoxir and palmitate oxidation to 14CO2 was measured at low (2.5 mM) 
and high (15 mM) glucose (Fig. 10). 
Fig. 10. Fatty acid oxidation in INS(832/13) cells infected with Ad-LCPTI wt and Ad-LCPTI M593S and
incubated with or without etomoxir. INS(832/13) cells were infected with Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI
M593S. 24 h after viral treatment cells were preincubated for 30 min at 37ºC in KRBH medium containing 1% BSA 
with or without 200 µM etomoxir, washed with KRBH 0.1% BSA to completely eliminate etomoxir and then 
incubated for 2 h at 2.5 or 15 mM glucose in the presence of 0.8 mM carnitine, 1 µCi/ml [1-14C]palmitate and 0.25
mM unlabeled palmitate bound to 1% (w/v) BSA. Palmitate oxidation to CO2 was measured as described in 
MATERIALS AND METHODS (Section 10.1). Data are the mean ± SE of 3 independent experiments performed in 
triplicate. *P<0.05 vs Ad-LacZ; #P<0.05 vs Ad-LCPTI wt.
This irreversible CPTI inhibitor decreased palmitate oxidation at low glucose 
and to a lesser extent at high glucose in both Ad-LCPTI wt- and Ad-LCPTI M593S-
infected cells. However, the LCPTI M593S construct continued to produce a higher 
palmitate oxidation rate than those obtained when overexpression was performed with 
Ad-LCPTI wt, either at low or at high glucose. In the presence of etomoxir, fatty acid 
oxidation to CO2 was increased by 11.8 and 11.0 fold at 2.5 and 15 mM glucose 
respectively, compared with Ad-LacZ-infected cells, while LCPTI wt produced an
increase of 4.2 and 4.1 at 2.5 and 15 mM glucose respectively.
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It is important to notice that, in all cases, LCPTI M593S construct caused higher 
palmitate oxidation than LCPTI wt despite the fact that INS(832/13) cells were infected 
with the appropriate amount of each virus to yield the same LCPTI activity, a 6-fold
increase respect to control Ad-LacZ- infected cells. Thus, the increase in palmitate 
oxidation of LCPTI M593S compared to LCPTI wt was due to its insensitiveness to 
malonyl-CoA, which is effective either at low or at high glucose, i.e. either at low or at 
high malonyl-CoA levels.
1.5 MALONYL-CoA LEVELS
To examine the effect of the expression of LCPTI wt and LCPTI M593S on
malonyl-CoA levels in the β-cell, the malonyl-CoA content was measured at the same 
infection and preincubation conditions as those used in palmitate oxidation assays.
INS(832/13) cells were infected with Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI M593S and
24 h later cells were incubated for 30 min at 2.5 or 15 mM glucose. Then, malonyl-CoA
was extracted from the cells and measured with a radioactive method using purified 
fatty acid synthase.
Malonyl-CoA levels were not modified by LCPTI wt or LCPTI M593S
overexpression, compared with LacZ control cells, either at 2.5 mM glucose or at 15 
mM glucose (Fig. 11).
Fig. 11. Malonyl -CoA content in INS(832/13) cells overexpressing LCPTI wt and LCPTI M593S. INS(832/13)
cells were infected with Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI M593S and 24 h later, cells were incubated for 30 min 
with KRBH 0.1% BSA containing 2.5 or 15 mM glucose. Malonyl-CoA was extracted and assayed with a radioactive 
method using purified fatty acid synthase as detailed in MATERIALS AND METHODS (Section 11.2). Data are the
mean ± SE of 4 independent exp eriments performed in duplicate. *P<0.05 vs 2.5 mM glucose.
0
0,5
1
1,5
2
2,5
2.5 15Glucose (mM)
Ad-LacZ
Ad-LCPTI wt
Ad-LCPTI M593S
M
al
o
n
yl
-C
o
A
(p
m
o
l/m
g
p
ro
t)
*
* *
.
.
.
M
al
o
n
yl
-C
o
A
(p
m
o
l/m
g
p
ro
t)
M
al
o
n
yl
-C
o
A
(p
m
o
l/m
g
p
ro
t)
Results
173
Therefore, the differences seen in palmitate oxidation between LCPTI M593S 
and LCPTI wt were not due to changes in malonyl-CoA levels in the β-cell.
1.6 GLUCOSE OXIDATION
No toxicity was seen in INS(832/13) cells or rat islets infected with any of the 
adenoviruses used, but the adenovirus expression of an enzyme could alter the cellular 
metabolism. Thus, as a control, [U-14C]glucose utilization was measured in INS(832/13) 
cells infected with the different adenoviruses at the same infection and incubation
conditions used in palmitate oxidation assays.
INS(832/13) cells were infected with Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI
M593S and 24 h later, [U-14C]glucose oxidation to 14CO2 was measured after a 2 h 
incubation of the cells at 2.5 or 15 mM glucose.
Glucose oxidation at low (2.5 mM) and high (15 mM) glucose remained
unaltered in cells overexpressing both the wt and mutated LCPTI constructs (Fig. 12). 
This is in accordance with the view that a Randle cycle is inoperative in the β-cell6 and 
that adenovirus expression did not affect glucose metabolism.
Fig. 12. Glucose oxidation in INS(832/13) cells expressing LCPTI M593S. INS(832/13) cells were infected with 
Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI M593S and 24 h later, they were preincubated for 30 min at 37ºC in KRBH 
medium containing 1% BSA. Glucose oxidation to 14CO2 was measured after a 2 h incubation of the cells at 2.5 or 15 
mM glucose in the presence of 0.5 µCi/ml [U-14C]glucose as described in MATERIALS AND METHODS (Section
10.2). Data are the mean ± SE of 4 independent experiments performed in triplicate. *P<0.05 vs 2.5 mM glucose.
6 Segall L, Lameloise N, Assimacopoulos-Jeannet F, Roche E, Corkey P, Thumelin S, Corkey BE, Prentki M. Lipid 
rather than glucose metabolism is implicated in altered insulin secretion caused by oleate in INS-1 cells. Am. J. 
Physiol. 277:E521-528, 1999
0
2
4
6
8
10
12
14
16
2.5 15Glucose (mM)
G
lu
co
se
 o
xi
d
at
io
n
(n
m
o
l/m
g
p
ro
t/
h
)
Ad-LacZ
Ad-LCPTI wt
Ad-LCPTI M593S
* * *
G
lu
co
se
 o
xi
d
at
io
n
(n
m
o
l/m
g
p
ro
t/
h
)
Results
174
1.7 GLUCOSE-STIMULATED INSULIN SECRETION IN Ad-LCPTI M593S-
INFECTED INS(832/13) CELLS AND RAT ISLETS
1.7.1 GSIS in INS(832/13) cells expressing LCPTI M593S
At the same CPTI activity and protein levels, LCPTI M593S produced higher 
rates of palmitate oxidation than LCPTI wt, although control experiments of malonyl-
CoA content and glucose utilization indicated that adenovirus infection or LCPTI
expression did not affect these parameters. We then examined if β-cells transduced with 
LCPTI M593S had more impaired GSIS than cells transduced with LCPTI wt. 
We used the same culture, infection and preincubation conditions as in the
previous experiments. INS(832/13) cells were infected with Ad-LacZ, Ad-LCPTI wt or 
Ad-LCPTI M593S and 24 h later, cells were incubated for 1 h in KRBH 0.1% BSA 
containing the different secretagogues.
Fig. 13. Effect of LCPTI M593S expression on GSIS  in INS(832/13) cells. INS(832/13) cells were infected with 
Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI M593S. 24 h later, cells were preincubated for 30 min in KRBH 1% BSA and 
incubated for 1 h in KRBH 0.1% BSA containing either 2.5, 15 mM glucose, 15 mM glucose plus 0.25 mM palmitate 
bound to 1% (w/v) BSA or 2.5 mM glucose plus 30 mM KCl as described in MATERIALS AND METHODS (Section
12). Insulin release was determined by RIA. Data are the mean ± SE of 4 independent experiments performed in 
triplicate. *P<0.05 vs Ad-LacZ and #P<0.05 vs Ad-LCPTI wt.
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As shown in Fig. 13, GSIS was reduced by 60% in INS(832/13) cells infected 
with Ad-LCPTI M593S and by 40% in Ad-LCPTI wt-infected cells, both with respect 
to control Ad-LacZ. The higher decrease in GSIS caused by LCPTI M593S expression
indicates the deep metabolic influence of a malonyl-CoA non-regulated fatty acid 
oxidation system. 
GSIS was recovered completely in the presence of 0.25 mM palmitate only in 
the case of LCPTI wt, suggesting that at high glucose the provision of exogenous FFA 
was not matched by a rise in intracellular FFA (non-esterified palmitate) in cells 
overexpressing the mutated enzyme due to the dramatically enhanced fatty acid
oxidation. The results in Fig. 18D described below are in total accordance with this 
view.
As a control of the insulin secretion mechanism, cells were incubated at low 
glucose in the presence of 30 mM KCl and insulin release was found to be similar in the 
three cases of adenovirus- infected cells, indicating that the exocytotic machinery is 
preserved in cells transduced with the various constructs.
Insulin secretion was also measured in the presence of etomoxir. Infected cells 
were preincubated for 30 min with or without 200 µM etomoxir. After that, cells were 
washed to remove etomoxir and then incubated for 1 h at 2.5 or 15 mM glucose. The
irreversible CPTI inhibitor restored the impairment in GSIS caused either by LCPTI wt 
or by LCPTI M593S overexpression (Fig. 14).
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Fig. 14. Effect of LCPTI M593S expression on GSIS in the presence of etomoxir. INS(832/13) cells were 
infected with Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI M593S. 24 h after viral treatment cells were preincubated for 30 
min at 37ºC in KRBH medium containing 1% BSA with or without 200 µM etomoxir, washed with KRBH 0.1% 
BSA to completely eliminate etomoxir and then incubated for 1 h in KRBH 0.1% BSA containing either 2.5 or 15 
mM glucose. Insulin release was determined by RIA. Data are the mean ± SE of 3 independent experiments
performed in triplicate. *P<0.05 vs Ad-LacZ, #P<0.05 vs Ad-LCPTI wt and **P<0.05 vs without etomoxir.
Insulin secretion was also studied in the presence of 35 mM K+ plus 250 µM
diazoxide, a condition revealing the KATP channel- independent pathway of glucose 
sensing7. The expression of LCPTI wt and LCPTI M593S led to a decrease in insulin 
release (the difference between 15 and 2.5 mM glucose) of 55 ± 12% and 85 ± 17% 
(n=3) respectively, compared with Ad-LacZ-infected cells. This is consistent with the 
view that KATP-independent signalling (also referred as the amplification pathway) was 
affected in cells overexpressing LCPTI construct (Fig. 15).
7 Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes  49:1751-
1769, 2000
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Fig. 15. Effect of LCPTI M593S expression on the KATP channel-independent GSIS in INS(832/13) cells.
INS(832/13) cells were infected with Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI M593S. 24 h later, cells were
preincubated for 30 min in KRBH 1% BSA and incubated for 1 h with KRBH 0.1% BSA in the presence of 
depolarizing K+ (35 mM) and 250 µM diazoxide at 2.5 mM glucose or 15 mM glucose, to measure KATP channel-
independent glucose sensing as described in MATERIALS AND METHODS (Section 12). Insulin release was 
determined by RIA. Data are the mean ± SE of 4 independent experiments performed in triplicate. *P<0.05 vs Ad-
LacZ.
1.7.2 GSIS in rat islets expressing LCPTI M593S
The insulin secretion experiments described above were performed in a rat 
insulinoma cell line that do not function in the same manner as normal islets and 
therefore may not entirely reflect the situation in native β-cells. For this reason we 
performed insulin secretion experiments with isolated rat islets overexpressing LCPTI 
wt and LCPTI M593S.
Isolated rat islets were infected with Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI
M593S as described in MATERIALS AND METHODS (Section 13.3) and 24 h after 
infection batches of 10 islets each were incubated for 30 min at 2.8 and 16.7 mM 
glucose.
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Fig. 16. Effect of LCPTI M593S expression on GSIS in rat islets. Isolated rat islets were infected with Ad-LacZ,
Ad-LCPTI wt or Ad-LCPTI M593S as detailed in MATERIALS AND METHODS (Section 13.3). Batches of 10 islets 
each were washed and incubated for 30 min in KRBH 0.1% BSA containing 2.8 or 16.7 mM glucose and insulin 
release was determined by RIA. Data are the mean ± SE of 3 independent experiments performed in triplicate. 
*P<0.05 vs Ad-LacZ.
In control islets, raising glucose from 2.8 mM to 16.7 mM induced insulin 
secretion 6.8-fold (Fig. 16). In islets overexpressing LCPTI M593S, GSIS was
decreased by 40% compared to the Ad-LacZ control, while no difference was seen with 
Ad-LCPTI wt-infected islets. To explain the difference in the results between
INS(832/13) cells and islets we hypothesize that normal β-cells are more protected than 
INS cells against lipid depletion due to enhanced fat oxidation such that only the more 
efficient LCPTI M593S construct is active in rat islets.
1.8 ESTERIFICATION PROCESSES
To examine whether the increase in fatty acid oxidation could reduce the 
availability of LC-CoA for lipid signalling we measured esterification processes in
INS(832/13) cells transduced with LCPTI wt and LCPTI M593S. 
INS(832/13) cells infected with Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI M593S 
were preincubated for 30 min in KRBH medium containing 1% BSA and then
incubated for 2 h at 2.5 or 15 mM glucose in the presence [1-14C]palmitate. The levels 
of [1-14C]palmitate incorporated to phospholipids (PL), diacylglycerol (DAG),
triacylglycerides (TG), cholesterol esters (CE) as well as the levels of non-esterified
palmitate (NE Palm) were measured as described in MATERIALS AND METHODS
(Section 10.3) (Fig. 17).
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Fig. 17. Representative experiment of TLC in esterification processes measurements. INS(832/13) infected with 
Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI M593S were preincubated for 30 min at 37ºC in KRBH medium containing 
1% BSA and then incubated for 2 h at 2.5 or 15 mM glucose in the presence of 0.8 mM carnitine, 1 µCi/ml [1-
14C]palmitate and 0.25 mM unlabeled palmitate bound to 1% (w/v) BSA. Total lipids were extracted and fatty acid 
esterification into phospholipids (PL), diacylglycerol (DAG), triglyceride (TG), non-esterified palmitate (NE Palm)
and cholesterol esters (CE) were separated by  thin layer chromatography (TLC) and identified using migration 
references. Plates are eluted with hexan:diethylether:acetic acid (70:30:1, v/v/v) and quantified with a Storm 840 
Laser scanning system. The lowest and darkest spots are other cellular lipids that did not migrate with the solvent and 
were retained at the application point. Data are a representative experiment out of 4 performed in duplicate.
We also measured the total triglyceride content in Ad-LacZ, Ad-LCPTI wt and
Ad-LCPTI M593S-infected cells. TG content was extracted by the Folch method and 
measured with a spectrophotometric assay.
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Fig. 18. Glucose-induced fatty acid esterification processes in INS(832/13) cells expressing LCPTI.  INS(832/13)
infected with Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI M593S were preincubated for 30 min at 37ºC in KRBH medium 
containing 1% BSA and then incubated for 2 h at 2.5 or 15 mM glucose in the presence of 0.8 mM carnitine, 1 
µCi/ml [1-14C]palmitate and 0.25 mM unlabeled palmitate bound to 1% (w/v) BSA. Fatty acid esterification into 
phospholipids (A), diacylglycerol (B), triglyceride (C), non-esterified palmitate (D) and cholesterol esters (E) were 
assessed using thin layer chromatography after lipid extraction. ∆G is the difference between the incorporation of 
palmitate in the particular lipid class at 15 mM glucose vs 2.5 mM glucose. Total triglyceride content (F) was 
extracted by Folch method and measured with a spectrophotometric assay. Data are the mean ± SE of 4 independent
experiments performed in duplicate. *P<0.05 vs Ad-LacZ.
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Glucose- induced palmitate esterification into the different complex lipid species 
was expressed as the differences (∆G) between high (15 mM) and low (2.5 mM) 
glucose (Fig. 18). The glucose- induced rise in PL, DAG, TG and NE Palm was
decreased by 20%, 25%, 35% and 38% respectively for Ad-LCPTI wt- infected cells and 
by 37%, 58%, 59% and 71% respectively, for Ad-LCPTI M593S-infected cells (Fig. 18
A, B, C, D), both compared to Ad-LacZ-infected cells. Palmitate esterification to CE 
was reduced by 23% and 50% for Ad-LCPTI wt and Ad-LCPTI M593S respectively at 
low glucose and by 42% and 60% for Ad-LCPTI wt and Ad-LCPTI M593S respectively 
at high glucose, both compared to the Ad-LacZ control (Fig. 18E). The cellular TG 
content was not changed by the overexpression of LCPTI wt nor LCPTI M593S (Fig. 
18F), supporting the results on Fig. 18 showing that increased fatty acid oxidation in the 
β-cell affects lipid esterification processes mostly upon a glucose challenge. However,
at low glucose, palmitate incorporation into TG was decreased in LCPTI transduced 
cells (Fig. 18C), indicating that LCPTI overexpression could affect TG incorporation 
while the general pool of TG content remains constant. This is probably due to the fact 
that differences in the incorporation of LC-CoA into TG are not reflected in the large 
and stable total TG pool. Fig. 18D also shows that the glucose- induced rise in NE 
Palm, an indirect measurement of cytosolic fatty acyl-CoA4, was markedly curtailed in 
cells overexpressing the LCPTI construct and that the CPTI mutant was most effective 
in this respect.
1.9 PKC ACTIVITY
DAG and FA-CoA activate many PKC enzymes8,9. To assess whether the
decrease of the glucose- induced rise in DAG and NE Palm seen in Ad-LCPTI wt and
Ad-LCPTI M593S-infected cells was associated with alteration in PKC activity in the 
β-cell, we measured PKC activation as estimated by its translocation from cytosol to 
membranes.
INS(832/13) cells were infected with Ad-LacZ,  Ad-LCPTI wt and Ad-LCPTI
M593S. 24 h after viral treatment, cells were incubated for 30 min at 2.5 mM or 15 mM 
glucose and cytosolic and membrane fractions were obtained as described in
8 Yaney GC, Korchak HM, Corkey BE. Long-chain acyl-CoA regulation of protein kinase C and fatty acid 
potentiation of glucose-stimulated insulin secretion. Endocrinology 141:1989-1998, 2000
9 Alcázar O, Qiu-yue Z, Giné E, Tamarit-Rodriguez J. Stimulation of islet protein kinase C translocation by palmitate 
requires metabolism of the fatty acid. Diabetes 46:1153-1158, 1997
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MATERIALS AND METHODS (Section 9). Western blot of membrane and cytosolic
fractions was performed using a specific antibody against the PKC isoforms expressed 
in pancreatic β-cells (α, β  and γ) giving a unique PKC band of 80 kDa. Band intensity
was quantified with a Storm 840 Laser scanning system (Fig. 19).
Fig. 19. PKC activation in Ad-LCPTI wt and Ad-LCPTI M593S-INS(832/13)-infected cells. INS(832/13) cells
were infected with Ad-LacZ, Ad-LCPTI wt and Ad-LCPTI M593S. 24 h after infection cells were incubated for 30 
min at low (2.5 mM) (A) or high (15 mM) (B) glucose. Western blot of membrane (M) and cytosolic (C) fractions 
was performed using a specific antibody against the PKC isoforms expressed in pancreatic β-cells (α, β and γ) giving
a unique band of 80 kDa. Intensity of the PKC bands were quantified with a Storm 840 Laser scanning system. The
lower panels in A and B show mean results ± SE of 3 experiments. (A.U.; arbitrary optical units). *P<0.05 vs Ad-
LacZ.
Western blot carried out on membrane and cytosol proteins of INS(832/13) cells 
incubated at high (15 mM) glucose showed that PKC translocation of Ad-LCPTI wt and 
Ad-LCPTI M593S-infected cells was decreased by 63% and 78%, respectively,
compared with Ad-LacZ-infected cells. No change in PKC translocation between Ad-
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LacZ, Ad-LCPTI wt and Ad-LCPTI M593S-infected cells was seen at low glucose (2.5 
mM). Since both DAG and FA-CoA activate a number of PKC enzymes, the lower 
values of DAG and NE Palm (an indirect determination of FA-CoA levels) observed in 
the LCPTI M593S-overexpressing cells suggest that enhanced β-oxidation by the 
LCPTI M593S mutant reduces GSIS as a result of a decrease in PKC activation. 
2. STABLE EXPRESSION OF LCPTI wt AND LCPTI M593S
2.1 CLONING OF pTRE2-LCPTI wt AND pTRE2-LCPTI M593S
To stably express LCPTI wt and LCPTI M593S in INS cells we utilized the tet-
on system, where the protein could be induced by doxycycline incubation.
A) Cloning of pTRE2-LCPTI wt
The cDNA of LCPTI wt had been previously cloned in our group 10 from the 
screening of a rat liver cDNA library. This cDNA includes the complete LCPTI
codifying domain and the TAA stop codon giving a sequence of 2,700 bp. The LCPTI 
wt cDNA subcloned into the pCMV4 vector was used to obtain the pTRE2-LCPTI wt
plasmid as follows.
The LCPTI cDNA was obtained from pCMV4-LCPTI by digestion with ClaI
and XbaI. This insert was ligated with the pTRE2 vector also digested with ClaI and 
XbaI and the plasmid obtained was checked by sequenc ing and by enzymatic digestions 
(Fig. 20A). 
B) Cloning of pTRE2-LCPTI M593S
The LCPTI M593S cDNA had been previously constructed in our group1 using
the QuickChange polymerase chain reaction-based mutagenesis procedure (Stratagene) 
with the pYES-LCPTI wt plasmid as template. 
To obtain pTRE2-LCPTI M593S, the mutated region of LCPTI was acquired 
from the pYES-LCPTI M593S plasmid by digestion with BclI and XbaI. The pTRE2-
LCPTI wt plasmid, described above, was also digested with BclI and XbaI and ligated 
10 Rubi B. El glutamato y los ácidos grasos participan en la transducción de la señal para la liberación de insulina 
estimulada por glucosa en la célula β del páncreas. Thesis, 2001
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with the mutated region of LCPTI. The resultant pTRE2-LCPTI M593S plasmid was 
checked by sequencing to confirm the presence of the mutation (Fig. 20B).
Fig. 20. pTRE2-LCPTI wt and pTRE2-LCPTI M593S construction. (A) pCMV4-LCPTI wt was digested with 
ClaI and XbaI. The fragment of 2,700 bp corresponding to the LCPTI wt was subcloned into the pTRE2 vector also 
digested with ClaI and XbaI to obtain pTRE2-LCPTI wt. (B) pYES-LCPTI M593S was digested with BclI and XbaI.
The fragment containing the LCPTI mutation was ligated with pTRE2-LCPTI wt previously digested with BclI and 
XbaI to obtain the pTRE2-LCPTI M593S plasmid. 
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2.2 TRANSIENT EXPRESSION OF pTRE2-LCPTI wt
The functionality of the pTRE2-LCPTI wt construct and the correct LCPTI
protein expression were checked by transient expression of pTRE2-LCPTI wt into HEK 
293 rtTA cells which stably express the transactivator rtTA. HEK 293 rtTA cells were 
transfected by calcium phosphate with 25 µg of pTRE2-LCPTI wt as described in
MATERIALS AND METHODS (Section 4) and incubated for 48 h with 1µg/ml doxycycline
immediately after transfection. The cell lysate was then analyzed by Western blot using 
an anti-LCPTI specific antibody.
Figure 21 shows the immunoblot of HEK 293 rtTA cells transfected or not with 
pTRE2-LCPTI wt and incubated with or without doxycycline. 
Fig. 21. Western blot of HEK 293 rtTA cells transfected with pTRE2-LCPTI wt. Untransfected HEK 293 rtTA 
cells (control),  HEK 293 rtTA cells transfected with pTRE2-LCPTI wt and incubated with 1µg/ml doxycycline (+
dox) or without doxycycline (- dox) were analyzed by Western blot using an anti-LCPTI specific antibody. A unique 
band of 88 kDa corresponding to LCPTI was seen in pTRE2-LCPTI wt-transfected cells incubated with doxycycline.
A small band of basal expression was observed in pTRE2-LCPTI wt-transfected cells incubated without doxycycline.
A unique band of 88 kDa corresponding to LCPTI was seen in HEK 293 rtTA 
cells transfected with pTRE2-LCPTI wt and incubated with doxycycline, while the 
endogenous LCPTI band corresponding to untransfected cells was almost undetected. A 
faint band was seen in pTRE2-LCPTI wt-transfected cells without doxycycline
probably due to basal expression of the plasmid even in the absence of doxycycline
incubation. Therefore, pTRE2-LCPTI wt was efficient in transient expression of LCPTI 
wt under the tet-on system.
2.3 STABLE CELLS CONSTRUCTION
Once the functionality of the pTRE2 vector and the expression of the LCPTI 
protein had been checked, INS cells which stably express LCPTI wt and LCPTI M593S 
under the tet-on system were constructed as follows.
control + dox - dox
88 kDa
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INS-r9 cells, that stably express rtTA, were transfected with 25 µg of pTRE2-
LCPTI wt or pTRE2-LCPTI M593S along with 5 µg of hygromicin selection plasmid
(pTK-Hyg) as described in MATERIALS AND METHODS (Section 5). Three weeks after 
starting the selection with 0.1 mg/ml hygromycin, approximately 45 clones of pTRE2-
LCPTI wt and 65 clones of pTRE2-LCPTI M593S appeared. They were incubated with 
500 ng/ml doxycycline for 24 h and cell lysates were analyzed by Western blot with the 
anti-LCPTI specific antibody. Immunoblot of some of these clones is shown in Fig. 22.
Fig. 22. Western blot of INS-r9 cells transfected with pTRE2-LCPTI wt and pTRE2-LCPTI M593S. Clones of 
INS-r9 cells transfected with pTRE2-LCPTI wt and pTRE2-LCPTI M593S resulting from the selection with 0.1 
mg/ml hygromycin were induced for 24 h with 500 ng/ml doxycycline and analyzed by Western blot using an anti-
LCPTI antibody. Clones with higher LCPTI expression (red circles) were selected for further analysis.
Western blot was performed after incubation of the clones with 500 ng/ml 
doxycycline to see the maximum LCPTI expression. Incubation without doxycycline 
was not necessary since clones which do not express pTRE2-LCPTI wt or pTRE2-
LCPTI M593S serve as negative controls of the Western blot. 
Clones with a higher LCPTI protein expression were chosen (red circles). After 
performing the Western blot of all the LCPTI wt and LCPTI M593S clones, we
obtained four stable clones of LCPTI wt (numbers 1, 3, 6 and 37) and nine stable clones 
of LCPTI M593S (numbers 3, 25, 26, 27, 28, 51, 52, 57 and 58). These clones were 
selected and further cultured for additional analysis.
2.4 WESTERN BLOT ANALYSIS OF THE STABLE CLONES 
To choose within the selected clones the one with the highest LCPTI expression, 
clones were incubated for 24 h with or without 500 ng/ml doxycycline. After that, the 
cell lysate was collected and a Western blot was performed with the anti-LCPTI
antibody (Fig. 23).
1 3 6 7 8 9 10 11 51 52 53 54 55 56 57 58 59 60 61
LCPTI wt LCPTI M593S
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Fig. 23. Western blot of the selected LCPTI wt and LCPTI M593S clones. LCPTI wt clones (1, 3, 6 and 37) and 
LCPTI M593S clones (3, 25, 26, 27, 28, 51, 52, 57 and 58) were incubated with (+) or without (-) 500 ng/ml 
doxycycline for 24 h and cell lysates were analyzed by Western blot with the anti-LCPTI antibody. Data are a 
representative experiment out of 5.
Western blot showed no differences in LCPTI expression in any of the clones 
when they were incubated with or without doxycycline. The band seen in all of them 
was probably the endogenous LCPTI protein present in INS-r9 cells. 
2.5 PCR ANALYSIS 
To check whether the lack of differences in LCPTI expression in the selected 
clones incubated with or without doxycycline was due to the loss of the pTRE2-LCPTI
wt or pTRE2-LCPTI M593S plasmids, a PCR analysis was performed. Total genomic 
DNA was obtained from each clone and a specific amplification for the transfected 
plasmids was done with the pTRE2.for and CPTINcoI.rev primers, which give a band of 
1028 bp. As a control of the quality of the genomic DNA obtained as well as an internal 
control of the PCR, we amplified a band of 300 bp of the COT gene using the 
COTH131A.for and COTXbaI.rev primers (Fig. 24A). 
- + - - -+ + +
1 3 6 37
- - - -+ + + +
3 25 26 27
- - - - -+ + + + +
28 51 52 57 58
88 kDa
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To rule out the possibility that the clones do not respond to doxycycline because 
of the loss of the rtTA transactivator stably expressed in the INS-r9 cells, the presence 
of the rtTA construct was also checked by specific PCR amplification of a 216 bp band 
with the rtTA.for and rtTA.rev primers (Fig. 24B). 
Fig. 24. PCR analysis of the genomic DNA of the clones. The genomic DNA was obtained from the LCPTI wt 
clones (1, 3, 6 and 37) and LCPTI M593S clones (3, 25, 26, 27, 28, 51, 52, 57 and 58). (A) The presence of the 
pTRE2-LCPTI wt and pTRE2-LCPTI M593S plasmids was analyzed by a specific PCR amplification of a 1028 bp 
band with the pTRE2.for and CPTINcoI.rev primers. The amplification of 300 bp with COTH131A.for and
COTXbaI.rev primers was an internal PCR control as well as a quality control of the genomic DNA obtained. The 
plasmid pTRE2-LCPTI wt (p) and a genomic DNA (g) previously obtained were used as positive controls of the 
PCR. (B) The presence of the rtTA construct was checked by a specific PCR amplification of a 216 bp band with the 
rtTA.for and rtTA.rev primers. The plasmid pRIP-rtTA was used as a positive control (p) of the PCR. The DNA 
marker is represented as (M) and the negative PCR control as (-).
Although the presence of the 300 bp band demonstrated the quality of the 
genomic DNA obtained, Fig. 24A shows that little of the pTRE2-LCPTI wt construct
1 3 6 25337 5857525128 -M
LCPTI M593SLCPTI wt
26 27p
216 bp
B
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was present in clone 26, and the pTRE2-LCPTI M593S construct was only present in 
clones 52 and 57, as is shown by the presence of the 1028 bp band. The rest of the 
clones had lost the transfected plasmids while the rtTA construct was present in all of 
them, as shown by the presence of the 216 bp band (Fig. 24B). This indicates that only
those clones that did not overexpress LCPTI survived during growth.
The medium for the stable clones contained G418, the selection antibiotic for 
INS-r9 cells which stably express rtTA, and hygromycin, the selection antibiotic for 
stable clones transfected with pTK-Hyg along with the pTRE2-LCPTI wt and pTRE2-
LCPTI M593S plasmids. We hypothesize that a slight basal overexpression of LCPTI,
even in the absence of doxycycline, which continued during cell growth, could be toxic 
for the cells and so only those cells which do not contain the LCPTI plasmids survived 
throughout cell passages. 
2.6 CPTI ACTIVITY 
Among the clones selected, only one clone of LCPTI wt, number 26, and two 
clones of LCPTI M593S, numbers 52 and 57, retained the transfected construct.
Although no differences in LCPTI protein expression were revealed by Western blot 
when clones were incubated with or without doxycycline, to check if the presence of the 
LCPTI construct seen by PCR could produce changes in CPTI activity, we performed a 
CPTI activity assay of the three clones.
Clones 26, 52 and 57 were incubated with or without 500 ng/ml doxycycline for 
24 h. After that, mitochondrion-enriched cell fractions were obtained and CPTI activity 
assay was performed with 8 µg of protein from each clone.
Figure 25 shows no differences in CPTI activity between the incubation with or 
without doxycycline for any clone.
Results
190
Fig. 25. CPTI activity of the clones 26, 52 and 57. Clones 26, 52 and 57 were incubated with or without 500 ng/ml 
doxycycline for 24 h and CPTI activity assay was performed with 8 µg of mitochondrion-enriched cell fractions of 
each clone. Data are the mean ± SE of 3 independent experiments.
In conclusion, when these clones were incubated with doxycycline the lack of 
increase in LCPTI protein expression compared to endogenous LCPTI seen by Western 
blot was correlated with the lack of increase in CPTI activity. Therefore, slight basal 
overexpression of LCPTI even in the absence of doxycycline could probably be toxic 
for the cells, as a result of which only those cells that do not contain the LCPTI 
plasmids survived throughout cell passages. The presence of the LCPTI construct in the 
genome of the clones 26, 52 and 57 suggests that the construc t is not well integrated 
into the genome causing no LCPTI overexpression.
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3. STUDY OF THE INTERACTION BETWEEN C75 AND LCPTI IN 
THE PANCREATIC β-CELL
C75 is a chemically stable synthetic inhibitor of fatty acid synthase (FAS) which 
has been described to act both centrally to reduce food intake and peripherally to 
stimulate CPTI activity11,12 and increase fatty acid oxidation, leading to rapid and
profound weight loss by reducing the fat mass. When FAS is inhibited by C75, the high 
content of malonyl-CoA should inhibit CPTI activity, but paradoxically, in peripheral 
tissues, this effect seems to be overcome by C75-stimulated CPTI activity. On the other 
hand, cerulenin, the natural FAS inhibitor, has been described to decrease CPTI
activity13,14 in vivo and in vitro accompanied with a reduction in fatty acid oxidation. 
We wanted to further investigate the effect of C75 on CPTI activity in vitro and 
in vivo in the pancreatic β-cell, where the FAS expression is very low, thus allowing us 
to study the C75/CPTI interaction more directly.
3.1 MALDI-TOF ANALYSIS OF C75-COA
Studies performed in our group 15 demonstrated that C75 itself neither inhibited 
nor activated mitochondrial LCPTI or MCPTI enzymes overexpressed in yeast. The
same occurred with the incubation with etomoxir itself. As it has been described3 that 
the active inhibitory form of etomoxir is its CoA-derivative, etomoxiryl-CoA, C75 was 
also converted to C75-CoA and effectively, only when C75 or etomoxir were
transformed to their CoA derivatives did they alter CPTI activity in yeast
overexpressing L or MCPTI.
11 Thupari JN, Landree LE, Ronnett GV, Kuhajda FP. C75 increases peripheral energy utilization and fatty acid 
oxidation in diet-induced obesity. Proc. Natl. Acad. Sci. USA. 99:9498-9502, 2002
12 Yang N, Kays JS, Skillman TR, Burris L, Seng TW, Hammond C. C75 activates carnitine palmitoyltransferase-1
in isolated mitochondria and intact cells without displacement of bound malonyl-CoA. J. Pharmacol. Exp. Ther .
PMID: 15356215, 2004
13 Thupari JN, Pinn ML, Kuhajda FP. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-
CoA-induced inhibition of fatty acid oxidation and cytotoxicity. BBRC. 285:217-223, 2001
14 Jin YJ, Li SZ, Zhao ZS, An JJ, Kim RY, Kim YM, Baik JH, Lim SK. Carnitine palmitoyltransferase-1 (CPT-1)
activity stimulation by cerulenin via sympathetic nervous system activation overrides cerulenin’s peripheral effect. 
Endocrinology. 145:3197-3204, 2004
15 Bentebibel A, Sebastián D, Herrero L, Serra D, Asins G, Hegardt FG. C75-CoA inhibits Carnitine
Palmitoyltransferase I activity thus decreasing palmitate oxidation. Submitted.
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To confirm that either C75 or etomoxir had reacted with CoA to produce a stable 
derivative, a MALDI-TOF analysis was carried out. Both drugs were converted into 
their CoA-derivatives in the presence of CoA and by the action of acyl-CoA synthase as 
described in MATERIALS AND METHODS (Section 8.4), and a sample of the activation 
reaction was directly analyzed by MALDI-TOF. Figure 26A shows the peak of 1020.4 
Da corresponding to the molecular mass of the product formed by reaction of the two 
compounds, C75 and CoA. A similar analysis for etomoxiryl-CoA (Fig. 26B)
corroborates its formation, in the peak of 1064.0 Da. Other peaks present in the spectra 
correspond to the matrix used in the analysis, the compound CoA in excess or products 
of its fragmentation.
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Fig. 26. MALDI-TOF spectra of C75-CoA and etomoxiryl -CoA. Spectra were directly obtained from the
activation reaction product of C75-CoA and etomoxiryl-CoA using a Voyager-DE-RP from Applied Biosystems with 
DHB (10 mg/ml in water: methanol, 1:1) as described in MATERIALS AND METHODS (Section 14). The detection 
was done with a reflector and in the negative mode. The product C75-CoA (A) is confirmed by the peak at 1020.4 Da 
and etomoxiryl-CoA (B) by the peak at 1064.0 Da.
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3.2 EFFECT OF C75 ON CPTI ACTIVITY IN INS(832/13) CELLS AND
MITOCHONDRION-ENRICHED CELL FRACTIONS
To test the effect of C75 on CPTI activity in the β-cell, INS(832/13) cells were 
incubated with C75 and CPTI activity was measured. 
INS(832/13) cells grown in 15-cm dishes were incubated for 1 h with complete 
medium containing either 0, 10 and 30 µg/ml C75 or 30 µg/ml etomoxir as a control. It 
was not necessary in this case to transform the drugs to their CoA derivatives, since this 
conversion occurs inside the cells via the mitochondrial long-chain acyl-CoA synthase.
After that, mitochondrion-enriched cell fractions were obtained and CPTI activity assay
was performed with 10 µg of protein.
Figure 27 shows that CPTI activity decreased at increasing C75 concentrations. 
CPTI activity was reduced by 34% and 49% at 10 and 30 µg/ml C75, respectively and 
by 80% at 30 µg/ml etomoxir. Thus, C75 in pancreatic β-cells behaves as a CPTI 
inhibitor.
Fig. 27. CPTI activity in INS(832/13) cells incubated with C75. INS(832/13) cells were incubated for 1 h with 
complete medium containing either 0, 10, and 30 µg/ml C75 or 30 µg/ml o etomoxir. Mitochondrion-enriched cell 
fractions were obtained and 10 µg of protein were used for the CPTI activity assay. Data are presented as the mean ± 
SE of 3 independent experiments performed in duplicate. **P<0.01 vs control without C75. 
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To study the effect of C75 directly on the CPTI protein, purified mitochondria
from INS(832/13) cells were preincubated for 1 min with increasing concentrations of 
C75-CoA or etomoxiryl-CoA and CPTI activity assay was performed with 10 µg of 
protein. As shown in Fig. 28, C75-CoA inhibited CPTI activity with similar kinetics to
etomoxiryl-CoA. At 50 µM of each drug CPTI activity was almost completely
inhibited. Therefore, in vitro C75 behaves as a potent inhibitor of CPTI activity in 
pancreatic β-cells.
Fig. 28. Effect of C75-CoA and etomoxiryl-CoA on CPTI activity. Mitochondrion-enriched fractions of
INS(823/13) cells were preincubated for 1 min with increasing concentrations of C75-CoA (black circles) or 
etomoxiryl-CoA (open  circles) and CPTI activity was assayed as described in MATERIALS AND METHODS (Section 
8.2). Data are the mean ± SE of 3 independent experiments and are expressed relative to control values in the absence 
of inhibitor (100%). Insert: expanded dose-response curve for the two inhibitors.
3.3 CPTI PROTEIN IN INS(832/13) CELLS INCUBATED WITH C75
A Western blot analysis of INS(832/13) cells treated with C75 and etomoxir was 
performed. INS(832/13) cells were incubated for 1 h with complete medium containing 
either 0, 10 and 30 µg/ml C75 or 30 µg/ml etomoxir as a control. Cell lysate was 
analyzed by Western blot with the anti-LCPTI antibody (Fig. 29). 
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Fig. 29. Western blot of C75-treated INS(832/13) cells. INS(832/13) cells were incubated for 1 h with complete 
medium containing either 0, 10 and 30 µg/ml C75 or 30 µg/ml etomoxir as a control. Protein extracts were separated 
by SDS/PAGE (8% gels) and subjected to immunoblotting by using a specific antibody for CPTI from liver. A 
unique band of approx. 88 kDa corresponding to LCPTI was observed.
No differences were seen in the LCPTI protein expression between the cells 
incubated either with or without C75 nor etomoxir, indicating that the drugs did not 
affect the protein expression.
3.4 EFFECT OF C75 ON PALMITATE OXIDATION IN INS(832/13) CELLS 
To assess whether CPTI inhibition by C75 in pancreatic β-cells is followed by a 
similar decrease in fatty acid oxidation, INS(812/13) cells were incubated with or 
without C75 and etomoxir as a control, and palmitate oxidation assay was performed.
INS(832/13) cells were incubated for 1 h with complete medium containing 
either 0, 10 and 30 µg/ml C75 or 30 µg/ml etomoxir as a control. After that, cells were
preincubated for 30 min in KRBH medium containing 1% BSA and then incubated for 
2 h at 2.5 mM glucose in the presence of [1-14C]palmitate. Palmitate oxidation to 14CO2
was measured as detailed in MATERIALS AND METHODS (Section 10.1).
Figure 30 shows that palmitate oxidation was reduced by 62% and by 71% at 30 
µg/ml C75 and etomoxir respectively. Thus, C75 inhibits β-oxidation in INS(832/13) 
cells in acute accordance with CPTI activity inhibition. 
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Fig. 30. Palmitate oxidation in INS(832/13) cells incubated with C75. INS(832/13) cells were incubated for 1 h 
with complete medium containing either 0, 10 and 30 µg/ml C75 or 30 µg/ml etomoxir. Cells were then preincubated 
for 30 min at 37 ºC with KRBH 1% BSA and then incubated for 2 h at 2.5 mM glucose in the presence of 0.8 mM 
carnitine, 0.25 mM palmitate and 1 µCi/ml [1-14C]palmitate. Palmitate oxidation to CO2 was measured as described 
in MATERIALS AND METHODS (Section 10.1). Data are the mean ± SE of 3 independent experiments performed in 
triplicate. **P<0.01 vs control without C75. 
3.5 CELL VIABILITY
To rule out the possibility that the inhibition of palmitate oxidation was not due
to an increase in cell death caused by C75, we performed viability experiments using 
the MTT assay. 
INS(832/13) cells were incubated for 1 h with complete medium containing 
either 0, 10 and 30 µg/ml C75 or 30 µg/ml etomoxir as a control. After that, cells were 
cultured for 2 h with the MTT solution as detailed in MATERIALS AND METHODS
(Section 3.6). Results are expressed as the percentage of absorbance related to control 
cells.
Figure 31 shows that in all cases cell viability was higher than 98% of control,
so the decrease seen in the palmitate oxidation assay was due to the inhibitory effect of 
C75 on CPTI activity rather than a C75 toxicity effect.
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Fig. 31. Cell  viability assay in INS(832/13) cells incubated with C75. INS(832/13) cells were incubated for 1 h 
with complete medium containing either 0, 10 and 30 µg/ml C75 or 30 µg/ml etomoxir as a control. After that, cells 
were cultured for 2 h with the MTT solution as detailed in MATERIALS AND METHODS (Section 3.6) and the 
formazan dye produced was quantified with a spectrophotometer at 570 nm with the MTT lysis solution as the blank. 
Results are expressed as the percentage of absorbance related to control cells. Data are the mean ± SE of 3 
independent experiments.
3.6 EFFECT OF C75 TREATMENT ON MICE LIVER AND PANCREAS
We examined the effect of C75 on CPTI activity in vivo. Mice were injected ip
with a single dose of C75 (20 mg/kg body weight) or only RPMI medium as a control 
and sacrificed at 0, 0.5, 3 and 5 h after injection. Liver and pancreas tissue samples were 
taken and mitochondria were isolated as described in MATERIALS AND METHODS
(Section 8.1.2) and used for the CPTI activity assay.
Fig. 32 shows that CPTI activity was decreased at short times, but then
recovered, the kinetics depending on the tissue. Inhibition of liver CPTI decreased by 
59% at 1 h and by 70% after 3 h of treatment and at 5 h CPTI values were similar to 
control. In pancreas CPTI activity was decreased by 35% of control after 30 min of C75 
treatment. In no case did CPTI activation exceed control; therefore the in vivo
experiments were also consistent with the in vitro assays on CPTI activity and palmitate 
oxidation. C75 produced a short-term inhibition of CPTI in liver and pancreas in mice,
with the maximum CPTI- inhibitory properties shown in the liver. The differential extent 
of inhibition of CPTI could be explained by differences in the rate of C75-CoA
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endogenous activation, tissue pharmacokinetics or time scale turn over of the CPTI 
protein in each tissue.
Fig. 32. C75 effect on CPTI activity in mice liver and pancreas. C75 was injected ip in mice at 20 mg/kg body 
weight and animals were sacrificed at 0, 0.5, 1, 3, and 5 h after injection. Mitochondrion-enriched fractions from liver 
and pancreas were obtained and CPTI activity was assayed. Results are the mean ± SE of data obtained from 6 mice. 
*P<0.05 vs control (0 h).
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DISCUSSION
1. ALTERATION OF THE MALONYL-CoA/CPTI INTERACTION 
IN THE PANCREATIC β-CELL
Lipid metabolism in the ß-cell is critical for the regulation of insulin secretion1.
Depletion of lipid stores together with deprivation of free fatty acids (FFA) alters
glucose-stimulated insulin secretion (GSIS) in rats and humans 2,3. FFAs, presumably 
via long-chain fatty acyl-CoA (LC-CoA), generate signals for insulin secretion4.
Stimulation of insulin secretion by glucose alters levels of CoA derivatives in
clonal pancreatic β-cells, in particular malonyl-CoA and LC-CoAs. The malonyl-
CoA/LC-CoA model of GSIS holds that in addition to the KATP channel-dependent
pathway, a parallel anaplerotic/lipid signaling pathway exists wherein malonyl-CoA
acts as a coupling factor4. Both malonyl-CoA and LC-CoA are thought to participate in 
the signal transduction for insulin secretion: the former as a regulator and the latter as an 
effector5. Systems that regulate both malonyl-CoA and LC-CoA appear to be involved 
in insulin secretion. Accordingly, ACC, which controls the synthesis of malonyl-CoA,
MCD, which catalyzes malonyl-CoA degradation, and CPTI which is regulated by
malonyl-CoA, are components of a metabolic signalling network that senses the level of 
fuel stimuli. Moreover, since the level of fatty acid synthase in normal β-cells is very 
low6, the physiological role of malonyl-CoA in the endocrine pancreas, unlike many 
1
Yaney GC, Corkey BE. Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia.  46:1297-
1312, 2003
2 Stein DT, Esser V, Stevenson BE, Lane KE, Whiteside JH, Daniels MB, Chen S, McGarry JD. Essentiality of 
circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J. Clin. Invest. 97:2728-2735, 1996
3 Dobbins RL, Chester MW, Daniels MB, McGarry JD, Stein DT. Circulating fatty acids are essential for efficient 
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other tissues, is not de novo synthesis of fatty acids but rather the regulation of CPTI
activity. Therefore, the metabolism of several nutrients that converge to form malonyl-
CoA and increase LC-CoA esters might play a key role in fuel regulated- insulin
secretion in the β-cell.
In an earlier study our group evaluated the capacity of LCPTI wt overexpression 
to alter the insulin response to glucose in ß-cells7. The results showed that adenovirus-
mediated overexpression of a cDNA encoding LCPTI not only increased β-oxidation in 
INS-1E cells but also decreased GSIS by 40%. However, using this approach, glucose-
derived malonyl-CoA is still able to inhibit LCPTI in cells overexpressing the enzyme 
and consequently fat oxidation was moderately altered. 
In view of the interest in the malonyl-CoA/LC-CoA model of GSIS, which is still 
under discussion8,9, we decided to overexpress LCPTI M593S, a mutant enzyme that is 
insensitive to malonyl-CoA10, in pancreatic β-cells. This would test the hypothesis that 
the CPTI/malonyl-CoA interaction is involved in GSIS. Since liver CPTI is the only 
isoform present in the β-cell, we used the rat liver isoform of CPTI to construct the 
adenovirus. Therefore, the LCPTI mutant and the native LCPTI were overexpressed in 
INS(832/13) cells and rat islets using recombinant adenoviruses.
1.1 CPTI ACTIVITY IS NOT INHIBITED BY MALONYL-CoA IN INS(832/13) 
CELLS EXPRESSING LCPTI M593S
The capacity of the LCPTI mutant to show enzyme activity despite the presence 
of malonyl-CoA was evaluated in pancreatic β-cells. In the presence of 100 µM
malonyl-CoA mitochondrion-enriched fractions of cells infected with Ad-LCPTI
7 Rubi B, Antinozzi PA, Herrero L, Ishihara H, Asins G, Serra D, Wollheim CB, Maechler P, Hegardt FG. 
Adenovirus-mediated overexpression of liver carnitine palmitoyltransferase I in INS1E cells: effects on cell 
metabolism and insulin secretion. Biochem. J. 364:219-226, 2002
8 Mulder H, Lu D, Finley IV J, An J, Cohen J, Antinozzi PA, McGarry JD, Newgard CB. Overexpression of a 
modified human malonyl-CoA decarboxylase blocks the glucose-induced increase in malonyl-CoA level but has no 
impact on insulin secretion in INS-1-derived (832/13) β-cells. J. Biol. Chem. 276: 6479-6484, 2001
9 Boucher A, Lu D, Burgess SC, Telemaque-Potts S, Jensen MV, Mulder H, Wang MY, Unger RH, Sherry AD, 
Newgard CB. Biochemical mechanism of lipid-induced impairment of glucose-stimulated insulin secretion and 
reversal with a malate analogue. J. Biol. Chem. 279:27263-27271, 2004
10 Morillas M, Gomez-Puertas P, Bentebibel A, Selles E, Casals N, Valencia A, Hegardt FG, Asins G, Serra D. 
Identification of conserved amino acid residues in rat liver carnitine palmitoyltransferase I critical for malonyl-CoA
inhibition. Mutation of methionine 593 abolishes malonyl-CoA inhibition. J. Biol. Chem. 278:9058-9063, 2003
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M593S retained 84% of their activity while that of the LCPTI wt was almost completely 
inhibited. This lack of sensitivity to malonyl-CoA was described in yeast
overexpressing LCPTI M593S10, but the results in the present thesis provide the first 
evidence that LCPTI M593S is insensitive to malonyl-CoA in pancreatic β-cells.
We attempted to study the effect of the irreversible CPTI inhibitor etomoxir on 
CPTI activity in INS(832/13) cells transduced with LCPTI wt or LCPTI M593S.
Etomoxir blocked CPTI activity in Ad-LacZ and Ad-LCPTI wt- infected cells, but left 
65% of CPTI activity in Ad-LCPTI M593S-infected cells. However, when
mitochondrion-enriched cell fractions were incubated with 100 µM etomoxiryl-CoA,
the LCPTI M593S form retained certain sensitivity to etomoxiryl-CoA (18% remaining 
activity). Etomoxiryl-CoA binds covalently and irreversibly to the protein LCPTI in the 
mitochondrion-enriched cell fractions, while when cells are incubated for 30 min with 
etomoxir, the inhibitor has to be converted to its CoA derivative and reach the protein. 
This could explain the different extent of inhibition seen in etomoxir- incubated cells or 
mitochondrion-enriched cell fractions.
Nevertheless, the LCPTI mutant was designed to be insensitive to the
physiological inhibitor malonyl-CoA and the effects of etomoxir were only tested as a 
control. A thorough study of the amino acid in CPTI which covalently bound to 
etomoxir, and the location of this drug on the CPTI model remains to be performed.
1.2 EXPRESSION OF LCPTI M593S INCREASES CPTI ACTIVITY AND
PROTEIN LEVELS
Having shown that the LCPTI mutant acted as a malonyl-CoA insensitive
LCPTI in pancreatic β-cells, we established the conditions for subsequent experiments. 
Comparison of the effects of Ad-LCPTI M593S with the control Ad-LCPTI wt requires
equal CPTI activity conditions. Therefore, the variations of CPTI activity vs the amount 
of virus used were studied in each case. In both cases CPTI activity increased to a 
plateau of 9-10 fold compared with the endogenous LCPTI. This plateau may be 
attributable to a saturation effect in the mitochondrial membrane, which may have 
altered the conformation of CPTI, leading to an increase in the protein level without
more than a 9-10 fold increase in CPTI activity.
For subsequent experiments we decided to use the amount of adenovirus LCPTI 
wt and LCPTI M593S that increased CPTI activity 6-fold with respect to the control 
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Ad-LacZ (CPTI endogenous). In these conditions, consistent with the activity assays, 
Ad-LCPTI wt and Ad-LCPTI M593S-infected INS(832/13) cells and rat islets showed 
similar LCPTI protein levels. 
1.3 LCPTI M593S EXPRESSION INCREASES PALMITATE OXIDATION
WITHOUT CHANGING MALONYL-CoA LEVELS OR GLUCOSE
OXIDATION
Overexpression of the malonyl-CoA-insensitive form of LCPTI increased fatty-
acid oxidation rates in INS(832/13) cells at all the glucose concentrations tested. Fat 
oxidation rates were much higher than in control Ad-LacZ-infected cells and still higher 
than in cells infected with Ad-LCPTI wt, even at high malonyl-CoA concentrations 
(high glucose). Moreover, palmitate oxidation increased whereas malonyl-CoA content 
and glucose oxidation remained unaltered, indicating that LCPTI expression did not
modify the malonyl-CoA levels or the glucose metabolism in the β-cell. The unaltered 
glucose oxidation is consistent with the view that a Randle cycle is inoperative in the β-
cell11.
In a previous study7, LCPTI wt-overexpression induced a slight inc rease in ATP 
generation due to the over-activity of CPTI and the consequent increase in fatty acid 
oxidation. However, the percentage increase in ATP between LCPTI wt-overexpressing
cells and control cells was identical when glucose was increased from low to high 
concentrations, indicating that LCPTI wt overexpression had no effect on the electron 
transport chain. 
1.4 GLUCOSE-STIMULATED INSULIN SECRETION IS REDUCED IN
INS(832/13) CELLS AND RAT ISLETS EXPRESSING LCPTI M593S
INS(832/13) cells overexpressing LCPTI M593S secreted less insulin in
response to high glucose concentration (60% reduction) but not in response to a
depolarizing concentration of KCl. Thus, exocytosis per se was preserved in cells 
overexpressing the mutated LCPTI, since the effect of the Ca2+ raising agent (30 mM 
KCl) was unaltered. The control Ad-LCPTI wt-infected cells showed 40% decrease in 
GSIS, as previously reported by our group7. The higher decrease in GSIS caused by 
11 Segall L, Lameloise N, Assimacopoulos-Jeannet F, Roche E, Corkey P, Thumelin S, Corkey BE, Prentki M. Lipid 
rather than glucose metabolism is implicated in altered insulin secretion caused by oleate in INS-1 cells. Am. J. 
Physiol. 277:E521-528, 1999
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LCPTI M593S expression indicates the strong metabolic influence of a malonyl-CoA
non-regulated fatty acid oxidation system.
The utilization of elevated K+ and diazoxide to discern between the KATP
channel-dependent and -independent pathways of glucose sensing showed that LCPTI 
wt and LCPTI M593S overexpression affected the KATP-independent pathway of GSIS, 
thus supporting the view that the malonyl-CoA/CPTI interaction is involved in the 
amplification arm of secretion. 
Insulin secretion experiments in the presence of etomoxir showed that the
irreversible CPTI inhibitor restored the impairment in GSIS caused by either LCPTI wt 
or LCPTI M593S overexpression. However, CPTI activity was not completely inhibited 
by etomoxir in Ad-LCPTI M593S-infected cells. The slight inhibition of CPTI activity 
by etomoxir, although covalent and irreversible, may have been enough to inhibit
palmitate oxidation (as was shown in the results) and to restore impaired GSIS in
LCPTI M593S-transduced cells. This indicates that insulin secretion is sensitive to 
slight changes in palmitate oxidation, and therefore to slight variations  in the LC-CoA
cytosolic pool. To prevent any non-specific effect on the secretory machinery, etomoxir 
was eliminated after the preincubation and the cells were washed prior to the
experiments. Thus, we consider that the only effect of etomoxir was the inhibition of 
CPTI through direct and irreversible covalent binding of CPTI and that it did not act as 
a fatty acid analogue. Under these conditions control cells did not show any
enhancement of GSIS, in contrast with what has been shown previously12. In the work 
of Chen et al.12 200 µM etomoxir, added with the glucose in rat perfusion experiments 
stimulated GSIS. This discrepancy could be explained by the presence of etomoxir 
throughout all the secretion experiments.
Similar results were obtained in isolated rat islets, i.e., reduced secretory
responses to high glucose upon LCPTI M593S expression (40% reduction).
Interestingly, overexpression of LCPTI wt did not affect GSIS in islets, suggesting 
preserved lipid signalling above a critical threshold of cytosolic LC-CoA. To explain 
the difference in the results between INS(832/13) cells and islets we hypothesize that 
normal β-cells are more protected than INS cells against lipid depletion due to enhanced 
fat oxidation, such that only the more efficient LCPTI M593S construct is active in rat 
12 Chen S, Ogawa A, Ohneda M, Unger RH, Foster D, McGarry JD. More direct evidence for a malonyl-CoA-
carnitine palmitoyltransferase I interaction as a key event in pancreatic beta-cell signalling. Diabetes. 43:878-883,
1994
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islets. In addition, DNA transfer efficiency in insulinoma cell line models approaches
100% while in islets it is about 70-80%, which could also explain the different
effectiveness of the LCPTI constructs in clonal β-cells and islets.
Incubation of LCPTI M593S transduced cells with 0.25 mM palmitate did not 
completely restore GSIS, while LCPTI wt did. This shows the strong metabolic
influence of LCPTI M593S on fatty acid oxidation and insulin secretion in the
pancreatic β-cell. This result points to a possible mechanism by which increased
metabolic flux through LCPTI diminishes insulin secretion via the depletion of a critical 
lipid synthesized at or near the mitochondrial outer membrane that would act as a signal 
molecule.
It is interesting to compare the present results with those of Roduit et al.13, who 
overexpressed MCD in the cytosol (MCDc) by infecting INS(832/13) cells and rat islets 
with an adenovirus containing the cDNA for MCD devoid of its mitochondrial and 
peroxisomal targeting sequences. The authors found that MCDc overexpression in the 
absence of exogenous FFA had no effect on GSIS and that MCDc overexpression 
suppressed the additional secretion in response to glucose provided by the presence of 
exogenous FFA (0.1-0.25 mM palmitate complexed to 0.5% BSA). This is in
concordance with the malonyl-CoA/LC-CoA model, which predicts tha t the
effectiveness of malonyl-CoA to couple nutrient sensing to insulin secretion depends on 
the availability of FFAs to the β-cell.
Potentiation of insulin secretion by palmitate has been described in HIT cells4
and islets14. In HIT cells examination of the dose dependence of the effect of palmitate 
at a fixed concentration of albumin (1%) indicated that the threshold concentration of 
the fatty acid was 0.2-0.5 mM and that a marked potentiating action on secretion
occurred at 1 mM4. They also showed that the free (unbound) palmitate is the important 
factor causing secretion. In the present study, however, exogenous fatty acids had no 
effect on GSIS at 15 mM glucose, perhaps because we used a relatively low
13 Roduit R, Nolan C, Alarcon C, Moore P, Barbeau A, Delghingaro-Augusto V, Przybykowski E, Morin J, Masse F, 
Massie B, Ruderman N, Rhodes C, Poitout V, Prentki M. A Role for the Malonyl-CoA/Long-Chain Acyl-CoA
Pathway of Lipid Signaling in the Regulation of Insulin Secretion in Response to Both Fuel and Nonfuel Stimuli. 
Diabetes. 53:1007-1019, 2004
14 Malaisse WJ, Malaisse-Lagae F. Stimulation of insulin secretion by noncarbohydrate metabolites. J. Lab. Clin. 
Med. 72:438-448, 1968
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concentration of fatty acids (0.25 mM bound to 1% BSA) or possibly because lipolysis 
was higher in the current study. 
Nonetheless, it is interesting to note that altering β-cell lipid partitioning with 
the malonyl-CoA-insensitive mutant of LCPTI had more profound consequences for 
both GSIS and lipid partitioning than doing so with the overexpression of cytosolic 
MCD13. Fat oxidation was more enhanced and esterification processes were more 
reduced at both low and elevated glucose. The enhanced fat oxidation caused by LCPTI
M593S was also higher than that obtained with the stable expression of an ACC-
antisense construct in INS-1 cells15. It is important to highlight that both MCD and ACC 
modulate CPTI activity through changes in malonyl-CoA levels, whereas CPTI directly 
controls the LC-CoA flux into the mitochondria for their oxidation.
In other studies8,9, however, the lack of correlation between malonyl-CoA levels 
and β-oxidation has been remarked on. In the former8 the authors showed unimpaired 
secretion of insulin in β-cells overexpressing MCD in the cytoplasm in the absence of 
exogenous FFAs. They also performed experiments in the presence of 1 mM
oleate/palmitate, but this high concentration of FFAs might have overridden the
consequences of reducing malonyl-CoA and LC-CoA in the cytoplasm. These authors 
proposed that glucose might regulate cytosolic LC-CoA in a manner not entirely
dependent on malonyl-CoA, suggesting that in the β-cell, ATP-different factors derived 
from glucose metabolism could regulate CPTI activity. Interestingly, malonyl-CoA-
independent regulation of CPTI has been demonstrated in several studies16,17,18,19.
Another explanation could be the presence of different pools of malonyl-CoA in the 
15 Zhang S, Kim K H. Essential role of acetyl-CoA carboxylase in the glucose-induced insulin secretion in a β-cell
line. Cell Signal. 10:35-42, 1998
16 Kerner J, Distler AM, Minkler PE, Parland W, Peterman SM, Hoppel CL. Phosphorylation of rat liver
mitochondrial carnitine palmitoyltransferase-I (CPT-I): Effect on the kinetic properties of the enzyme.
J. Biol.Chem. 279:41104-41113, 2004
17 Velasco G, Geelen MJH, Gomez del Pulgar T, Guzman M. Malonyl-CoA-independent acute control of hepatic 
carnitine palmitoyltransferase I activity. J. Biol. Chem. 273:21497-21504, 1998
18 Velasco G, Gomez del Pulgar T, Carling M, Guzman M. Evidence that the AMP-activated protein kinase 
stimulates rat liver carnitine palmitoyltransferase I by phosphorylating cytoskeletal components. FEBS Lett. 439:317-
320, 1998
19 Sleboda J, Risan KA, Spydevold O, Bremen J. Short-term regulation of carnitine palmitoyltransferase I in cultured 
rat hepatocytes: spontaneous inactivation and reactivation by fatty acids. Biochim. Biophys. Acta. 1436:541-594,
1999
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cell. There are two ACCs, one in the cytosol the other in the mitochondrion, the latter
directly modulating the malonyl-CoA levels accessible to CPTI20.
Whatever the explanation for the differences in alterations in GSIS in the
absence or presence of exogenous FFA when MCDc13, ACC-antisense15 or CPTI
(present thesis) are expressed, these studies show clearly a reduction of GSIS when the 
malonyl-CoA/CPTI interaction is perturbed. 
1.5 EXPRESSION OF LCPTI M593S REDUCES LIPID PARTITIONING
The results of the present study with cells overexpressing a malonyl-CoA
insensitive CPTI together with previous results7,13 provide evidence that malonyl-CoA
acts as a glucose-driven coupling factor that regulates the partitioning of fatty acids into
effector molecules in the insulin secretory pathway.  The nature of these molecules (NE 
palm, LC-CoA, PL and/or DAG) and their mechanisms of action on insulin secretion 
are poorly understood. 
In the present study, overexpression of LCPTI M593S altered lipid partitioning 
of exogenous palmitate from oxidation into esterification products. The incorporation of 
palmitate into PL, DAG, TG, NE Palm and CE was reduced compared to controls.
Thus, the increase in fatty acid oxidation reduced the availability of LC-CoA for lipid 
signalling in INS(832/13) cells. Moreover, the glucose- induced rise in NE Palm, an 
indirect measurement of cytosolic LC-CoA13, was markedly curtailed in cells
expressing the LCPTI construct and, interestingly, the CPTI mutant was more effective
in this respect. However, the TG content was not changed by the expression of the 
LCPTI constructs. This is probably due to the fact that little differences in the
incorporation of LC-CoA into TG are not reflected in the large and stable total TG pool.
This is consistent with previous studies7,13.
1.6 PKC ACTIVITY IS IMPAIRED IN INS(832/13) CELLS EXPRESSING
LCPTI M593S
Possible candidates for the effector molecules involved in the insulin secretory 
pathway are NE Palm, LC-CoA, phospholipids and/or DAG. PKC isoforms are also 
reasonable candidates to either initiate secretion or augment GSIS, as they respond to 
20 Ha J, Lee JK, Kim KS, Witters LA, Kim KH. Cloning of human acetyl-CoA carboxylase-β and its unique features. 
Proc. Natl. Acad. Sci. USA. 93:11466-11470, 1996
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both lipid signals and Ca2+. Insulin exocytosis is a likely process for regulation by fatty 
acid moieties, acting directly on signal transducing effectors of secretion or indirectly 
via activation of some kinases, in particular the PKC enzymes. In addition, three recent 
reports suggested that exogenous FFAs could also act directly on β-cells as ligand for 
the orphan G-protein receptor GPR4021,22,23. Possibilities of more direct distal effects 
include: 1) DAG modulation of exocytotic machinery proteins such as the synaptic 
vesicle priming protein Munc-1324 and 2) LC-CoA acylation of proteins, such as the 
exocytotic proteins synaptosomal-associated protein-2525 and synaptogamin26, which
can enhance their association with target membranes, and PKC, which has been
suggested as a possible target for acylation, because its translocation to membrane
bilayers was facilitated upon palmitoylation27.
As both DAG and LC-CoA activate a number of PKC enzymes28,29 and the
glucose- induced rise in DAG and NE Palm (an indirect determination of LC-CoA
levels) were decreased in INS(832/13) cells overexpressing the LCPTI constructs, we 
assessed whether these events could PKC activity. Determination of PKC translocation 
21 Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, Uejima H, 
Tanaka H, Maruyama M, Satoh R, Okubo S, Kizawa H, Komatsu H, Matsumura F, Noguchi Y, Shinohara T, Hinuma 
S, Fujisawa Y, Fujino M. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. 
Nature. 422:173-176, 2003
22 Kotarsky K, Nilsson NE, Flodgren E, Owman C, Olde B. A human cell surface receptor activated by free fatty
acids and thiazolidinedione drugs. Biochem Biophys Res Commun. 301:406-410, 2003
23 Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, Ellis C, Elshourbagy NA, Goetz 
AS, Minnick DT, Murdock PR, Sauls HR Jr, Shabon U, Spinage LD, Strum JC, Szekeres PG, Tan KB, Way JM, 
Ignar DM, Wilson S, Muir AI. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain 
fatty acids. J. Biol. Chem. 278:11303-11311, 2003
24 Rhee JS, Betz A, Pyott S, Reim K, Varoqueaux F, Augustin I, Hesse D, Sudhof TC, Takahashi M, Rosenmund C, 
Brose N. Beta phorbol ester- and diacylglycerol-induced augmentation of transmitter release is mediated by Munc13s 
and not by PKCs. Cell. 108:121-133, 2002
25 Gonzalo S, Linder ME. SNAP-25 palmitoylation and plasma membrane targeting require a functional secretory 
pathway. Mol. Biol. Cell. 9:585-597, 1998
26 Chapman ER, Blasi J, An S, Brose N, Johnston PA, Sudhof TC, Jahn R. Fatty acylation of synaptotagmin in PC12 
cells and synaptosomes. Biochem. Biophys. Res. Commun. 225:326-332, 1996
27 Ford DA, Horner CC, Gross RW. Protein kinase C acylation by palmitoyl coenzyme A facilitates its translocation 
to membranes. Biochemistry. 37:11953-11961, 1998
28 Yaney GC, Korchak HM, Corkey BE. Long-chain acyl-CoA regulation of protein kinase C and fatty acid 
potentiation of glucose-stimulated insulin secretion. Endocrinology. 141:1989-1998, 2000
29 Alcázar O, Qiu-yue Z, Giné E, Tamarit-Rodriguez J. Stimulation of islet protein kinase C translocation by 
palmitate requires metabolism of the fatty acid. Diabetes. 46:1153-1158, 1997
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from cytosol to membrane showed that PKC activation was decreased in Ad-LCPTI wt-
infected cells and was even more reduced in Ad-LCPTI M593S-infected cells, both
compared with control LacZ. This suggests that enhanced beta oxidation of fatty acids 
by the LCPTI M593S mutant and LCPTI wt reduces GSIS as a result of a decrease in 
PKC activation. 
1.7 GLUCOSE-STIMULATED INSULIN SECRETION IN THE β -CELL
The results presented in this thesis are in accordance with the malonyl-CoA/LC-
CoA model. However, this model does not oppose, but rather complements, other 
candidate mechanisms of the metabolic signal transduction, such as the cataplerotic
output of glutamate or the exchange of pyruvate with TCA cycle intermediates
(pyruvate cycling). Figure 1 provides a general view obtained from the literature of the 
potential mechanisms involved in the glucose-stimulated insulin secretion of the
pancreatic β-cell.
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Fig. 1. Metabolic signal transduction mechanisms involved in GSIS. Glucose metabolism raises the ATP/ADP 
ratio, which results in calcium influx and leads to the release of insulin through the KATP channel-dependent pathway. 
The increase in ATP (decrease in AMP) inhibits AMPK, which in turn activates ACC, resulting in an increase of the 
CPTI inhibitor malonyl-CoA. Malonyl-CoA, also derived from the anaplerosis pathway, modulates partitioning of 
exogenous FFAs via LC-CoA from fatty acid β-oxidation (β-ox) to lipid signalling involved in insulin vesicle 
exocytosis. LC-CoAs may provide substrate for acylation of proteins such as the exocytotic proteins synaptosomal-
associated protein-25 (SNAP-25) and synaptogamin or, through the production of phosphatidic acid (PA) and DAG,
LC-CoA may promote DAG modulation of exocytotic machinery proteins such as the synaptic vesicle priming 
protein Munc-13, or modulate PKC enzyme activity resulting in insulin release. FFAs can either enter the cell and be 
activated into LC-CoAs, or bind to and activate the G-protein coupled receptor (GPR40). This binding activates a 
heterotrimeric G-protein containing the α-subunit Gq, which leads to the activation of PKC and the release of insulin. 
The cataplerotic output of glutamate could act on the secretory vesicle, enhancing its fusion with the plasma 
membrane and stimulating insulin secretion. Finally, other mechanisms such as the glucose-mediated increment in 
pyruvate cycling, i.e., the exchange of pyruvate with the Krebs cycle (KC) intermediates, could participate in the 
release of insulin.
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Pancreatic β-cells detect the energy excess through the glucose metabolism,
which gives metabolic signals that lead to the release of insulin. Mitochondrial
metabolism plays a pivotal role by generating signals that couple glucose sensing to 
insulin secretion. These metabolic coupling signals are proposed to be: ATP, LC-CoA,
glutamate and pyruvate cycling. 
1) Mitochondrial metabolism is crucial in generating ATP, leading to a rise in 
[Ca2+], which is the main and necessary signal triggering insulin exocytosis. 
2) An early metabolic event caused by glucose is a shift from fatty acids to 
glucose as an oxidative fuel.  This occurs through glucose conversion to the "switch 
compound" malonyl-CoA, which, by inhibiting CPTI, blocks LC-CoA transport into the 
mitochondrion where they are oxidized.  Therefore, the increase in malonyl-CoA may 
be responsible for the accumulation of LC-CoA in the cytosol30. The identification of 
LC-CoA or complex lipids rather than malonyl-CoA as candidate coupling factors 
during β-cell activation stems from the fact that LC-CoA and complex lipids such as 
DAG, lysophosphatidic acid (LPA) and PA are known to directly influence many
biological processes31,32,33,34.  On the other hand, malonyl-CoA, by modulating CPTI 
and the level of cytosolic LC-CoA, regulates fuel partitioning (the relative rates of 
glucose and FFA oxidation) and the fate of LC-CoA (oxidation, esterification and 
acylation).  Thus, malonyl-CoA may be considered a regulatory signaling molecule in 
insulin secretion, whereas LC-CoA or complex lipids act as effector signals. This 
malonyl-CoA/LC-CoA model holds that the malonyl-CoA “signal of plenty” plays a 
pivotal role through inhibition of CPTI and thus leads to the accumulation of LC-CoA
in the cytoplasm which stimulates insulin release, either directly on exocytosis or 
indirectly via complex lipid formation, PKC activation or protein acylation. 
30 Liang Y, Matschinsky FM. Content of CoA-esters in perifused rat islets stimulated by glucose and other fuels. 
Diabetes. 40:327-333, 1991
31 Goetzl EJ, An S. Diversity of cellular receptors and functions for the lysophospholipid growth factors
lysophosphatidic acid and sphingosine 1-phosphate. Faseb J. 12:1589-1598, 1998
32 Hodgkin MN, Pettitt TR, Martin A, Michell RH, Pemberton AJ, Wakelam MJ. Diacylglycerols and
phosphatidates: which molecular species are intracellular messengers? Trends Biochem Sci. 23:200-204, 1998
33 Nietgen GW, Durieux ME. Intercellular signaling by lysophosphatidate. Cell Adhes. Commun. 5:221-235, 1998
34 Brindley DN, Waggoner DW. Phosphatidate phosphohydrolase and signal transduction. Chem. Phys. Lipids 80:45-
57, 1996
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3) Other glucose-derived factors participating in insulin secretion are proposed 
to be glutamate and pyruvate cycling. Glutamate, which can be produced from the 
Krebs cycle intermediate α-ketoglutarate by glutamate dehydrogenase, is proposed to 
act on the secretory vesicle, by undefined mechanisms which may involve granule 
priming or modification of vesicles pH, enhancing the competence of the vesicle for 
fusion with the plasma membrane 35,36. Thus, glutamate would act as a potentiator of
insulin release, sensitizing exocytosis to the effect of calcium. Glutamate and fatty acid 
metabolism would be related, as glutamate activates ACC increasing malonyl-CoA and 
thus, LC-CoA levels in the cytosol37. On the other hand, pyruvate cycling has been
correlated with glucose-stimulated insulin secretion and with the degree of glucose 
responsiveness in INS-1-derived cell lines9,38. The term pyruvate cycling refers to the 
exchange of pyruvate with TCA cycle intermediates or the flux through either the 
pyruvate-malate or pyruvate-citrate cycles. It has been described that long-term
exposure of pancreatic β-cells to FFA inhibits GSIS via the decreased NADPH content 
due to the inhibition of pyruvate carboxylase and malate pyruvate shuttle flux39.
Therefore, NADPH could be a candidate coupling factor which may link mitochondrial
reducing equivalents and GSIS, indicting a direct relationship between changes in
NADPH levels, mitochondrial activation and insulin secretion.
Overall, the results presented in this thesis show, for the first time, that when the 
malonyl-CoA/CPTI interaction is altered, glucose- induced insulin release is impaired. 
The results also indicate the importance of a tight control in lipid homeostasis and the 
implication of LC-CoA as effector signals in GSIS.
35 Maechler P, Wollheim CB. Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis. 
Nature. 402:685-689, 1999
36 Rubi B, Ishihara H, Hegardt FG, Wollheim CB, Maechler P. GAD65-mediated glutamate decarboxylation reduces 
glucosa-stimulated insulin secretion in pancreatic beta cells. J. Biol. Chem. 276:36391-36396, 2001
37 Kowluru A, Chen HQ, Mordirck L, Stefanelli C. Activation of acetyl-CoA carboxylase by a glutamate and 
magnesium sensitive protein phosphatase in the islet β-cell. Diabetes. 50:1580-1587, 2001
38 Lu D, Mulder H, Zhao P, Burgess SC, Jensen MV, Kamzolova S, Newgard CB, Sherry AD. 13C isotopomer 
analysis reveals a connection between pyruvate cycling and glucose-stimulated insulin secretion (GSIS). Proc. Natl. 
Acad. Sci. USA.  99:2708-2713, 2002
39 Iizuka K, Nakajima H, Namba M, Miyagawa J, Miyazaki J, Hanafusa T, Matsuzawa Y. Metabolic consequence of 
long-term exposure of pancreatic beta cells to free fatty acid with special reference to glucose insensitivity. Biochim.
Biophys. Acta. 1586:23-31, 2002
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1.8 FUTURE: ALTERATION OF MALONYL-CoA/CPTI INTERACTION IN
THE STUDY OF DIABETES AND OBESITY
Many studies implicate FFAs in Type 2 diabetes40,41. Long-term exposure of β-cells
to FFAs in vitro has several effects: 1) it increases basal insulin release and decreases 
secretion in response to glucose42; 2) it alters the coupling of glucose metabolism to 
insulin secretion by acting on the expression of specific genes, such as UCP-243,44; 3) it 
increases the expression of CPTI, which is considered the rate- limiting step in fatty acid 
oxidation45. Low levels of lipid oxidation are associated with, and predictive for, obesity 
in both humans and rodents46,47, and decreased CPTI activity has been demonstrated in
obese patient populations48,49.
Taking into account the results presented in this study of the LCPTI M593S 
mutant, fatty acid oxidation would be markedly increased in a system where the 
malonyl-CoA/CPTI interaction was altered and the CPTI was insensitive to its inhibitor 
malonyl-CoA. This would lead to dysregulation of β-oxidation even at high malonyl-
CoA levels (high glucose like in a diabetic state), and probably to the impairment of 
GSIS due to the huge presence of FFAs (like in an obese state) will be restored. Related 
to this hypothesis, a recent and very interesting study showed that in rats fed a high-fat-
40 Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. 
Diabetes. 44:863-870, 1995
41 McGarry JD. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 51:7-18, 2002
42 Zhou YP, Grill V. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin 
secretion and biosynthesis through a glucose fatty acid cycle. J. Clin. Invest. 93:870-876, 1994
43 Lameloise N, Muzzin P, Prentki M, Assimacopoulos-Jeannet F. Uncoupling protein 2: a possible link between 
fatty acid excess and impaired glucose-induced insulin secretion? Diabetes . 50:803-809, 2001
44 Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, Hagen T, Vidal-Puig AJ, Boss O, Kim YB, Zheng 
XX, Wheeler MB, Shulman GI, Chan CB, Lowell BB. Uncoupling protein-2 negatively regulates insulin secretion 
and is a major link between obesity, beta cell dysfunction and type 2 diabetes. Cell. 105:745-755, 2001
45 Assimacopoulos-Jeannet F, Thumelin S, Roche E, Esser V, McGarry JD, Prentki M. Fatty acids rapidly induce the 
carnitine palmitoyltransferase I gene in the pancreatic β-cell line INS-1. J. Biol. Chem. 272:1659-1664, 1997
46 Zurlo F, Lillioja S, Esposito-Del Puente A, Nyomba BL, Raz I, Saad MF, Swinburn BA, Knowler WC, Bogardus 
C, Ravussin E. Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ. Am. J. 
Physiol. 259:E650-E657, 1990
47 Pagliassotti MJ, Gayles EC, Hill JO. Fat and energy balance. Ann. N Y Acad. Sci. 827:431-448. Review, 1997
48 Simoneau JA, Veerkamp JH, Turcotte LP, Kelley DE. Markers of capacity to utilize fatty acids in human skeletal 
muscle: relation to insulin resistance and obesity and effects of weight loss. FASEB J. 13:2051-2060, 1999
49 Kim JY, Hickner RC, Cortright RL, Dohm GL, Houmard JA. Lipid oxidation is reduced in obese human skeletal 
muscle. Am. J. Physiol. Endocrinol. Metab. 279:E1039-E1044, 2000
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diet, whole-animal, muscle and liver insulin resistance was ameliorated following
hepatic overexpression of MCD by tail vein injection of an adenovirus encoding
MCD50. In addition, insulin action was enhanced within the liver and at a remote site 
(muscle). These changes were associated with a fall in circulating FFA, a rise or no 
significant change in muscle triglycerides and LC-CoA levels, and a marked decrease in 
intramuscular β-OH-butyrate levels. The authors propose that hepatic expression of
MCD lowered circulating FFA levels, which led to lowering of muscle β-OH-butyrate
levels and improvement of insulin sensitivity. In addition, ACC mutant mice (ACCβ-/-)
had been reported to be protected against obesity and diabetes induced by high-fat/high-
carbohydrate diets51. ACCβ -/- mice have a normal lifespan, a higher fatty acid oxidation 
rate and lower amounts of fat52. When these mutant mice were fed with a high-fat/high-
carbohydrate diets they weighed less than their wt cohorts, accumulated less fat, and 
maintained normal levels of insulin and glucose, whereas the wt mice became Type 2 
diabetic with hyperglycemic and hyperinsulinemic status. The broader implication of 
these findings is that enzymes involved in lipid partitioning such as MCD, ACC and 
CPTI could be potential targets in therapy against obesity and related diseases such as 
diabetes. Therefore, a parallel study on the LCPTI M593S mutant might be expected to
lead to similar or even more enhanced results because it is insensitive to malonyl-CoA
and because, unlike MCD and ACC, CPTI directly controls the flux of LC-CoAs into
the mitochondria for their oxidation.
Moreover, in pancreatic β-cells chronically exposed to high glucose and/or high 
fatty acids, overexpression of the LCPTI M593S mutant may prevent the impairment of 
GSIS and β-cell apoptosis. This hypothesis, however, is challenged by a recent study of
the MCD overexpression in chronic culture of INS(832/13) cells with high
concentrations of FFAs and lipid- laden islets from Zucker diabetic fatty rats9.
Adenovirus-mediated MCD overexpression resulted in reduced TG stores, but no
50 An J, Muoio DM, Shiota M, Fujimoto Y, Cline GW, Shulman GI, Koves TR, Stevens R, Millington D, Newgard 
CB. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. 
Nat. Med. 10:268-274, 2004
51 Abu-Elheiga L, Oh W, Kordari P, Wakil SJ. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity 
and diabetes induced by high-fat/high-carbohydrate diets. Proc. Natl. Acad. Sci. USA.100:10207-10212, 2003
52 Abu-Elheiga L, Matzuk MM, Abo-Hashema KAH, Wakil SJ. Continuous fatty acid oxidation and reduced fat 
storage in mice lacking acetyl-CoA carboxylase 2. Science. 291:2613-2616, 2001
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improvement in GSIS. We hypothesize that the more direct effect of CPTI on LC-CoA
oxidation may allow the LCPTI M593S mutant to restore the impairment in GSIS.
Further research is needed on the aetiology of obesity and Type 2 diabetes and 
the potential use of CPTI as an effective drug target.
2. STABLE EXPRESSION OF LCPTI wt AND LCPTI M593S
We aimed to corroborate the results obtained with the adenoviruses encoding for 
LCPTI wt and LCPTI M593S cDNAs by generating INS-1 cells which stably expressed 
these constructs under the Tet-on system. This system allows temporary control of gene
expression upon doxycycline treatment of the cells. 
The functionality and correct protein expression of the construct were checked
by transient expression in HEK 293 rtTA cells. However, when the INS-1 clones
obtained were incubated with doxycycline, a lack of increase in LCPTI protein
expression compared to endogenous LCPTI was correlated with a lack of increase in 
CPTI activity. We conclude that probably a slight basal overexpression of LCPTI even 
in the absence of doxycycline could be toxic for the cells, as a result of which only that
cells which did not contain the LCPTI plasmids survived throughout cell passages. The 
presence of the LCPTI construct in the genome of the clones 26, 52 and 57, suggests 
that maybe the transgene may not have been well integrated into the genome, which 
caused non LCPTI overexpression.
These events could be compared with previous studies performed in our group 53,
in which the effect of LCPTI in vivo was examined to investigate the involvement of 
LCPTI in obesity and diabetes. Six transgenic mouse lines were generated using the 
construct RIP-β-globin-LCPTI wt which conducted the LCPTI wt transgene to the 
pancreas of the mice under the rat insulin promoter (RIP). However, none of these 
mouse lines expressed the desired construct, indicating that LCPTI expression could
lead to a defect in the development of the animals, preventing their survival. Therefore, 
these results along with that obtained in the present study with the LCPTI wt and LCPTI 
M593S stable cell lines, suggest that a tight control of lipid homeostasis is essential for 
development and survival. 
53 Rubi B. El glutamato y los ácidos grasos participan en la transducción de la señal para la liberación de insulina 
estimulada por glucosa en la célula β del páncreas. Thesis, 2001
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3. STUDY OF THE INTERACTION BETWEEN C75 AND CPTI IN 
THE PANCREATIC β-CELL
The fatty acid synthase (FAS) synthetic inhibitor C75 has been described as the 
first pharmacological agonist of CPTI54, identifying CPTI as a therapeutic target for
obesity and Type 2 diabetes. Thus, these authors54 explained the profound weigh loss
peripherally seen in C75-treated mice by a C75-stimulation of CPTI activity and an 
increase in fatty acid oxidation. However, when FAS is inhibited by C75, the ensuing
high content of malonyl-CoA should inhibit CPTI activity. However, paradoxically, in 
peripheral tissues, this effect seems to be overcome by C75-stimulated CPTI activity. 
On the other hand, cerulenin, a natural FAS inhibitor, has been reported to decrease 
CPTI activity55,56 in vivo and in vitro, accompanied by a reduction in fatty acid
oxidation.
Taking into account these paradoxical actions of C75 and the interesting fact that 
C75 could be a CPTI agonist with similar properties to our LCPTI M593S mutant, we 
decided to further investigate the effect of C75 on CPTI activity in pancreatic β-cells in
vitro and in vivo. In the β-cell, the FAS expression is very low6, thus allowing us to 
study the C75/CPTI interaction directly.
3.1 C75 INHIBITS CPTI ACTIVITY IN PANCREATIC β -CELLS
Recent studies by our group 57 have demonstrated that C75 itself neither inhibited 
nor activated mitochondrial LCPTI or MCPTI enzymes overexpressed in yeast. The 
same occurred with etomoxir itself. As it has been described58 that the active inhibitory 
54 Thupari JN, Landree LE, Ronnett GV, Kuhajda FP. C75 increases peripheral energy utilization and fatty acid 
oxidation in diet-induced obesity. Proc. Natl. Acad. Sci. USA. 99:9498-9502, 2002
55 Thupari JN, Pinn ML, Kuhajda FP. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-
CoA-induced inhibition of fatty acid oxidation and cytotoxicity. BBRC. 285:217-223, 2001
56 Jin YJ, Li SZ, Zhao ZS, An JJ, Kim RY, Kim YM, Baik JH, Lim SK. Carnitine palmitoyltransferase-1 (CPT-1)
activity stimulation by cerulenin via sympathetic nervous system activation overrides cerulenin’s peripheral effect. 
Endocrinology. 145:3197-3204, 2004
57 Bentebibel A, Sebastián D, Herrero L, Serra D, Asins G, Hegardt FG. C75-CoA inhibits Carnitine
Palmitoyltransferase I activity thus decreasing palmitate oxidation. Submitted.
58 Weis BC, Cowan AT, Brown N, Foster DW, McGarry JD. Use of a selective inhibitor of liver carnitine
palmitoyltransferase I (CPT I) allows quantification of its contribution to total CPT I activity in rat heart. Evidence 
that the dominant cardiac CPT I isoform is identical to the skeletal muscle enzyme. J. Biol. Chem. 269:26443-26448,
1994
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form of etomoxir is its CoA-derivative, etomoxiryl-CoA, we also demonstrated that C75
was also converted to C75-CoA. The formation of both compounds, C75-CoA and 
etomoxiryl-CoA, was confirmed by MALDI-TOF analysis and indeed, only when C75 
or etomoxir were transformed to their CoA derivatives could alter CPTI activity in yeast 
overexpressing L or M CPTI. In the case of pancreatic β-cells, mitochondrion-enriched
cell fractions were incubated with C75-CoA for CPTI activity assays, but INS(832/13) 
cells were directly incubated with C75 as the activation to CoA could occur inside the
cells via mitochondrial acyl-CoA synthase. 
In pancreatic β-cells, surprisingly, we found that CPTI activity was not activated 
but inhibited by C75 in INS(832/13) cells and by C75-CoA in mitochondrion-enriched
cell fractions. This inhibition was also seen in HEK 293 cells and in L6E9 muscle 
cells57.
It is interesting to compare the present results where CPTI is inhibited, with 
those obtained by others54,59,60 who observed CPTI activation. In the study of Yang et
al.59 human hepatocarcinoma cells (Hep G2) were directly incubated with C75 plus
labelled carnitine and an increase in CPTI activity was found, as measured by the
synthesis of palmitoylcarnitine. In the other studies54,60, the authors observed a C75-
stimulation of CPTI activity in human breast cancer cells (MCF-7) and in rodent
adipocytes (3T3-L1) and primary hepatocytes and cortical neurons. The discrepancy 
may be explained by differences in the method used to measure CPTI activity. These
authors54,60 performed CPTI assays in digitonin-permeabilized cells, while in the present 
study isolated and purified mitochondria from tissues and cultured cells were used.
Interestingly, when the experiments of digitonin permeabilization in L6E9 muscle cells 
were repeated in our laboratory following Thupari’s protocol, it was also found that 
CPTI was activated. We hypothesized that digitonine permeabilization together with the
C75 treatment might alter interactions between mitochondria and the cytoskeleton17,61
which may either alter CPTI activity or disturb the assay. It has been suggested that 
59 Yang N, Kays JS, Skillman TR, Burris L, Seng TW, Hammond C. C75 activates carnitine palmitoyltransferase-1
in isolated mitochondria and intact cells without displacement of bound malonyl-CoA. J. Pharmacol. Exp. Ther .
PMID: 15356215, 2004
60 Landree LE, Hanlon AL, Strong DW, Rumbaugh G, Miller IM, Thupari JN, Connolly EC, Hunganir RL, 
Richardson C, Witters LA, Kuhajda FP, Ronnet GV. C75, a Fatty acid synthase inhibitor, modulates AMP-activated
protein kinase to alter neuronal energy metabolism. J. Biol. Chem. 279:3817-3827, 2004
61 Guzmán M, Velasco G, Geelen MJH. Do cytoskeletal components control fatty acid translocation into liver 
mitochondria? Trends Endocrinol. Metab. 11:49-53, 2000
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changes in the lipid composition of the membrane microenvironment in which CPTI
resides cause alteration of CPTI activity62,63,64,65, indicating the importance of CPTI’s 
interaction with the mitochondrial membrane for its activity and regulation. Numerous
approaches10,66,67,68,69 suggest that modulation of interdomain interactions, for instance 
by covalent modification (phosphorylation)16 of the protein, may be also involved in 
changes of CPTI activity. These events may occur as a consequence of an indirect 
action of C75 on permeabilized cells.
3.2 C75 INHIBITS PALMITATE OXIDATION IN PANCREATIC β -CELLS
The experiments performed in the present study on palmitate oxidation on
INS(832/13) cells reveal that C75 inhibits β-oxidation, in acute accordance with
inhibition of CPTI. This inhibition was also seen in HEK 293 cells and in L6E9 muscle 
cells57. Again, we find a discrepancy between our results and those obtained by
others54,60 performed in rodent adipocytes and primary hepatocytes and cortical neurons,
in which they reported an increase in fatty acid oxidation. However, a slightly decrease 
62 Zammit VA, Corstorphine CG, Kolodziej MP, Fraser F. Lipid molecular order in liver mitochondrial outer 
membranes, and sensitivity of carnitine palmitoyltransferase I to malonyl-CoA. Lipids. 33:371-376, 1998
63 Mynatt RL, Greenhaw JJ, Cook GA. Cholate extracts of mitochondrial outer membranes increase inhibition by 
malonyl-CoA of carnitine palmitoyltransferase-I by a mechanism involving phospholipids. Biochem. J. 299:761-767,
1994
64 Zammit VA. Carnitine acyltransferases: functional significance of subcellular distribution and membrane topology. 
Progress in lipid research. 38:199-224, 1999
65 Fraser F, Padovese R, Zammit VA. Distinct kinetics of carnitine palmitoyltransferase in contact sites and outer 
membranes of rat liver mitochondria. J. Biol. Chem. 276:20182-20185, 2001
66 Swanson ST, Foster DW, McGarry JD, Brown NF. Roles of the N- and C-terminal domains of carnitine 
palmitoyltransferase I isoforms in malonyl-CoA sensitivity of the enzymes: insights from expression of chimaeric 
proteins and mutation of conserved histidine residues. Biochem. J. 335:513-519, 1998
67 Jackson VN, Zammit VA, Price NT. Identification of positive and negative determinants of malonyl-CoA
sensitivity and carnitine affinity within the amino termini of rat liver- and palmitoyltransferase I. J. Biol. Chem.
275:38410-38416, 2000
68 Jackson VN, Price NT, Zammit VA. Specificity of the interactions between Glu-3, Ser-24, and Gln-30 within the 
N-terminal segment of rat liver mitochondrial overt carnitine palmitoyltransferase (L-CPT I) in determining the 
malonyl-CoA sensitivity of the enzyme. Biochemistry. 40:14629-14634, 2001
69 Shi J, Zhu H, Arvidson DN, Cregg JM, Woldegiorgis G. Deletion of the conserved first 18 N-terminal amino acid 
residues in rat liver carnitine palmitoyltransferase I abolishes malonyl-CoA sensitivity and binding. Biochemistry.
37:11033-11038, 1998
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in palmitate oxidation has been described in rat islets treated with cerulenin70. It is
difficult to explain these discrepancies, which could be attributed to differences in cell 
line or experimental conditions, or unknown effects of C75 on other cellular signalling
pathways.
Recent data suggest that modulation of FAS activity by C75 in the hypothalamus 
can alter energy perception by reducing AMPK, enzyme that functions as a
physiological energy sensor in the hypothalamus71. AMPK activates MCD and
suppresses the synthesis of ACC, FAS and other enzymes of lipid biogenesis in many 
tissues by inhibiting the generation of the transcriptional factor SREBP-1c72. The net 
effect of AMPK activation is therefore to increase fatty acid oxidation (at least in part 
by lowering the concentration of malonyl-CoA) and to decrease their esterification and 
use in other non-β-oxidative pathways 73. Thus, as C75 has been reported to reduce
AMPK activity71 this could lead to a decrease in fatty acid oxidation, which would
reconcile the inhibition of β-oxidation seen in the present study in pancreatic β-cells.
In addition, it has been recently shown that inhibition of hypothalamic CPTI in
rats causes a reduction in food intake and glucose production74, suggesting that the 
increase in LC-CoAs due to CPTI inhibition represents a central signal of “nutrient 
abundance”. Moreover, central delivery of the LCFA oleic acid also inhibits glucose 
production and food intake75. These findings support the idea that increased LC-CoAs
function as a sensor of nutrient availability in hypothalamic neurons. Finally,
endocannabinoids, which have potent orexigenic (appetite-stimulating) effects,
stimulate CPTI activity and fatty acid oxidation in cultured astrocytes independently of 
70 Yajima H, Komatsu M, Yamada S, Straub SG, Kaneko T, Sato Y, Yamauchi K, Hashizume K, Sharp GWG, 
Aizawa T. Cerulenin, an inhibitor of protein acylation, selectively attenuates nutrient stimulation of insulin release. 
Diabetes. 49:712-717, 2000
71 Kim EK, Miller I, Aja S, Landree LE, Pinn M, McFadden J, Kuhajda FP, Moran TH, Ronnett GV. C75, a fatty 
acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase. J. Biol. Chem.
279:19970-19976, 2004
72 Ferre P, Azzout -Marniche D, Foufelle F. AMP-activated protein kinase and hepatic genes involved in glucose 
metabolism. Biochem. Soc. Trans. 31:220-223, 2003
73 Ruderman N, Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nature.
3:340-351, 2004
74 Obici S, Feng Z, Arduini A, Conti R, Rossetti L. Inhibition of hypothalamic carnitine palmitoyltransferase-1
decreases food intake and glucose production. Nat Med. 9:756-761, 2003
75 Obici S, Feng Z, Morgan K, Stein D, Karkanias G, Rossetti L. Central administration of oleic acid inhibits glucose 
production and food intake. Diabetes. 51:271-275, 2002
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malonyl-CoA and through interaction with CB1 receptors76,77. All together, these studies 
support evidence in favour of the implication of CPTI inhibition in the loss of food 
intake.
However, this does not explain the increase in energy expenditure and the 
profound weight loss observed peripherally in mice54. One possib le explanation of this
increased energy production could be the C75-mediated up-regulation of UCPs. It has 
recently been reported that long-term treatment with C75 increases expression of UCP-3
mRNA in skeletal muscle of obese mice, suggesting that this up-regulation of UCP-3
may increase thermogenesis and thereby explain the increase in energy expenditure78.
Nevertheless, further investigations are needed to clarify the effect of C75 on the whole 
metabolism.
It has been reported that C75 treatment of human cancer cells in vitro led to 
rapid inhibition of fatty acid synthesis, followed by inhibition of DNA replication,
culminating in apoptosis79,80. Whereas induction of apoptosis appeared to be related to 
accumulation of the substrate, malonyl-CoA, after FAS inhibition, the cytostatic effects 
were independent of malonyl-CoA accumulation and may have resulted from product 
depletion80. To rule out the possibility that the inhibition of palmitate oxidation seen in 
INS(832/13) cells was due to cytotoxic effects of C75, viability assays were performed.
They showed that in our conditions viability of pancreatic β-cells was above 98%. The
sensitivity of the cell to the cytotoxic effect of C75 may depend on the lipid
composition and metabolism. For instance, breast carcinoma cell line SKBR3, with 
higher lipid content, needs 6 h of C75-preincubation to show the cytotoxic effect79.
However, in pancreatic β-cells, where the expression of FAS and fatty acid biosynthesis 
76 Blazquez C, Sanchez C, Daza A, Galve-Roperh I, Guzman M. The stimulation of ketogenesis by cannabinoids in 
cultured astrocytes defines carnitine palmitoyltransferase I as a new ceramide-activated enzyme. J. Neurochem.
72:1759-1768, 1999
77 Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G. 
Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 410:822-825, 2001
78 Cha SH, Hu Z, Lane MD. Long-term effects of a fatty acid synthase inhibitor on obese mice: food intake, 
hypothalamic neuropeptides, and UCP3. BBRC. 317:301-308, 2004
79 Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, Townsend CA, Kuhajda FP. Malonyl-coenzyme-
A is a potential mediator of cytotoxicity induced by fatty acid synthase inhibition in human breast cancer cells and 
xenografts. Cancer Res. 60:213-218, 2000
80 Li JN, Gorospe M, Chrest FJ, Kumaravel TS, Evans MK, Han WF, Pizer ES. Pharmacological inhibition of fatty 
acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Research. 61:1493-
1499, 2001
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are low, more than 2h of C75-preincubation or concentrations of C75 higher than 40 
µg/ml were toxic for the cells.
3.3 IN VIVO C75 INHIBITS CPTI ACTIVITY AT SHORT TIMES
The experiments in vitro, which consistently indicate that C75 inhibits CPTI
activity and fatty acid oxidation, were also corroborated by the experiments in vivo. C75 
produced short-term inhibition of CPTI activity in mouse liver and pancreas, with the 
maximum CPTI-inhibitory properties shown in the liver. The differential extent of
inhibition of CPTI could be explained by differences in the rate of C75-CoA
endogenous activation and pharmacokinetics in each tissue. Inhibition of CPTI by the
drug may remain stable until the C75-modified CPTI is replaced by a new molecule. It 
is possible that the proteasome recognizes the drug-modified CPTI and promotes its 
disappearance. This time scale would be tissue dependent. This increased turnover of 
the CPTI protein or the unknown effects of C75 on other cellular signalling pathways of 
cellular fuel state, like that observed in UCP-378 or in hypothalamic AMPK60,71, which 
in turn could affect CPTI activity, could explain the increases in energy expenditure
observed by Thupary et al.54.
Interestingly, cerulenin, a natural FAS inhibitor, has been reported to decrease 
CPTI activity81,82. In the former study81, performed with human breast cancer cells
cultured with cerulenin, the decrease in CPTI activity was correlated with a reduction in 
fatty acid oxidation and an increase in the cytotoxicity effect. In the latter study82, the 
authors showed that the effect of cerulenin on CPTI activity in mice was biphasic in 
liver and muscle, with an early suppression followed by a late stimulation after
intraperitoneal treatment. They concluded that the late stimulating effect of cerulenin on 
CPTI activity occurred via the sympathetic nervous system. C75 may behave like 
cerulenin in mice, producing a dual effect on CPTI: first inhibition and later activation. 
This would also be consistent with the increased peripheral fatty acid oxidation
observed in mice after several hours of treatment.
81 Thupari JN, Pinn ML, Kuhajda FP. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-
CoA-induced inhibition of fatty acid oxidation and cytotoxicity. BBRC. 285:217-223, 2001
82 Jin YJ, Li SZ, Zhao ZS, An JJ, Kim RY, Kim YM, Baik JH, Lim SK. Carnitine palmitoyltransferase-1 (CPT-1)
activity stimulation by cerulenin via sympathetic nervous system activation overrides cerulenin’s peripheral effect. 
Endocrinology. 145:3197-3204, 2004
Discussion
225
3.4 FUTURE: FURTHER INVESTIGATION
The results presented in this thesis provide compelling evidence that C75 is a 
potent and direct inhibitor of LCPTI in pancreatic β-cells in vitro and in vivo. A
summary of our results and the effects of C75 published in the literature is shown in 
Table. 1.
Table. 1. Central and peripheral effects of C75. Centrally (hypothalamus) C75 increases malonyl-CoA levels as a 
result of FAS inhibition83. Hypothalamic malonyl-CoA is an indicator of energy status and mediates feeding 
behaviour. C75 prevents the up-regulation of the orexigenic neuropeptides (NYP and AgRP) and down-regulation of 
the anorexigenic neuropeptides (POMC, CART)84 thus decreasing food consumption85. In addition, C75 has been 
reported to inhibit AMPK71 by increasing ATP levels71 and to increase CPTI activity60 and palmitate oxidation60.
Peripherally, C75 reduces body weight (loss of adipose tissue78 and resolution of hepatic steatosis85) by increasing 
energy expenditure as a result of CPTI activation and increased palmitate oxidation54. Long-term treatment with C75 
results in increased expression of UCP-3 mRNA in skeletal muscle of obese mice78. This may increase thermogenesis 
and thereby explain the increase in energy expenditure. C75 inhibits CPTI activity in mitochondria isolated from rat 
liver and muscle57. Finally, in the present study we found that C75 inhibits CPTI activity both in vitro and in vivo in
acute accordance with inhibition of palmitate oxidation. NPY; neuropeptide Y, AgRP; agouti-related protein, POMC; 
pro-opiomelanocortin, CART; cocaine-amphetamine-regulated transcript.
83 Hu Z, Cha SH, Chohnan S, Lane MD. Hypothalamic malonyl-CoA as a mediator of feeding behavior, Proc. Natl. 
Acad. Sci. USA. 100:12624-12629, 2003
84 Shimokawa T, Kumar MV, Lane MD. Effect of fatty acid synthase inhibitor on food intake and expression of 
hypothalamic neuropeptides. Proc. Natl. Acad. Sci. USA. 99:66-71, 2002
85 Loftus TM, Jaworsky DE, Freywot GL, Townsend CA, Ronet GV, Lane MD, Kuhajda FP. Reduced food intake 
and body weight in mice treated with fatty acid synthase inhibitors. Science 288:2379-2381, 2000
Adipocyte
Adipose tissue78
CPTI54
Palmitate oxidation54
Hypothalamus
Malonyl-CoA83
Food consumption85
NYP, AgRP84
POMC, CART84
ATP levels71
AMPK71
CPTI60
Palmitate oxidation60
CENTRAL PERIPHERAL
Liver
Fatty liver85
CPTI54
Palmitate oxidation54
CPTI57
Pancreatic β-cell
CPTI (Thesis)
Palmitate oxidation
(Thesis)
Muscle
UCP-378
CPTI57
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Further investigation is needed to explain the stimulation of fatty acid oxidation 
of C75 observed by others in peripheral tissues and the loss of body weight. It would be 
interesting to perform a three-dimensional structural model for CPTI on which the 
position of C75 could be assigned by superposition and docking analysis. This study 
would help us to improve our knowledge of the interaction between CPTI and C75 and 
to discern between covalent and non-covalent interaction and activation or inhibition of 
the CPTI activity. In addition, octanoate oxidation experiments may rule out distant C75 
effects on CPTI, as octanoate is a medium-chain fatty acid that does not require CPTI to 
enter the mitochondria and be oxidized. 
CONCLUSIONS
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CONCLUSIONS
1. CPTI activity is not inhibited by malonyl-CoA in INS(832/13) cells expressing
LCPTI M593S. CPTI activity of INS(832/13) cells expressing LCPTI M593S is less 
sensitive to etomoxir than LCPTI wt-expressing cells.
2. Expression of LCPTI wt and LCPTI M593S in INS(832/13) cells increases enzymatic
activity of CPTI, correlated with the amount of adenovirus used. CPTI activity increases
in both cases to a plateau of 9-10 fold compared with the endogenous LCPTI. The 
increase in CPTI activity is correlated with similar levels of LCPTI protein in
INS(832/13) cells and rat islets overexpressing LCPTI wt and LCPTI M593S.
3. Overexpression of LCPTI M593S increases palmitate oxidation rates in INS(832/13) 
cells at all glucose concentrations tested. Fat oxidation rates were much higher than in 
control Ad-LacZ-infected cells and still higher than in cells infected with Ad-LCPTI wt, 
even at high malonyl-CoA concentrations (high glucose).
4. Malonyl-CoA levels and glucose oxidation are not modified by LCPTI wt or LCPTI 
M593S overexpression, compared with LacZ control cells. 
5. GSIS is reduced by 60% in INS(832/13) cells expressing LCPTI M593S, but not in 
response to a depolarizing concentration of KCl, indicating that exocytosis per se is 
preserved in those cells. GSIS is recovered completely in the presence of 0.25 mM 
palmitate only in the case of LCPTI wt, showing the strong metabolic influence of 
LCPTI M593S on fatty acid oxidation and insulin secretion in the pancreatic β-cell. The 
GSIS impairment is restored in both cases after 200 µM etomoxir incubation.
6. LCPTI wt and LCPTI M593S overexpression impair s KATP channel- independent
GSIS in INS(832/13) cells, which is consistent with the view that malonyl-CoA/CPTI
interaction is involved in the amplification arm of secretion. 
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7. In islets overexpressing LCPTI M593S GSIS was decreased by 40%, while no 
difference was seen in Ad-LCPTI wt- infected islets, suggesting preserved lipid
signalling above a critical threshold of cytosolic FA-CoA.
8. Glucose- induced esterification processes are reduced in INS(832/13) cells expressing 
LCPTI wt and even more decreased in LCPTI M593S-expressing cells. 
9. PKC activation is impaired in INS(832/13) cells expressing LCPTI M593S
suggesting that enhanced β-oxidation by the LCPTI M593S mutant reduces GSIS as a 
result of a decrease in PKC activation.
10. The attempt to establish an LCPTI wt or an LCPTI M593S stable cell line by the 
Tet-on system was unsuccessful, probably because a slight basal overexpression of 
LCPTI, even in the absence of doxycycline, could be toxic to the cells.
11. CPTI activity is inhibited in INS(832/13) cells and in mitochondrion-enriched cell 
fractions incubated with C75. This is correlated with an inhibition of palmitate
oxidation whereas viability of the cells was not affected by the drug.
12. A single intraperitoneal injection of C75 to mice produces short-term inhibition of 
CPTI activity in vivo in mitochondria from liver and pancreas, recovering upon time.
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APPENDIX
1. PRIMER SEQUENCES
PRIMER SEQUENCE (5’ 3’)
Myc.for GGC GAA TGG GTG AGT AAC ACG
Myc.rev CGG ATA ACG CTT GCG ACC TAT
pTRE2.for GGC CTA TAT AAG CAG AGC TCG
CPTINcoI.rev GCT GCC TGG ATA TGG GTT GG
COTH131A.for GCA TAC TAC TGT  GGG CCA AAC TTG AAC TAC 
TGG C
COTXbaI.rev TCA TGT CTA GAG GAG TAT TTC C
rtTA.for CTC GCC AGA AGC TTG GTG TAG
rtTA.rev CTG AAT GTA CTT TTG CTC CAT TGC G
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2. SEQUENCE OF THE RAT LIVER CARNITINE
PALMITOYLTRANSFERASE I
Sequence of the rat liver carnitine palmitoyltransferase I (LCPTI), published by 
Esser V. et al in 1993, with accession number in GeneBank Data Libraries L00736.
DEFINITION: Rat carnitine palmitoyltransferase I mRNA, complete cDNAs.
ACCESSION NUMBER: L07736
EC NUMBER: 2.3.1.21
SOURCE: Rattus norvegicus (Norway rat) male adult liver cDNA to mRNA.
AUTHORS: Esser V, Britton CH, Weis BC, Foster DW and McGarry JD.
TITLE: Cloning, sequencing, and expression of a cDNA encoding rat liver
carnitine palmitoyltransferase I. Direct evidence that a single polypeptide is involved in 
inhibitor interaction and catalytic function.
JOURNAL: J. Biol. Chem. 268: 5817-5822, 1993
CODIFYING SEQUENCE: 103..2424
translation="MAEAHQAVAFQFTVTPDGIDLRLSHEALKQICLSGLHSWKKKFIRF
KNGIITGVFPANPSSWLIVVVGVISSMHAKVDPSLGMIAKISRTLDTTGRMSSQT
KNIVSGVLFGTGLWVAVIMTMRYSLKVLLSYHGWMFAEHGKMSRSTKIWMA
MVKVLSGRKPMLYSFQTSLPRLPVPAVKDTVSRYLESVRPLMKEEDFQRMTAL
AQDFAVNLGPKLQWYLKLKSWWATNYVSDWWEEYIYLRGRGPLMVNSNYY
AMEMLYITPTHIQAARAGNTIHAILLYRRTLDREELKPIRLLGSTIPLCSAQWER
LFNTSRIPGEETDTIQHIKDSRHIVVYHRGRYFKVWLYHDGRLLRPRELEQQMQ
QILDDPSEPQPGEAKLAALTAADRVPWAKCRQTYFARGKNKQSLDAVEKAAFF
VTLDESEQGYREEDPEASIDSYAKSLLHGRCFDRWFDKSITFVVFKNSKIGINAE
HSWADAPIVGHLWEYVMATDVFQLGYSEDGHCKGDTNPNIPKPTRLQWDIPG
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ECQEVIDASLSSASLLANDVDLHSFPFDSFGKGLIKKCRTSPDAFIQLALQLAHY
KDMGKFCLTYEASMTRLFREGRTETVRSCTMESCNFVQAMMDPKSTAEQRLK
LFKIACEKHQHLYRLAMTGAGIDRHLFCLYVVSKYLAVDSPFLKEVLSEPWRLS
TSQTPQQQVELFDFEKNPDYVSCGGGFGPVADDGYGVSYIIVGENFIHFHISSKF
SSPETDSHRFGKHLRQAMMDIITLFGLTINSKK"
BASES: 1109 a     1115 c     1121 g     1032 t
1 agtcggtcga ctccgagctc agtgaggacc taaagcagag gactgtggtg cggaggacag
61 tgcttgctcc ggggagtgca gagcaatagg tccccactca agatggcaga ggctcaccaa
121  gctgtggcct tccagttcac cgtcaccccc gatggcattg acctccgcct gagccacgaa
181  gccctcaaac agatctgcct gtcggggctg cactcctgga agaagaagtt catccggttc
241  aagaatggca tcatcactgg tgtgttcccc gcgaatccgt ccagctggct tatcgtggtg
301  gtgggtgtga tttcatccat gcatgccaaa gtggacccct ccctgggcat gatcgcaaag
361  atcagtcgga ccctagacac cactggccgc atgtcaagcc agacgaagaa cattgtgagc
421  ggcgtcctct ttggtacagg gctctgggtg gcagtcatca tgaccatgcg ctactcgctg
481  aaggtgctgc tctcctacca cggctggatg tttgcagaac acggcaaaat gagccgcagc
541  accaagatct ggatggctat ggtcaaggtc ctctcaggtc ggaagcccat gttgtacagc
601  ttccagacgt ctctgccacg cctgcctgtc ccagctgtca aagatactgt gagcaggtac
661  ctggaatctg taaggccact gatgaaggaa gaagacttcc agcgcatgac agcactggcc
721  caggattttg ctgtcaacct cggacccaaa ttgcagtggt atttgaagct aaaatcctgg
781  tgggccacaa attacgtgag tgactggtgg gaagaatata tctacctgcg gggccgaggg
841  ccgctcatgg tcaacagcaa ctactacgcc atggagatgc tgtacatcac cccaacccat
901 atccaggcag cgagagctgg caacaccatc cacgccatac tgctgtatcg tcgcacatta
961  gaccgtgagg aactcaaacc cattcgtctt ctgggatcca ccattccact ctgctcagcc
1021 cagtgggagc gactcttcaa tacttcccgg atccctgggg aggagacaga caccatccaa
1081 catatcaagg acagcaggca cattgttgtg taccacagag ggcggtactt caaggtctgg
1141 ctctaccacg atgggaggct gctgaggccc cgagagctgg agcagcagat gcagcagatc
1201 ctggatgatc cctcagagcc acagcctggg gaggccaagc tggccgccct cactgctgca
1261 gacagagtgc cctgggcaaa gtgtcggcag acctattttg cacgagggaa aaataagcag
1321 tccctggatg cggtggaaaa ggcagcgttc ttcgtgacgt tggacgaatc ggagcaggga
1381 tacagagagg aggatcctga ggcatccatc gacagctacg ccaaatccct gctgcatgga
1441 agatgctttg acaggtggtt tgacaagtcc atcacctttg ttgtcttcaa aaacagcaag
1501 ataggcataa atgcagagca ctcctgggcg gacgcgccca tcgtgggcca tttgtgggag
1561 tatgtcatgg ccaccgacgt cttccagctg ggttactcag aggatggaca ctgtaaagga
1621 gacaccaacc ccaacatccc taagcccaca aggctacaat gggacattcc aggagagtgc
1681 caggaggtca tagatgcatc cctgagcagc gccagtcttt tggcaaatga tgtggacctg
1741 cattccttcc catttgactc tttcggcaaa ggcttgatca agaagtgccg gacgagtccc
1801 gatgccttca tccagctggc gctgcagctc gcacattaca aggacatggg caagttctgc
1861 ctcacatatg aggcctccat gacccggctc ttccgagaag ggaggacaga gactgtacgc
1921 tcctgcacta tggagtcctg caactttgtg caggccatga tggaccccaa gtcaacggca
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1981 gagcagaggc tcaagctgtt caagatagct tgtgagaagc accagcacct gtaccgcctc
2041 gccatgacgg gcgccggcat cgaccgccat ctcttctgcc tctatgtggt gtccaagtat
2101 cttgcagtcg actcaccttt cctgaaggag gtattgtctg agccatggag gttgtctacg
2161 agccagactc ctcagcagca ggtggagctc tttgactttg agaaaaaccc tgactatgtg
2221 tcctgtggag ggggctttgg gccggttgcc gatgacggct atggtgtctc ctacattata
2281 gtgggagaga atttcatcca cttccatatt tcttccaagt tctctagccc tgagacagac
2341 tcacaccgct ttgggaagca cttgagacaa gccatgatgg acattatcac cttgtttggc
2401 ctcaccatca attctaaaaa gtaaacccct gagccacacg gaaggaaaac ggaccctcgt
2461 gatacaaacc aaatgaatag atgttgctcc tgaccatagg acaggcagaa aattgctctt
2521 ataaaactca gttttccttc cagaaggttt accgtcagtc tccctagaac aacagtaggc
2581 ttcacgtgtg aattgtgacc ctactacatc cagagatgcc ttggctccag gaatattggg
2641 cacagtcccc tgatgtcttt tgaatcggct cctactggat aaagggattt aaatgctggt
2701 gaattcctgg attctggggg ttgtttcttc acatgtgttg gaggtgacag acttcctcag
2761 tggtgaccct gtgaatactt gggcgtctga ctccacccag gcagtgtgag catcaccttg
2821 tggaaagaga aagtgtcttc agagccagca gaggcaacag ctgtagctaa cacatctgta
2881 acacactaat ggaatggtta ggcctgggga ttaaggttct gctatgagtg acagccactg
2941 tccctttgga agttcacatt tccaggaagc agagtaccac ctccccagtg ccaccttcct
3001 cacacatctt caaaacccag tgccttaaag aaggggccca ttggcaagcg ggaccataga
3061 gaagacttag catctgtgaa gcctttgggt ggatatgtga ggatgctgct tccccttact
3121 ggttcctgca taaagatgtc cctaagtaag cacttccccc acccctagaa aatgaggtcc
3181 ttggtgaagg cagggatgct ggagtctcat tgcctgccag ttccattaag ccacaaaata
3241 gcagacatgt gtccacagag ggaggggctt ggtagtcaaa ggctgcatag ctggacaaca
3301 gcgggagagt gtggcttgct gtatttgaca gctgttggca agaggagtga gaccctggtc
3361 accaagtcag acatactgac acaggcagcc aaagctcacg gagccaggag atatagatag
3421 atactggctt gtattctggc agatacaccc ctgggcttat cttctaatcc cacccagtca
3481 gattccaacc agagtcaaat tccatagaag gctaggtcat tttggcgaca gactcaggga
3541 tctcaagtaa tgggtgcttt tacccacatg ccatccctca gtgggagtgc ctttcttgaa
3601 agcatccaat gggctaaagc agctctacca agtctgtttg gtatttaatg taaacattag
3661 cattaatgga gtggtctctc ctacctgtca ccatcctgtc ctgacaagct tagctctccg
3721 aggtttacat catgtattta ttttccagtg cccctttggc cttgtttgat tcctgcccct
3781 gtgccagaag tggcccagaa gtgaggggtg gggtgaccag cagtgcagag aggtgctggc
3841 tgaacagttc atgtgtgtct tatgggtata catgtataaa ttttgtaatg taaaaaaaaa
3901 aatcatacct aaaagggcca aagttttttt tttttttact aaaaccaaga aaacaaaaga
3961 caacataaag acataagcag aaacaaactg ttgtaagtca gagcggcctg actctcgctg
4021 ctgtgaccac tcaccaacct gtgttactca gagtagcccg gctagtgccc gagtgggaca
4081 ttcctctctc aggtttccag tgtccttgct gctcctgagc agttaccaat gcaatttcgc
4141 attccttaca aggcagaaga gtgggctctc actgtatgtg ttcaaaggag gaggtaagac
4201 tattgtgtat ttaatttaat gtggaacaaa atatagtctt accgcagcca aggttcaaat
4261 ttggtgttct aatctgtcca ttgcatgtaa ataccatatc tgtttggata taaatcttag
4321 aagtgcatgt gtgagcgaat gtagctggcc attaataaaa cattaatact gtctact
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Adenovirus-mediated overexpression of liver carnitine palmitoyltransferase I
in INS1E cells : effects on cell metabolism and insulin secretion
Blanca RUBI *, Peter A. ANTINOZZI†, Laura HERRERO*, Hisamitsu ISHIHARA†, Guillermina ASINS*, Dolors SERRA*,
Claes B. WOLLHEIM†, Pierre MAECHLER† and Fausto G. HEGARDT*1
*Department of Biochemistry and Molecular Biology, University of Barcelona, School of Pharmacy, Diagonal 643, E-08028 Barcelona, Spain, and †Department of
Biochemistry, Centre Medical Universitaire, Michel Servet 1, 1211 Geneva-4, Switzerland
Lipid metabolism in the β-cell is critical for the regulation of
insulin secretion. Pancreatic β-cells chronically exposed to fatty
acids showhigher carnitine palmitoyltransferase I (CPT I) protein
levels, higher palmitate oxidation rates and an altered insulin
response to glucose. We examined the eﬀect of increasing CPT I
levels on insulin secretion in cultured β-cells. We prepared a
recombinant adenovirus containing the cDNA for the rat liver
isoform of CPT I. The overexpression of CPT I in INS1E cells
caused a more than a 5-fold increase in the levels of CPT I
protein (detected by Western blotting), a 6-fold increase in the
CPT activity, and an increase in fatty acid oxidation at 2.5 mM
glucose (1.7-fold) and 15 mMglucose (3.1-fold). Insulin secretion
was stimulated in control cells by 15 mM glucose or 30 mM KCl.
INS1E cells overexpressing CPT I showed lower insulin secretion
on stimulation with 15 mM glucose (40% ; P 0.05). This
decrease depended on CPT I activity, since the presence of
etomoxir, a speciﬁc inhibitor of CPT I, in the preincubation
INTRODUCTION
Lipid metabolism in the β-cell is critical for the normal regulation
of insulin secretion [1,2]. Depletion of lipid stores together with
deprivation of non-esteriﬁed fatty acids (NEFA) alters glucose-
stimulated insulin secretion (GSIS) in rats and humans [3–5].
NEFAs, presumably via long-chain acyl-CoA (LC-CoA), gen-
erate signals for insulin secretion [6].
Stimulation of insulin secretion by glucose alters the CoA
derivatives in clonal pancreatic β-cells, especially malonyl-
CoA and fatty acyl-CoA. The LC-CoA model of GSIS holds
that during glucose stimulation, anaplerosis in the mitochondria
increases citrate [7], which is exported and converted into
malonyl-CoA, resulting in inhibition of carnitine palmitoyltrans-
ferase I (CPT I) [8] and fatty acid oxidation [2,6,9]. Therefore the
increase inmalonyl-CoAmaybe responsible for the accumulation
of fatty acyl-CoAs in the cytosol [10]. Moreover cytosolic acyl-
CoA content increases with the addition of exogenous fatty
acids. In addition, glucose metabolism in the β-cell raises acyl-
CoA levels, which, in combination with α-glycerophosphate,
may increase the levels of triacylglycerols, phosphatidic acid and
diacylglycerol [2]. Fatty acyl-CoAs may act as coupling factors in
insulin secretion by stimulating several isoforms of protein kinase
C [11,12], by overcoming malonyl-CoA inhibition of CPT I [13],
by stimulating the ATP-sensitive K+ channel [14], and by
acetylating proteins to target them to appropriate membrane
sites [15].
Abbreviations used: AdCA, adeno-chicken actin promoter ; CPT I, carnitine palmitoyltransferase I ; DMEM, Dulbecco’s modiﬁed Eagle’s medium;
DNA-TPC, DNA-terminal protein complex ; FBS, fetal bovine serum; GSIS, glucose-stimulated insulin secretion; LC-CoA, long-chain acyl-CoA; NEFA,
non-esteriﬁed fatty acids ; TBS, Tris-buﬀered saline ; KRBH buﬀer, Krebs–Ringer bicarbonate Hepes buﬀer ; UCP2, uncoupling protein 2.
1 To whom correspondence should be addressed (e-mail hegardtfarmacia.far.ub.es).
medium normalized the CPT I activity, the fatty-acid oxidation
rate and the insulin secretion in response to glucose. Exogenous
palmitate (0.25 mM) rescued glucose-stimulated insulin secretion
(GSIS) in CPT I-overexpressing cells, indicating that the mech-
anism of impaired GSIS was through the depletion of a critical
lipid. Depolarizing the cells with KCl or intermediary glucose
concentrations (7.5 mM) elicited similar insulin secretion in
control cells and cells overexpressing CPT I. Glucose-induced
ATP increase, glucosemetabolism and the triacylglycerol content
remained unchanged. These results provide further evidence that
CPT I activity regulates insulin secretion in the β-cell. They also
indicate that up-regulation of CPT I contributes to the loss of
response to high glucose in β-cells exposed to fatty acids.
Key words: beta cells, etomoxir, fatty acid oxidation, glucose-
stimulated insulin secretion, pancreas.
Both malonyl-CoA and LC-CoA participate in the signal
transduction for insulin secretion: malonyl-CoA as a regulator
and LC-CoA as an eﬀector signal [16]. Systems that regulate
both malonyl-CoA and LC-CoA appear to be involved in insulin
secretion. Accordingly, acetyl-CoA carboxylase, which controls
the synthesis of malonyl-CoA, and CPT I, which is regulated by
it, are considered to integrate the circulating fuel stimuli. The fate
of malonyl-CoA in the pancreatic β-cell, in contrast with other
tissues, is not de noo synthesis of fatty acids, but the regulation
of CPT I activity, due to the very low levels of fatty acid synthase
in the β-cell [17]. The metabolism of several nutrients that
converge to form malonyl-CoA and increase LC-CoA esters
(carbohydrate, amino acids and ketoacids) might act as fuel
sensors in the β-cell. Therefore stable expression of an acetyl-
CoA carboxylase antisense construct in INS1 cells decreased
malonyl-CoA levels and insulin secretion [18]. Moreover, hy-
droxycitrate, which inhibits ATP-citrate lyase, and consequently
malonyl-CoA formation, inhibited GSIS from the perifused rat
pancreas [19]. Inhibition of fatty acid oxidation by a CPT I-
speciﬁc irreversible inhibitor, etomoxir [19], or non-metabolizable
fatty acid analogues [20] stimulates GSIS in perfused pancreas
and isolated islets.
In the present study the CPT I liver isoform, predominantly
expressed in rat pancreatic islets, was overexpressed in rat
insulinoma INS1E cells by a recombinant adenovirus vector. The
transduced cells had increased CPT I protein levels, an increased
palmitate oxidation rate and impaired GSIS, and these eﬀects
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were overcome by incubation with etomoxir. Incubation of
INS1E cells with KCl had no eﬀect on insulin secretion in CPT
I overexpressed cells. CPT I overexpression did not change
glucose-induced ATP generation, glucose oxidation, or the
triacylglycerol levels. These results show that an increase in fatty
acid oxidation rate in the β-cell impairs GSIS, conﬁrming data of
other authors on the role of fatty acyl-CoA. They are also
compatible with the hypothesis that an increase in CPT I [1],
together with an increase in uncoupling protein 2 (UCP2) [21,22],
could contribute to the altered insulin response to glucose in β-
cells after fatty acid exposure.
MATERIAL AND METHODS
Cell culture and materials
INS1E cells [23] were chosen since they secrete more insulin in
response to glucose in the range 5–20 mM than the parental INS-
1 cells [24]. INS1E cells (passages 46–70) were cultured in a
humidiﬁed atmosphere containing 5% CO

in a medium com-
posed of RPMI 1640 supplemented with 10 mM Hepes, 5%
(vv) heat-inactivated fetal bovine serum (FBS), 2 mM glut-
amine, 100 unitsml penicillin, 100 µgml streptomycin, 1 mM
sodium pyruvate and 50 µM 2-mercaptoethanol as originally
described [24]. An antibody against rat insulin was purchased
from LINCO (St. Louis, MO, U.S.A.). RPMI 1640, Dulbecco’s
modiﬁed Eagle’s medium (DMEM) and FBS were obtained from
Life Technologies, Inc. Reagents commonly used for the experi-
ments were from Sigma Chemical Co. and Fluka Chemie AG.
Secondary antibody and radioactively labelled compounds were
obtained from Amersham Biosciences. Chemiluminescent re-
agent (Supersignal West Pico Chemiluminescent substrate) was
obtained from Pierce.
Adenovirus construction
Recombinant adenoviruswas constructed as described previously
[25]. Brieﬂy, the expression unit to be introduced into the
recombinant adenovirus was ﬁrst inserted into the unique SwaI
site of the E1-substitution type full-length adenovirus genome
cloned in a cassette cosmid. The cassette bearing the expression
unit was then co-transfected into HEK-293 cells together with
the adenovirus DNA-terminal protein complex (DNA-TPC)
digested at several sites with EcoT22I.
The CPT I cDNA, containing the whole coding sequence, was
obtained by reverse-transcriptase PCR from rat liver mRNA,
subcloned in BlueScript and sequenced, revealing no change with
the previously reported rat liver CPT I [26]. The CPT I cDNA
was then digested, blunt-ended and subcloned into the cosmid
pAdCA (where AdCA corresponds to adeno-chicken actin
promoter) previously cut with SwaI and dephosphorylated. The
CPT I insert (nt 58–2700 of the previously reported mRNA)
contained the ATG codon and the stop codon. The presence of
the insert was checked with the restriction enzyme ClaI and its
correct orientation was checked with BglII. The cosmid con-
taining the full coding sequence for rat liver CPT I was called
pAdCA-CPT I. The adenovirus DNA-TPC of the parent adeno-
virus was prepared through a buoyant CsCl density gradient
with 4 M guanidine hydrochloride [25]. Cassette cosmid pAdCA-
CPT I (8 µg) and 1 µg of the EcoT22I-digested DNA-TPC were
co-transfected in a 6-cm dish with calcium phosphate (Cellfect
Transphection Kit ; Pharmacia) in HEK-293 cells and 1 day later
the cells were distributed in 96-well plates [27]. The desired
recombinant adenovirus was generated by overlapping recom-
bination. At 10 days after transfection, the cell lysate from
the selected viral clones was used to infect 24-well dishes, the
adenoviral DNA was extracted from these cells and the DNA
was analysed by digestion with ClaI to check the CPT I insert.
To amplify and purify the selected virus the cell lysate
containing the virus with full-length rat liver CPT I (AdCA-CPT
I) was used to infect two 138-mm dishes of HEK-293 cells.
The AdCA-CPT I and AdCA-LacZ viruses, which express the
bacterial β-galactosidase [28] were ampliﬁed and puriﬁed by
CsCl ultracentrifugation. Adenovirus ampliﬁcation was per-
formed in HEK-293 cells cultured in DMEM containing 5 or
10% (vv) FBS.
Viral treatment of INS1E cells
INS1E cells (500000) were seeded in 12-well dishes (Falcon) and
cultured for 48 h prior to infection. For infection, cells were
incubated with 500 µl of medium containing 20 plaque-forming
units of the recombinant adenoviruscell for 90 min, washed
once in the medium, and cultured in RPMI medium for 20 h
before experiments to allow the transgenes to be expressed, before
initiating metabolic studies or measurements of insulin secretion.
Immunoblot analysis
For detection of rat liver CPT I protein, infected INS1E cells
were collected and dissolved in SDS sample buﬀer. Proteins were
subjected to SDSPAGE (10% gels) and transferred on to
nitrocellulose membranes. The membranes were blocked for 1 h
with Tris-buﬀered saline (TBS) containing 0.1% Tween-20 and
5% (wv) non-fat dried milk. The membrane was washed three
times in TBSTween at 22 C. Membranes were probed with the
CPT I-speciﬁc antibody [29] by overnight incubation, and then
incubated for 1 h with anti-sheep IgG conjugated to horseradish
peroxidase (1:5000 dilution). The signal was detected by chemi-
luminescence.
Determination of CPT I activity in INS1E cells
INS1E cells (12 million) were seeded in 15-cm dishes and cultured
for 48 h prior to infection. For infection, cells were incubated
with 10 ml of medium containing 20 plaque-forming units of the
recombinant adenovirus (AdCA-LacZ and AdCA-CPT I)cell
for 90 min, washed once in the medium, and cultured in RPMI
medium for 20 h. Prior to obtaining the mitochondria-enriched
cell fraction, cells were preincubated for 30 min in Krebs–Ringer
bicarbonateHepes buﬀer (KRBHbuﬀer; 140 mMNaCl, 3.6 mM
KCl, 0.5 mM NaH

PO

, 0.5 mM MgSO

, 1.5 mM CaCl

,
2 mM NaHCO

and 10 mM Hepes)1% (wv) BSA without
glucose in the absence or the presence of etomoxir at 50 and
200 µM. After preincubation, the cells were washed with 10 ml of
PBS and resuspended in 5 ml of the same solution. The cells were
pooled at this point and sedimented by centrifugation at 1200 g
for 5 min at 4 C. After resuspension in 1 ml of 5 mM TrisHCl
(pH 7.2)150 mM KCl (buﬀer A), they were broken with 10
cycles of a glass homogenizer ﬁtted with a tight pestle. Further
centrifugation was performed in a microfuge for 5 min at 4 C at
16000 g, and the ﬁnal pellet was resuspended in the desired
volume of buﬀer A. CPT I was assayed in these preparations
where the mitochondria remain largely intact [30]. Carnitine
acyltransferase activity of 10 µg of protein was determined by the
radiometric method as previously described [31].
[1-14C]Palmitate oxidation
At 20 h after infection, INS1E cells seeded in 12-well dishes were
placed in a water bath at 37 C, washed once in 1 ml of solution
A, which contained KRBH0.1% BSA (essentially fatty acid
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free). The cells were then preincubated for 30 min with 500 µl of
KRBH containing 1% (wv) BSA (solution B), with or without
200 µM etomoxir and washed in 1 ml of KRBH.
The rate of fatty acid oxidation was measured essentially as
described by Chen et al. [19]. Brieﬂy, the cells were washed in 1 ml
of solution A and harvested by resuspension in 300 µl of KRBH.
Cell suspension (160 µl) was added to a centre well containing
20 µl of 2.5 mM palmitate complexed to 10% (wv) BSA, with
0.5 µCi of [1-C]palmitic acid as a tracer and 20 µl of a solution
containing 25 or 150 mM -()-glucose plus 8 mM carnitine,
and the centre well was immediately placed in a sealed vial. After
2 h at 37 C, the reaction was stopped by the addition of 100 µl
of 7% (wv) perchloric acid. The rate of [1-C]palmitate
oxidation was measured as released CO

, which was trapped by
300 µl of benzethonium chloride, added to the bottom of the
sealed vials. After 5 h, the centre wells and the rubber stoppers
were discarded and 10 ml of scintillation mixture was added.
Control incubations without INS1E cells were run with each
series. Following overnight incubation at 22 C, CO

pro-
duction was counted in an LS6500 liquid scintillation counter
(Beckman Instruments Inc.). Palmitate oxidation was expressed
as nmol of palmitate oxidizedh per mg of cell protein.
ATP determinations
ATP was generated in 6-well plates following 30 min of preincu-
bation in KRBH. Cells were incubated for 10 min in KRBH with
2.5 or 15 mM glucose before the stimulation was arrested on ice
by washing with ice-cold KRBH and the addition of 0.4 M
perchloric acid. ATP levels were determined using a biolumin-
escence assay kit (Roche, Rotkreuz, Switzerland).
Measurements of cellular insulin secretion and insulin content
Insulin was measured essentially as described previously [32].
INS1E cells (500000) were seeded in 12 wells. Two days after
seeding the cells were treated with the recombinant adenovirus
and 20 h later INS1E infected cells were placed in a water bath
at 37C, washed once in 1 ml of solution A, preincubated for
30 min with 500 µl of solution B, with or without 200 µM
etomoxir, and washed again in solution A.
Insulin secretion was measured for 30 min. Brieﬂy, 1 ml of
solution A containing 2.5, 7.5 or 15 mM glucose, or 2.5 mM
glucose plus 30 mM KCl, was added. After 30 min the solution
was collected and centrifuged at 10000 rev.min in a microcen-
trifuge for 1 min to remove cell debris. To measure insulin
content, INS1E cells remaining in the wells were extracted with
1 ml of 75% ethanol0.2 M HCl added to each well. The
supernatant and cell insulin samples were immediately stored at
20 C until insulin determination by RIA, using rat insulin as
a standard and an antibody speciﬁc for rat insulin. The insulin
secretion was expressed as a percentage of the cell insulin content.
[U-14C]Glucose oxidation
Glucose oxidation was measured as CO

production from [U-
C]glucose with the same experimental design as for themeasure-
ment of palmitate oxidation, except that cells were incubated for
1 h with [U-C]glucose in the absence or in the presence of
0.25 mM palmitate [32].
INS1E cells infected with recombinant adenovirus as described
above were washed with 1 ml of solution A and harvested by
light resuspension in 600 µl of KRBH; 180 µl of the cell
suspension was added to a centre well containing 20 µl of 25 or
150 mM -()-glucose with 0.5 µCi of [U-C]glucose as a tracer,
and the centre well was placed immediately in a sealed vial. After
1 h at 37 C, the reaction was stopped by the addition of 100 µl
of 7% (wv) perchloric acid. The rate of [U-C]glucose oxidation
was measured as released CO

, which was trapped by 300 µl of
benzethonium chloride at the bottom of the sealed vials to bind
the liberated CO

. Labelled CO

was measured as described
above. The data were expressed as nmol of glucose oxidizedh
per mg of cell protein.
Triacylglycerol content measurements
At 20 h after infection, INS1E cells seeded in 12-well dishes were
placed in a water bath at 37 C, washed once with 1 ml of
solution A, preincubated for 30 min with 500 µl of solution B
and washed with solution A.
Lipids were extracted as described elsewhere [33]. Brieﬂy, 1 ml
of methanolPBS (2:3, vv) was added to each well and the cells
were gently collected in a pipette, centrifuged at 700 g for 5 min
and washed with PBS; 200 µl of 0.2 M NaCl was then added to
the pellet and the mixture was immediately frozen in liquid N

.
To separate aqueous and lipid phases, 750 µl of chloroform
methanol (2 :1, vv) and 50 µl of 0.1 M KOH were added and,
after vigorous vortex-mixing, the phases were separated by
15 min of centrifugation at 2000 g. The top aqueous phase was
removed and the lipid phase was washed with 200 µl of meth-
anolwaterchloroform (48:47:3, by vol.). After vortex-mixing
and centrifugation, 400 µl of the lower phase was taken and
dried. Triacylglycerols were measured in each sample using the
Sigma 334 triacylglycerol kit. The method involves the hydrolysis
of triacylglycerols by lipoprotein lipase and measures ‘ true
triacylglycerols ’.
Statistical analysis
Unless otherwise indicated data are represented as the means
S.E.M. for at least three independent experiments performed in
triplicate. Diﬀerences between groups are assessed by the Stu-
dent’s t test for unpaired data.
RESULTS
Assessment of adenovirus-mediated CPT I overexpression in
INS1E cells
The capacity of AdCA-CPT I to direct expression of liver CPT
I in insulinoma INS1E cells was evaluated by Western-blot ana-
lysis of extracts from cells infected with AdCA-CPT I andAdCA-
LacZ as a control. The conditions of the infection are described
in the Materials and methods section. Immunoblotting revealed
a band of the expected size of 88 kDa and the signal increased
according to the viral amount from 0 to 40 plaque-forming units
cell (Figure 1A). An infection titre of 20 plaque-forming
unitscell was used for the rest of the experiments. There was
a 6-fold increase in the CPT activity in the mitochondria-
enriched fractions of the cells infected with AdCA-CPT I
compared with the cells infected with AdCA-LacZ. In contrast,
preincubation of the AdCA-CPT I-infected INS1E cells with
increasing amounts of etomoxir diminished the CPT activity (60
and 9% of the control with 50 and 200 µMetomoxir respectively)
(Figure 1B).
Impact of recombinant CPT I adenovirus on palmitate oxidation in
INS1E cells
We evaluated the metabolic eﬀects of the AdCA-CPT I virus. [1-
C]Palmitate oxidation was measured in adenovirus-treated
INS1E cells for 2 h, after a 30 min preincubation in KRBH with
no glucose and no fatty acids, in the absence or in the presence
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Figure 1 Immunoblot analysis of CPT I expressed in INS1E infected cells
and CPT activity in mitochondria-enriched INS1E fractions
(A) Samples were prepared and analysed as described in the Materials and methods section.
At 20 h after the infection of INS1E cells with 20 and 40 plaque-forming units (pfu) of
recombinant adenovirus/cell, cells were collected and protein extracts (100 µg) were separated
by SDS/PAGE (10% gels) and subjected to immunoblotting by using speciﬁc antibodies for CPT
I from rat liver. A unique band corresponding to a protein of approx. 88 kDa was seen in control
and AdCA-CPT I-infected cells. (B) CPT I activity was measured in mitochondrial-enriched
fractions of LacZ and CPT I-overexpressing cells, before and after treatment with etomoxir.
Results are the means of three experiments performed in duplicate.
Figure 2 [1-14C]Palmitate oxidation in INS1E infected cells
INS1E cells were treated with AdCA-LacZ or AdCA-CPT I. At 20 h after viral treatment, [1-
14C]palmitate oxidation was measured after 30 min of preincubation with either 2.5 or 15 mM
glucose with or without etomoxir. Results are expressed as meansS.E.M. for three
independent experiments, which were performed in triplicate. *P 0.01 compared with AdCA-
LacZ ; §P 0.05 compared with AdCA-CPT I without etomoxir.
of 200 µM etomoxir. Incubation with AdCA-LacZ at 15 mM
glucose reduced the rate of palmitate oxidation to 20% in
comparison with cells incubated with 2.5 mM glucose (Figure 2).
This decrease in fatty acid oxidation rate has been reported
previously and in similar fashion for rat islets [19] and INS1 cells
[34]. According to these results [19,34], when glucose is raised
from non-stimulatory to stimulatory concentration, INS1E cells
(like INS1 cells and islet β-cells) increase glycolytic ﬂux and
decrease the rate of palmitate oxidation.
Figure 3 Effect of CPT I overexpression on GSIS in INS1E infected cells
(A) INS1E cells were treated with the indicated adenovirus and cultured for 20 h in regular
medium. After a 30 min preincubation in KRBH solution without glucose and with or without
200 µM etomoxir, cells were washed and incubated in KRBH solution containing either 2.5 or
15 mM glucose for 30 min and insulin release was determined. Results represent the
meansS.E.M. for three independent experiments performed in triplicate. (B) A similar set of
experiments was performed, in the absence of etomoxir preincubation, testing 2.5, 15 mM
glucose and 2.5 mM glucose plus 30 mM KCl. Results are the meansS.E.M. of one
representative experiment out of three, performed in triplicate. *P 0.05 compared with AdCA-
LacZ. (C) To test the eﬀect of intermediate glucose concentrations and of 0.25 mM palmitate,
cells were seeded on 24 wells and insulin secretion was measured in a 1 h period and expressed
as a percentage of the content. Results are the meansS.E.M. for three experiments performed
in triplicate. *P 0.05 compared with AdCA-LacZ ; §P 0.05 compared with 15 mM glucose.
The overexpression ofCPT I in INS1E cells increased palmitate
oxidation at low (1.7-fold) and high (3.1-fold) glucose concentra-
tions (P 0.01). An increase in palmitate oxidation at high
glucose was also described for INS1 and INS1-derived (83213)
β-cells overexpressing malonyl-CoA decarboxylase, the enzyme
which eliminates malonyl-CoA, the CPT I physiological inhibitor
[34,35]. Nevertheless the increase in fatty acid oxidation at low
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Figure 4 Glucose-induced ATP generation
Cytosolic ATP levels were measured in INS1E cells overexpressing LacZ or CPT I, preincubated
for 30 min without glucose and exposed to 2.5 and 15 mM glucose for 10 min. Results
represent the meansS.E.M. *P 0.05 compared with 2.5 mM glucose ; §P 0.05 AdCA-
CPT I compared with AdCA-LacZ.
glucose concentration was not observed by these authors, since
at low glucose the malonyl-CoA levels are low.
The stimulatory glucose concentration was more eﬀective in
suppressing fatty acid oxidation in control cells (20% residual
palmitate oxidation) than in CPT I-overexpressing cells, which
showed a 40% residual palmitate oxidation after the switch from
low glucose to high glucose.
Control and CPT I-overexpressing INS1E cells treated with
etomoxir showed a lower fatty acid oxidation rate, as expected
from its capacity to inhibit CPT I irreversibly. The presence of
etomoxir decreased the high oxidation rate in CPT I-overexpress-
ing cells from 0.4 to 0.17 nmolh per mg of protein (P 0.05).
The fatty acid oxidation rate in etomoxir-treated CPT I-over-
expressing cells was similar to the control cells without etomoxir
and high concentrations of glucose (0.176 compared with 0.128).
This indicates that the treatment with etomoxir reversed the
eﬀect of CPT I overexpression.
Effect of CPT I overexpression on INS1E insulin secretion
Having established that AdCA-CPT I increases the rate of fatty
acid oxidation in all the conditions studied we evaluated the
eﬀect of CPT I on insulin secretion. INS1E cells were maintained
in culture for 2 days, infected with AdCA-LacZ and AdCA-CPT
I and cultured for 20 h prior to the experiments. For insulin
secretion experiments, cells were preincubated for 30 min in
solution Bwith or without 200 µMetomoxir. After this treatment
cells were washed to eliminate etomoxir, and insulin secretion
was determined for 30 min with KRBH plus 2.5 mM glucose and
15 mM glucose.
In INS1E cells treated with the control virus AdCA-LacZ,
15 mM glucose caused an 8-fold increase in insulin secretion
relative to secretion at 2.5 mM glucose, while cells treated with
AdCA-CPT I exhibited only a 3.5-fold increase, indicating that
the increase in lipid metabolism caused by the overexpression of
CPT I aﬀects GSIS (Figure 3A). In these conditions insulin
secretion was reduced by 40% (P 0.01) in overexpressed CPT
I cells in relation to control cells.
Control cells treated with 200 µM etomoxir gave the same
response to glucose as non-treated control cells (8.5-fold com-
pared with 8-fold) (Figure 3A). Moreover, AdCA-CPT I-infected
cells pre-treated with etomoxir showed a signiﬁcantly higher
increase in insulin secretion (5.5-fold compared with 3.5-fold,
P 0.05). The treatment of the AdCA-CPT I-infected cells with
etomoxir suggests a speciﬁc eﬀect of CPT I on insulin secretion,
since etomoxir partially restores the normal insulin secretion in
these cells. Insulin secretion was also stimulated at basal 2.5 mM
glucose with 30 mM KCl, as a Ca+-raising agent. As shown in
Figure 3(B), the eﬀects of 30 mM KCl on insulin exocytosis were
similar in control cells and cells overexpressing CPT I. These
results distinguish between the K+–Ca+ axis and the anaplerotic
eﬀects of glucose and fatty acid oxidation.
To test the eﬀect of intermediate glucose concentrations and
long-chain fatty acids in insulin secretion in INS1E cells, insulin
secretion was performed over a 1 h period in infected INS1E cells
seeded in 24 wells. In control cells (AdCA-LacZ-infected), raising
glucose concentrations from a basal concentration of 2.5 mM to
7.5 and 15 mM stimulated insulin secretion 2.8-fold (P 0.05)
and 5.4-fold (P 0.01) respectively (Figure 3C). Insulin release
at basal (2.5 mM) or intermediate (7.5 mM) glucose concen-
trationwas not aﬀected in cells overexpressing CPT I. In contrast,
insulin secretion stimulated by 15 mM glucose (3-fold versus
basal glucose, P 0.05) was inhibited by 27% (P 0.05)
compared with the corresponding control at high glucose. In the
same experiments palmitate potentiated GSIS in control and
CPT I-overexpressing cells (9.3 compared with 6.1 in control
cells, and 9.3 compared with 4.5 in CPT I-overexpressing cells)
(Figure 3C), emphasizing the role of fatty acids in the signal
transduction of insulin secretion.
Effect of CPT I overexpression on glucose-induced ATP
generation and ATP levels
Incubation of INS1E cells with glucose stimulated the synthesis
of ATP by activation of the electron transport chain. The
levels of ATPmg of protein were measured following a 10 min
incubation period, at low and high glucose. ATP levels at 15 mM
glucose compared with 2.5 mM glucose were elevated by 23.1%
(36749 compared with 29842 respectively) in AdCA-LacZ
control cells and by 23.3% (481101 compared with 39066
respectively) (P 0.05) in AdCA-CPT I cells (Figure 4). There-
fore CPT I overexpression did not modify the glucose-induced
ATP increase. However, there was a 31% elevation in ATP levels
in CPT I- versus Lac Z-overexpressing cells (P 0.05) at low and
high glucose concentrations.
Effect of CPT I expression on glucose utilization
To investigate whether the impaired GSIS in INS1E cells
overexpressing CPT I could be due to a decrease in glucose
utilization in INS1E cells we measured the release of CO

at the
same glucose concentrations used for the insulin secretion
experiments in INS1E cells overexpressing LacZ or CPT I
and using [U-C]glucose. The use of [U-C]glucose allows
the measurement of the CO

released not only at the steps in the
tricarboxylic acid cycle but at the pyruvate dehydrogenase step.
The release of CO

was determined for 1 h in the presence of
2.5 and 15 mM glucose after a 30 min preincubation with or
without 200 µM etomoxir. The presence of a stimulatory glucose
concentration increased the rate of CO

release from 2.5 to
15 mM glucose by 5.2-fold both in cells overexpressing LacZ and
in cells overexpressing CPT I (Figure 5). The treatment of the
cells with etomoxir did not change the CO

formation from
glucose in either LacZ- or CPT I- overexpressing cells. This result
shows that, in the absence of external fatty acids, there is no
diﬀerence in the rate of glucose utilization between control and
CPT I-overexpressing cells. Etomoxir had no eﬀect on glucose
utilization in either control or CPT I-overexpressing cells. This
result suggests that the mechanism by which the overexpression
of CPT I decreases GSIS in INS1E cells is not a decrease in
glucose oxidation. Glucose oxidation was determined in LacZ-
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Figure 5 Glucose oxidation in INS1E infected cells
[U-14C]Glucose oxidation was measured in INS1E cells overexpressing LacZ or CPT I. After a
30 min preincubation in KRBH solution without glucose and with or without 200 µM etomoxir,
cells were washed and resuspended in KRBH with [U-14C]glucose at the indicated concentrations
for 1 h and the CO2 released was measured as described in the Materials and methods section.
Data are the meansS.E.M. for three independent experiments performed in triplicate and are
expressed as nmol of oxidized glucose/h per mg of protein.
and CPT I-overexpressing cells and the eﬀect of 0.25 mM
palmitate was tested. The addition of 0.25 mM palmitate had no
signiﬁcant eﬀect on glucose oxidation in control or CPTI-
overexpressing cells over a 1 h period (results not shown).
Comparison of Figures 2 and 5 shows that at high glucose
concentration, glucose oxidation in INS1E cells is much higher
(32 times) than fatty acid oxidation, these results agreeing with
those described in INS1 cells [1] and in islets [36,37] ; therefore it
appears unlikely that accelerated fatty acid oxidation inﬂuences
glucose metabolism.
Effect of CPT I overexpression on triacylglycerol levels
It has been shown that a depletion of β-cell lipids, measured as
triacylglycerols [5], blocks insulin secretion in response to glucose
and other secretagogues, and that perifusion with a mixture of
fatty acids restored insulin responses to supranormal levels. To
address the question of whether the impaired insulin response
to glucose seen in INS1E cells overexpressing CPT I was due to a
decrease in triacylglycerol levels, we measured triacylglycerol
content in INS1E cells infected with either the control virus
AdCA-LacZ or AdCA-CPT I. The cells were infected and 20 h
later incubated in KRBH without glucose for 30 min as pre-
viously described. After this incubation cells were washed and
collected for the triacylglycerol measurement. The triacylglycerol
content was not signiﬁcantly diﬀerent between LacZ- and CPT I-
overexpressing cells (14.81.2 compared with 13.61.3 ng of
triacylglycerolsmg of protein). Thus a decrease in triacylgly-
cerols does not seem to account for the lower insulin secretion
at stimulatory glucose concentrations seen in CPT I-overexpress-
ing cells.
DISCUSSION
Many studies implicate NEFAs in type II diabetes [2,38,39].
Long term exposure of β-cells to NEFAs in itro has several
eﬀects : (1) it increases basal insulin release and strongly decreases
secretion in response to glucose [2] ; (2) it alters the coupling of
glucose metabolism to insulin secretion by acting on the ex-
pression of speciﬁc genes, such as that for UCP2 [21,22] ; and (3)
it increases the expression of CPT I, which is considered to be the
rate-limiting step in fatty acid oxidation [1]. CPT I up-regulation
may contribute to the change in insulin secretion. The aim of the
present study was to evaluate the capacity of CPT I overexpres-
sion to alter the insulin response to glucose in β-cells. In view of
the interest in the LC-CoA model of GSIS, which is still under
discussion [40], we examined this eﬀect in a β-cell-derived cell
line, which is more sensitive at physiological glucose concentra-
tions than the parenteral INS1 cell line.
Recent advances in adenoviral vector technology have facilitat-
ed the transfer of multiple foreign genes into well-diﬀerentiated
cell lines. The chicken actin promoter [25,41] allows the use of
low adenoviral infection titres, with high levels of protein
expression. The rat liver CPT I is the only isoform present in both
the β-cell and INS1E cells. Therefore, since the muscle CPT I
isoform has diﬀerent malonyl-CoA inhibition properties, we used
the rat liver isoform to construct the adenovirus.
The overexpression of CPT I increased fatty acid oxidation
rates in the INS1E cells, as expected. However, the percentage
increase in ATP (23%) in CPT I-overexpressing cells and in
controls was identical when glucose was increased from 2.5 to
15 mM, showing that CPT I overexpression had no eﬀect on the
electron transport chain. Stimulation of fatty acid oxidation by
CPT I was higher than that induced by malonyl-CoA decarboxy-
lase or acetyl-CoA carboxylase [18,34]. These enzymes modulate
CPT I activity indirectly through changes in malonyl-CoA,
whereas CPT I controls the fatty acid oxidation ﬂux directly.
Interestingly, the overexpression of CPT I increased the rate of
fatty acid oxidation not only at high glucose, but also at low
glucose concentrations. INS1E cells overexpressing CPT I se-
creted less insulin in response to high glucose concentration, but
not in response to intermediate glucose concentrations or non-
nutrient secretagogues, such as KCl. Thus exocytosis was pre-
served, since the eﬀect of the cytosolic [Ca+]-raising agent
(30 mM KCl) was not altered by CPT I overexpression. The
increase in fatty acid oxidation may be responsible for the change
in the insulin response. This indicates that lipid homoeostasis is
necessary for the correct insulin response to glucose.
The speciﬁcity of the CPT I eﬀect on insulin secretion was
tested by the use of etomoxir, an irreversible inhibitor of CPT I
activity. Etomoxir reversed the CPT I eﬀect on fatty acid
oxidation and insulin secretion, which indicates that the eﬀect on
insulin response is due to the increase in fatty acid oxidation [42].
Only preincubation of the INS1E cells with 200 µM etomoxir
abolished the higher CPT I activity after infection with AdCA-
CPT I (Figure 1B). To avoid any non-speciﬁc eﬀect on the
secretory machinery, etomoxir was eliminated after the preincu-
bation and the cells were washed prior to the experiments. Under
these conditions we consider that the only eﬀect of etomoxir was
the inhibition of CPT I through direct and irreversible covalent
binding of CPT I and not as a fatty acid analogue. Under these
conditions our control INS1E cells did not show any enhance-
ment of GSIS, in contrast with what has been shown previously
[19]. In the work of Chen et al. [19], 200 µM etomoxir, added
with the glucose in rat perfusion experiments stimulated GSIS.
This discrepancy could be explained by the presence of etomoxir
throughout all the secretion experiments. Palmitate, which poten-
tiates insulin secretion in HIT cells [6] and islets [43], increased
insulin secretion to the same extent in control and CPT I-
overexpressing INS1E cells. This could indicate the mechanism
by which CPT I diminishes insulin secretion, that is, the depletion
of a critical lipid which could act as a signal molecule. In fact,
palmitate has been shown to increase the long chain acyl-CoA
ester content in HIT cells [6].
Some authors did not ﬁnd a correlation of cell malonyl-CoA
levels with insulin secretion since the reduction of malonyl-
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CoA levels by overexpression of malonyl-CoA decarboxylase in
an INS1 cell-derived clone had no eﬀect on insulin secretion [34,
35]. However, malonyl-CoA depletion incompletely reverses the
glucose-induced suppression of fatty acid oxidation. The authors
attribute this to the regulation of CPT I activity by factors
derived from glucose metabolism other than malonyl-CoA in the
β-cell [35]. Interestingly, a regulation of CPT I that is independent
of malonyl-CoA has been demonstrated in rat hepatocytes [44].
Another explanation for this lack of correlation betweenmalonyl-
CoA levels and fatty acid oxidation could be the presence of
diﬀerent pools of malonyl-CoA in the cell. There are two acetyl-
CoA carboxylases, one in the cytosol the other in the mito-
chondria, the latter directly modulating the malonyl-CoA levels
accessible to CPT I [45].
INS1 cells overexpressing CPT I show higher rates of palmitate
oxidation at low and high glucose concentrations (Figure 2) than
control cells, yet the rates of glucose oxidation were nearly
identical in the CPT I-non-expressing and expressing cells. This
would mean that the excess of CPT I activity would increase fatty
acid oxidation, without aﬀecting the oxidation of glucose. This
excess of fatty acid oxidation under CPT I overexpression would
explain the 31% increase in ATP generation observed in these
cells, which therefore would be exclusively produced by the over-
activity of CPT I under the conditions of the assay. The increased
CPT I, in addition, slightly decreased the triacylglycerol content,
indicating that the pool of fatty acyl-CoA present in the cell was
responsible for generation of ATP, without the need to hydrolyse
triacylglycerols.
In conclusion, the present study shows that the overexpression
of CPT I increases the fatty acid oxidation rate at high and low
glucose concentrations. The increase in fatty acid oxidation
aﬀected insulin response to high glucose but not to intermediate
glucose concentrations and non-metabolizable secretagogues,
like KCl, while other cell parameters remained unchanged. The
eﬀect of CPT I was reverted by the use of etomoxir and by
the exogenous addition of fatty acids. These results show that
CPT I activity regulates insulin secretion, probably allowing a cer-
tain level of fatty acids to be available for exocytosis of insulin
[46]. These results also favour the hypothesis that up-regulation
of CPT I [1] contributes to the early loss of glucose responsiveness
seen in β-cells chronically exposed to high concentrations of fatty
acids.
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Accumulation of lipids in non-adipose tissues is often
associated with Type 2 diabetes and its complications.
Elevated expression of the lipogenic transcription fac-
tor, sterol regulatory element binding protein-1c
(SREBP-1c), has been demonstrated in islets and liver of
diabetic animals. To elucidate the molecular mecha-
nisms underlying SREBP-1c-induced -cell dysfunction,
we employed the Tet-On inducible system to achieve
tightly controlled and conditional expression of the nu-
clear active form of SREBP-1c (naSREBP-1c) in INS-1
cells. Controlled expression of naSREBP-1c induced
massive accumulation of lipid droplets and blunted nu-
trient-stimulated insulin secretion in INS-1 cells. K-
evoked insulin exocytosis was unaltered. Quantification
of the gene expression profile in this INS-1 stable clone
revealed that naSREBP-1c induced -cell dysfunction
by targeting multiple genes dedicated to carbohydrate
metabolism, lipid biosynthesis, cell growth, and apopto-
sis. naSREBP-1c elicits cell growth-arrest and eventu-
ally apoptosis. We also found that the SREBP-1c proc-
essing in -cells was irresponsive to acute stimulation of
glucose and insulin, which was distinct from that in
lipogenic tissues. However, 2-day exposure to these
agents promoted SREBP-1c processing. Therefore, the
SREBP-1c maturation could be implicated in the patho-
genesis of -cell glucolipotoxicity.
The lipogenic transcription factors, sterol regulatory element
binding proteins (SREBPs)1 are transmembrane proteins of the
endoplasmic reticulum (ER). In response to low sterol and
other unidentified factors, SREBP cleavage-activating protein
escorts SREBPs from the ER to the Golgi, where SREBPs are
sequentially cleaved by Site-1 protease and Site-2 protease.
The processed mature SREBPs enter the nucleus and transac-
tivate target genes (1). Three SREBP isoforms have been iden-
tified: SREBP-1a and -1c (alternatively known as adipocyte
determination and differentiation factor-1 (ADD1)) (2), which
are derived from the same gene through alternative splicing,
and SREBP-2, which is encoded by a distinct gene (1). SREBPs
play an essential role in regulation of lipid homeostasis in
animals and have been shown to directly activate the expres-
sion of more than 30 genes dedicated to the biosynthesis of
cholesterol, fatty acids, triglycerides, and phospholipids (3).
SREBP-1 preferentially regulates genes implicated in fatty
acid synthesis, whereas SREBP-2 preferentially activates
genes involved in cholesterol synthesis (1). In particular,
SREBP-1c mediates insulin effects on lipogenic gene expres-
sion in both adipocytes and liver (4, 5).
Type 2 diabetes mellitus is a common disorder that affects
5% of the population worldwide, especially in industrialized
countries (6). Affected patients are usually obese with accumu-
lation of lipids in non-adipose tissues such as the pancreatic
islets, liver, heart, skeletal muscle, and blood vessels (7–9).
This is associated with impaired glucose-stimulated insulin
secretion, increased hepatic glucose production, peripheral in-
sulin resistance, and late complications in various organs (10,
11). The ultimate precipitating process responsible for the de-
velopment of Type 2 diabetes is the failure of the pancreatic
-cells to compensate for insulin resistance (7, 10, 11). How-
ever, the mechanism by which the -cells become unable to
meet increased insulin demands remains to be established.
Elevated expression of SREBP-1c has been demonstrated in
islets or liver of diabetic animals, such as Zucker diabetic fatty
rats, ob/ob mice, insulin receptor substrate-2-deficient mice,
and a transgenic mouse model of lipodystrophy (7, 12–16). On
the other hand, preventing SREBP-1c overexpression is a com-
mon function of leptin, metformin, and PPAR agonists, which
is well correlated with their antidiabetic effects (7, 12–15). An
important function of leptin in the regulation of fatty acid
homeostasis is to restrict the lipid storage in adipocytes and to
limit lipid accumulation in non-adipocytes, thereby protecting
them from lipotoxicity (7, 9). Infusion of recombinant leptin
reverses insulin resistance and hyperglycemia in the trans-
genic model of congenital generalized lipodystrophy and in
ob/ob mice (13). Adenovirus-mediated hyperleptinemia also de-
creases the expression of SREBP-1c and lipogenic genes in liver
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and islets of wild-type fa/fa rats (12). Leptin also prevents the
SREBP-1c overexpression in insulin receptor substrate (IRS)-
2-null mice (15). It is noteworthy that metformin, an oral an-
tihyperglycemic agent, also corrects fatty liver disease in ob/ob
mice by inhibition of obesity-related induction of SREBP-1c
(14). The inhibitory effects of metformin on hepatic SREBP-1c
expression involves activation of AMP-activated protein kinase
(17). Similarly, Troglitazone, an antidiabetic agent and a high-
affinity ligand for the PPAR, prevents SREBP-1c overexpres-
sion in Zucker diabetic fatty rats (12). In addition, it has re-
cently been reported that adenovirus-mediated overexpression
of SREBP-1c in MIN6 cells results in impaired glucose-stimu-
lated insulin secretion (18). Therefore, these studies suggest
that overexpression of SREBP-1c may be the cause of both liver
steatosis and islet -cell dysfunction.
The present study was designed to evaluate the direct cor-
relation between SREBP-1c overexpression and -cell dysfunc-
tion and to elucidate the underlying molecular mechanism. The
Tet-On system was employed in INS-1 cells to achieve tightly
controlled and inducible expression of a nuclear active form of
SREBP-1c (naSREBP-1c; N-terminal 1–403 amino acids) (19).
Quantification of the gene expression profile in this INS-1
stable cell line revealed that naSREBP-1c induced -cell dys-
function by targeting multiple genes implicated in carbohy-
drate metabolism, lipid biosynthesis, cell growth, and eventu-
ally apoptosis.
EXPERIMENTAL PROCEDURES
Establishment of INS-1 Cells Permitting Inducible Expression of
naSREBP-1c—Rat insulinoma INS-1 cell-derived clones were cultured
in RPMI 1640 containing 11.2 mM glucose (20), unless otherwise indi-
cated. The first step stable clone INS-r cell line, which carries the
reverse tetracycline/doxycycline-dependent transactivator (21) was de-
scribed previously (22, 23). The plasmid used in the secondary stable
transfection were constructed by subcloning the cDNA encoding the
nuclear active form of SREBP-1c (naSREBP-1c/ADD1-(1–403) (19),
kindly supplied by Dr. B. M. Spiegelman) into the expression vector
PUHD10–3 (21) (a generous gift from Dr. H. Bujard). The procedures
for stable transfection, clone selection and screening were described
previously (22).
Immunofluorescence and Western Blotting—For immunofluores-
cence, cells grown on polyornithine-treated glass coverslips were
treated for 24 h with or without 500 ng/ml doxycycline. Cells were then
washed, fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton
X-100 in phosphate-buffered saline containing 1% BSA (PBS-BSA). The
preparation was then blocked with PBS-BSA before incubating with the
first antibody, anti-SREBP-1 (Santa Cruz, Basel, Switzerland) (1:100
dilution), followed by the second antibody labeling.
For Western blotting cells were cultured with 0, 75, 150, and 500
ng/ml doxycycline for 24 h. Rat islets were isolated by collagenase
digestion as described (24), and their nuclear proteins were extracted as
previously reported (25). Total cell proteins were prepared by lysis and
sonication of naSREBP-1c#233 and INS-1E cells in buffer containing 20
mM Tris-HCl, pH 7.4, 2 mM EDTA, 2 mM EGTA, 1% Triton X-100, and
1 mM phenylmethylsulfonyl fluoride. Nuclear extracts and total cellular
proteins were fractionated by 9% SDS-PAGE. The dilution for SREBP-1
antibody is 1:1,000. Immunoblotting procedures were performed as
described previously (26) using enhanced chemiluminescence (Pierce)
for detection.
Staining of Lipid Accumulation by Oil Red O and Measurements of
Triglyceride Content—Cells were cultured with 0, 75, 150, and 500
ng/ml doxycycline for 24 h. Cells were fixed and stained as previously
reported (19). Lipid droplets were visualized using phase-contrast mi-
croscopy (Nikon Diaphot). Cellular triglyceride content was determined
using Triglyceride (GPO-TRINDER) kit (Sigma) according to the man-
ufacturer’s protocol.
Measurements of Insulin Secretion and Cellular Insulin Content—
Insulin secretion in naSREBP-1c#233 cells was measured in 12-well
plates over a period of 30 min, in Krebs-Ringer-bicarbonate-HEPES
buffer (KRBH, 140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.5 mM
MgSO4, 1.5 mM CaCl2, 2 mM NaHCO3, 10 mM HEPES, 0.1% BSA)
containing indicated concentrations of glucose. Insulin content was
determined after extraction with acid ethanol following the procedures
of Wang et al. (26). Insulin was detected by radioimmunoassay using rat
insulin as a standard (26).
Total RNA Isolation and Northern Blotting—Cells were cultured
with or without 500 ng/ml doxycycline in 2.5 mM glucose medium for
16 h and then incubated for a further 8 h at 2.5, 6, 12, and 24 mM
glucose concentrations. Alternatively, naSREBP-1c#233 cells were cul-
tured with or without 75 ng/ml doxycycline in standard medium (11.2
mM glucose) for 0, 24, 48, and 96 h. Total RNAwas extracted and blotted
to nylon membranes as described previously (22). The membrane was
prehybridized and then hybridized to 32P-labeled random primer cDNA
probes according to Wang and Iynedijian (22). To ensure equal RNA
loading and even transfer, all membranes were stripped and re-hybrid-
ized with a “housekeeping gene” probe cyclophilin. cDNA fragments
used as probes for SREBP-1c, hepatocyte nuclear factor (HNF)-1,
HNF-4, glucokinase, Glut-2, insulin, Sur1, Kir6.2, and pancreas duo-
denum homeobox (Pdx-1) mRNA detection were digested from the cor-
responding plasmids. cDNA probes for rat islet amyloid polypeptide,
Nkx6.1, adenine nucleotide translocator 1 and 2, mitochondrial uncou-
pling protein 2 (UCP2), mitochondrial glutamate dehydrogenase, cit-
rate synthase, glyceraldehydes-3 phosphate dehydrogenase, fatty acid
synthase, acetyl-CoA carboxylase, glycerol-phosphate acyltransferase,
carnitine palmitoyltransferase-1, acyl-CoA oxidase, 3-hydroxy-3-meth-
ylglutaryl-CoA reductase, P21WAF1/CIP1, P27KIP1, Bax, Bad, APO-1,
Cdk-4, IRS-2, and glucagon-like peptide-1 receptor were prepared by
reverse transcription-PCR and confirmed by sequencing.
Mitochondrial Membrane Potential (m)—Cells seeded in 24-well
plates were cultured with or without 500 ng/ml doxycycline in 11.2 mM
glucose medium for 24, 48, and 96 h (day 1, day 2, and day 4, respec-
tively). Cells were then maintained for 2 h in 2.5 mM glucose medium at
37 °C before loading with 10 g/ml rhodamine-123 for 20 min at 37 °C
in KRBH (28). The m was monitored in a plate-reader fluorimeter
(Fluostar Optima, BMG Labtechnologies, Offenburg, Germany) with
excitation and emission filters set at 485 and 520 nm, respectively, at
37 °C with automated injectors for glucose (addition of 13 mM on top of
basal 2.5 mM) and carbonyl cyanide 4-trifluoromethoxyphenylhydra-
zone (FCCP).
Cell Proliferation/Viability and Apoptosis—Quantification of cell pro-
liferation/viability was measured by a Quick Cell Proliferation Assay
Kit (LabForce/MBL, Nunningen, Switzerland) according to the manu-
facturer’s protocol. This assay is based on the reduction of a tetrazolium
salt WST-1 to formazan by cellular mitochondrial dehydrogenases.
Expansion in the number of viable cells results in an increase in the
overall activity of the mitochondrial dehydrogenases and subsequently
an augmentation in the amount of formazan dye formed. The formazan
dye produced by viable cells was quantified with a multiwell spectro-
photometer by measuring the absorbance at 440 nm.
Experiments for DNA fragmentation were performed using a Quick
Apoptosis DNA Ladder Detection Kit (LabForce/MBL) following the
manufacturer’s protocol. Detection of mitochondrial cytochrome c re-
lease into cytosol was performed as described previously (29). Briefly,
cells in 15-cm dishes were harvested and suspended in Buffer A (20 mM
HEPES-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 1 mM dithiothreitol, 250 mM sucrose, 1 mM phenylmethylsulfo-
nyl fluoride) and homogenized by a Dounce homogenizer. Cell debris
and nuclei were removed by centrifugation at 1000  g for 10 min at
4 °C. The supernatant was further centrifuged at 10,000 g for 20 min.
The cytosolic proteins (supernatant fractions) were separated by 15%
SDS-PAGE and analyzed by Western blotting with a specific antibody
against cytochrome c (LabForce/MBL).
RESULTS
Establishment of a Stable INS-1 Cell Line Permitting Induc-
ible Expression of naSREBP-1c—A rat insulinoma INS-1-de-
rived stable cell line, INSr (23), which expresses the reverse
tetracycline-dependent activator (21), was used for the second-
ary stable transfection with an expression vector, PUHD10–3
(21), carrying the naSREBP-1c and a plasmid pTKhygro con-
taining the hygromycin-resistant marker. Five-round stable
transfection experiments were performed, and a total of 400
hygromycin-resistant clones were screened by Northern blot-
ting for clones positively expressing naSREBP-1c after doxycy-
cline induction. Our persistent effort was rewarded. Only one
clone, termed naSREBP-1c#233, which actually represented
undetectable background expression under non-induced condi-
tions, showed remarkable expression of naSREBP-1c mRNA
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after doxycycline induction. From experience, we would have
anticipated that 10–20% of hygromycin-resistant clones should
positively express the transgene. The unexpected results indi-
cate that expression of naSREBP-1c even at leakage level was
sufficient to cause “-cell toxicity.” The INS-1 stable cell line
naSREBP-1c#233 provided a unique chance to study the impact
of naSREBP-1c expression on -cell function.
All Cells Uniformly Express the Nuclear Localized
naSREBP1c Protein in a Doxycycline Dose-dependent Man-
ner—Immunofluorescence (Fig. 1A) with an antibody against
the N terminus of SREBP1c illustrated that nuclear localized
naSREBP1c protein was induced homogeneously in naSREBP-
1c#233 cells cultured with 500 ng/ml doxycycline for 24 h.
Western blotting (Fig. 1B) with the same antibody demon-
strated that naSREBP-1c#233 cells expressed the transgene-
encoded protein in a doxycycline dose-dependent manner. As
predicted, naSREBP-1c#233 cells did not show detectable ex-
pression of naSREBP-1c protein under non-induced conditions
(Fig. 1). The protein levels of naSREBP-1c in cells cultured
with 75, 150, and 500 ng/ml were 10%, 25%, and 150%,
respectively, of endogenous level of SREBP-1c precursor pro-
tein (Fig. 1B).
Induction of naSREBP-1c Causes Rapid Accumulation of
Lipid Droplets by Increasing Lipogenic Gene Expression—Oil
Red O staining showed that induction of naSREBP-1c with 75,
150, and 500 ng/ml doxycycline for 24 h resulted in accumula-
tion of lipid droplets in INS-1 cells cultured in standard me-
dium (10% fetal calf serum) (Fig. 2A). Cellular triglyceride
content was increased by 39% (Dox: 0.536  0.08; Dox:
0.745  0.10 mg/mg protein, p  0.001, n  14) after 24 h of
induction with 500 ng/ml doxycycline. Similar results were
obtained in cells cultured in serum-free medium (data not
shown), suggesting that the naSREBP-1c-induced lipid accu-
mulation was not due to uptake of fatty acids by the cells. This
contention was supported by results of quantitative Northern
blotting. Induction of naSREBP-1c significantly increased the
FIG. 1. Induction of naSREBP-1c protein in a dose-dependent
and an all-or-none manner. A, immunofluorescence staining with an
antibody against the N terminus of SREBP-1c. The phase contrast
image is shown in the upper panel. The naSREBP-1c#233 cells were
cultured with (Dox) or without (Dox) 500 ng/ml doxycycline for 24 h.
B, Western blotting of total cell extracts (100 g) with the same anti-
body. Cells were cultured with 0, 75, 150, and 500 ng/ml doxycycline for
24 h.
FIG. 2. Accumulation of lipid droplets and increased lipogenic
gene expression are shown in INS-1 cells expressing naSREBP-
1c. A, Oil Red O staining naSREBP-1c#233 cells cultured with 0, 75,
150, and 500 ng/ml doxycycline for 24 h. B, Northern blotting was
performed using total RNA isolated from cells cultured with 500 ng/ml
doxycycline in 2.5 mM glucose medium for 16 h and continued in 2.5, 6,
12, and 24 mM glucose medium for a further 8 h. The experiments were
repeated two times with similar results. C, Northern blotting was
conducted using total RNA isolated from cells cultured in standard
glucose medium (11.2 mM glucose) with 75 ng/ml doxycycline for 0, 24,
48, and 96 h. Two independent experiments are shown side by side to
demonstrate the consistency of the results.
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expression of genes dedicated to biosynthesis of fatty acids and
cholesterol but did not alter the expression of genes involved in
-oxidation of fatty acids (Fig. 2, B and C). The increased
mRNA levels of fatty acid synthase, acetyl-CoA carboxylase,
glycerol-phosphate acyltransferase, and 3-hydroxy-3-methyl-
glutaryl-CoA reductase would explain the naSREBP-1c-in-
duced lipid accumulation. In addition, the increased lipogene-
sis did not raise the transcript levels of carnitine
palmitoyltransferase-1 and acyl-CoA oxidase, which are impor-
tant for fatty acid metabolism.
Induction of naSREBP-1c Impairs Nutrient-stimulated Insu-
lin Secretion—Induction of naSREBP1c with 500 ng/ml doxy-
cycline for 24 h (Fig. 3A) or 75 ng/ml doxycycline for 96 h (Fig.
3B) caused blunted glucose- and leucine-stimulated but not
K-depolarization-induced insulin secretion. Glucose gener-
ates ATP and other metabolic-coupling factors important for
insulin exocytosis through glycolysis and mitochondrial oxida-
tion (30). Leucine stimulates insulin release through direct
uptake and metabolism by the mitochondria, thereby providing
substrates for the tricarboxylic acid cycle (30). K causes insu-
lin secretion by depolarization of the -cell membrane, result-
ing in increased cytosolic Ca2 (30). To explore the molecular
targets of naSREBP-1c responsible for the impaired metabo-
lism-secretion coupling, we examined the gene expression pro-
file in naSREBP-1c#233 cells.
Induction of naSREBP-1c Alters the Expression of Genes
Important for Glucose Metabolism and -Cell Function—Quan-
titative Northern blotting revealed that similar induction of
naSREBP1c also caused marked down-regulation of glucoki-
nase and Glut2 but up-regulation of mitochondrial UCP-2 (Fig.
4, A and B). In contrast, naSREBP-1c did not alter the mRNA
levels of glyceraldehydes-3-phosphate dehydrogenase, mito-
chondrial adenine nucleotide translocator-1 and -2, glutamate
dehydrogenase, citrate synthase, KATP channel subunits SUR1
and KIR6.2 (Fig. 4, A and B). Glucokinase is the rate-limiting
enzyme for glycolysis and thereby determines -cell glucose
sensing (22, 31). The effect of naSEBP-1c on -glucokinase
expression is opposite to its action on liver glucokinase, which
is transcribed from a distinct liver-specific promoter (5, 32).
UCP-2 may act as a protonophore and dissipate the mitochon-
drial membrane potential, thereby uncoupling respiration from
ATP synthesis (33–36).
Induction of naSREBP1c also suppressed the expression of
Pdx-1, HNF-4, and CCAAT/enhancer-binding protein- in a
dose- and time-dependent manner (Fig. 4, C and D). The
HNF-1 expression was unaffected, whereas the mRNA level of
a -cell transcription factor Nkx6.1 was increased by naS-
REBP-1c (Fig. 4, C andD). High-level induction of naSREBP-1c
also decreased the transcript levels of insulin and islet amyloid
polypeptide (Fig. 4C).
Induction of naSREBP-1c Disrupts Mitochondrial Mem-
brane Potential—Mitochondrial membrane potential (m), re-
flecting electron transport chain activity, was measured in
attached cells by monitoring rhodamine-123 fluorescence. In
non-induced control cells, the addition of 13 mM glucose (15.5
mM final) hyperpolarized m and 1 M the protonophore FCCP
deploarized m. After induction of naSREBP1c, glucose-in-
duced mitochondrial hyperpolarization was markedly inhibited
as early as day 1 (24 h of induction) and completely abolished
at days 2 and 4 (Fig. 5). Basal activity of the electron transport
chain was progressively lost, as indicated by the dissipation of
m by FCCP, and completely abrogated at day 4 (Fig. 5). The
mitochondrion is not only the powerhouse for cell growth and
survival but also the arsenal for cell apoptosis (37). Disruption
of mitochondrial membrane potential is an essential event that
commits a cell to undergo apoptosis (38, 39). Consistently, we
also found that expression of naSREBP-1c even at leakage level
was sufficient to cause “cell toxicity” during the screening pro-
cedure for naSREBP-1c-positive clones. To elucidate the molec-
ular mechanism underlying naSREBP-1c-induced cell toxicity,
we investigated the effect of naSREBP-1c on the expression of
genes important for cell proliferation and apoptosis.
SREBP-1c Targets Multiple Genes Implicated in -Cell
Growth and Survival—As shown in Fig. 6, induction of naS-
REBP-1c decreased the expression of cyclin-dependent kinase 4
and IRS-2 in a dose- and time-dependent manner. In contrast,
the mRNA level of glucagon-like polypeptide-1 receptor was
barely changed (Fig. 6). Both cyclin-dependent kinase 4 and
IRS-2 have been reported to promote -cell development, pro-
liferation, or survival (40, 41). In addition, the mRNA level of
P21WAF1/CIP1 was dramatically increased by naSREBP-1c in-
duction, whereas the P27KIP1 remained constant (Fig. 6). The
increased expression of the P21WAF1/CIP1, a cyclin-dependent
kinase inhibitor, could also lead to INS-1 cell growth arrest.
Furthermore, as demonstrated in Fig. 6, naSREBP-1c up-reg-
FIG. 3. Induction of naSREBP-1c results in impaired nutrient-
stimulated insulin secretion. A, cells were cultured with (Dox) or
without (Dox) 500 ng/ml doxycycline in standard medium (11.2 mM
glucose) for 19 h and then equilibrated in 2.5 mM glucose medium for a
further 5 h. B, cells were cultured with (Dox) or without (Dox) 75
ng/ml doxycycline in standard glucose medium (11.2 mM) for 91 h
followed by an additional 5 h of equilibration in 2.5 mM glucose medium.
Cellular insulin content in A and B was reduced, respectively, by 24.6
4.8 (n  6) and 21  5.3 (n  6) after naSREBP-1c induction. Insulin
release from naSREBP-1c#233 cells stimulated by 21.5 mM glucose, 20
mM leucine, and 20 mM KCl in KRBH buffer (140 mM NaCl, 3.6 mM KCl,
0.5 mM NaH2PO4, 0.5 mM MgSO4, 1.5 mM CaCl2, 2 mM NaHCO3, 10 mM
HEPES, 0.1% BSA) containing 2.5 mM glucose (Basal) was quantified
by radio-immunoassay and normalized by cellular insulin content. Data
represent mean  S.E. of six independent experiments. **, p  0.0001.
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ulated the expression of proapoptotic genes, APO-1/Fas/CD95
and Bax (37, 38), but did not alter the mRNA levels of Bad and
tumor necrosis factor (TNF)-1. The up-regulation of APO-1
and Bax could contribute to the naSREBP-1c-induced INS-1
cell apoptosis (see below).
Induction of naSREBP-1c Results in Cell Growth Arrest and
Apoptosis in INS-1 Cells—To assess the impact of naSREBP-1c
on INS-1 cell growth and viability, we performed the WST-1
assay. This assay is based on the reduction of a tetrazolium salt
WST-1 to formazan by cellular mitochondrial dehydrogenases.
Expansion in the number of viable cells results in an increase
in the overall activity of the mitochondrial dehydrogenases and
subsequently an augmentation in the amount of formazan dye
formed. Induction of naSREBP-1c with 500 ng/ml doxycycline
for 24 h or with 75 ng/ml doxycycline for 4 days in naSREBP-
1c#233 cells significantly inhibited INS-1 cell growth/viability.
The measurements of optical density at 440 nM were reduced
by, respectively, 31.6  4.2% and 36.3  5.5% relative to
non-induced cells (n  4, p  0.001). Mitochondrial cytochrome
c release and DNA fragmentation are characteristic hallmarks
FIG. 4. Induction of naSREBP-1c causes defective expression
of genes implicated in glucose metabolism and -cell function. A
and C, cells were cultured with or without 500 ng/ml doxycycline in 2.5
mM glucose medium for 16 h and then incubated for a further 8 h at
indicated glucose concentrations. The experiments were repeated two
times with similar results. B and D, cells were cultured with or without
75 ng/ml doxycycline in standard medium (11.2 mM glucose) for 0, 24,
48, and 96 h. Two independent experiments are shown side by side to
demonstrate the consistency of the results. The gene expression pat-
terns in naSREBP-1c#233 cells were quantified by Northern blotting.
Total RNA samples (20 g/lane) were analyzed by hybridizing with
indicated cDNA probes.
FIG. 5. Induction of naSREBP-1c dissipates mitochondrial
membrane potential (m) in naSREBP-1c
#233 cells. Cells were
cultured without (Dox) or with (Dox) 500 ng/ml doxycycline for 24,
48, and 96 h (day 1, day 2, and day 4, respectively). The m was
measured on attached cells in KRBH containing basal 2.5 mM glucose
using rhodamine-123 fluorescence. Electron transport chain activation
observed as hyperpolarization of m was induced by the addition of 13
mM glucose (15.5 mM final), followed by the complete depolarization of
m using 1 M of the uncoupler FCCP. Values are means plus stand-
ard deviations (n  4) of one of a total of four to six independent
experiments.
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of cells undergoing apoptosis (37, 42). Extensive DNA fragmen-
tation was observed in naSREBP-1c#233 cells cultured with
500 ng/ml doxycycline for 48 h or with 75 ng/ml doxycycline for
a week (Fig. 7A). Consistently, similar induction of na-
SREBP-1c also induced mitochondrial cytochrome c release
(Fig. 7B). These results suggest that naSREBP-1c induces
INS-1 cell apoptosis in a dose- and time-dependent manner.
SREBP-1c Processing in -Cells Is Distinct from Lipogenic
Tissues—Unlike liver and adipose tissue, pancreatic -cells
have evolved to secrete insulin rather than store energy in
response to rising blood glucose and nutrient levels. The re-
leased insulin subsequently promotes the lipogenic gene ex-
pression in liver and adipocytes through up-regulation of
SREBP-1 expression and increase of its processing (4, 5, 43).
The molecular mechanism by which -cells restrict lipogenesis
in response to physiological glucose and insulin stimulation
remains undefined. We performed Western blotting using an
antibody specific for the N terminus of SREBP-1, which should
recognize both precursor and mature SREBP-1. As shown in
Figure 7C, the mature nuclear form of SREBP-1 was not de-
tectable in nuclear extracts from freshly isolated rat islets.
Consistently, only the precursor but not the mature nuclear
form of SREBP-1 protein was detected in total cell extracts
from native INS-1E cells (Fig. 7C). Similar results were ob-
tained in INS-1E cells treated for 6 h with 30 mM glucose and
100 nM exogenous insulin (Fig. 7C).
Low sterol-mediated cleavage of SREBP precursor proteins
is not the only mechanism for the processing of SREBPs. It has
been suggested that insulin and cytokines stimulate phospho-
rylation and transcriptional activity of SREBPs via the mito-
gen-activated protein kinase cascade (44–48). Caspase-3/
CPP32, a cysteine protease and mediator of apoptosis, also
induces cleavage of SREBPs and release of their transactive
N-terminal fragments (42). In addition, TNF- stimulates the
maturation of SREBP-1c in human hepatocytes (49). Further-
more, hyperglycemia in animal models of diabetes causes in-
creased SREBP-1 maturation and renal lipid accumulation
leading to diabetic nephropathy (50). Moreover, ethanol, ER
stress, shear stress, and cytokines have been reported to up-
regulate the lipogenic gene expression in hepatocytes and/or
vascular endothelial cells by activation of SREBPs (14, 49,
51–54).
Hyperglycemia, hyperlipidemia, elevated TNF-, and in-
creased oxidative stress have been linked to -cell dysfunction
in Type 2 diabetes (9, 55–63). We therefore studied the
SREBP-1 maturation in native INS-1E cells, the most differ-
entiated INS-1 cell clone (64). The cells were exposed for 48 h to
30 mM glucose, 100 nM insulin, 1.5 mM long-chain free fatty
acids (2:1 oleate/palmitate), 10 ng/ml TNF-, and 10 M H2O2
(Fig. 7C). The mature nuclear form of SREBP-1 was detected in
FIG. 6. Induction of naSREBP-1c alters the expression of genes
important for -cell growth and survival. A, cells were cultured
with or without 500 ng/ml doxycycline in 2.5 mM glucose medium for
16 h and then incubated for a further 8 h at indicated glucose concen-
trations. The experiments were repeated two times with similar results.
B, cells were cultured with or without 75 ng/ml doxycycline in standard
medium (11.2 mM glucose) for 0, 24, 48, and 96 h. Two separate exper-
iments are demonstrated in parallel. The gene expression profile in
naSREBP-1c#233 cells was quantified by Northern blotting. Total RNA
samples (20 g/lane) were analyzed by hybridizing with indicated
cDNA probes.
FIG. 7. Apoptosis in INS-1 cells induced by naSREBP-1c and
maturation of SREBP-1 protein in INS-1E cells regulated by
factors causing -cell dysfunction. A, DNA fragmentation in naS-
REBP-1c#233 cells cultured either with 500 ng/ml doxycycline for 1, 2,
and 4 days (left panel) or with 75 ng/ml doxycycline for 1, 4, and 7 days
(right panel). B, cytochrome c released in cytosolic fractions isolated
from naSREBP-1c#233 cells cultured either with 500 ng/ml doxycycline
for 1, 2, and 4 days (left panel) or with 75 ng/ml doxycycline for 1, 4, and
7 days (right panel). Cytosolic proteins (100 mg/lane) were separated
with 15% SDS-PAGE and analyzed by immunoblotting with an anti-
cytochrome c antibody. C, immunoblotting with antibody against the N
terminus of SREBP-1. Total cell extracts (100 g of protein/lane) from
INS-1E cells (lanes 1–8) or nuclear proteins (50 g of protein) from
freshly isolated rat islets (lane 9) were separated by 9% SDS-PAGE.
INS-1E cells were treated for either 6 h (lanes 1 and 2) or 48 h (lanes 3
and 4) with 30 mM glucose or 100 nM exogenous insulin as indicated.
Lanes 5–7 represent, respectively, total cell extracts from INS-1E cul-
tured for 48 h in standard medium (11.2 mM glucose) containing 1.5 mM
long-chain free fatty acids (2:1 oleate/palmitate), 10 ng/ml TNF-, and
10 M H2O2. Total cell lysates from INS-1E cells under standard culture
conditions are shown in lane 8 as control.
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INS-1E cells treated for 48 h with glucose, insulin, TNF-, or
H2O2 (Fig. 7C). In contrast, free fatty acids were without effects
(Fig. 7C). The level of the mature form of SREBP-1 in INS-1E
cells treated with high glucose for 48 h is 10% of that of the
endogenous precursor protein (Fig. 7C). This corresponds to the
induction observed with 75 ng/ml doxycycline in naSREBP-
1c#233 cells (Fig. 1B).
DISCUSSION
Intracellular lipid accumulation, termed lipotoxicity (meta-
bolic syndrome X), in skeletal muscle, myocardium, blood ves-
sels, kidney, liver, and pancreatic islets has been speculated to
cause, respectively, insulin resistance, cardiac dysfunction,
vascular complications, nephropathy, fatty liver (hepatic stea-
tosis), and -cell dysfunction in Type 2 diabetes (9, 50). How-
ever the molecular mechanism underlying the pathogenesis of
lipotoxicity in pancreatic -cells and other non-adipose tissues
remains undefined. In fact, lipotoxicity is a confusing concept.
Some investigators refer to lipotoxicity as the consequence of
increased circulating free fatty acids and cellular lipid accumu-
lation (7–9), whereas others suggest that glucotoxicity is the
prerequisite for lipotoxicity, at least in -cells (58, 59, 65–68).
The present study and other observations2 support the latter
(see bellow). In creased expression of SREBP-1c has been dem-
onstrated in islets and/or liver in several animal models of
diabetes (7, 12–16). Overexpression of SREBP-1 has been sug-
gested to be the cause of hepatic steatosis (14, 16, 51, 53, 69, 70)
and diabetic nephropathy (50). The present study provides
direct and strong evidence proving that the transcriptional
activity of SREBP-1c also mediates -cell dysfunction.
Conditional expression of naSREBP-1c, a nuclear localized
N-terminal form of SREBP-1c with intact transcriptional ac-
tivity, results in massive accumulation of lipid-droplets in
INS-1 cells, a clonal -cell line. This could be explained by
marked increases in lipogenic gene expression and unaltered
mRNA levels of genes involved in fatty acid -oxidation. The
lipogenic transcription factor naSREBP-1c also induces impair-
ment of nutrient-induced insulin secretion, suggesting defec-
tive glucose metabolism. This could be caused by the down-
regulation of glucokinase, up-regulation of UCP-2, and
disrupted mitochondrial membrane potential observed in these
INS-1 cells expressing naSREBP-1c. In addition, we also show
that naSREBP-1c suppresses the expression of insulin, Pdx-1,
and HNF-4. Induction of naSREBP-1c also leads to INS-1 cell
growth arrest and apoptosis possibly by both suppressing the
expression of cyclin-dependent kinase 4 and IRS-2 and promot-
ing the expression of P21WAF1/CIP1, APO-1/Fas/CD95, and Bax.
Since the SREBP-1c precursor is a known substrate for caspase
3, we postulate that SREBP-1c may function as a proapoptotic
gene in -cells. Similarly, lipid accumulation, impaired glucose-
stimulated insulin secretion, defective -cell gene expression
(insulin, Pdx-1, glucokinase, and Glut-2), disorganized mito-
chondrial ultrastructure, and “lipoapoptosis” have been re-
ported in islet -cells of diabetic animals (7, 71–73). We have,
therefore, not only established an in vitro cellular model for
-cell glucolipotoxicity but also elucidated the underlying
mechanism.
In addition, the present study also suggests that, in contrast
to hepatocytes and adipocytes, islet -cells have evolved to limit
the lipogenic gene expression in response to acute stimulation
of glucose and insulin by restricting the SREBP-1c processing.
Our data are in disagreement with a previous study, claiming
that SREBP-1c maturation in MIN-6 cells is acutely regulated
by glucose (18). Whereas 6 h of stimulation with glucose had no
effect in the present study, we could indeed detect the mature
form of SREBP-1c in INS-1E cells after 48 h of exposure to high
concentrations of glucose or insulin. In contrast, 48 h of treat-
ment with free fatty acids did not increase the levels of the
active form of SREBP-1c. Glucotoxicity, a phenomenon occur-
ring after prolonged exposure to high concentrations of glucose,
has been reported to induce lipid accumulation in INS-1 cells
by raising lipogenic gene expression (58). Our study may have
established a link between glucotoxicity and lipotoxicity and
provided an explanation for the predominant role of high glu-
cose in -cell dysfunction (59, 65). A similar effect may account
for the increased apoptosis and subsequent decreased -cell
mass in Type 2 diabetic patients compared with obese subjects
(27). We also found that a 48-h culture of INS-1E cells with 30
mM glucose caused cell apoptosis and defective gene expression
similar to naSREBP-1c induction, whereas 72 h of incubation
with 1.5 mM free fatty acids (2:1 oleate/palmitate) did not have
such deleterious effects.2 Therefore, naSREBP-1c may induce
-cell dysfunction independent of lipid accumulation. Hyper-
glycemia and hyperinsulinemia are characteristics of Type 2
diabetes. We hypothesize that as a result of the persistent
hyperglycemia and hyperinsulinemia present in diabetes,
SREBP-1c protein is processed and modified to an active form.
Activated SREBP-1c alters the expression of various target
genes that contribute to -cell dysfunction and therefore exac-
erbates the progression of Type 2 diabetes. Furthermore, our
results suggest that the SREBP-1c maturation regulated by
cytokines and oxidative stress may also play a role in -cell
dysfunction in Type 2 diabetes. It should be noted that the
present work was performed in a rat insulinoma cell line and
therefore may not entirely reflect the situation in native
-cells, necessitating caution in the interpretation.
We hypothesize that SREBPs have evolved to allow animals
adapting to starvation by mediating insulin action on energy
storage and promoting cell survival by maintaining constant
lipid composition of membranes. Overnutrition and sedentary
life-style in industrialized modern society may lead to lipotox-
icity in non-adipose tissue. The important contribution of our
study is that the transcription factor SREBP-1c is instrumental
in the pathogenesis of -cell lipotoxicity by targeting multiple
genes implicated in carbohydrate metabolism, lipid biosynthe-
sis, cell growth, and apoptosis. Similar mechanisms may also
apply to the lipotoxicity in other non-adipose tissues. Develop-
ment of chemical compounds acting like leptin, PPAR ago-
nists, and metformin through suppression of SREBP-1c func-
tion should have therapeutic potential in the treatment of Type
2 diabetes and its complications.
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ABSTRACT
Carnitine palmitoyltransferase I, which is expressed in the pancreas as the liver isoform
(LCPTI), catalyzes the rate- limiting step in the transport of fatty acids into the mitochondria for 
their oxidation. Malonyl-CoA derived from glucose metabolism regulates fatty acid oxidation 
by inhibiting LCPTI. To directly examine whether the availability of long-chain fatty acyl-CoA
(LC-CoA) affects the regulation of insulin secretion in the β-cell and whether malonyl-CoA
may act as a metabolic coupling factor in the β-cell, we infected INS(832/13) cells and rat 
islets with an adenovirus encoding a mutant form of LCPTI (Ad-LCPTI M593S) that is
insensitive to malonyl-CoA. In Ad-LCPTI M593S infected INS(832/13) cells LCPTI activity 
increased six-fold. This was associated with enhanced fatty acid oxidation, at any glucose
concentration, and a 60% suppression of glucose-stimulated insulin secretion (GSIS). In
isolated rat islets in which LCPTI M593S was overexpressed, GSIS decreased 40%. The
impairment of GSIS in Ad-LCPTI M593S infected INS(832/13) cells was not recovered when 
cells were incubated with 0.25 mM palmitate, indicating the deep metabolic influence of a non-
regulated fatty acid oxidation system. At high glucose concentration, overexpression of a
malonyl-CoA-insensitive form of LCPTI reduced partitioning of exogenous palmitate into lipid 
esterification products, and decreased PKC activation. Moreover, LCPTI M593S expression
impaired KATP channel- independent GSIS in INS(832/13) cells. The LCPTI M593S mutant
caused more pronounced alterations in GSIS and lipid partitioning (fat oxidation, esterification, 
the level of non-esterified palmitate) than LCPTI wt in INS(832/13) cells transduced with these 
constructs. The results provide direct support for the hypothesis proposing that the malonyl-
CoA/CPTI interaction is a component of a metabolic signalling network that controls insulin 
secretion.
INTRODUCTION
Lipid metabolism in the ß-cell is critical for the regulation of insulin secretion (1, 2).
Depletion of lipid stores together with deprivation of non-esterified fatty acids (NEFA) alters 
glucose-stimulated insulin secretion (GSIS) in rats and humans (3-5). NEFAs, presumably via 
long-chain fatty acyl-CoA (LC-CoA), generate signals for insulin secretion (6).
Stimulation of insulin secretion by glucose alters CoA derivatives levels in clonal
pancreatic β-cells, in particular malonyl-CoA and LC-CoAs. The malonyl-CoA/LC-CoA
model of GSIS holds that during glucose stimulation, anaplerosis increases citrate (7), which is 
exported and finally converted to malonyl-CoA, resulting in inhibition of carnitine
palmitoyltransferase I (CPTI) (8) and fatty acid oxidation (6, 9). Therefore, the increase in
malonyl-CoA may be responsible for the accumulation of LC-CoAs in the cytosol (10).
Moreover, the β-cell LC-CoA content increases with the supplement  of exogenous NEFA. In 
addition, glucose metabolism in the β−cell raises cytosolic LC-CoA levels, which in
combination with α-glycerophosphate may increase the levels of triglycerides, phosphatidic
acid and diacylglycerol (1). LC-CoA may act as coupling factors in insulin secretion by
stimulating several isoforms of protein kinase C (11, 12), through acylation of exocytotic 
proteins or by generating complex lipid signalling molecules such as diacylglycerol and
phosphatidate (1).
Both malonyl-CoA and LC-CoA are thought to participate in the signal transduction for 
insulin secretion: the former as a regulator and the latter as an effector (13). Systems that 
regulate both malonyl-CoA and LC-CoA appear to be involved in insulin secretion.
Accordingly, acetyl-CoA carboxylase (ACC), which controls the synthesis of malonyl-CoA,
malonyl-CoA decarboxylase (MCD), which catalyzes malonyl-CoA degradation, and CPTI
which is regulated by malonyl-CoA, are components of a metabolic signalling network that 
senses the level of fuel stimuli (1, 8). The physiological role of malonyl-CoA in the endocrine 
pancreas, unlike many other tissues, is not de novo synthesis of fatty acids but rather the
regulation of CPTI activity, since the level of fatty acid synthetase in normal β-cells is very
low (14). The metabolism of several nutrients that converge to form malonyl-CoA and increase 
LC-CoA esters (carbohydrate, amino acids and ketoacids) might play a key role in fuel
regulated-insulin secretion in the β-cell (2). Thus, for example, stable expression of an ACC-
antisense construct in INS1 cells (15) or overexpression of MCD in rat insulinoma
INS(832/13) cells (16) decreased malonyl-CoA levels, increased LC-CoA oxidation and
decreased insulin secretion.
The overexpression of native LCPTI in clonal INS-1E β-cells increased beta oxidation of
fatty acids and decreased insulin secretion at high glucose (17). The effect of LCPTI was
reverted by etomoxir, an irreversible inhibitor of CPTI, and by the exogenous addition of fatty
acids. However, using this approach glucose-derived malonyl-CoA is still able to inhibit
LCPTI in cells overexpressing the enzyme and consequently fat oxidation is moderately altered 
(17). To directly test the hypothesis that the CPTI/malonyl-CoA interaction is involved in 
GSIS we chose to overexpress LCPTI M593S, a mutant enzyme that is insensitive to malonyl-
CoA (18). The LCPTI mutant and the native LCPTI were overexpressed in INS(832/13) cells 
and rat islets using recombinant adenoviruses. 
INS(832/13) cells transduced with the M593S mutant had increased CPTI activity and 
protein levels, a markedly increased palmitate oxidation rate and a more impaired GSIS than 
cells transduced with LCPTI wt. At high glucose, esterification products and protein kinase C 
activation were decreased in cells expressing the mutated CPTI. Overall, the data provide 
direct support for the view that the malonyl-CoA/CPTI interaction is involved in glucose-
regulated insulin secretion.
RESEARCH DESIGN AND METHODS
Materials. The collagenase used to isolate rat pancreatic islets was from Serva Electrophoresis 
(Heidelberg, Germany). Protran nitrocellulose membranes for protein analysis were from
Schleicher & Schuell and the Bradford solution for protein assay was from Bio-Rad
Laboratories. The enhanced chemifluorescence (ECF) reagent pack from Amersham
Biosciences was used for Western blot analysis. TLC plates were purchased from Merck.
Defatted bovine serum albumin (BSA), palmitic acid (sodium salt) and the migration standards 
phosphatidyl-serine, dipalmitoyl-glycerol, glyceryl tripalmitate and cholesteryl palmitate were
from Sigma-Aldrich. Radioactive compounds, [1-14C]palmitic acid, [U-14C]glucose, [1-
14C]acetyl-CoA and L-[methyl-3H]carnitine were from Amersham Biosciences. 
Construction of recombinant adenoviruses. Ad-LCPTI wt encoding LCPTI wt was
constructed as previously described (17). Ad-LacZ, which expresses bacterial β-galactosidase,
was used as a control adenovirus. Ad-LCPTI M593S, encoding the malonyl-CoA-insensitive
LCPTI M593S cDNA under the chicken actin (CA) promoter, was constructed using the
Adenovirus Expression Vector Kit (Takara, Biomedicals). Briefly, blunt-ended LCPTI M593S 
cDNA (18) was subcloned into the cosmid pAdCA previously cut with SwaI and
dephosphorylated. The resulting cosmid was packaged using the Gigapack III Plus Packaging 
Extract (Stratagene). The presence and right orientation of the insert were checked by
restriction enzyme digestions using ClaI and BglII and the presence of the mutation by
sequencing. The cosmid was cotransfected with DNA-TPC (adenovirus DNA of terminal
protein complex) in a 10-cm dish with calcium phosphate (CellPhect, Amersham Pharmacia 
Biotech) in human embryonic kidney (HEK 293) cells (17). Cell lysate from selected viral 
clones was analyzed by Western Blot and probed with a LCPTI-specific antibody. The
adenovirus was amplified, purified by CsCl ultracentrifugation and carefully titrated using the 
Adeno-X Rapid Titer kit (Clontech Laboratories, Inc.).
INS cell culture. The clonal β−cell line INS(832/13) (19), derived and selected from the 
parental rat insulinoma INS-1 (20) was cultured (passages 48-60) in a 5% CO2 humidified 
atmosphere in complete medium composed of RPMI 1640 (Life Technologies, Inc) containing 
11 mM glucose and supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Wisent 
Inc, USA), 10 mM HEPES (pH 7.4), 2 mM glutamine, 1 mM sodium pyruvate, 50 µM 2-
mercaptoethanol, 100 U/ml penicillin and 100 µg/ml streptomycin. The maintenance culture 
was passaged once a week by gentle trypsinization, cells were seeded in Falcon dishes and 
medium was changed every 2-3 days.
Pancreatic islet isolation. Islets were prepared from male Wistar rats weighing 250–350 g by
collagenase digestion and handpicking (21). At the end of the isolation step, islets were
maintained in culture in regular RPMI 1640 medium containing 11 mM glucose supplemented 
with 10% (v/v) fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin at 37ºC in 
a humidified atmosphere containing 5% CO2.
Viral treatment. INS(832/13) cells were seeded in 12-well plates (0.5 x 106 cells/well), 25-
cm2 flasks (2 x 106 cells), 10-cm dishes (7 x 106 cells) or 15-cm dishes (10 x 106 cells) and
cultured 48 h before infection. For infection cells were incubated for 90 min with complete
RPMI medium containing 4.1 pfu/cell of Ad-LacZ, 1.7 pfu/cell of Ad-LCPTI wt or 4.1 pfu/cell 
of Ad-LCPTI M953S. Cells were cultured for 24 h before experiments to allow the transgenes 
to be expressed before initiating metabolic studies or measurements of insulin secretion. One 
day after the isolation, batches of 100-200 islets were infected in 1 ml of RPMI 1640 medium 
for 1 h with 10-150 x 104 pfu/islet (22) of the recombinant adenoviruses and further cultured 
for 24 h before experiments were performed. At these incubation times no toxicity effects were 
seen.
Western blot analysis. For detection of LCPTI protein, infected INS(832/13) cells or islets
were resuspended directly in SDS sample buffer and sonicated. Proteins obtained from cell 
extracts were analyzed by SDS/PAGE (8% gels) and transferred onto nitrocellulose
membranes using a Mini Trans-Blot Electrophoretic Cell according to the manufacturer’s
instructions (Bio-Rad). Immunoblots were developed by incubation with the LCPTI-specific
polyclonal antibody against amino acids 317-430 of the rat liver CPTI (23) (1/6,000 dilution) 
and the anti-rabbit IgG alkaline phosphatase goat antibody (1/10,000 dilution). Detection was 
carried out with the enhanced chemifluorescence (ECF) immunoblotting detection system
(Amersham Biosciences). For detection of PKC protein, cytosolic or membrane proteins of
infected INS(832/13) cells were separated on an 8% SDS/PAGE gel and trans ferred to a 
nitrocellulose membrane as described above. Membranes were incubated with mouse anti-PKC
monoclonal antibody (MC5, Santa Cruz Biotechnology, Santa Cruz, CA) (1/100 dilution)
followed by incubation with an anti-mouse IgG + IgM alkaline phosphatase goat antibody
(1/10,000 dilution). Antibody binding was visualized using the ECF system as described above 
and band intensities were quantified using a Storm 840 Laser scanning system (Molecular 
dynamics, Amersham Pharmacia Biotech). Intensities of the spots were expressed as arbitrary
optical units.
CPTI activity assay. INS(832/13) cells (10 x 106) were seeded in 15-cm dishes and cultured 
for 48 h prior to infection with the different adenoviruses. 24h later cells were pretreated as 
follows: cells were washed in Krebs-Ringer Bicarbonate HEPES buffer (KRBH buffer; 135 
mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.5 mM MgSO4, 1.5 mM CaCl2, 2 mM NaHCO3
and 10 mM HEPES, pH 7.4) containing 0.1% (w/v) deffatted BSA, preincubated at 37ºC for 30 
min in KRBH plus 1% BSA without glucose in the absence or  presence of etomoxir at 200 
µM and washed again in KRBH 0.1% BSA. Mitochondrion-enriched cell fractions were
obtained as previously described (17). LCPTI was assayed in those preparations where the 
mitochondria remain largely intact. CPTI activity in 8 µg of protein was determined by the 
radiometric method as previously described (24) with minor modifications. The substrates
were L-[methyl-3H]carnitine and palmitoyl-CoA. Enzyme activity was assayed for 5 min at 
30ºC in a total volume of 200 µl. For malonyl-CoA inhibition assays 8 µg of mitochondrion-
enriched cell fractions were preincubated for 1 min at 30ºC with different amounts of malonyl-
CoA prior to CPTI activity assay.
Fatty acid oxidation. Fatty acid oxidation to CO2 and acid soluble products (ASP), essentially 
ketone bodies (25), were measured in INS(832/13) cells cultured in 25-cm2 flasks. Cells were 
pretreated as described above and incubated for 2 h at 37ºC with fresh KRBH containing 2.5, 
7.5 or 15 mM glucose in the presence of 0.8 mM carnitine plus 0.25 palmitate and 1 µCi/ml [1-
14C]palmitic acid complexed to 1% (w/v) BSA. Oxidation to CO2 and ASP were measured as 
previously described (16).
Fatty acid esterification. Fatty acid esterification to complex lipids was measured in
INS(832/13) cells cultured in 12-well plates and pretreated as described above. Cells were 
incubated for 2 h at 37ºC with fresh KRBH containing 2.5 or 15 mM glucose in the presence of 
0.8 mM carnitine plus 0.25 palmitate and 1 µCi/ml [1-14C]palmitic acid complexed to 1% 
(w/v) BSA. Cells were washed in cold PBS and lipids were extracted as described in (17).
Total lipids dissolved in 30 µl of chloroform were separated by thin layer chromatography to 
measure the incorporation of labeled fatty acid into phospholipids (PL), diacylglycerol (DAG), 
triacylglycerols (TG), non-esterified labeled palmitate (NE palm) and cholesterol esters (CE) as 
described before (16). Phosphatidyl-serine, dipalmitoyl-glycerol, glyceryl tripalmitate,
cholesteryl palmitate and labeled control palmitate were used as migration references. Plates
were developed with hexane:diethylether:acetic acid (70:30:1, v/v/v) as described before (26)
and quantified with a Storm 840 Laser scanning system (Molecular dynamics, Amersham 
Pharmacia Biotech).
Triglyceride content. For the cellular triglyceride content measurement, INS(832/13) cells 
were cultured in 12-well plates and pretreated as described above. Total lipids were extracted 
as described in (17) and dissolved in 30 µl of chloroform. 10 µl of Thesit (Sigma-Aldrich) 20%
(v/v) in chloroform were added,  samples were air dried, dissolved in 50 µl of water and 
triglyceride content was measured with triolein as a standard using the Sigma 337
triacylglycerol kit.
Malonyl-CoA assay. INS(832/13) cells were cultured in 10-cm dishes and pretreated as 
described above. Cells were then incubated for 30 min at 37ºC with fresh KRBH containing 
2.5 or 15 mM glucose. Malonyl-CoA was extracted as described in (27) and assayed with a 
radioenzymatic method (28) using [1-14C] acetyl-CoA. The fatty acid synthetase required for 
the assay was isolated from rat liver as described in (29).
Insulin secretion. Insulin secretion was measured as previously described with minor changes 
(30). INS(832/13) cells (0.5 x 106) seeded in 12-well plates were pretreated as described above.
Insulin secretion was measured during a 1 h incubation at 37ºC in 1 ml of KRBH 0.1% BSA in 
the presence of either 2.5 mM glucose, 15 mM glucose, 15 mM glucose plus 0.25 mM
palmitate complexed to 1% (w/v) BSA or 2.5 mM glucose plus 30 mM KCl. After this time 
insulin content, obtained as described in (17), was determined by radioimmunoassay using rat 
insulin standards with the Coated Tube Insulin RIA kit (Insulin-CT, Schering).
For studies of KATP channel- independent insulin secretion, assays were performed as described 
above except that 35 mM KCl (depolarizing K+) was included; consequently, the Na+
concentration in the KRBH was reduced from 135 to 89.9 mM to maintain osmolarity, and 250 
µM diazoxide was added. 
Isolated rat islets were transduced with Ad-LCPTI wt, Ad-LCPTI M593S or Ad-LacZ and used
after 24 h for insulin secretion experiments. Batches of 10 islets each were incubated for 30 
min in KRBH 0.1% BSA containing 2.8 or 16.7 mM glucose. Insulin was determined by 
radioimmunoassay (30)
PKC translocation assay. INS(832/13) cells (7 x 106) seeded in 10-cm dishes were infected
and pretreated as described above. To promote PKC translocation cells were incubated for 30 
min at 37ºC in 2 ml of KRBH 0.1% BSA in the presence of 15 mM glucose. For the control 
situation, cells were incubated at low (2.5 mM) glucose. Then, cells were washed in cold PBS 
and used directly for preparation of membrane and cytosol fractions as described in (12).
Western blot of membrane and cytosol proteins was performed using a specific antibody
(MC5, Santa Cruz Biotechnology, Santa Cruz, CA) against the pancreatic β-cell isoforms of 
PKC (α, β  and γ) as described above. Band intensities were assessed using a Storm 840 Laser 
scanning system.
Glucose oxidation. Glucose oxidation to CO2 was measured in INS(832/13) cells cultured in 
25-cm2 flasks, infected and pretreated as described above. Cells were incubated for 2h at 37ºC 
with fresh KRBH 1% BSA containing 2.5 or 15 mM glucose in the presence of 0.5 µCi/ml [U-
14C]glucose. Oxidation to CO2 was measured as previously described (16).
Statistical analysis. Data are expressed as means ± SE for at least four independent
experiments performed in triplicate. Different experimental groups were compared with one-
way ANOVA followed by Bonferroni’s test for comparisons post hoc. A probability level of 
P<0.05 was considered to be statistically significant.
RESULTS
CPTI activity is not inhibited by malonyl-CoA in INS(832/13) cells expressing LCPTI
M593S. In a previous study we documented a LCPTI M593S mutant which was insensitive to 
malonyl-CoA (18). The capacity of LCPTI M593S to show enzyme activity despite the 
presence of malonyl-CoA was evaluated in pancreatic β-cells. INS(832/13) cells were infected 
with Ad-LCPTI wt and Ad-LCPTI M593S. Mitochondrion-enriched fractions of cells were 
incubated with different amounts of malonyl-CoA and CPTI activity assay was performed. In
the presence of malonyl-CoA (100 µM) mitochondrion-enriched fractions of cells infected with
Ad-LCPTI M593S retained 80% of their activity while that of the LCPTI wt was almost 
completely inhibited (Fig. 1).
CPTI protein and activity in INS(832/13) cells infected with Ad-LCPTI wt and Ad-
LCPTI M593S. INS(832/13) cells were infected with different amounts of Ad-LCPTI wt (Fig.
2A) and Ad-LCPTI M593S (Fig. 2B). CPTI activity assay was performed with mitochondrion-
enriched cell fractions. In both cases CPTI activity increased to a plateau of 9-10 fold
compared with the endogenous LCPTI, calculated from Ad-LacZ infected cells (5.0 ± 1.8 
nmol.mg-1 prot.min-1, mean ± SE of 6 experiments). For subsequent experiments we used the
amount of adenovirus LCPTI wt (1.7 pfu/cell) and LCPTI M593S (4.1 pfu/cell) that increased
CPTI activity 6-fold (30 nmol. mg-1prot. min-1) with respect to the control Ad-LacZ. In an 
additional experiment, as a control, cells were also incubated for 30 min with or without 200 
µM of etomoxir. This irreversible CPTI inhibitor blocked CPTI activity in Ad-LacZ and Ad-
LCPTI wt infected cells, but left 65% CPTI activity in Ad-LCPTI M593S infected cells (Fig. 
2C). LCPTI protein expression was measured by Western blot. Total protein was isolated from
INS(832/13) cells infected with the amounts of adenoviruses that gave a 6-fold increase in 
CPTI activity. Consistent with the activity assays, Western blots showed similar amounts of 
protein in Ad-LCPTI wt and Ad-LCPTI M593S-infected cells (Fig. 2D) and fold increase over 
the control situation (Ad-LacZ). Similar results were obtained in Western blots performed with 
infected rat islets (Fig. 2E). Thus, expression of LCPTI wt and LCPTI M593S in the β-cell was
successful in markedly increasing the protein and enzymatic activity of CPTI.
Effect of LCPTI M593S expression on palmitate oxidation in INS(832/13) cells. To
evaluate the metabolic effects of the Ad-LCPTI wt and Ad-LCPTI M593S constructs we
measured fatty acid oxidation in pancreatic β-cells. [1-14C]palmitate oxidation was determined
in adenovirus-treated INS(832/13) cells. Fatty acid oxidation was highest in cells infected with 
Ad-LCPTI M593S at all tested glucose concentrations (Fig. 3). At high glucose (15 mM) fatty 
acid oxidation to CO2, acid soluble products (ASP), and the ir sum were increased by 8.3, 3.4
and 4.4 fold respectively, compared with Ad-LacZ infected cells. These oxidation rates were
higher than those obtained when overexpression was performed with Ad-LCPTI wt (3.3, 1.5 
and 1.8 fold, respectively). Malonyl-CoA levels were not modified following LCPTI wt or 
LCPTI M593S overexpression, compared with LacZ control cells, either at 2.5 or 15 mM 
glucose (Fig. 4A). These findings confirm that even at high malonyl-CoA concentrations (high 
glucose), fatty acid oxidation in LCPTI M593S overexpressing cells is much higher than in the
control Ad-LacZ adenovirus- infected cells and still higher than in cells infected with Ad-
LCPTI wt. Since LCPTI M593 is resistant to malonyl-CoA, beta oxidation to CO2 and ketone 
bodies (acid soluble compounds) is accelerated in cells overexpressing the mutated enzyme.
Glucose oxidation at low (2.5 mM) and high (15 mM) glucose remained unaltered in cells 
expressing both the wt and mutated LCPTI constructs (Fig. 4B). This is in accordance with the 
view that a Randle cycle is inoperative in the β-cell (31).
GSIS is reduced in INS(832/13) cells and rat islets expressing LCPTI M593S. GSIS was 
reduced by 60% in INS(832/13) cells infected with Ad-LCPTI M593S and by 40% in Ad-
LCPTI wt-infected cells, both with respect to the control Ad-LacZ (Fig. 5A). GSIS was
recovered completely in the presence of 0.25 mM palmitate only in the case of LCPTI wt,
suggesting that at high glucose, the provision of exogenous FFA was not matched with a rise in
intracellular FFA (non esterified palmitate) in cells overexpressing the mutated enzyme due to 
the dramatically enhanced fatty acid oxidation. The results in Fig. 6D are in total accordance
with this view.
As a control of the insulin secretion mechanism, incubation at low glucose in the 
presence of 30 mM KCl was performed and insulin release was similar in the three cases of 
adenovirus- infected cells indicating that the exocytotic machinery is preserved in cells
transduced with the various constructs. Insulin secretion was also studied in the presence of 35 
mM K+ plus 250 µM diazoxide, a condition revealing the KATP channel- independent pathway
of glucose sensing (32). The expression of LCPTI wt and LCPTI M593S led to a decrease in 
insulin release (the difference between 15 and 2.5 mM glucose) of 55 ± 12% and 85 ± 17% 
(n=3) respectively, compared with Ad-LacZ-infected cells. This is consistent with the view that 
KATP-independent signalling (also referred as the amplification pathway) was affected in cells 
overexpressing the LCPTI construct (Fig. 5B).
Isolated rat islets infected with Ad-LCPTI wt or Ad-LCPTI M593S showed increased 
levels of LCPTI protein in Western blots analysis compared with Ad-LacZ-infected islets (Fig.
2C). In control islets, raising glucose from 2.8 mM to 16.7 mM resulted to a 6.8-fold insulin 
secretion. In islets overexpressing LCPTI M593S, GSIS was decreased by 40% compared to 
the Ad-LacZ control, while no difference was seen with Ad-LCPTI wt- infected islets (Fig. 5C).
To explain the difference in the results between INS(832/13) cells and islets we hypothesize
that normal β-cells are more protected than INS cells against lipid depletion due to enhanced 
fat oxidation, such that only the more efficient LCPTI M593S construct is active in rat islets.
Effect of LCPTI M593S on glucose-induced changes in lipid partitioning. To examine
whether the increase in fatty acid oxidation could reduce the availability of LC-CoA for lipid 
signalling we measured esterification processes in INS(832/13) cells infected with Ad-LCPTI
wt and Ad-LCPTI M593S. The levels of [1-14C]palmitate incorporated to phospholipids (PL), 
diacylglycerol (DAG), triacylglycerides (TG), cholesterol esters (CE) as well as the levels of 
non-esterified palmitate (NE Palm) were measured. Glucose-induced palmitate esterification 
into the different complex lipid species was expressed as the differences (∆G) between high 
(15 mM) and low (2.5 mM) glucose (Fig. 6). The glucose-induced rise in PL, DAG, TG and 
NE Palm was decreased by 20%, 25%, 35% and 38% respectively for Ad-LCPTI wt-infected
cells and by 37%, 58%, 59% and 71% respectively, for Ad-LCPTI M593S-infected cells (Fig.
6 A, B, C, D), both compared to Ad-LacZ-infected cells. Palmitate esterification to CE was
reduced by 23% and 50% for Ad-LCPTI wt and Ad-LCPTI M593S respectively at low glucose 
and by 42% and 60% for Ad-LCPTI wt and Ad-LCPTI M593S respectively at high glucose,
compared to the Ad-LacZ control (Fig. 6E). Fig. 6D also shows that the glucose- induced rise in 
NE Palm, an indirect measurement of cytosolic LC-CoA (16), was markedly curtailed in cells 
expressing the LCPTI construct and that the CPTI mutant was most effective in this respect. 
Changes in the cellular TG content were not observed by the expression of LCPTI wt nor
LCPTI M593S (Fig. 6F). This is probably due to the fact that differences in the incorporation
of LC-CoA into TG are not reflected in the large and stable total TG pool.
PKC activation is impaired in INS(832/13) cells expressing LCPTI M593S. DAG and LC-
CoA activate many PKC enzymes (11, 12). To assess whether the decrease of the glucose-
induced rise in DAG and NE Palm seen in Ad-LCPTI wt and Ad-LCPTI M593S-infected cells 
is associated with alteration in PKC activity in the β-cell, we measured PKC activation as
estimated by its translocation from cytosol to membranes. Western blot carried out  on
membrane and cytosol proteins of INS(832/13) cells incubated at high (15 mM) glucose
showed that PKC translocation of Ad-LCPTI wt and Ad-LCPTI M593S-infected cells was
decreased by 63% and 78%, respectively, in comparison with Ad-LacZ-infected cells. No
difference in the partitioning of PKC enzyme between the cytosolic and membrane
compartments was noted in Ad-LacZ, Ad-LCPTI wt and Ad-LCPTI M593S-infected cells 
incubated at low glucose (2.5 mM) (Fig. 7).
DISCUSSION
Many studies implicate NEFAs in type II diabetes (33, 34). Long-term exposure of β-cells
to NEFAs in vitro has several effects: 1) it increases basal insulin release and decreases
secretion in response to glucose (35); 2) it alters the coupling of glucose metabolism to insulin 
secretion by acting on the expression of specific genes, such as UCP2 (36, 37); 3) it increases 
the expression of CPTI, which is considered the rate- limiting step in fatty acid oxidation (38).
CPTI upregulation following chronic NEFA exposure of the β-cell may contribute to reduced
GSIS. In an earlier study we evaluated the capacity of LCPTI wt overexpression to alter the 
insulin response to glucose in ß-cells (17). The results showed that overexpression of a cDNA 
encoding LCPTI using an adenovirus not only increased beta-oxidation in INS-1E cells but 
also decreased GSIS by 40%. In the search for a malonyl-CoA insensitive LCPTI we found
that the M593S LCPTI mutant was almost completely refractory to malonyl-CoA (18).  In 
view of the interest in the malonyl-CoA/LC-CoA model of GSIS, which is still under
discussion (27, 39), we directly tested the hypothesis that the malonyl-CoA/CPTI interaction is 
implicated in GSIS using a β-cell derived cell line overexpressing the malonyl-CoA insensitive 
LCPTI. Since liver CPTI is the only isoform present in the β-cell, we used the rat liver isoform 
of CPTI to construct the adenovirus.
Overexpression of the malonyl-CoA-insensitive form of LCPTI increased fatty-acid
oxidation rates in INS(832/13) at all glucose concentrations. Fat oxidation rates were much
higher than in control Ad-LacZ-infected cells or in cells overexpressing malonyl-CoA-sensitive
LCPTI wt. INS(832/13) cells overexpressing LCPTI M593S secreted less insulin in response to
high glucose concentration (approximately 60% reduction) but not in response to a
depolarizing concentration of KCl. Thus, exocytosis per se was preserved in cells
overexpressing the mutated LCPTI, since the effect of the Ca2+ raising agent (30 mM KCl) was
unaltered. The utilization of elevated K+ and diazoxide to discern between the KATP channel-
dependent and - independent pathways of glucose sensing showed that LCPTI M593S
overexpression affected the KATP-independent pathway of GSIS, thus providing direct support 
for the view that the malonyl-CoA/CPTI interaction is involved in the amplification arm of 
secretion. In isolated rat islets, similar results were obtained, i.e. reduced secretory responses to 
high glucose upon LCPTI M593S expression. Interestingly, overexpression of LCPTI wt did 
not affect GSIS in islets, suggesting preserved lipid signalling above a critical threshold of 
cytosolic LC-CoA.
Incubation of LCPTI M593S transduced cells with 0.25 mM palmitate did not
completely restore GSIS, showing the strong metabolic influence of LCPTI M593S on fatty 
acid oxidation and insulin secretion in the pancreatic β-cell. This points to a possible
mechanism by which increased metabolic flux through LCPTI diminishes insulin secretion via
the depletion of a critical lipid synthesized at or near the mitochondrial outer membrane that 
would act as a signal molecule. 
It is interesting to compare the present results with those of Roduit et al. (16) who
overexpressed malonyl-CoA decarboxylase (MCD) in the cytosol (MCDc) by infecting
INS(832/13) cells and rat islets with an adenovirus containing the cDNA for MCD devoid of 
its mitochondrial and peroxysomal targeting sequences. The authors found that MCDc
overexpression in the absence of exogenous FFA had no effect on GSIS and that MCDc 
overexpression suppressed the additional secretion in response to glucose provided by the
presence of exogenous FFA (16). In the present study exogenous fatty acids had no effect on 
GSIS at 15 mM glucose, perhaps because we used a relatively low concentration of fatty acids 
(0.25 mM bound to 1% BSA) or possibly because lipolysis was higher in the current study. 
Nonetheless it is interesting to note that altering β-cell lipid partitioning with the malonyl-
CoA-insensitive mutant of LCPTI had more profound consequence than with the
overexpression of cytosolic MCD on both GSIS and lipid partitioning with more enhanced fat 
oxidation and reduced esterification processes at both low and elevated glucose. In other 
studies (27), the lack of correlation between malonyl-CoA levels and β-oxidation has been 
remarked on, suggesting that glucose might regulate cytosolic LC-CoA in a manner not
entirely dependent of malonyl-CoA.  Whatever is the explanation for the differences in
alterations in GSIS in the absence or presence of exogenous FFA when MCDc (16) or CPTI 
(present study) are overexpressed, both studies show a reduction of GSIS when the malonyl-
CoA/CPTI interaction is perturbed.
The data of the current study in cells overexpressing a malonyl-CoA insensitive CPTI 
together with previous results obtained in INS cells or islets overexpressing MCDc in the 
cytoplasm provide evidence that malonyl-CoA acts as a glucose-driven coupling factor that
regulates the partitioning of fatty acids into effector molecules in the insulin secretory pathway. 
The nature of these molecules (NE palm, LC-CoA, PL and/or DAG) and their mechanisms of 
action on insulin secretion are poorly understood. Overexpression of LCPTI M593S altered 
lipid partitioning of exogenous palmitate from oxidation into esterification products at high 
glucose. The incorporation of palmitate into PL, DAG, TG, NE palm and CE were reduced 
compared to controls. Determination of PKC translocation from cytosol to membrane showed
that PKC activation in Ad-LCPTI wt and Ad-LCPTI M593S-infected cells was decreased 
compared with Ad-LacZ-infected cells. This suggests that enhanced beta oxidation of fatty
acids by the LCPTI M593S mutant reduces GSIS as a result of a decrease in PKC activation.
The lower values of DAG and NE Palm (an indirect determination of LC-CoA levels ) observed
in the LCPTI M593S-overexpressing cells support this view since both DAG and LC-CoA
activate a number of PKC enzymes (11, 12).
In conclusion, this study shows directly for the first time that when the malonyl-
CoA/CPTI interaction is altered glucose- induced insulin release is impaired. Together with the 
results obtained in previous studies in which MCDc was overexpressed (16) or ACC
expression was reduced (15), the data point out to a critical role of the malonyl-CoA/CPTI
metabolic signalling network in the coupling mechanism of insulin secretion. These results also 
favor the hypothesis that upregulation of CPTI (33) contributes to the early loss of glucose 
responsiveness seen in β-cells chronically exposed to high concentrations of fatty acids and 
provide direct support for the malonyl-CoA/LC-CoA model of fuel- induced insulin secretion.
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LEGENDS TO FIGURES
Fig.1. CPTI activity of INS(832/13) cells infected with Ad-LCPTI M593S is insensitive to 
malonyl-CoA. INS(832/13) cells were infected with Ad-LCPTI wt or Ad-LCPTI M593S and 
24 h later CPTI activity assay was performed with 8 µg of mitochondrion-enriched cell
fractions incubated with different amounts of malonyl-CoA. Data are the mean ± SE of 6 
experiments.
Fig. 2. CPTI activity and immunoblot analysis of LCPTI expressed in infected
INS(832/13) cells and rat islets. INS(832/13) cells were infected with different pfu/cell of Ad-
LCPTI wt (A) or Ad-LCPTI M593S (B), 24 h later mitochondrion-enriched cell fractions were 
obtained and 8 µg of protein were used for the CPTI activity assay. The amount of both viruses 
which increased CPTI activity 6- fold, compared with Ad-LacZ (0 pfu/cell), were chosen for 
further experiments (1.7 pfu/cell for Ad-LCPTI wt and 4.1 pfu/cell for Ad-LCPTI M593S).
Insert: expanded dose-response curve. (C) INS(832/13) cells infected with Ad-LacZ, Ad-
LCPTI wt or Ad-LCPTI M593S were incubated for 30 min in KRBH 1% BSA with or without 
etomoxir (200 µM). After that, mitochondrion-enriched cell fractions were obtained and CPTI
activity assay was performed. (D) INS(832/13) cells infected with Ad-LacZ, Ad-LCPTI wt or
Ad-LCPTI M593S were collected and protein extracts were separated by SDS/PAGE (8% 
gels) and subjected to immunoblotting by using specific antibodies for CPTI from liver. A
unique band corresponding to a protein of approx. 88 kDa was seen in control, Ad-LCPTI wt 
and Ad-LCPTI M593S infected cells. (E) Rat islets (batches of 100-200) were infected with 
the different adenoviruses as described in RESEARCH DESIGN AND METHODS and 24 h later 
LCPTI protein expression was determined by Western blot. Data in A, B and C are the mean ± 
SE of 4 experiments. *P<0.05 vs Ad-LCPTI M593S without etomoxir; **P<0.001 vs Ad-LacZ.
Fig.3. Fatty acid oxidation is increased in INS(832/13) cells expressing LCPTI M593S.
INS(832/13) were infected with Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI M593S. 24 h after viral 
treatment cells were preincubated for 30 min at 37ºC in KRBH medium containing 1% BSA 
and then incubated for 2 h at 2.5, 7.5 or 15 mM glucose in the presence of 0.8 mM carnitine, 1 
µCi/ml [1-14C]-palmitic acid and 0.25 mM unlabeled palmitate complexed to 1% (w/v) BSA. 
Palmitate oxidation to CO2 (A), acid soluble products (ASP) (B), and total palmitate oxidation 
(CO2 + ASP) (C) was measured as described in RESEARCH DESIGN AND METHODS. Data are 
the mean ± SE of 5 experiments. *P<0.05 vs Ad-LacZ; #P<0.05 vs Ad-LCPTI wt.
Fig. 4. Malonyl-CoA content and glucose oxidation are unaltered in INS(832/13) cells
expressing LCPTI M593S. INS(832/13) cells were infected with Ad-LacZ, Ad-LCPTI wt or 
Ad-LCPTI M593S and 24 h later, they were preincubated for 30 min at 37ºC in KRBH
medium containing 1% BSA. (A) For the malonyl-CoA content measurements, cells were 
incubated for 30 min with KRBH containing 2.5 or 15 mM glucose and malonyl-CoA was 
extracted and assayed with a radioactive method using purified fatty acid synthetase as detailed 
in RESEARCH DESIGN AND METHODS. (B) Glucose oxidation to CO2 was measured after a 2 h 
incubation of the cells at 2.5 or 15 mM glucose in the presence of 0.5 µCi/ml [U-14C]-glucose
as described in RESEARCH DESIGN AND METHODS. Data are the mean ± SE of 4 experiments. 
*P<0.05 vs 2.5 mM glucose.
Fig. 5. Glucose-induced insulin release is impaired in INS(832/13) cells and in isolated rat
islets expressing LCPTI M593S. INS(832/13) cells or rat islets were infected with Ad-LacZ,
Ad-LCPTI wt or Ad-LCPTI M593S as detailed in RESEARCH DESIGN AND METHODS. (A)
After a 30 min preincubation in KRBH 1% BSA without glucose, INS(832/13) cells were 
washed and incubated for 1 h in KRBH 0.1% BSA containing either 2.5, 15 mM glucose, 15 
mM glucose plus 0.25 mM palmitate complexed to 1% (w/v) BSA or 2.5 mM glucose plus 30 
mM KCl. Insulin release was determined by RIA. (B) Experiments conducted in the presence 
of depolarizing K+ (35 mM) and 250 µM diazoxide to measure KATP channel- independent
glucose sensing. (C) Batches of 10 islets each were washed and incubated for 30 min in KRBH 
0.1% BSA containing 2.8 or 16.7 mM glucose and insulin release was determined by RIA.
Data are the mean ± SE of 4 experiments. *P<0.05 vs Ad-LacZ and #P<0.05 vs Ad-LCPTI wt.
Fig. 6. Glucose-induced fatty acid esterification processes are reduced in INS(832/13) cells
expressing LCPTI. INS(832/13) infected with Ad-LacZ, Ad-LCPTI wt or Ad-LCPTI M593S 
were preincubated for 30 min at 37ºC in KRBH medium containing 1% BSA and then
incubated for 2 h at 2.5 or 15 mM glucose in the presence of 0.8 mM carnitine, 1 µCi/ml [1-
14C]-palmitic acid and 0.25 mM unlabeled palmitate complexed to 1% (w/v) BSA. Fatty acid 
esterification into phospholipids (A), diacylglycerol (B), triglyceride (C), non-esterified
palmitate (D) and cholesterol esters (E) were assessed using thin layer chromatography after 
lipid extraction. G is the difference between the incorporation of palmitate in the particular 
lipid classes at 15 mM vs 2.5 mM glucose. (F) total triglyceride content. Data are the mean ± 
SE of 4 experiments. *P<0.05 vs Ad-LacZ.
Fig. 7. PKC activation is impaired in Ad-LCPTI wt and Ad-LCPTI M593S-infected cells.
Ad-LacZ, Ad-LCPTI wt and Ad-LCPTI M593S INS(832/13)- infected cells were incubated for
30 min at low (2.5 mM) (A) or high (15 mM) (B) glucose. Western blot of membrane (M) and
cytosolic (C) fractions was performed using a specific antibody against the PKC isoforms 
expressed in pancreatic β-cells (α, β  and γ) giving a unique band of 80 KDa. The intensity of 
the PKC bands were quantified using a Laser scanning system. The lower panels in A and B 
show mean results ± SE of 3 experiments. (A.U.; arbitrary optical units). *P<0.05 vs Ad-LacZ.
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ABSTRACT
C75 is described as a potential drug for treatment of obesity and type II diabetes. First 
known as a synthetic inhibitor of fatty acid synthase (FAS), it has been also described as 
an activator of carnitine palmitoyltransferase I (CPT I), increasing peripheral energy 
utilization and fatty acid oxidation in mice. To further investigate the C75/CPT I 
interaction, we have characterized the effects of C75 on CPT I in vitro and in vivo. C75 
itself has no effect on either yeast-overexpressed L- and M- CPT I isoforms or in 
purified mitochondria from rat liver and muscle. However, the CoA derivative, C75-
CoA, strongly inhibits yeast-overexpressed L- and M- CPT I isoforms, as does
etomoxiryl-CoA, a potent inhibitor of CPT I. The binding of CPT I to C75-CoA is 
irreversible. Moreover, C75-CoA inhibits CPT I activity in purified mitochondria from 
rat liver and muscle. The IC50 values for either L- or M-CPT I isoforms fall in a similar 
micromolar range to those observed for etomoxiryl-CoA. When INS(823/13), L6E9 or 
HEK293 cell lines are incubated with C75, CPT I activity is inhibited, as is fatty acid 
oxidation. In vivo, a single intraperitoneal injection of C75 to mice produces a short-
term inhibition of CPT I activity in mitochondria from liver, soleus and pancreas, 
suggesting that in cellular models and in lean mice, C75 is transformed into its C75-
CoA derivative, which directly inhibits CPT I activity. Overall, these findings provide 
compelling evidence that C75, through its activated form C75-CoA, is a potent inhibitor 
of CPT I.
Abbreviations used: FAS: Fatty acid synthase; L-CPT I: carnitine palmitoyltransferase 
I, liver isoform; M-CPT I: carnitine palmitoyltransferase I, muscle isoform; KRBH 
buffer: Krebs-Ringer Bicarbonate Hepes buffer
INTRODUCTION
C75 is a chemically stable synthetic inhibitor of fatty acid synthase (FAS) 
derived from cerulenin, a natural product obtained from the fungus Cephalosporium
caerulens. It binds irreversibly to the catalytic site of both type I (mammalian and yeast) 
and type II (bacterial) FAS, by covalent modification of the β-ketoacyl-acyl carrier 
protein synthase domain (1, 2). Structurally, C75 is a cell-permeable α-methylene-γ-
butyrolactone, designed to be less reactive and potentially safer than cerulenin. It lacks 
the reactive epoxide present on cerulenin, which enhances chemical stability and
specificity (Fig. 1). C75 inhibits purified mammalian FAS with the characteristics of a 
slow-binding inhibitor (3), inducing cytostatic and cytotoxic effects in cultured tumour 
cells, and exhibiting significant growth inhibitory effects on human breast cancer
xenografts (4, 5). 
C75 has several other interesting properties. It decreases food intake and fat 
mass and results in a strong loss of weight in both lean and fat mice (leptin-deficient
(ob/ob) or diet- induced obese (DIO) mice) (6-10).  It has been hypothesized that C75 
may alter the metabolism of neurons in the hypothalamus that regulate feeding
behaviour. Recent evidence (6, 11, 12) has implicated malonyl-CoA, an intermediate in 
fatty acid biosynthesis, as a possible mediator in the hypothalamic pathway that
indicates energy status and mediates the feeding behaviour of mice. Intra-
cerebroventricular administration of C75 increases cellular malonyl-CoA in the
hypothalamus (12), caused by inhibition of FAS, and blocks fasting- induced up-
regulation of hypothalamic neuropeptide Y, thus reducing food intake (6). Furthermore, 
it appears that C75 exerts its short and long-term effects on food intake by preventing 
the up-regulation of the orexigenic neuropeptides and down-regulation of the
anorexigenic neuropeptides (9, 13).
In addition to the hypothalamic actions, it has been described that C75 decreases 
fat mass in peripheral tissues by increasing fatty acid oxidation through the stimulation 
of carnitine palmitoyltransferase (CPT) I (7, 8). This enzyme is the main regulatory 
mitochondrial step of fatty acid oxidation (14) and it facilitates the transport of long-
chain acyl-CoA into mitochondria, thus leading to the release of energy by β-oxidation
of fatty acids. Mammalian tissues express three isoforms of CPT I: liver (L-CPT I) (15, 
16) muscle (M-CPT I) (17, 18) and brain (CPT I-C) (19). CPT I is tightly regulated by 
its physiological inhibitor malonyl-CoA, and thus it confers to CPT I the ability to 
signal the availability of lipid and carbohydrate fuels to the cell (14). The malonyl-CoA
sensitivity of L-CPT I in the adult rat depends on the physiological state. It is increased 
by re-feeding carbohydrates to fasted rats, by obesity or after insulin administration to 
diabetic rats, whereas it is decreased by starvation and diabetes (20, 21)
When C75 is given to mice, the inhibition of FAS produces an increase of
cellular malonyl-CoA content which should decrease CPT I activity. Paradoxically,
however, in vivo, the inhibitory effect on CPT I, caused by the high content of malonyl-
CoA in peripheral tissues, is overcome by C75-stimulated CPT I activity (7, 8). In order 
to examine this paradox we tested the direct effect of C75 on CPT I activity. We show 
that C75 itself neither inhibits nor activates CPT I. In contrast, C75-CoA inhibits both 
L- and M-CPT I isoforms with similar kinetics to etomoxiryl-CoA, a well-known
inhibitor of CPT I. The inhibition of CPT I activity is also observed in pancreas, muscle 
and kidney cell cultures incubated with C75. These effects were followed by a decrease 
of fatty acid oxidation. Finally, in mice treated with a single intraperitoneal (i.p.) 
injection of C75, CPT I activity decreased but  later recovered.
EXPERIMENTAL PROCEDURES
Animals
Six-week-old C57BL/6J male mice were purchased from Harlam Co. Animals 
were maintained under a 12-h dark/light cycle at 23ºC with free access to food and 
water. After a 1-week acclimatization, experiments with animals were performed. Male 
Sprague Dawley rats (180-200 g) bred in our laboratory were used to obtain liver and 
soleus. All the experimental protocols were approved by the Animal Ethics Committee 
at the University of Barcelona. 
Materials
L-[methyl-3H]carnitine hydrochloride and [1-14C]palmitic acid were purchased 
from Amersham Biosciences. C75 was purchased from Alexis Biochemicals and
etomoxir was provided by Dr. H.P.O. Wolf (GMBH, Allensbach, Germany). Yeast 
culture media products were from Difco. Bradford solution for protein assay was from 
Bio-Rad. Dulbecco’s modified Eagle’s medium (DMEM), RPMI 1640 and antibiotics 
were from Gibco-Invitrogen Corporation. Defatted bovine serum albumin (BSA),
palmitate, malonyl-CoA and other chemicals were purchased from Sigma-Aldrich.
Acyl-CoA synthase from Pseudomonas sp. was obtained from Fluka.
Activation of C75 and etomoxir to C75-CoA and etomoxiryl-CoA
Etomoxir and C75 were activated to CoA derivatives in the presence of CoA-SH
(22). The reaction was performed with 1 µmol of each drug separately in a total volume 
of 1 ml of a buffer containing 0.1% (w/v) Triton X-100, 5 mM CoA-SH, 10 mM ATP, 1 
mM DTT, 10 mM MgCl2, 100 mM MOPS-NaOH pH 7.5 and 0.25 U of Acyl-CoA
synthase from Pseudomonas sp. The reaction was carried out at 35 ºC for 2 h. We 
assumed that the conversion of C75 and etomoxir to their CoA derivatives was
complete. Stock aliquots, where the final concentration of each CoA derivative was 1 
mM, were stored at –20ºC and diluted in 100 mM MOPS-NaOH pH 7.5 for activity 
assays.
Mass spectrometry
The MALDI-TOF mass spectra of C75-CoA and etomoxiryl-CoA were obtained 
on a Voyager DE-RP (Applied Biosystems) mass spectrometer equipped with a nitrogen 
laser (337 nm, 3 ns pulse). The acceleration voltage was set to 20 kV. Data were 
acquired in the reflector mode with delay times of 320 ns for both the positive and 
negative polarities. Spectra were calibrated externally using a calibration mixture
(Calibration Mixture 1, Applied Biosystems): CHCA, des-Arg1-Bradykinin,
Angiotensin I, Glu1-Fibrinopeptide B, Neurotensin m/z 300-1700.
Samples were prepared by diluting 1 µl of each drug in the activation buffer to 
100 µl with H2O, and mixing 1 µl of this diluted solution with 1 µl of matrix solution 
(10 mg/ml of 2,5-dihydroxybenzoic acid (2,5-DHB, Aldrich) in methanol:water 1:1). 
One microliter of the sample:matrix mixture was spotted onto the stainless steel sample 
plate, allowed to evaporate to dryness in air and introduced into the mass spectrometer.
Spectra were acquired in the positive and negative ion mode. MALDI-TOF spectra were 
performed by the Mass Spectrometry Service (SCT, University of Barcelona).
Expression of CPT I in Saccharomyces cerevisiae
Saccharomyces cerevisiae was chosen as a heterologous expression system
because it does not express endogenous CPT activity. The plasmid, pYES2-L-CPT I 
encoding the liver isoform of CPT I was obtained as previously described (23). The 
plasmid pYES-M-CPT I was obtained from the plasmid DS112-36 (18) containing the 
coding cDNA of rat muscle CPT I isoform. The fragment that encompassed nucleotides 
27-2432, including the coding region of M-CPT I, was subcloned into the S. cerevisiae
expression plasmid pYES2 (Invitrogen). A HindIII site (underlined) was introduced by 
PCR immediately 5' of the ATG start codon of M-CPT I to enable cloning into the
unique HindIII site of plasmid pYES2. A consensus sequence (in boldface type), 
optimized for efficient translation in yeast, was also introduced in the same PCR, using 
the forward primer CPT I HindIII.for (5'-TCG ATA AGC TTA TAA AAT GGC GGA
AGC ACA CCA GGC AG-3') and the reverse primer CPT I HindIII.rev (5'-GGA AGC 
TTG GGC AGT GAT GT-3'). The resulting fragment of 550 pb obtained after the 
digestion of PCR products with HindIII, was ligated on pYES2 plasmid digested with 
the same restriction enzyme, yielding the plasmid pYES2-M-CPT I-ATG. This plasmid
was digested with SalI (in cDNA of M-CPT I) and SphI (in plasmid pYES2) and ligated 
with the CPT I fragment SalI - SphI (purified band of 2351 bp), producing pYES2-M-
CPT Ipre. The sequence TTTTTTA (387-393 nt) present in the M-CPT I cDNA, which
resembles a known yeast polyadenylation signal (24), was subsequently changed by 
PCR in order to increase expression levels in yeast without changing the amino acid
sequence, producing pYES-M-CPT I. The appropriate substitutions and the absence of 
unwanted mutations were confirmed by sequencing the inserts in both directions with 
an Applied Biosystems 373 automated DNA sequencer. The expression of the plasmids 
pYES-L-CPT I and pYES-M-CPT I in yeast was performed as described in (23).
Cell culture
The clonal β  cell line INS(832/13) (25), derived and selected from the parental 
rat insulinoma INS-1 (26), was kindly given by Dr. M. Prentki (Montreal, Canada). 
Cells were cultured (passages 48-60) in a humidified atmosphere containing 5% CO2 in 
complete medium composed of RPMI 1640 containing 11 mM glucose and
supplemented with 10% heat inactivated FBS (Wisent Inc, USA), 10 mM HEPES, 2 
mM glutamine, 1 mM sodium pyruvate, 50 mM 2-mercaptoethanol, 100 U/ml penicillin 
and 100 µg/ml streptomycin. The maintenance culture was passaged once a week by 
gentle trypsinization and cells were grown until confluence in Falcon dishes. 
The L6E9 rat skeletal muscle cell line was kindly provided by Dr. A. Zorzano 
(University of Barcelona). Cells were cultured in a humidified atmosphere containing 
5% CO2 in complete medium composed of DMEM containing 10% FBS (Gibco-
Invitrogen Corporation), 100 units/ml penicillin, 100 µg/ml streptomycin and 25 mM 
HEPES pH 7.4 (Growth Medium). Pre-confluent myoblasts (80-90%) were induced to 
differentiate by lowering FBS to a final concentration of 2% (Differentiation Medium). 
All the experiments were performed with completely differentiated myotubes (after 4 
days in Differentiation Medium). 
Human Embryonic Kidney (HEK) 293 cells obtained from ECACC (European 
Collection of Cell Cultures) were cultured in a humidified atmosphere containing 5% 
CO2 in complete medium composed of DMEM containing 10% FCS (Biological
Industries), 100 units/ml penicillin and 100 µg/ml streptomycin. For experiments cells 
were grown until 80% confluence.
Preparation of mitochondrial fractions
Mitochondria-enriched fractions from yeast overexpressing L- and M-CPT I 
were obtained as described previously (23). Mitochondria-enriched cell fractions from 
INS(832/13), L6E9 and HEK293 cells cultured in 15-cm dishes, were obtained with a 
glass homogenizer as previously described (27). The pellet, in which the mitochondria 
remain largely intact, was used directly for CPT I activity assay. 
To obtain mitochondria-enriched fractions from rat and mice muscle, two soleus 
muscle samples of each animal were homogenized separately in 250 mM sucrose buffer 
using an omni mixer and then centrifuged at 1,000 xg for 15 min. The pellet was 
homogenized and centrifuged at 600 xg for 10 min. The resulting supernatant was 
centrifuged at 15,000 xg for 15 min and the pellet was resuspended in 100 µl of 250 
mM sucrose and 150 mM KCl solution (28). Mitochondria-enriched fractions from rat 
and mouse liver were obtained and mechanically homogenized in a buffer containing 
250 mM sucrose, 1 mM EDTA and 10 mM Tris/HCl, pH 7.4. Liver suspension was 
centrifuged at 560 xg for 15 min and the supernatant was further centrifuged at 12,000 
xg for 20 min. Pellet was resuspended in 2 ml of homogenization buffer, centrifuged for 
10 min at 7,000 xg, washed and resuspended in 1 ml of the same buffer (28). To obtain 
mitochondria-enriched fractions from mice pancreas, tissue was homogenized in a 
buffer containing 250 mM sucrose, 20 mM Tris/HCl pH 7.4, 0.5 mM EDTA, 0.5 mM 
EGTA, 1 mM DTT, 10 µg/ml leupeptine, 4 µg/ml aprotinin, 2 µg/ml pepstatin and 100 
µM PMSF. The homogenate was subjected to differential centrifugation at 900 xg for 
10 min and at 5,500 xg for 10 min. The pellet was resuspended with a Dounce 
homogenizer and centrifuged at 2,000 xg for 2 min and at 4,000 xg for 8 min. Finally, 
the pellet was resuspended in 250 µl of 250 mM sucrose (29). All the processes were 
performed at 4 ºC and fractions were assayed immediately for determination of CPT I 
activity.
Determination of CPT I activity 
CPT I activity was measured in mitochondria-enriched fractions obtained from
yeast, cells or tissues as described above. CPT I activity in 3-4 µg of yeast protein 
extracts, 10-15 µg of mitochondria-enriched cell fractions or 20 µg of mitochondria
fractions from tissues was determined by the radiometric method as previously described 
(23). Extracts were preincubated at 30 ºC for different times in the presence or absence of 
drugs. Enzyme activity was assayed for 4 min at 30 °C in a total volume of 200 µl. The 
substrates were 50 µM palmitoyl-CoA and 400 µM or 1000 µM L-[methyl-3H]carnitine
for L- and M- CPT I isoforms respectively. In yeast extracts only the overexpressed L-CPT
I or M-CPT I activity is present. In tissues and cell culture extracts both CPT I (sensitive to 
malonyl-CoA) and CPT II (insensitive to malonyl-CoA) are present, therefore in these 
fractions CPT I activity was determined as the malonyl-CoA/etomoxiryl-CoA sensitive 
CPT activity. CPT II activity was always subtracted from total activity to calculate specific
CPT I activity. The presence of CPT activity sensitive to malonyl-CoA in cell cultures is 
less than 5% and thus it was not taken into consideration. Concentrations of drugs ranging 
from 0.02 to 50 µM were used to estimate the IC50 value. 50 µM malonyl-CoA was used 
for malonyl-CoA inhibition assay. All protein concentrations were determined using the 
Bio Rad protein assay with bovine albumin as standard.
Binding assays
To evaluate the binding of CoA derivatives to CPT I, experiments were
performed based on the procedures described in (30) with some modifications. Yeast 
mitochondria preincubated for 5 min at 30 ºC with 50 µM of each derivative-CoA were 
directly used for the CPT I activity assay (unwashed) or centrifuged at 13,000 xg for 5 
min at 4 ºC and resuspended (washed) in buffer 5 mM Tris/HCl pH 7.2, 150 mM KCl, 
10 µg/ml leupeptine, 500 µΜ benzamidine, 1 µg/ml pepstatin and 100 µM PMSF 
before the assay. CPT I activity assay was performed for 4 min at 30 ºC as described 
above.
C75 treatment of cell cultures and administration to mice 
Cells were incubated with either C75 at 10, 20, 30 or 40 µg/ml or etomoxir at 30 
or 40 µg/ml in the culture medium. Stock solutions of C75 and etomoxir were prepared 
at 100 mM in DMSO. Control cells were incubated with the same amount of DMSO. 
L6E9 myotubes were incubated for 2 h at 37 ºC and INS(832/13) and HEK293 cells 
were incubated for 1 h at 37ºC. After this time, cells were washed in PBS and either the 
CPT I activity, palmitate oxidation or cell viability were measured. 
Mice were given a single i.p. injection of C75, dissolved in RPMI 1640 medium, 
at 20 mg/kg body weight or medium alone for control. Animals were sacrificed at 
different times post-injection and mitochondria-enriched fractions from liver, soleus and 
pancreas were obtained as described above. Fractions were assayed immediately for 
determination of CPT I activity.
Measurement of fatty acid oxidation 
Palmitate oxidation to CO2 was measured in culture cells grown in 12-well
plates. On the day of the assay cells were washed in KRBH plus 0.1% defatted BSA, 
preincubated at 37 ºC for 30 min in KRBH 1% BSA and washed in KRBH 0.1% BSA. 
Cells were then incubated for 2 h at 37 ºC with fresh KRBH containing 2.5 mM glucose 
in the presence of 0.8 mM carnitine plus 0.25 mM palmitate and 1 µCi/ml [1-
14C]palmitic acid bound to 1% (w/v) BSA. Oxidation measurements were performed by 
a CO2-capture system assay as previously described (31).
Viability cell culture assay
To evaluate the cytotoxic effect of the drugs, the MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide] assay was performed (32). Cells were seeded in 
12-well plates and incubated with drugs as described above. After this, 200 µl of 0.25% 
(w/v) MTT was added to each well and cells were further incubated for 2 h. After that, 
the formazan crystals formed were solubilized by adding 1 ml of MTT lysis solution 
(10% (w/v) SDS and 1 mM acetic acid in DMSO) and the absorbance at 570 nm was
measured. The results are expressed as the percentage of absorbance related to control 
cells.
Statistical Analysis
Data are expressed as means ± SE for at least three independent experiments. 
The significance of differences was assessed by unpaired Student’s t test.
RESULTS
 Effect of C75 and C75-CoA on yeast-expressed L- and M-CPT I activity
Yeast-overexpressed mitochondrial L-CPT I and M-CPT I were incubated
independently with different concentrations of C75 (Fig. 1). The drug neither inhibited 
nor activated CPT I from either L- or M- isoform (Fig. 2A and 2B). In parallel, we also 
determined the inhibition of both CPT I isoforms with etomoxir, a well-known inhibitor 
of CPT I activity. Etomoxir did not inhibit either form of CPT I (Fig. 2C and 2D).This
is in agreement with the fact that the active inhibitory form of etomoxir is its CoA-
derivative, etomoxiryl-CoA (33). To test whether C75 needs to be converted to C75-
CoA derivative to be pharmacologically active, both drugs were transformed to their 
CoA derivatives in the presence of CoA by the action of acyl-CoA synthase as 
described in EXPERIMENTAL PROCEDURES. The CoA derivatives of both drugs strongly 
inhibited both CPT I isoforms with similar kinetics (Fig. 2). IC50 values for C75-CoA
were 0.24 and 0.36 µM for L- and M-CPT I isoforms respectively (Table I). 
To confirm that C75 reacted with CoA to produce a stable derivative, a MALDI-
TOF analysis was carried out. Figure 3A shows the peak of 1020.4 Da corresponding to 
the molecular mass of the product formed by the reaction of the two compounds C75 
and CoA. A similar analysis for etomoxiryl-CoA (Fig. 3B) shows the peak of 1064.0 
Da. Other peaks correspond to products derived from either CoA, C75 or etomoxir. 
The binding of C75-CoA to CPT I is stable
To assess whether binding of C75-CoA to CPT I is stable, yeast mitochondrial 
enriched fractions overexpressing L-CPT I were incubated with 50 µM C75-CoA,
etomoxiryl-CoA or malonyl-CoA, or with buffer alone as a control. After 5 min of 
preincubation, extracts were assayed directly (unwashed samples) or centrifuged and 
resuspended in buffer (washed samples) (see EXPERIMENTAL PROCEDURES ) and
assayed for CPT I activity. As shown in Figure 4, malonyl-CoA inhibition was
reversible, and CPT I activity was recovered at 91% after washing with respect to 
control washed fractions. However, both C75-CoA and etomoxiryl-CoA produced a 
permanent inhibition, 75% and 79% respectively with respect to control washed
fractions. The experiments with C75-CoA show that it is tightly bound to CPT I, as is 
etomoxiryl-CoA, a well-known irreversible covalently-bound inhibitor of CPT I.
C75-CoA inhibits CPT I activity from rat liver and muscle mitochondria
Since it had been reported that C75 activated but did not inhibit CPT I (7), we 
carried out additional experiments with isolated mitochondria from rat liver and muscle. 
C75 did not inhibit nor activated liver or muscle CPT I activity. However, both C75-
CoA and etomoxiryl-CoA inhibited CPT I activity from mitochondria with similar 
kinetics (Fig. 5A and 5B). At 50 µM of each product, CPT I was almost completely 
inhibited. IC50 values for C75-CoA and etomoxiryl-CoA were respectively 0.37 µM and 
0.56 µM for L-CPT I and 0.015 and 0.71 µM for M-CPT I (Table I). C75-CoA appears 
to be a stronger inhibitor for M- than L-CPT I.
C75-CoA inhibits CPT I activity of mitochondrial-enriched fractions from pancreatic 
and muscle cultured cells. 
The inhibitory effect of C75-CoA and etomoxiryl-CoA was also tested on
purified mitochondria from cultured cells from pancreas (INS(832/13)) and muscle 
(L6E9). In all cases CPT I activity was strongly inhibited at increasing concentrations of 
both CoA-derivatives (Fig. 5C and 5D). The IC50 values for C75-CoA were 0.25 µM
and 0.46 µM for INS(812/13) and L6E9 cells respectively. The IC50 values for
etomoxiryl-CoA were 1.21 µM and 2.87 µM for INS(823/13) and L6E9 cells,
respectively (Table I). Again, C75-CoA was a slightly more potent CPT I inhibitor than 
etomoxiryl-CoA.
Effects of C75 on CPT I activity and fatty acid oxidation in cultured cells 
To assess whether CPT I inhibition by C75-CoA is followed by a similar 
decrease in fatty acid oxidation, three cultured cell lines INS(812/13), L6E9 and
HEK293 were incubated with C75, and etomoxir as a control. It was not necessary in 
this case to transform the drugs to their CoA derivatives, since this conversion occurs 
inside the cells via the mitochondrial long-chain acyl-CoA synthase. CPT I activity 
decreased at increasing C75 concentrations. CPT I activity was reduced by 49%, 62% 
and 62% respectively in pancreatic INS(832/13), muscle L6E9 and kidney HEK293 
cells at maximal C75 concentrations of 30, 40 and 30 µg/ml respectively. In parallel, [1-
14C]palmitate oxidation decreased at increasing concentrations of C75 in all cultured 
cells. Palmitate oxidation was reduced by 62%, 84% and 68% respectively in pancreatic 
INS(832/13), muscle L6E9 and kidney HEK293 cells at maximal C75 concentrations of 
30, 40 and 30 µg/ml respectively (Fig. 6). Etomoxir also decreased CPT I activity and 
palmitate oxidation in all cell types assayed. CPT I activity was reduced by 80%, 52% 
and 71% respectively in pancreatic INS(832/13), muscle L6E9 and kidney HEK293 
cells, and palmitate oxidation was consequently reduced by 71%, 78% and 77% 
respectively, with respect to control. To rule out the possibility that the inhibition of 
palmitate oxidation was due to an increase in cell death caused by C75, we performed 
viability experiments using the MTT assay. In all cases cell viability was higher than 
98% of control. 
Effect of C75 treatment on whole animal
We examined the effect of C75 on CPT I activity in vivo. Mice were injected 
(i.p.) with a single dose of C75 (20 mg/kg body weight) and sacrificed at different time 
points thereafter. Tissue samples (liver, soleus and pancreas) were taken to isolate 
mitochondria as described in EXPERIMENTAL PROCEDURES. CPT I activity decreased in 
all tissues assayed at short times (Fig. 7), but then recovered, the kinetics depending on 
the tissue. Inhibition of liver CPT I decreased by 59% at 1 h and by 70% after 3 h of 
treatment, and at 5 h CPT I values were similar to control. Muscle CPT I was inhibited 
by 61% at 30 min of treatment and recovered faster than the liver isoform. In pancreas 
CPT I activity decreased by 35% of control after 30 min of C75 treatment but
recovered thereafter. In no case did CPT I activation exceed control.
DISCUSSION
In this study we investigate the interaction between C75 and CPT I. Recently, it
has been published that C75 activated CPT I and fatty acid oxidation in primary cortical 
neurones, hypothalamus (34) and peripheral tissues (7) contributing to the weight loss 
observed in mice treated with C75. To further investigate this action, we choose the S.
cerevisiae heterologous overexpression system of CPT I , which allows the separate 
expression of each CPT I isoforms (L- and M-), thus avoiding the occurrence of other 
carnitine acyltransferases like carnitine palmitoyltransferase II (CPT II), carnitine
octanoyltransferase (COT) or carnitine acetyltransferase (CrAT), which are present in 
all mammals systems. This procedure has been used successfully by ourselves (35, 36) 
and others (37, 38) to study the kinetic characteristics of the various carnitine
acyltransferases.
In the present study, yeast-overexpressed CPT I was clearly inhibited by C75-
CoA, in a dose-dependent manner. We never observed any activation of CPT I by either 
C75 or C75-CoA in spite of the large number of experiments we carried out. It is 
important to emphasize that the drug is not active unless it is transformed to its CoA 
derivative. This was also observed with etomoxir, whose activated CoA derivative was 
identified as the active inhibitory form (33). MALDI-TOF analysis clearly showed that 
C75-CoA is formed when C75 is incubated with CoA in the presence of acyl-CoA
synthase and ATP. As a control, etomoxiryl-CoA was also produced under the same 
conditions. As observed for etomoxiryl-CoA, C75-CoA binds stably to CPT I, at 
variance with malonyl-CoA, which releases CPT I when its concentration is decreased 
(by dilution).
C75-CoA, but not C75, also inhibited mitochondrial CPT I from rat liver and 
muscle. Isolation of mitochondrial fractions provides an excellent source of CPT I. The
kinetics of inhibition were quite similar to those of etomoxiryl-CoA and malonyl-CoA
(data not shown). The IC50 observed for CPT I from liver mitochondrial fractions (L-
CPT I isoform) is 25-fold higher than that observed for M-CPT I isoform (from muscle 
mitochondria). M-CPT I isoform is more sensitive to C75-CoA than L-CPT I isoform. 
However, these differences were not observed in overexpressed yeast extracts. 
The experiments performed in the present study on CPT I activity and palmitate 
oxidation in cultured pancreatic, muscle and kidney cells reveal a strong correlation
between inhibition of CPT I activity and decrease of palmitate β−oxidation. These cells 
were directly incubated with etomoxir or C75, which could enter the cell where they are 
converted to their CoA derivatives by endogenous acyl-CoA synthase and intracellular 
ATP. It is interesting to compare the present results, where CPT I is inhibited, with
those obtained by others (7, 39), who observed CPT I activation in primary hepatocytes, 
adipocytes and in MCF-7 cells after C75 treatment. The discrepancy may be explained 
by differences in the method used to measure CPT I activity. Thupari et al. (7) 
performed CPT I assays in permeabilized cells, while we isolated and purified
mitochondria from tissues and cultured cells. When we repeated the experiments of 
digitonin permeabilization in muscle cells following Thupari’s protocol, we also found 
that CPT I is activated. However, when mitochondria were purified from these cells, we 
found CPT I to be inhibited. We hypothesise that digitonin permeabilization together 
with the C75 treatment might alter interactions between mitochondria and the
cytoskeleton (40), which may either alter CPT I activity or disturb the assay. It has been 
suggested that changes in the lipid composition of the membrane microenvironment in 
which CPT I resides are important for alteration of CPT I activity (41-45). Numerous 
approaches (36, 38, 46-49) suggest that modulation of inter-domain interactions, for 
instance by covalent modification (phosphorylation) (50) of the protein, may also be 
involved in changes of CPT I activity. All these events may occur as a consequence of 
an indirect action of C75 on permeabilized cells.
It has been reported that C75 treatment of human cancer cells in vitro led to 
rapid inhibition of fatty acid synthesis, followed by inhibition of DNA replication
culminating in apoptosis (4, 5). Whereas induction of apoptosis appeared related to 
accumulation of the substrate, malonyl-CoA, after FAS inhibition, the cytostatic effects 
were independent of malonyl-CoA accumulation and may have resulted from product 
depletion (4). To rule out the possibility that the decrease of palmitate oxidation could 
be produced by C75 cytotoxicity, viability studies were performed. In our conditions, 
viability of the three cellular models is higher than 98%. Each clonal cellular type 
shows characteristics distinctive of viability. For instance, pancreatic β-cells
INS(832/13) and kidney HEK293 were incubated at shorter times and lower C75
concentrations than L6E9 myotubes. Depending on the lipid composition and
metabolism, each cell line may be more sensitive to the cytotoxic effect of C75. For 
instance, breast carcinoma cell line SKBR3, with higher lipid content, needs 6 h of C75-
preincubation to achieve the cytotoxic effect (5). Therefore, the decrease on palmitate 
oxidation, could be produced only by the inhibition of CPT I.
The in vitro experiments are also corroborated by the experiments in vivo. A 
single intraperitoneal C75 injection produced a short-term inhibition of CPT I in liver, 
muscle (soleus) and pancreas in mice. The differential extent of inhibition of CPT I seen 
in the different tissues could be explained by differences in the rate of C75-CoA
endogenous activation and pharmacokinetics in each tissue. It is important to stress that 
C75 shows its maximum CPT I-inhibitory properties in the liver. As binding of C75-
CoA to CPT I appears to be irreversible, inhibition of CPT I by the drug may remain 
stable until the modified CPT I is replaced by a new molecule. This time scale would be 
tissue dependent (Fig. 7). This increased turnover of the CPT I protein or different 
effects of C75 on other cellular signalling pathways of cellular fuel state, like the up-
regulation of the expression of skeletal muscle UCP-3 (51) a protein involved cellular 
fatty acid metabolism, may increase the energy expenditure observed by Thupari et al.
(7) as a consequence of a long-term action of C75.
The effects of cerulenin on CPT I activity and on fatty acid oxidation also 
support the present study. Cerulenin, the natural FAS inhibitor on the basis of which 
C75 was designed, has been shown to be an inhibitor of CPT I in vitro (52) and in vivo
(53). Moreover, rat pancreatic islets treated with cerulenin did not increase palmitate 
oxidation (54). In vivo, cerulenin inhibits liver and muscle CPT I in mice after i.p. 
injection (53), being recovered and slightly activated after a few hours. These authors 
concluded that the late stimulating effect of cerulenin on CPT I activity occurred via the 
sympathetic nervous system. C75 may behave like cerulenin in mice, producing a 
biphasic effect on CPT I (an initial inhibition followed by recovery). This would also be
consistent with he increased peripheral fatty acid oxidation observed in mice after 
several hours of treatment.
In conclusion, all the results presented here provide compelling evidence that 
C75-CoA is a potent and direct inhibitor of both isoforms L- and M-CPT I in vitro and 
in vivo, and suggest that in cellular models and in lean mice, C75 is transformed into its 
C75-CoA derivative, which directly inhibits CPT I activity. Further investigation is 
needed to explain the stimulation of fatty acid oxidation of C75 observed by others in 
peripheral tissues and the loss of body weight.
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LEGENDS TO FIGURES
Fig.1. Structure of compounds affecting CPT I activity
Fig. 2. Effect of C75, etomoxir and their derivative-CoAs on the activity of liver (L) 
and muscle (M) isoforms of CPT I overexpressed in yeast S. cerevisiae.
L-CPT I (A and C) and M-CPT I (B and D) were overexpressed in yeast and
preincubated for 5 min with increasing concentrations of etomoxir (open triangles), C75 
(black triangles), etomoxiryl-CoA (open circles) and C75-CoA (black circles). CPT I 
activity was measured and data are expressed relative to control values in the absence of 
drugs (100%) as the mean of three independent experiments.
Fig. 3. MALDI-TOF spectra of C75-CoA and etomoxiryl-CoA.
Spectra were directly obtained from the activation reaction product of C75-CoA and 
etomoxiryl-CoA using a Voyager-DE-RP from Applied Biosystems with DHB (10 
mg/ml in water: methanol, 1:1). The detection was done with a reflector and in the 
negative mode. The product C75-CoA (A) is confirmed by the peak at 1020.4 Da and 
etomoxiryl-CoA (B) by the peak at 1064.0 Da.
Fig. 4. Effect of C75-CoA, etomoxiryl-CoA and malonyl-CoA on CPT I activity 
overexpressed in yeast S. cerevisiae.
3 µg of mitochondria from yeast overexpressing L-CPT I was preincubated for 5 min 
with 50 µM of C75-CoA, etomoxiryl-CoA and malonyl-CoA, washed or not with buffer 
as described in EXPERIMENTAL PROCEDURES. Specific activity was represented as the 
mean of three independent experiments. 
Fig. 5. Effect of C75-CoA and etomoxiryl-CoA on CPT I activity. 
Mitochondria isolated from rat liver (A), rat muscle (B), INS(823/13) cells (C) or L6E9 
myotubes (D) were preincubated for 1 min with increasing concentrations of C75-CoA
(black circles) or etomoxiryl-CoA (open circles) and CPT I activity was assayed as 
described in EXPERIMENTAL PROCEDURES. Rat liver and muscle mitochondria were 
also incubated with increasing concentrations of C75 (black triangles). Data are the 
mean for at least three independent experiments and are expressed relative to control 
values in the absence of inhibitor (100%). Insert: expanded dose-response curve for the 
two inhibitors.
Fig. 6. CPT I activity and palmitate oxidation in cell cultures. 
Cells were incubated for 2 h (L6E9) or 1 h (INS(832/13) and HEK293) with complete 
medium containing either 0, 10, 20, 30 and 40 µg/ml of C75 or 30 and 40 µg/ml of 
etomoxir. Mitochondria-enriched cell fractions were obtained and 10 µg of protein were 
used for the CPT I activity assay. In palmitate oxidation assays, cells were preincubated 
for 30 min at 37 ºC with KRBH 1% BSA and then incubated for 2 h at 2.5 mM glucose 
in the presence of 0.8 mM carnitine, 0.25 mM palmitate and 1 µCi/ml [1-14C]-palmitate.
Palmitate oxidation to CO2 was measured as described in EXPERIMENTAL PROCEDURES.
Data are presented as the mean ± SE of three independent experiments. *P<0.05;
**P<0.01 and ***P<0.001 compared with control without inhibitors. 
Fig. 7. C75 effect on the whole animal.
C75 was injected i.p. in mice and animals were sacrificed at 0, 0.5, 1, 3, and 5 h after 
injection. Mitochondria-enriched fractions from liver, soleus, and pancreas were
obtained and CPT I activity was assayed. Results are the mean ± SE of data obtained 
from 6 mice. *P<0.05 v.s. control (0 h).
Table I. IC50 values of CPT I for C75-CoA and etomoxiryl-CoA.
Mitochondrial fractions obtained from yeast overexpressing CPT I, rat liver, rat muscle 
and cultured cells were assayed for CPT I activity in the presence of C75-CoA and 
etomoxiryl-CoA. IC50 values were calculated as described in EXPERIMENTAL
PROCEDURES.
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Table I
2,87 ± 0,870,46 ± 0,21L6E9 myotubes
1,21 ± 0,350,25 ± 0,16INS(832/13) cells
0,71 ± 0,050,015 ± 0,005Rat Muscle 
0,56 ± 0,040,37 ± 0,23Rat liver
3,10 ± 0,060,36 ± 0,18Yeast overexpressing M-CPT I
4,06 ± 0,780,24 ± 0,01Yeast overexpressing L-CPT I
etomoxiryl-CoAC75-CoA
IC50 (µM)
